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It has been known that anthracycline-based chemotherapy has the potential to 
cause cardiac dysfunction in breast cancer patients; however, recently evidence has 
shown that the addition of trastuzumab increases this risk. The study objective was to 
compare the cost-effectiveness of monitoring for cardiotoxicity with B-type natriuretic 
peptide (BNP), multi-gated acquisition scanning (MUGA), echocardiography (ECHO) or 
no monitoring from a payer’s prospective. Cost-effectiveness was compared between 
alternatives using an incremental cost-effectiveness ratio with outcomes of 1) quality-
adjusted life-years and 2) percentage of patients diagnosed with each monitoring strategy. 
Costs estimates (in 2010 U.S. Dollars) of each strategy (obtained from the Center for 
Medicare and Medicaid Services website [www.cms.gov]) included the cost of the test, 
cost of treating heart failure once discovered (which includes medications, routine office 
visits, medication management) and the cost of potential acute care (which includes 
emergency department visits and hospitalizations). Estimates for the probabilities of heart 
failure development, disease progression, need for acute care, and mortality, as well as 
utility estimates for all disease stages were obtained from published literature.  A 15-year 
time-frame was used with a 3% discount rate for both costs and QALYs.  
 vi 
In the base-case analysis, the average costs and QALYs for monitoring patients 
were $10,062/ 6.92 QALY, $13,627/4.22 QALY, $14,739/ 6.61 QALY and $15,656/ 
6.49 QALY for BNP, No Monitoring, ECHO and MUGA respectively. When comparing 
all alternatives to BNP, the ICER values were negative, indicating that BNP was the 
dominant monitoring strategy. Percent detection was similar between the three 
monitoring methods [21-22 % for HER-2(-) and 30-31% for HER-2(+) patients]. Again 
BNP was dominant over the other monitoring strategies. Sensitivity analyses were robust 
to changes in discount rate, probability of patients testing HER-2 (+), probability of 
patients being diagnosed in an asymptomatic stage, incidence of cardiac dysfunction in 
patients receiving anthracycline therapy ± trastuzumab and estimate of disutility 
associated with additional testing. A probabilistic sensitivity analysis conducted via 
Monte Carlo simulation led to the same conclusion as the base-case analysis; BNP was 
the dominant strategy over all monitoring alternatives.  
 vii 
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CHAPTER ONE: BACKGROUND 
 
1.1 Introduction 
Heart failure resulting from therapy is a relatively common adverse effect 
experienced in breast cancer patients.  While true incidence and prevalence estimates are 
not known, published literature reports estimates that can range anywhere from 1 to 57%. 
The differences largely depend on the drug combination, degree of dysfunction reported, 
length of follow-up, and methods used for detection.  
Treatment regimens vary in the amount of risk they confer, while use of an 
anthracycline agent alone is known to cause risk, combination with the targeted agent 
trastuzumab, is known to amplify that risk substantially. This poses somewhat of a 
dilemma in the treatment of patients. Anthracyclines, especially, doxorubicin, are a 
mainstay in breast cancer treatment and have been shown to have high activity against 
these tumors, essentially making breast cancer curable. Therefore, not administering 
anthracyclines because of the cardiac risk may diminish that patient’s possibility of a 
cure. Trastuzumab is also extremely important in the treatment of breast cancer. 
Trastuzumab was specifically engineered to have activity in patients who over-express 
the HER-2 gene.  
Although heart failure can be experienced by patients a number of years after 
therapy has been concluded, guidelines have yet to be developed that explicitly 
recommend a specific method or frequency to monitor cardiac function during routine 
surveillance.  Patients can develop left ventricular dysfunction anytime during or after 
treatment, however, heart failure most commonly develops within the first year after the 
completion of chemotherapy.  
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In clinical trials, especially older trials, heart failure was not screened for unless 
the study participant had specific complaints suggestive of a heart failure diagnosis. This 
results in bias toward later stage (i.e. NYHA class III or IV) reporting.  In more recent 
trials, where the risk of left ventricular dysfunction was known to be a possible effect, 
trial investigators screened patients using methods such as ECHO and MUGA scans.  
A frequently encountered barrier to monitoring cardiac function is cost. 
Traditional methods to assess cardiac function include echocardiography (ECHO) and 
multi-gated acquisition scan (MUGA), both of which are costly and resource-intensive 
radiological procedures.  Less invasive methods such as chest x-rays (CXR) and 
electrocardiograms (ECG) are significantly less costly; however, neither is sensitive nor 
specific enough to small changes in cardiac function to be useful for screening purposes. 
These factors make non-invasive, less expensive laboratory tests attractive alternatives 
for screening. 
Numerous studies have evaluated the utility of B-type natriuretic peptide (BNP) 
levels in the heart failure setting and have concluded that BNP can adequately 
discriminate between patients with left ventricular dysfunction and those without.  There 
have been additional studies examining the cost-effectiveness of BNP in patients 
presenting with acute symptoms and BNP was found to have saved resources when 






The purpose of this dissertation is to assess the cost-effectiveness of B-type 
natriuretic peptide monitoring in breast cancer patients receiving cardiotoxic therapies. 
To understand the importance of cost-effective strategies to screen for heart failure in 
breast cancer patients, one must understand the impact both disease states have on our 
society and the healthcare system. This requires knowledge of both breast cancer and 
heart failure disease processes, diagnoses, treatments and outcomes. Chapter one of this 
dissertation will give the necessary background regarding the diseases under 
investigation.  
Chapters two and three will provide a review of the literature regarding cardiac 
dysfunction as a possible consequence of breast cancer therapy and possible strategies to 
detect potential cardiac dysfunction. Chapter two will provide a review of the literature 
regarding the cardiovascular consequences of breast cancer therapy. This will include a 
discussion of the mechanism of toxicity of various cancer therapies as well as the toxicity 
of specific agents and toxicity criteria. This chapter will also review the literature 
regarding heart failure in breast cancer patients. This discussion will include the 
incidence of dysfunction, risk factors, preventive strategies and management. This 
chapter will conclude with an overview of the outcomes and prognosis associated with 
therapy-induced cardiotoxicity as well as economic implications.  Additionally, this 
chapter will provide evidence that will serve as data inputs for the Markov models that 
will be used to test the hypotheses under study.  Chapter three will provide a review of 
the literature regarding detection of cardiovascular dysfunction in breast cancer patients. 
This will include the discussion of the various available methods, an overview of the 
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evidence for each testing procedure, comparison of available methods and the economic 
implications of various alternatives.   
Chapter four will describe the methodology used for this dissertation. This chapter 
will provide details of the study methodology. This includes the purpose of the study and 
problem statement, study objectives with corresponding hypotheses to be tested. 
Additionally, this chapter gives an introduction to the economic evaluation in healthcare,  
types of analyses – with greater detail on cost-effectiveness analyses, as well as the use of 
decision analysis and Markov analyses. This chapter will also provide the specific 
estimates and parameters used for the model in this study as well as the sources of those 
estimates.   
Chapter five will present the results for each of the study objectives with testable 
hypotheses, information on strategies under comparison, incidence of treatment-induced 
cardiac dysfunction, cost of monitoring, costs of outpatient heart failure treatment, and 
costs of acute care. The detailed results of cost-effectiveness analysis and sensitivity 
analyses are also included in this chapter. Chapter six includes a description of the study 
population, strategies under comparison and incidence of cardiac dysfunction. This 
chapter also includes a discussion of the base-case results, results of the sensitivity 




1.3 Breast Cancer 
Breast cancer is the most frequently diagnosed cancer in women in the United 
States accounting for an estimated 193,000 new cases and 40,000 deaths in 2009. 1  Age-
specific incidence of breast cancer increases with age to a lifetime risk of one in eight or 
12.67% (if living to 110 years of age); by age 40, approximately one in 250 women will 
be diagnosed with breast cancer annually, at age 60, the figure is one in 35. 2 
In the last decade, there has been a sharp decline in breast cancer incidence and 
disease-related mortality. The decrease in incidence has been attributed to the decreasing 
use of post-menopausal hormone replacement therapy, and the decrease in mortality has 
been attributed to improved treatments in the adjuvant and metastatic settings as well as 
the effects of early diagnosis through screening efforts. The five-year survival for all 
stages is approximately 89%; this improves to 98% for local disease. However, patients 
with regional lymph node involvement have a five-year survival of 83% and those with 
distant lymph node involvement approximately 26%. 3  
Due to therapy and earlier diagnosis, patients are seeing an increase in survival; 
however, there is also the possibility of experiencing delayed toxicities that do not 
present until after the treatment has concluded. Treatment-related toxicities happen 
relatively frequently in breast cancer, and the most common and deadly toxicity is 
chemotherapy-related heart failure.4 Anthracyclines are a mainstay of breast cancer 
                                                 
1 N. Howlader et al., eds., “SEER Cancer Statistics Review 1975-2008” (Bethesda, Maryland: National 
Cancer Institute, 2011), http://seer.cancer.gov/csr/1975_2008/index.html. 
2 Ibid.; Rebecca Siegel et al., “Cancer Statistics, 2011,” CA: A Cancer Journal for Clinicians 61, no. 4 
(July 2011): 212–236. 
3 Howlader et al., “SEER Cancer Statistics Review 1975-2008.” 
4 Mohamed M. Haq et al., “Doxorubicin-induced Congestive Heart Failure in Adults,” Cancer 56, no. 6 
(1985): 1361–1365; Jan S. Moreb and David J. Oblon, “Outcome of Clinical Congestive Heart Failure 
Induced by Anthracycline Chemotherapy,” Cancer 70, no. 11 (1992): 2637–2641. 
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therapy, however, their main limitation for use is the potential for cardiotoxicity; this 
potential increases substantially when use is combined with trastuzumab. 5  
The actual incidence of chemotherapy-related cardiotoxicity varies depending on 
the criteria used for reporting (e.g., any decline in left ventricular ejection fraction versus 
overt symptomatic heart failure) and how long patients are monitored for adverse effects 
(since patients can present with left ventricular dysfunction as many as 15 years after 
receiving an anthracycline). 6 There is an increasing number of breast cancer survivors 
resulting from improved therapy and screening; therefore, it has become apparent that a 
cost-effective mechanism for long-term monitoring of cardiotoxicity is needed after 
treatment is concluded. 7 
 
1.3.1 DISEASE PROCESS/EPIDEMIOLOGY 
 
In the United States (U.S.) and worldwide, breast cancer is the most common type 
of cancer in women. In the U.S. breast cancer accounts for approximately 15% of cancer 
deaths (second to lung cancer), and is the main cause of death in women between the 
ages of 45-55. Worldwide, there are approximately one million new cases annually. The 
National Cancer Institute (NCI) estimates that approximately 12% of women will be 
diagnosed with breast cancer in their lifetime, and while improvements in early diagnosis 
                                                 
5 Moreb and Oblon, “Outcome of Clinical Congestive Heart Failure Induced by Anthracycline 
Chemotherapy.” 
6 Dawn L Hershman et al., “Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients 
With Diffuse B-Cell Non-Hodgkin’s Lymphoma,” J Clin Oncol 26, no. 19 (2008): 3159–3165; Robin L 
Jones, Charles Swanton, and Michael S Ewer, “Anthracycline Cardiotoxicity,” Expert Opinion on Drug 
Safety 5, no. 6 (2006): 791–809. 
7 Michael R. Bristow et al., “Efficacy and Cost of Cardiac Monitoring in Patients Receiving Doxorubicin,” 
Cancer 50, no. 1 (1982): 32–41; M.J. Horner et al., “SEER Cancer Statistics Review 1975-2006,” 
Surveillance Epidemiology and End Results, 2010, http://seer.cancer.gov/csr/1975_2006/index.html. 
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and treatment have decreased mortality over the last decade, there are still approximately 
40,000 deaths each year attributed to breast cancer. 8 In the U.S., approximately 200,000 
women are diagnosed annually; this represents 26% of cancer diagnoses.  While the 
incidence of breast cancer in the U.S. had been increasing steadily, partially due to an 
increase in use of mammographic screening, the number of new cases has recently 
stabilized and is beginning to decline. Despite this recent decline in the US, the incidence 
in the rest of the world is expected to continue to increase. From 2002-2006, the median 
age of diagnosis was 61, with no new cases under the age of 20.  The SEER age-adjusted 
incidence rate was 123.8 cases per 100,000 women annually. 9 
 
1.3.2 RISK FACTORS 
 
There are a number of risk factors that have been associated with breast cancer. 
These include both modifiable lifestyle risk factors and hereditary or genetic factors. 10 
Prominent risk factors include age, race/ethnicity, diet, alcohol intake, weight and 
exogenous hormone use. Table 1.1 lists known risk factors for breast cancer, the relative 
risk (RR) for that risk factor as well as the definition for the “high-risk” group. 
  
                                                 
8 Horner et al., “SEER Cancer Statistics Review 1975-2006.” 
9 Ibid. 
10 J. L Kelsey and G. S Berkowitz, “Breast Cancer Epidemiology,” Cancer Research 48, no. 20 (1988): 
5615; T. J Key, P. K Verkasalo, and E. Banks, “Epidemiology of Breast Cancer,” The Lancet Oncology 2, 
no. 3 (2001): 133–140; K McPherson, C. M. Steel, and J. M. Dixon, “ABC of Breast Diseases: Breast 
Cancer---epidemiology, Risk Factors, and Genetics,” British Medical Journal 321, no. 7261 (September 9, 
2000): 624–628. 
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Table 1.1 Established and Probable Risk Factors for Breast Cancer11 
 
Risk Factor Relative Risk High Risk Group 
Age   
Advanced Age > 10 Elderly 
Age at menarche 3 Before age 11 
Age at menopause 2 After age 54 
Age at first full pregnancy 3 First child in early 40’s 
Family History   
First Degree Relative ≥ 2 Diagnosis at  younger age 
Previous benign disease 4 - 5 Atypical hyperplasia 
Cancer in other breast > 4  
Diet   
Saturated Fats 1.5 High intake   
Alcohol  1.3 Excessive intake 
Body Weight   
Premenopausal 0.7 BMI >35 
Postmenopausal 2 BMI > 35 
Exogenous Hormones   
OC’s 1.24 Current use 
HRT 1.35 Use over 10 years 
DES 2 Use during pregnancy 
Other   
Ionizing Radiation 3 Abnormal exposure in young females after age 10 
Geographic Location 5 Developed countries 
BMI: Body Mass Index, OC’s: Oral Contraceptives, HRT: Hormone Replacement 
Therapy,   DES: Diethyl Stilbestrol 
  
                                                 
11 McPherson, Steel, and Dixon, “ABC of Breast Diseases.” 
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Increasing age is the most prominent risk factor for breast cancer. The incidence 
of breast cancer rapidly increases during reproductive years and then slows down after 
the age of 50 or the onset of menopause.  The cumulative incidence of breast cancer in 
the U.S. and Europe is approximately 2.7% by age 55, 5% by age 65 and 7.7% by age 65 
(giving a doubling rate every 10 years). 12 Some countries see a flattening of the 
incidence-age curve after menopause because of the lack of hormone replacement 
therapy use seen abroad. 13 
In addition to age, there are racial differences in incidence for some groups. Non-
Hispanic white women have the highest incidence of breast cancer worldwide which is 
peaks between the ages of 50-70. Non-Hispanic whites have a one-in-15 chance of 
developing breast cancer, compared to one-in-20 for African American women, one-in-
26 in Asians or Pacific Islanders, and one-in-27 for Hispanics. Table 1.2 lists the breast 
cancer incidence rates by race as reported by SEER for calendar years 2002 to 2006.  
Mortality, however, is much higher in African Americans and Hispanics, which is 
commonly attributed to presentation at a more advanced stage.  Hispanic and African 
American women are also more likely to be estrogen receptor (ER) negative, have a 
poorly differentiated disease and be diagnosed at an earlier age (commonly prior to 
menopause). The P53 mutation is more common in African American women but less 
common in Hispanic women when compared to non-Hispanic white women.  14  
 
                                                 
12 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer”; McPherson, Steel, and Dixon, “ABC of 
Breast Diseases.” 
13 McPherson, Steel, and Dixon, “ABC of Breast Diseases.” 
14 Vinay Kumar et al., “Carcinoma of the Breast,” in Kumar: Robbins and Cotran Pathologic Basis of 
Disease, 8th ed. (Saunders Elsevier, 2009), http://www.mdconsult.com.ezproxy.lib.utexas.edu/. 
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Table 1.2 Breast Cancer Incidence Rates by Race for 2002 – 2006 15 
 




Asian/Pacific Islander 89.5 
American Indian/Alaska Native 74.4 
Hispanic 88.3 
    *Rates are incidence per 100,000 women 
 
 
Rates of breast cancer are highest in developed countries and lowest in non-
developed countries and Japan (however, rates in Japan are increasing), with up to a five-
fold difference worldwide in both incidence and mortality. Breast cancer rates in the U.S. 
and Western Europe are between four and seven times higher than the rest of the world 
with the risk in U.S. immigrants increasing with each generation (i.e., the immigrant risk 
is expected to be that of the host country within one to two generations). This is attributed 
to many modifiable risk factors (i.e., timing of childbirth, diet, exercise). 16 
There are several dietary factors that have been associated with breast cancer.  
Evidence supports a positive association between alcohol intake and diagnosis of breast 
cancer. There is equally strong evidence that an increase in folic acid intake is protective 
against breast cancer.  There are a number of older studies that suggest an increase in fat 
intake is associated with the development of breast cancer; however, this is no longer 
believed to be true. It has been suggested that an increased BMI is a risk factor for breast 
cancer; this could be due to an increase in the amount of endogenous estrogen in women 
                                                 
15 Horner et al., “SEER Cancer Statistics Review 1975-2006.” 
16 Kumar et al., “Carcinoma of the Breast.” 
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with an increased BMI. There is some evidence suggesting that intake of phytoestrogens 
or soy products may have a slight protective effect.   17  
Past medical history can also increase risk of developing breast cancer. Patients 
with a prior history of benign breast disease are at increased risk of developing 
subsequent breast cancer. Benign breast disease is divided into two types, proliferative 
and non-proliferative disorders. Non-proliferative breast disease does not confer a higher 
risk of breast cancer, whereas proliferative can increase risk two- to four-fold. 18 Patients 
with increased breast density on mammographic examination have a higher risk of 
developing breast cancer. 19 High breast density tends to cluster in families, is associated 
with both younger age and with hormone exposure. 20 It is suspected that high breast 
density is a result of incomplete or less complete involution of lobules at the end of each 
menstrual cycle, which may hypothetically increase the number of cells that are 
susceptible to neoplastic changes.  21 Breast density may be slightly modifiable in that 
hormone therapy appears to increase it whereas tamoxifen decreases density. Increased 
breast density also makes it more difficult to detect changes via mammography, which 
complicates the diagnosis. 22 
Radiation exposure as a risk factor for breast cancer was mainly based on studies 
of women exposed to atomic bomb radiation in World War II and studies of those who 
                                                 
17 Kelsey and Berkowitz, “Breast Cancer Epidemiology”; Key, Verkasalo, and Banks, “Epidemiology of 
Breast Cancer”; McPherson, Steel, and Dixon, “ABC of Breast Diseases.” 
18 L. C Hartmann et al., “Benign Breast Disease and the Risk of Breast Cancer,” New England Journal of 
Medicine 353, no. 3 (2005): 229; Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
19 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
20 G. A Colditz et al., “Family History, Age, and Risk of Breast Cancer: Prospective Data from the Nurses’ 
Health Study,” Jama 270, no. 3 (1993): 338. 
21 Kumar et al., “Carcinoma of the Breast.” 
22 Ibid. 
 12 
received therapeutic or diagnostic radiation. 23 Since levels of radiation received either 
therapeutically or during a diagnostic procedure are relatively low, it is extremely rare for 
these exposures to cause DNA mutations, and while radiation exposure is considered to 
be carcinogenic, it is extremely rare. It is estimated that about 1% of cases can be 
attributed to diagnostic radiology. 24 Those women under the age of 20 that receive 
radiation directly to the chest are theoretically at a higher risk than those women who are 
over the age of 50 or postmenopausal. 25 
There is an association between breast cancer and the number of ovarian cycles. 
The number of cycles depends on a number of things, including  age at  first menarche, 
age at  onset of menopause , age at time of  first full term child, or not having children. 
The younger the age at first menarche increases the number of cycles and increases risk, 
as does an older age at the onset of menopause and having no children. 26  However, the 
younger age at time of first full term pregnancy confers a lower risk of breast cancer, and 
the risk continues to decrease with an increasing number of full term pregnancies. 27 The 
effect of abortions (either spontaneous or induced) or miscarriages on breast cancer risk 
is not known. 28 There is evidence that a number of circulating hormones can increase 
risk of breast cancer. These include serum levels of estradiol, insulin-like growth factor-1 
(pre-menopause) and prolactin (pre- or post-menopause). 29 
                                                 
23 Kelsey and Berkowitz, “Breast Cancer Epidemiology”; McPherson, Steel, and Dixon, “ABC of Breast 
Diseases.” 
24 Martin Abeloff et al., “Cancer of the Breast,” in Abeloff: Abeloff’s Clinical Oncology (Philadelphia: 
Churchill Livingstone/Elsevier, 2008), Chapter 95, http://www.mdconsult.com.ezproxy.lib.utexas.edu/; 
Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
25 Abeloff et al., “Cancer of the Breast”; Kumar et al., “Carcinoma of the Breast.” 
26 Abeloff et al., “Cancer of the Breast.” 
27 Kumar et al., “Carcinoma of the Breast.” 
28 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
29 Abeloff et al., “Cancer of the Breast”; Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
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There have been many studies examining the use of exogenous hormones and 
their association with breast cancer. There is little evidence suggesting there is an 
association between oral contraceptive use and increased cancer risk. 30 Some studies 
suggest there may be an increase risk in current users of oral contraceptives (OC); 
however, since the incidence is extremely low in that age group, there are not many cases 
attributed to oral contraceptive use. Any additional risk from OC’s declines rapidly after 
cessation of use and disappears after ten years. 31  
There is a demonstrated increase in risk of breast cancer in women who take 
hormone replacement therapy (HRT); however, the risk is only slightly increased with a 
RR of 1.023 per year of use. 32 In fact, the use of HRT for ten years is estimated to 
increase risk of breast cancer by about 35%. 33 Those women who are actively using 
hormone replacement therapy are at an increased risk compared to those who have never 
used them, and like oral contraceptives, the risk declines after cessation of use and any 
increased risk disappears five years after HRT has been stopped. 34 There are additional 
factors that may add to the risk associated with HRT. Combination HRT appears to 
confer greater breast cancer risk than using estrogen alone, and heavier women appear to 
have a lower risk than lean women who use HRT. 35 
 
                                                 
30 Kumar et al., “Carcinoma of the Breast.” 
31 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer”; McPherson, Steel, and Dixon, “ABC of 
Breast Diseases.” 
32 McPherson, Steel, and Dixon, “ABC of Breast Diseases.” 
33 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
34 Zaid Abassi et al., “Implications of the Natriuretic Peptide System in the Pathogenesis of Heart Failure: 
Diagnostic and Therapeutic Importance,” Pharmacology & Therapeutics 102, no. 3 (June 2004): 223–241. 
35 Katrina Armstrong, Andrea Eisen, and Barbara Weber, “Assessing the Risk of Breast Cancer,” The New 
England Journal of Medicine 342, no. 8 (February 24, 2000): 564–571; Key, Verkasalo, and Banks, 
“Epidemiology of Breast Cancer.” 
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There are a number of older studies demonstrating an association between 
diethylstilbestrol (DES) and breast cancer. The estimated RR is approximately 1.5 and 
has been shown to be dose dependent; however today, the use of DES in pregnancy is 
banned.  There have been some small studies that have suggested a potential increase in 
risk in women who have been exposed to fertility treatment; however, this association has 
not been confirmed in large populations. 36 
Family history is associated with approximately 10% of breast cancer diagnoses.  
Women with a first degree relative with breast cancer have an approximately two-fold 
increase in risk of developing breast cancer than those without a positive family history.37 
There are a number of genetic factors that are known to be associated with increased risk 
and that play a role at each stage of tumor development. 38 The most well established 
genes known to convey increased risk are the low prevalence genes BRCA1 and BRCA2. 
These genes account for approximately 2-3% of all cancers and 15-20% of familial 
cancers. Genetic testing for these alterations is now routinely performed in women who 
are considered high risk. Other genes that are definitively responsible for breast cancer 
have yet to be identified, and the processes involved in developing disease are not 
completely understood. 39 
There are a number of risk prediction tools available that combine risk factors and 
assign risk categories to women. These categories allow for a more efficient use of 
screening and preventive therapies.  The breast cancer risk assessment tool (BCRAT) or 
Gail Model is a calculator-type tool. Table 1.3 lists the risk factors that the Gail Model 
                                                 
36 Key, Verkasalo, and Banks, “Epidemiology of Breast Cancer.” 
37 Colditz et al., “Family History, Age, and Risk of Breast Cancer.” 
38 Richard Wooster and Barbara Weber, “Breast and Ovarian Cancer,” New England Journal of Medicine 
348, no. 23 (June 5, 2003): 2339–47. 
39 Ibid. 
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considers when calculating patient risk.  There are separate calculators for blacks 
(African Americans) and non-Hispanic whites.  The Gail model appears to be a good 
predictor of breast cancer; however, it has poor discrimination at the individual level. 
There is another program called BRCAPRO®, which can assess the probability of 
developing breast cancer in individuals with a strong family history.  40 The calculation 
tool is available at the National Cancer Institute website: http://www.nci.nih.gov/.  
 
 
Table 1.3 Factors Used to Assess Risk in Modified Gail Model 41 
 
Item Risk Factors Assessed  Effect on Risk† 
1 Current Age Increases With Age 
2 Age at First Menarche Increases if  < 12 
3 Age at first Live Birth  * 
4 Number of First Degree Relatives With BC * 
5 Previous Benign Breast Biopsies Increases†  
6 Atypical Hyperplasia in Previous Breast Biopsy Increases   
7 Race/ Ethnicity Formula varies by race 
†Effect on risk determined by item response; *Responses to items 3 and 4 are combined to 
determine effect on risk; †the need for biopsy indicates histological change which increases risk; 












                                                 
40 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011,” Professional 
Organization, The National Comprehensive Cancer Network, November 19, 2010, www.nccn.org. 
41 Ibid. 
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1.3.3 RISK-REDUCTION STRATEGIES 
 
The American Cancer Society (ACS) has developed dietary guidelines for cancer 
prevention that include eating five or more servings of fruits/vegetables per day, eating 
whole grains instead of refined grains, limiting consumption of processed or red meats, 
and limiting alcohol consumption to ≤ one  alcoholic beverage per day. Calcium and 
vitamin D may confer a slight protective effect if consumed from low-fat or fat-free dairy 
products or supplements. Consumption of soy products may also confer a slight 
protective effect. Additionally, exercise for 45 - 60 minutes per day on five or more days 
per week, which is designed to promote a healthy weight, can decrease circulating 
endogenous estrogen and consequently may provide a slight protective effect. 42 
In addition to diet and exercise recommendations that the ACS makes for all 
women; those at high risk should consider alternatives to exogenous hormones. Pre-
menopausal women should consider using alternatives to oral contraceptives and consider 
having children earlier; post-menopausal women should forgo hormone replacement 
therapy and use other symptomatic treatment if possible. 43 
 Raloxifene and tamoxifen are both approved for use in women at high risk of 
developing breast cancer. These drugs are selective estrogen receptor modulators and 
essentially block estrogen in some tissues.  Aromatase inhibitors are being studied for 
protection in high risk women. Aromatase inhibitors are typically used in postmenopausal 
women with hormone receptor positive breast cancer and are not yet approved for use in 
preventive strategies. 44 
                                                 
42 NCCN Breast Cancer Risk Reduction Panel Members, “Breast Cancer Risk Reduction V3.2011,” 






Early stage disease is rarely symptomatic and is usually painless. Typically, early 
disease is discovered by noticing a hard lump warranting further examination by a health 
care professional. Lumps may make the breast appear asymmetric; however, often times 
there are no symptoms associated with early disease, and the disease can only be detected 
with more advanced screening methods such as mammography. 45 Screening methods 
include: breast self-exam, clinical breast exam, screen film mammography, digital 
mammography, computer aided detection, ultrasound and MRI. There are a number of 
factors that have to be considered when assessing the accuracy of screening methods and 
these factors include: availability of prior studies, body habitus, ethnicity, breast density, 
menstruating (changes in breast density due to cycle), and post-menopausal hormone 
therapy and breast surgery. 46  
It is estimated that about one-third of women in the U.S. perform regular breast 
self-exams with an estimated sensitivity between 20-30%. Although studies have shown 
that monthly self-exams do not affect mortality rates, and in fact, increase the number of 
biopsies performed due to false positives, many organizations still recommend that they 
be performed. 47  A Cochrane review of two large population studies (n = 388,535) 
compared self-exam to no intervention and found no difference in mortality between the 
groups. There were twice as many biopsies with benign results in the screening group 
than in the control group. There was an additional study included that compared self-
exam to clinical examination, and due to poor follow- up, no conclusions could be made. 
                                                 
45 Abeloff et al., “Cancer of the Breast.” 
46 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011.” 
47 Michael S. O’Malley and Suzanne W. Fletcher, “Screening for Breast Cancer With Breast Self-
examination,” JAMA: The Journal of the American Medical Association 257, no. 16 (April 24, 1987): 2196 
–2203. 
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The authors of the Cochrane review concluded that more harm was added due to 
screening. 48 
In randomized controlled trials examining screening methods, the sensitivity of 
clinical breast exam is estimated at 54% (95% CI: 48 - 60%), and specificity is 94% 
(95% CI: 90 - 97%). Screening at the community level is unlikely to match that of a trial, 
and estimates for sensitivity in the community range from 28% - 36% for clinical breast 
exams. 49 
Breast cancers detected with screening mammography are typically smaller and 
have more favorable histological and biological features than those detected outside of 
screening. Since favorable prognostic outcomes attributed to mammography could be due 
to bias, trials that use mortality as the outcome of interest have become important to 
demonstrate any improvement that mammography provides. 50 A Cochrane review which 
included seven trials with a total of 600,000 patients who were randomized to 
mammographic screening versus no screening concluded that screening reduces mortality 
by 15%, but there is also an increase of 30% in over-diagnosis and unnecessary 
treatment. These authors also concluded that breast cancer mortality was an unreliable 
outcome in these trials and was biased in favor of screening because the cause of death 
was often misclassified. 51 
Seven population-based screening programs in the U.S. yielded an overall 
sensitivity of 75% and a specificity of 92.3%. These results are similar to those reported 
                                                 
48 Jan Peter Kösters and Peter C Gøtzsche, “Regular Self-examination or Clinical Examination for Early 
Detection of Breast Cancer,” ed. The Cochrane Collaboration and Jan Peter Kösters, Cochrane Database of 
Systematic Reviews, no. 2 (2003), http://www2.cochrane.org/. 
49 J. G Elmore et al., “Screening for Breast Cancer,” Jama 293, no. 10 (2005): 1245. 
50 Ibid. 
51 Peter C Gøtzsche and Margrethe Nielsen, “Screening for Breast Cancer with Mammography,” ed. The 
Cochrane Collaboration and Peter C Gøtzsche, Cochrane Database of Systematic Reviews, no. 10 (2011), 
http://www2.cochrane.org/. 
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in numerous clinical trials examining screening mammography, yielding a sensitivity 
range of 68-88% and specificity range of 82-93%.  Important predictors of accuracy are 
the age of the patient and breast density. 52 
Since the publication of the Cochrane review, many organizations still 
recommend using mammography as a screening tool; however, in many published 
recommendations, the age to initiate routine screening has changed. Additionally, since 
the publication of the review, all but one of the randomized screening trials excluded by 
the authors has been deemed to be methodologically sound by other reviewers. There are 
conflicting sets of guidelines regarding the use of screening mammography. The majority 
of North American groups recommend routine screening for “normal-risk” patients 
beginning at age 50; this includes the NCCN and ASCO.53 The American College of 
Physicians (ACP) recommends that women in their 40s should consult with their 
physician to see if routine mammography is warranted, and The American Cancer 
Society recommends annual mammograms for women beginning at age 40. 54 
Although mammography is the most frequently utilized method for screening, 
there are an increasing number of studies reporting results using MRI as a screening tool 
for breast cancer. 55 A recent systematic review of 11 trials that compared MRI to 
mammography found that MRI had greater sensitivity than mammography (77% vs. 
39%) but the specificity was found to be lower (86.3% vs. 94.7%). 56 Using a 
                                                 
52 Elmore et al., “Screening for Breast Cancer.” 
53 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011.” 
54 Heidi D Nelson et al., “Screening for Breast Cancer: An Update for the U.S. Preventive Services Task 
Force,” Annals of Internal Medicine 151, no. 10 (November 17, 2009): 727–737; Robert A Smith et al., 
“Cancer Screening in the United States, 2011,” CA: A Cancer Journal for Clinicians 61, no. 1 (January 1, 
2011): 8–30. 
55 Elmore et al., “Screening for Breast Cancer.” 
56 Ellen Warner et al., “Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High 
Risk for Breast Cancer,” Annals of Internal Medicine 148, no. 9 (May 6, 2008): 671 –679. 
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combination is recommended by the ACS for women at very high risk as defined by risk 
prediction models, they also recommend against the use of MRI in women with a lifetime 
risk less than 15%.  There are no clear recommendations for the use of MRI in women 
who rate a lifetime risk between very high (20-25%) and 15%. 57 
The National Comprehensive Cancer Network (NCCN) recommends the 
consideration of MRI use in high-risk women with the following circumstances 58: Have 
a BRCA1 or BRCA2 mutation; Have a first-degree relative with a BRCA1 or BRCA2 
mutation and they themselves are untested; Have a lifetime risk of 20-25% or more as 
defined by models largely dependent on family history; Received radiation therapy to the 
chest between the ages of 10 and 30 for treatment of Hodgkin’s disease; Carry or have a 
first-degree relative who carries a genetic mutation in the TP53 or PTEN genes. 
Several issues need to be considered when determining who should be screened 
and what method should be used. These include risk stratification, age to begin screening, 
how often to perform screening and at what age to stop screening.  Most agree that 
routine screening mammography should be offered to women ages 50-69. The 
controversy lies in patients between the ages of 40 and 49 and those over 70. Many agree 
that for older patients who are in good health and would be able to undergo treatment, 
screening should be offered. Patients with significant comorbidities or those with a life 
expectancy of less than five years, (i.e., those patients in whom intervention is unlikely if 
breast cancer is found) probably should not be screened. The interval at which to perform 
screening is another issue with some controversy; typically, breast cancers grow more 
                                                 
57 Debbie Saslow et al., “American Cancer Society Guidelines for Breast Screening with MRI as an 
Adjunct to Mammography,” CA: A Cancer Journal for Clinicians 57, no. 2 (April 2007): 75–89. 
58 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011.” 
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slowly in older women therefore, it may be reasonable to extend the interval in those 
patients over the age of 50. 59 
For those patients who are carriers of either BRCA1 or 2, the NCCN and the ACS 
recommend the following strategy for screening: 60: Monthly breast self-exams beginning 
at age 18; Clinical breast exams 2 to 4 times annually beginning at age 25; Annual 
mammography and breast MRI beginning at age 25, or depending on the earliest age of 
onset in family. 
The NCCN stratifies women into two basic risk categories for screening purposes, 
those at normal risk and those at increased risk. Increased risk includes five separate 
groups, women who have received thoracic or mantle irradiation, women ages 35 and 
older who have a five-year risk of invasive carcinoma of 1.7% or lifetime risk of > 20%, 
women with a strong family history or genetic predisposition, women with LCIS or 
atypical hyperplasia, and women with a prior history of breast cancer. Table 1.4 lists the 
screening recommendations for each risk group as designated by the NCCN. 61 
  
                                                 
59 Ibid.; Saslow et al., “American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct 
to Mammography.” 
60 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011”; Saslow et 
al., “American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to 
Mammography.” 
61 NCCN Breast Cancer Panel Members, “Breast Cancer Screening and Diagnosis V1.2011.” 
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Table 1.4 NCCN Breast Cancer Screening Recommendations by Risk 62 
 
Group Screening Recommendation 
Women at Normal Risk 
        Ages 20-39 CBE Every 1-3 Years 
        Ages ≥40 Annual CBE with SM 
Women at Increased Risk 
Thoracic Irradiation  For patients <25: annual CBE 
For patients ≥25: CBE every 6-12 months and annual SM beginning 
8-10 years post-RT or age 25 whichever occurs last 
Possible annual breast MRI 
≥35 with 5-Year Risk of ≥ 1.7% or LCIS CBE every 6-12 months and annual SM 
Consider risk-reduction strategies 
Lifetime Risk of >20% CBE every 6-12 months and annual SM; consider risk-reduction 
strategies and annual breast MRI 
Strong Family History or Genetic Predisposition For patients <25, annual CBE and consider referral to genetic 
counselor, For patients ≥25, CBE every 6-12 months, annual SM 
beginning 5-10 years prior to the youngest breast cancer case in the 
family, and annual breast MRI, consider risk-reduction strategies and 
referral to genetic counselor 
CBE: Clinical Breast Exam; SM: Screening Mammography; MRI: Magnetic Resonance Imaging; LCIS: Lobular Carcinoma in situ;  
RT: Radiotherapy
                                                 
62 Ibid. 
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Screening for breast cancer can also have limitations/problems. Besides the actual 
physical discomfort experienced by women undergoing the screening and the radiation 
exposure, there is a risk of false positives and over-diagnosis. Over-diagnosis of breast 
cancer happens when screening leads to diagnosis of abnormalities such as ductal 
carcinoma in situ (DCIS), which would not be diagnosed without screening, and are 
unlikely to develop into invasive carcinomas.  In a systematic review by Jorgenson and 
Gotzsche, the authors pooled incidence results from five trials describing population 
based screening efforts. They included only incidence figures from the final year of 
observation. Trials had over diagnosis estimates ranging from 44-57%. The pooled effect 
size was concluded to be 52% (95% CI: 46 -58%). 63 
Clinicians, however, are more concerned with false positive readings as women 
can be harmed as a result of a false positive finding. This subsequently leads to 
unnecessary testing and treatment, and subjecting patients to procedures whom are 
without the disease. Factors that may increase the number of false positives include: 
younger patients, increased number of breast biopsies, a positive family history of breast 
cancer, hormone replacement therapy, increased interval between screenings, and lack of 
prior results. The numbers of false positives are also higher in patients with increasing 
breast density. False positives are more common in younger women both because the test 
is less specific and breast cancer in that age group is less common. As a result, more 
biopsies are performed on younger women and fewer cancers are found.  There are 
similar concerns in screening older women or women taking hormone therapy.  
Recommendations to reduce the number of false positives include: encouraging patients 
not to wait more than 18 months between screenings, obtain prior results for comparison 
                                                 
63 K. J. Jorgensen and P. C Gotzsche, “Overdiagnosis in Publicly Organised Mammography Screening 
Programmes: Systematic Review of Incidence Trends,” BMJ 339, no. jul09 1 (July 9, 2009): b2587–b2587. 
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especially if switching providers, and to refer patients to experienced radiologists who do 
not have more than a 10% recall rate. 64 
The majority of breast cancers (approximately 90%) are diagnosed as a result of 
an abnormal mammogram. After an abnormal mammogram, further evaluation is 
conducted.  Diagnostic evaluations can include one or more of the following: diagnostic 
mammography, ultrasonography, breast MRI and tissue sampling. Usually, a diagnostic 
mammogram with or without ultrasonography is performed to determine if there is a need 
for tissue sampling. The diagnostic mammography is different from screening 
mammography in that the latter uses two standard x-ray views, and the diagnostic 
mammography uses additional views to evaluate a positive finding. 65 
Breast ultrasonography is a complement to mammography, and can be used to 
differentiate between cystic and solid masses that are palpable or detected on 
mammograms. It can be used for guidance in interventional procedures. When a mass 
detected on physical exam is poorly visualized on mammogram, breast ultrasonography 
is useful. Poor visualization can occur as a result of highly dense breast tissue; therefore, 
ultrasonography may provide utility. Ultrasonography can also be used in patients who 
have a detected mass on a mammogram that is consistent with fibroadenoma or a benign 
cyst. It can also be used to determine whether a suspicious lesion on mammogram can be 
evaluated with a biopsy and to determine whether neoadjuvant therapy is appropriate in 
patients presenting with large or locally advanced tumors.  
Ultrasonography is recommended for women <30 who present with a lump or 
mass or asymmetric thickening or nodularity and in women >30 who present with a lump 
                                                 
64 L. L Humphrey et al., “Breast Cancer Screening: a Summary of the Evidence for the US Preventive 
Services Task Force,” Annals of Internal Medicine 137, no. 5 Part 1 (September 3, 2002): 347–360. 
65 Laura J. Esserman and Bonnie N. Joe, “Diagnostic Evaluation of Women Suspected With Breast 
Cancer,” Up To Date, September 2009, www.uptodate.com. 
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or mass and a mammography finding of BI-RADS 1-3. Ultrasonography may also be a 
consideration in patients of any age if skin changes are suggestive of serious breast 
disease and in women with BI-RADS Category 0. Table 1.5 lists each BI-RADS 
category, the corresponding finding, and the likelihood ratio of that finding leading to a 
diagnosis of breast cancer. 66  
A biopsy is recommended if the results of a diagnostic mammogram or 
ultrasonography are indeterminate or suspicious.  Micro-calcification and soft tissue 
density are the primary findings that are indications for biopsy after a mammogram. 
Biopsy could include a fine needle aspirate (FNA), core needle biopsy (CNB), excisional 
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 26 
Table 1.5 ACR BI-RADS Categories68 
 
Category Finding LR  
0 Incomplete Assessment 7 
1 Negative 0.1 
2 Benign 0.1 
3 Probably Benign - Short Interval Follow-up 
Suggested 1.2 
4 Suspicious Abnormality-Biopsy Should be 
Considered 125 
5 Highly Suggestive of Malignancy - 
Immediate Action Should be Taken  2200 
6 Known Biopsy - Proven Malignancy  





Staging is useful for clinicians because it assists in choosing treatment modalities 
and helps predict prognosis. Staging of breast cancer is typically done with the same 
staging system as other cancers, which is the TNM system which uses characteristics 
from the tumor, lymph nodes involved and metastasis to determine stage. The stage of 
disease is determined by using the TNM classification system. Each designation for 
tumor size, lymph node involvement and existence of metastases correspond to a disease 
stage. Stage designations and corresponding TNM values are listed in Table 1.6.  69  
 
                                                 
68 American College of Radiology, “BI-RADS® – Mammography, Fourth Edition,” Professional 
Organization, American College of Radiology, 2003, http://www.acr.org/; Elmore et al., “Screening for 
Breast Cancer.” 
69 S. E. Singletary and J. L. Connolly, “Breast Cancer Staging: Working With the Sixth Edition of the 
AJCC Cancer Staging Manual,” CA: A Cancer Journal for Clinicians 56, no. 1 (January 2006): 37–47; 
ibid. 
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Table 1.6 Stage Designation Based on TNM Classifications70 
 
Stage Designation Tumor Size Node Involvement Metastases 
0 Tis N0 M0 
I T1 N0 M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
TNM: Tumor, Node, Metastasis 
 
However, to accommodate changes with regard to classification, screening and 
diagnosis such as the use of screening mammography, use of sentinel lymph node biopsy, 
and changes in the approach to distant metastases that are common in breast cancer, 
supplementary detail were added. Additional caveats to the previous system account for 
detection of earlier disease and much smaller tumors and it has been adapted to reflect the 
change in standard of care from axillary lymph node dissection to the use of sentinel 
lymph node dissection. 71 Another reason that called for a change in the classic TNM 
classification was that therapy options are often determined by stage designation or TNM 
classifications. In the previous system, ductal carcinoma in situ (DCIS) or lobular 
                                                 




carcinoma in situ (LCIS) were grouped with malignant disease. The current thinking is 
that since in situ disease lacks the ability to metastasize, it should not be categorized as 
malignant. 72 
The TNM staging system includes four classifications: clinical, pathologic, 
recurrence, and autopsy, designated as cTNM, pTNM, rTNM and aTNM respectively.   
Clinical is used for local/regional treatment choices, pathologic is for prognosis or 
adjuvant treatment choices, recurrence is used when further treatment is necessary after 
disease recurrence, and autopsy is for cancers discovered post-mortem. 73 
In the TNM classification system, T refers to the tumor size. Tumor size must be 
measured before any tissue is removed, and it is a measurement of the invasive 
component only. The largest primary carcinoma is used to designate the T classification. 
The most recent revision to the classification system gave sub-categories to the T1 stage 
because evidence suggested differing outcomes and treatment needs on what was 
formerly just considered “micro-metastasis”. Table 1.7 lists each tumor classification and 
the corresponding definition. 74 
 
                                                 
72 Ibid.; ibid.; Umberto Veronesi et al., “Rethinking TNM: Breast Cancer TNM Classification for 
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Staging for Breast Cancer Dramatically Affect Stage-Specific Survival,” Journal of Clinical Oncology 21, 
no. 17 (2003): 3244 –3248. 
74 Singletary and Connolly, “Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer 
Staging Manual”; S. Eva Singletary et al., “Revision of the American Joint Committee on Cancer Staging 
System for Breast Cancer,” Journal of Clinical Oncology 20, no. 17 (September 2002): 3628 –3636. 
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Table 1.7 Breast Cancer Tumor (T) Classifications75 
 
Classification Criteria 
Tx  Primary tumor cannot be assessed 
T0  No evidence of tumor 
Tis  Carcinoma in situ 
T1  ≤ 2 cm 
 T1mic ≤ 0.1 cm 
 T1a > 0.1 - 0.5 cm 
 T1b > 0.5 – 1 cm 
 T1c > 1 – 2 cm 
T2  > 2 – 5 cm 
T3  > 5 cm 
T4  Any size; with direct extension to chest wall or skin 
 T4a Direct extension to chest wall (not including pectoralis muscle) 
 T4b Edema (including peau d’orange) or ulceration of skin or satellite skin nodules 
 T4c Both T4a and T4b 
 T4d Inflammatory carcinoma 
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N refers to the clinical involvement of lymph nodes and pN refers to the 
pathologic involvement of lymph nodes. The difference lies in the method used to 
confirm the involvement of lymph nodes. Clinically apparent is confirmation that is 
detected via imaging studies or by clinical examination or those that are grossly visible 
pathologically, whereas, a classification of pN would be detected only using 
immunohistochemical (IHC) or molecular methods. If distant nodal involvement is 
determined solely by sentinel lymph node biopsy (SLNB), a designation of (sn) will 
follow the classification. Isolated tumor cells (ITCs) are designated with (i+). Tables 1.8 
and 1.9 list the clinical and pathologic classifications for lymph nodes and their 
corresponding definitions. 76 
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Table 1.8 Clinical Lymph Nodes (N) Classification for Breast Cancer 77 
 
Classification Criteria 
Nx  Regional lymph nodes cannot be assessed (e.g. previously removed) 
N0  No regional Lymph node metastasis 
N1  Metastasis in movable ipsilateral axillary lymph node(s) 
N2 
 
Metastasis in axillary lymph(s) fixed or matted, or in clinically apparent ipsilateral internal mammary lymph node(s) in 
the absence of clinically evident axillary lymph node metastasis 
 N2a Metastasis in axillary lymph node(s) fixed to one another (matted) or to other structures 
 N2b Metastasis only in clinically apparent ipsilateral internal mammary nodes and in the absence of clinically evident axillary lymph node metastasis 
N3  
Metastasis in ipsilateral infraclavicular lymph node(s),  or in clinically apparent ipsilateral internal mammary node(s) 
and in the presence of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular 
lymph node(s) with or without axillary or internal mammary node involvement 
 
N3a Metastasis in ipsilateral infraclavicular node(s) and axillary lymph node(s) 
 
N3b Metastasis in ipsilateral internal mammary node(s) and axillary lymph node(s) 
 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
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Table 1.9 Pathologic Lymph Nodes (pN) Classification for Breast Cancer 78 
 
Classification Criteria 
pN0 No regional lymph node metastasis histologically 
pN1mi Micrometastasis (> 0.2 mm,  none  > 2mm) 
pN1 Metastasis in 1 - 3 axillary lymph nodes and/or internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent 
pN2 Metastasis in 4 - 9 axillary lymph nodes, or in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis 
pN3 
Metastasis in ≥ 10 axillary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ipsilateral 
internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than 3 
axillary lymph nodes with clinically negative microscopic metastasis  in internal mammary lymph nodes  or in 
ipsilateral supraclavicular lymph nodes 
mm: millimeter 
                                                 
78 Ibid. 
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M refers to whether the patient presents with distant metastases and is essentially 
scored as either yes, no or cannot be assessed.  In cases where distant metastases cannot 
be assessed, a designation of MX is given, although a negative history and physical exam 
are usually enough to give a designation of M0. Table 1.10 lists each classification and 
corresponding criteria for metastases 79 
 
 
Table 1.10 Classification of Distant Metastasis (M) for Breast Cancer 80 
 
Classification Criteria 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant Metastasis 
 
 
1.3.6 TREATMENT OPTIONS 
 
Treatment strategies are determined based on the stage of disease in which the 
patient has presented.  Treatments are defined as either local or systemic. Local 
treatments include surgery and radiation, while drug therapies are considered systemic. 
Drug therapies may be given as neoadjuvant (before surgery or radiation to shrink tumor 
size) or as adjuvant therapy (after surgery or radiation to prevent recurrence). Modalities 
                                                 
79 Ibid.; Singletary et al., “Revision of the American Joint Committee on Cancer Staging System for Breast 
Cancer.” 
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include surgical options ranging from breast conserving surgery to total mastectomy with 
or without breast reconstruction, radiation, and drug therapy, which can include cytotoxic 




Surgery is usually part of every patient’s treatment. Decades ago the standard of 
care in surgical treatment was total mastectomy of the affected breast. Now, eligible early 
stage patients may choose to have a lumpectomy or breast conserving surgery. 
Lumpectomy is when the tumor itself is removed, typically along with the lymph nodes 
in the armpit of the affected breast. Lymph node removal is meant as an additional 
diagnostic tool.  If the tumor is invasive and clear margins are not obtained, additional 
therapies are required (i.e., radiation). For women with stage I or II cancer, lumpectomy 
plus radiation is an effective strategy. Evidence suggests that lumpectomy plus radiation 
is as successful as total mastectomy in patients with theses stages of disease. 82  
Breast conserving surgery (BCS), which is also known as a quadrantectomy, is a 
procedure that removes the tumor and surrounding breast tissue, and sometimes includes 
the lining over the chest muscle. BCS is more invasive than a lumpectomy but much less 
invasive than a total mastectomy.  Quadrantectomy plus radiotherapy provides similar 
results to total mastectomy in women with early stage disease.  BCS is predicated on 
achieving a pathologically negative margin of resection. Those patients that have a 
positive margin will need to undergo more surgery, which may include additional 
                                                 
81 NCCN Breast Cancer Panel Members, “Breast Cancer Practice Guidelines V2.2011,” Professional 
Organization, National Comprehensive Cancer Network, March 25, 2011, www.nccn.org. 
82 Ibid. 
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excision or mastectomy. If multiple margins are positive, mastectomy will generally be 
required. 83  
 A total mastectomy involves removing the entire breast and often lymph nodes 
from the armpit, whereas a radical mastectomy involves removing the breast, the chest 
muscles, all of the lymph nodes from under the arm and some additional fat and skin. A 
modified radical mastectomy removes the entire breast, armpit lymph nodes and 
underlying chest wall muscle. There are usually no survival benefits to performing a 
radical mastectomy compared to the less invasive methods.  84 
After a mastectomy, women can elect to have breast reconstruction or prosthesis, 
and this can be done at the same time the tissue is removed.  Saline or silicone implants 
have been used and do not affect the rate of breast cancer recurrence. Patients can also 
elect to have reconstruction, which uses muscle tissue from elsewhere in their own body. 
Typically, if radiation is required post-surgically, reconstruction will have to be done 
after radiation. Some studies show that women who elect to have reconstruction surgery 




In initial treatment, radiation can be administered either before or after surgery. 
High powered x-rays are used to kill or shrink cancer cells. Radiation can be used for 
weeks following surgery to reduce cancer recurrence in the breast and chest wall. 
Radiation can also help alleviate symptoms and slow progression and is appropriate for 
use in patients of all ages, including those over 65.  Radiation therapy is administered 





usually four to six weeks after surgery as external beam radiation, where x-rays are 
delivered directly to either the whole breast or the lumpectomy surgical bed and chest 
wall in high risk patients (which includes those with close surgical margins, large tumors 
or lymph node involvement). Treatment is daily (5 days per week) for three to six weeks; 
shorter courses are occasionally used for patients with early stage disease.  Radiation can 
also be administered as an implant (brachytherapy) and can be used after whole breast 
irradiation. 86  
Partial breast irradiation (PBI) is now considered an option because recurrence is 
often found near the original lumpectomy surgical bed. The NCCN recommends that PBI 
only be used in patients with a low risk of recurrence.  Careful selection of patients is 
important to the success of PBI; appropriate patients would include those older than 45 
with unifocal, invasive ductal carcinoma that measures less than three cm with negative 
microscopic surgical margins and negative lymph nodes. Interstitial brachytherapy and 
inflatable balloon interstitial catheters are types of partial breast irradiation, however 
since brachytherapy requires an enormous amount of technical expertise, it is now done 
less frequently with the introduction of the balloon catheter method, which is now used 
extensively worldwide. PBI or brachytherapy is often used as a “boost” to the tumor bed 
in patients with an elevated risk of failure. These include patients younger than 50, 










Chemotherapy is a part of all treatment regimens for advanced disease and can be 
used in early disease as well. A general principle of cancer therapy is to tailor the 
chemotherapy choice to the type of cancer. Choice of chemotherapy can depend on 
whether the tumor is node-positive or node-negative, hormone receptor positive or 
negative or HER-2 positive or negative. In addition, different approaches are used 
depending on whether the patient presents with early or advanced disease.  Neoadjuvant 
chemotherapy is administered before surgery or radiation, and adjuvant is started after 
surgery but usually before radiation. Delaying chemotherapy for more than twelve weeks 
post-surgery increases the rate of recurrence and may increase mortality. Tables 1.11 and 
1.12 give the recommended chemotherapy regimens for the treatment of breast cancer.  88  
Classes of agents used in breast cancer are anthracyclines including doxorubicin 
(Adriamycin®) and epirubicin (Ellence®), which are used in regimens for both early and 
advanced disease.  Taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel 
(Taxotere®), appear to be particularly useful in node-positive disease, and Abraxane® is 
used as secondary treatment for advanced disease. Platinum agents including oxaliplatin 
(Eloxatin®) and carboplatin (Paraplatin®) are used in combination regimens for advanced 
disease and for cancers associated with BRCA genes.  Treatment regimens usually 








Table 1.11 Common Adjuvant Chemotherapy Regimens Used in Breast Cancer90 
 
Regimen Type Drugs and Sequencing 
Adjuvant-Preferred 
AC 
AC→ Paclitaxel  







Paclitaxel → FAC 
AC → Docetaxel  
AC → Paclitaxel  
EC 








AC→ Docetaxel + H 
Trastuzumab-Neoadjuvant Paclitaxel + H → CEF + H 
               See Appendix A for Regimen Abbreviations and Appendix B for Regimen 
  Schedules 
  
                                                 
90 Ibid. 
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Table 1.12 Common Metastatic Chemotherapy Regimens Used in Breast Cancer91 
 




















Docetaxel + Capcitabine 







Bevacizumab + Paclitaxel 
Combination- Other 
HER-2 (+) first Line 
Ixabepilone + Capcitabine 




Preferred for HER-2 (+) 
Trastuzumab  Exposed 
Lapatinib + Capcitabine 
H + Other First-Line 
H + Capcitabine 
H + Lapatinib 
   See Appendix A for Regimen Abbreviations and Appendix B for Regimen 
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1.3.6.4 Hormone Therapy 
 
NCCN guidelines state that estrogen receptor (ER) and progesterone receptor 
(PR) status should be determined in all primary invasive breast cancers. All patients who 
are ER or PR receptor positive should be offered adjuvant hormone therapy regardless of 
age, node status, or whether adjuvant chemotherapy is planned. There is evidence that 
some HER-2 positive tumors may be less sensitive to endocrine therapy, although these 
findings have yet to be confirmed.  The ATAC trial concluded that HER-2 positive status 
did render some patients resistant to endocrine therapies; however, since the side effect 
profile of endocrine agents is favorable, the recommendation remains to give endocrine 
therapy to patients whose tumors test ER or PR positive regardless of HER-2 status, pre- 
or post-menopause, or age. The exception is those patients with small tumors where there 
is little expected benefit with the addition of hormone therapy.  Pre-menopausal patients 
should have ovarian ablation or suppression followed by recommendations for 
postmenopausal patients, which include the use of: non-steroidal aromatase inhibitor 
(anastrazole or letrozole), steroidal aromatase inactivator (exemestane), fulvestrant, 
tamoxifen or toremifene, megesterol acetate, fluoxymesterone, or ethinyl estradiol. 




Trastuzumab is a monoclonal antibody with activity against the HER-2 receptor 
protein. The drug acts by binding a specific epitope of the HER-2 protein on the breast 
cancer cell surface. Once bound, the drug inhibits signal transduction that in turn inhibits 
cell growth. There are other proposed benefits such as reversal of resistance to endocrine 
                                                 
92 Ibid. 
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therapies and augmentation of both cellular and humoral immunity.  All patients 
diagnosed with breast cancer undergo HER-2 testing to select those who might benefit 
from the addition of trastuzumab to other regimens. Patients with metastatic disease who 
have a high level of HER-2 over-expression are likely to be sensitive to trastuzumab and 
see increased survival. There is also accumulating evidence that patients with earlier 
stage HER-2 positive disease can also benefit from the addition of trastuzumab in the 
adjuvant setting, giving up to a 50% reduction in recurrence. Current recommendations 
are that if patients test a 3+ IHC staining or amplified HER-2 genome copy number by 
FISH, they receive trastuzumab in the adjuvant or metastatic setting. 93 
 
1.3.7 RESPONSE TO THERAPY 
 
Tumor response after administration of anti-cancer agents is evaluated for at least 
three purposes and those include: tumor response as a prospective end-point in an early 
clinical trial, as an end-point in a more definitive clinical trial, and as a guide for the 
clinician/study subject regarding the continuation of treatment.  94 There are criteria used 
to quantify how a patient responds to treatment, including the response evaluation criteria 
in solid tumors (RECIST) 95 and the South West Oncology Group (SWOG) response 
criteria, endpoint definitions and toxicity criteria. 96 
The RECIST guidelines are a voluntary international standard used to assess the 
response to treatment of measurable disease and are a simplification of other response 
                                                 
93 Ibid. 
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criteria (i.e., ECOG and WHO). Table 1.13 lists the response criteria in the RECIST 
guideline. 97 There are plans to improve the RECIST guidelines to incorporate dynamic, 
functional contrast and volumetric imaging. There are hopes that the use of these more 
advanced imaging methods can be used as surrogate end points in clinical trials with the 
expectation that in future trial settings fewer patients would be required and this would 
improve efficiency in getting newer agents approved. 98  
 
Table 1.13 RECIST Response Criteria99 
 
Response  Criteria 
Complete 
Response (CR) Disappearance of all target lesions 
Partial Response (PR) 30% decrease in the sum of the longest diameter of target lesions 
Progressive 
Disease (PD) 
20% increase in the sum of the longest diameter of target 
lesions 
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The SWOG criteria are more applicable to patients in the trial setting and 
differentiate between disease status and objective status. 100 Disease status can fall into 
one of three categories, measurable disease, evaluable disease, and non-evaluable disease. 
Measurable disease is defined as lesions with clearly defined margins that can be 
measured either with a plain photograph or x-ray to be ≥ 0.5 cm, palpation with diameters 
greater than 2 cm, CT, MRI or other imaging that shows a diameter greater than the cuts 
of the scan. Evaluable disease is defined as lesions with more poorly defined margins, 
lesions with diameters < 0.5 cm, lesions on imaging that have diameters less than the cuts 
of the scan, palpable masses with diameters < 2 cm or bone disease. Non-evaluable 
disease is that which is documented with indirect evidence only (i.e. lab values) such as 
pleural effusions or ascites.  If the patient has too many lesions to measure, then three are 
followed and the rest are considered in the objective status.101 
The objective status considers all lesions, not only the largest lesions, which are 
used to determine the disease status. A complete response (CR) is obtained when all 
evidence of measurable and evaluable lesions disappears, the patient is absent of any 
disease related symptoms and there is no evidence of non-evaluable disease.  All 
measurements must be repeated with the same method used to obtain initial assessment 
of disease status. Partial response (PR) is a ≥ 50% decrease in sum total of all baseline 
criteria (i.e., diameter of all measurable lesions) without progression and no new lesions. 
A partial response in non-measurable disease (PRNM) is disease specific. Progression (P) 
is when there is a 50% increase or an increase of 10 cm whichever is smaller in the sum 
total of all lesion diameters or a clear progression in evaluable disease, or reappearance of 
                                                 
100 Green and Weiss, “Southwest Oncology Group Standard Response Criteria, Endpoint 
Definitions and Toxicity Criteria.” 
101 Ibid. 
 44 
a lesion that has disappeared, or appearance of new lesion, or death.  The patient may 
have unknown response because it could not be evaluated. Stable or No response is 
disease that does not qualify for CR, PR or P. 102 
Performance status can be used as a surrogate to other, more objective, findings to 
indicate a patient’s disease progression and potential prognosis. These measures could 
also be considered a proxy to determine if patients are tolerating treatment and if the level 
of their disease is affecting their ability to perform activities of daily living. 103 Examples 
of scales used to measure a patient’s performance status include the Eastern Cooperative 
Oncology Group (ECOG) Performance Status, which is also known as the WHO or 
Zubrod scale, and the Karnofsky Performance Status (KPS). 104  
The Eastern Cooperative Oncology Group (ECOG) has a scale (Table 1.14) that 
was developed in 1982 and is still commonly used by physicians and researchers to 
assess how a patients’ disease is progressing, assess how the disease is affecting activities 
of daily living and determine appropriate treatment and prognosis. The scale focuses on 
activity the patient is capable of doing; therefore, if the patient is hospitalized for an 
unrelated reason and can still carry on pre-disease performance, then that patient would 
be given a grade of zero. 105 
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Table 1.14 ECOG Grades and Criteria for Performance Statuses106 
 
Grade ECOG Criteria 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary nature, 
e.g., light house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry 
out any work activities. Up and about more than 50% of 
waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
ECOG: Eastern Cooperative Oncology Group 
 
 
The Karnofsky Performance Status (KPS) instrument was developed in the 1940’s 
and is commonly used as a proxy measure for a cancer patient’s quality of life, although 
the scale does not meet contemporary criteria to be considered a QOL measure. It allows 
patients to be classified according to their functional impairment and can give a sense of 
prognosis and appropriateness for treatment. The scale ranges from zero to 100, where 
100 represents perfect health and zero represents death. It can be used as a subjective 
measure of a therapy’s effectiveness and prognosis where lower scores indicate a poorer 
                                                 
106 Oken et al., “Toxicity and Response Criteria of the Eastern Cooperative Oncology Group.” 
 46 
outcome.  (Table 1.15)107 The KPS is similar to the Global Assessment of Functioning 
(GAF) in the DSM-IV. 108 There are also several modified indices that are used to make 
the scale more relevant to today’s practice. The Thorne-Modified KPS focuses on 
community based care and is more relevant to palliative care practices. The Australian 
Modified KPS is a hybrid of original KPS and the Thorne-Modified KPS. 109 
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Table 1.15 Karnofsky Performance Status Scale (KPS) Definitions and Rating (%) 
Criteria110 
 
Definition Score Original KPS Criteria 
Able to carry on normal 
activity and to work; no 
special care needed 
100 Normal no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
80 Normal activity with effort; some signs or symptoms of disease. 
Unable to work; able to 
live at home and care 
for most personal needs; 
varying amount of 
assistance needed. 
70 Cares for self; unable to carry on normal activity or to do active work. 
60 Requires occasional assistance, but is able to care for most of his personal needs. 
50 Requires considerable assistance and frequent medical care. 
Unable to care for self; 
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly. 
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is indicated although death not imminent. 
20 Very sick; hospital admission necessary; active supportive treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
0 Death 





The NCCN has guidelines for follow-up for those patients treated in Stages 0-3 
and for initial workup for stage four. 111 This includes an interval history and physical 
exam every four to six months for the first five years, then annually. During that office 
visit, the patient will likely have lab work performed including: complete blood count 
(CBC), platelets, and liver function tests (LFT’s).  They can expect periodic radiologic 
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procedures as well, which typically include chest x-rays, bone scans, and x-rays of any 
bones experiencing symptoms or long weight-bearing bones appearing abnormal on bone 
scan. Abdominal CT or PET scan can be performed although it is generally not 
encouraged unless other studies have suspicious or equivocal results. Patients will be 
advised to get a mammogram every 12 months starting 6 - 12 months after radiation for 
those patients who elected to have breast conserving surgery. Women who are taking 
tamoxifen are advised to have a gynecological exam annually if they have an intact 
uterus, and women who are taking aromatase inhibitors or those who experience ovarian 
failure due to treatment need to have a bone density scan at baseline and be monitored 
periodically.  112 
ASCO also has a guideline for surveillance. They recommend that patients return 
for an exam every 3 to 6 months for three years, every 6 - 12 months for two years, then 
annually thereafter.  In addition, ASCO recommends monthly self-exams and annual 
mammograms; however, they do not recommend laboratory or radiological tests during 
routine surveillance. 113 Additionally, if patients present with recurrent disease, they may 
have additional biopsies and HER-2 and ER/PR receptor status testing if status was 
originally unknown or negative. 114  
 A recent Cochrane review concluded that surveillance of patients (in stage I, II or 
III disease) using intensive measures (i.e. laboratory tests and radiological procedures) 
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did not yield significant improvements in mortality and thus, cannot be recommended. 115 
Contrary to that review, it is still common to tailor follow-up much in the same way 
initial therapy is individualized. 116  
 
1.3.9 DISEASE RECURRENCE 
 
Recurrence is most often seen within five years but may present as late as ten 
years after initial diagnosis. 117 The risk of recurrence is proportional to the grade and 
stage of tumor at initial diagnosis and is reduced by appropriate therapy. Further 
evaluation is indicated in patients presenting with non-specific symptoms including 
reports of new bone pain, shortness of breath, or neurological symptoms or if patient 
presents with jaundice. 118 Symptoms suggestive of recurrence include: change in chest 
wall, adenopathy, weight loss, persistent cough, cardiopulmonary symptoms and 
musculoskeletal pain. 119 Additional blood, radiological procedures or tumor-marker 
testing is not recommended in patients who are asymptomatic, in fact, this often leads to 
false-positives, which increase anxiety and stress along with overall treatment costs. 120  
If there is a recurrence of disease, the patient receives the same treatment as a 
patient diagnosed with stage 4 breast cancer, where therapy choices depend on whether 
there is local or systemic disease. Local disease in recurrence is treated much the same as 
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earlier stage disease, where initially the patient will receive some type of surgical 
intervention to reduce tumor burden. This choice depends on the initial surgery 
performed, where patients who elected for lumpectomy or breast conserving surgery will 
undergo a mastectomy and will have axillary node dissection if it was not previously 
done. Patients who already had a mastectomy, resection of the tumor will be performed if 
possible. Additionally, patients who did not have prior radiation will undergo radiation on 
recurrence. All patients will be considered for additional systemic therapies. The choice 
of therapy will depend on what the patient initially received, in addition to their hormone 
receptor and HER-2 status. 121 
Patients who are hormone receptor positive will receive some type of endocrine 
therapy with or without ovarian ablation. This therapy will continue until progression or 
there is unacceptable toxicity. Chemotherapy is considered if the patient has had three 
consecutive failed courses of endocrine therapy or presents with symptomatic visceral 
disease. If hormone receptor positive patients are also HER-2 positive, they will likely 
receive trastuzumab. Patients who are hormone receptor negative or refractory may 
receive a trial of endocrine therapy with chemotherapy.  Chemotherapy is continued until 
there is no response to three sequential regimens or the patient’s ECOG performance 
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1.3.10 NON-CARDIAC CONSEQUENCES OF THERAPY 
 
Surveillance of patients at the conclusion of treatment serves a number of 
purposes. Those include the detection of recurrent disease, the detection of a second 
primary tumor, and management of short and long term side effects. 123 Breast cancer 
treatment, similar to the treatment of any disease, is not without consequences.   
Consequences of therapy can be divided into local and systemic effects, both with unique 
risk factors. The adverse effects that are experienced by patients can range in severity, 
which is commonly related to the quantity of the offending therapy the patient received. 
Detection of effects can be monitored in a number of ways which can include physical 
exams, laboratory tests, and radiological procedures.  124  
Treatment recommendations for breast cancer include the use of both local 
(surgery/radiation) and systemic (cytotoxic and/or hormonal) therapies. 125 Local 
therapies include surgery and radiation, both of which are mainstays of breast cancer 
treatment. Effects from surgical intervention have been reported in patients up to 20 years 
after the procedure. The primary negative effect reported is lymphedema, which occurs as 
a result of lymph node removal. Risk of lymphedema is related to the extent of the lymph 
node dissection that is performed (i.e., risk is higher if all nodes are removed). The extent 
of node removal is typically dependent on whether metastatic disease is detected in the 
sentinel lymph node examination. 126 Other consequences related to surgery include 
seroma formation (can be prevented by leaving drains in place), pain, numbness, 
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limitations in range of motion, and weakness. These are often related to the type of 
surgery performed. 127 
Consequences of radiation treatment that was performed with outdated 
techniques, involved an increase in death from cardiac causes, however, this has 
decreased significantly with newer techniques.  There is no shown increase in cardiac 
toxicity in women who receive standard doses of anthracyclines; however, this risk 
increases as cumulative anthracycline dose also increases. 128 
Immediate effects of radiation therapy include nausea, vomiting, and fatigue, all 
of which typically get worse as treatment progresses. Short term side effects of radiation 
include pigmentation changes, skin burns, decreased range of motion and swelling of the 
arm on the affected side, and mild myelosuppression. The long term effect from radiation 
is the increased risk of other malignancies (more common in younger patients), rare 
occurrences of lung scarring.  Malignancies after radiation therapy can include 
contralateral breast cancer, sarcoma, leukemia and myelodysplasias, ipsilateral lung 
cancer, and esophageal cancer.129 Other effects include: pneumonitis, rib fracture, 
brachial plexopathy, and myocardial infarction. Additionally, women who receive 
radiation to the axilla after axillary dissection are at increased risk of lymphedema. All of 
these effects are decreased in patients receiving PBI as opposed to WBI.  130  
  






Table 1.16 Common Complications of Local Breast Cancer Treatment and 
Corresponding Risk Factors 131 
 
Complication Risk Factor 
Common (Affecting > 10% of Patients) 
Pain or numbness in breast, chest wall, or 
axilla Greater extent of surgery 
Arm swelling or lymphedema 
Greater extent of axillary surgery, 
weight gain, obesity, radiation therapy 
or infection 
Restriction of arm motion or weakness Greater extent of surgery, radiation therapy, recent surgery 
Re-operation after breast-implantation 
reconstruction Radiation therapy 
Uncommon (Affecting 1 - 10% of Patients) 
Cellulitis Radiation, seroma 
Plexopathy or Nerve Damage Higher dose of radiation or larger field 
Contralateral Breast Disease 
Familial or hereditary breast cancer, 
younger age at diagnosis, higher dose 
of radiation or larger field 
Increased Risk of Heart Disease 
Left-sided radiation with older 
techniques, anthracycline-based 
chemotherapy 
Pneumonitis Larger radiation field, older age, chemotherapy 
Rib Fracture Higher dose of radiation or larger field 
Rare (affecting < 1% of patients) 
Secondary Cancers (other than breast) Lymphedema, radiation therapy 
Arterial Insufficiency Radiation therapy 
Pulmonary Fibrosis Radiation therapy 
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Systemic therapies used include chemotherapy, endocrine therapy, and targeted 
agents; each therapy has its own unique adverse effect profile.132 The use of systemic 
agents in breast cancer is individualized where treatment regimens are selected based on 
a patients stage at diagnosis, node status, HER-2 status and estrogen/progesterone 
receptor status, therefore, a wide range of effects could be experienced by each patient. 
133 Chemotherapy has a number of consequences, some subside at the conclusion of 
treatment while others can appear months to years after treatment has concluded.  
Common side effects of virtually all chemotherapy agents include gastrointestinal issues 
(such as nausea, vomiting and stomatitis), reduced white blood cell and platelet counts, 
infections, and alopecia. 134  
Premature ovarian failure is a risk with a number of different chemotherapy 
agents; the risk varies with the regimen received, cumulative dose and the age of the 
patient. Ovarian failure is common in patients over 40 years of age with the incidence 
ranging from 80 to 95% but rarely occurs in women under the age of 30 with an 
estimated incidence of 19%. Ovarian failure and subsequent premature menopause is a 
result of decreased circulating estrogen and progesterone levels and increased follicle 
stimulating hormone and luteinizing hormones, these changes are consistent to those seen 
in naturally occurring menopause. 135 Although, pregnancy post-therapy has not been 
shown to affect breast cancer prognosis, it is common for clinicians to recommend that 
patients wait two to three years after the conclusion of therapy as this is the time disease 
recurrence is highest. 136 
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Survivors of breast cancer theoretically are at a lower risk of developing 
osteoporosis because of the role estrogen plays in disease development, it also acts to 
increase bone density, however, patients experiencing premature ovarian failure 
experience bone loss similar to menopausal women.137 Hot flashes, coupled with 
osteoporosis, are experienced secondary to premature ovarian failure. Not unlike hot 
flashes experienced by women without breast cancer, these can profoundly affect health-
related quality-of-life. Hot flash symptoms in patients with breast cancer can be treated 
similarly to those experienced by other patients. Agents often used include 
antidepressants such as fluoxetine and venlafaxine, both of which come with their own 
side effects. 138 
Myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) are 
both rare but are reported consequences of treatment with certain chemotherapy agents 
(e.g., alkylating agents and topoisomerase II inhibitors). Leukemia can present as soon as 
six months after the conclusion of therapy with reports of AML up to five years post 
chemotherapy.  Patients with MDS usually present between five and seven years after the 
conclusion of therapy. Risk of both AML and MDS appears to be dose dependent, and 
women who receive an anthracycline-based regimen appear at greater risk than those who 
receive standard dose CMF. 139 
Other effects that are more anecdotal and not well documented are cognitive 
impairment, weight gain, and depression.  Cognitive impairment has been reported in a 
number of smaller trials; however, because of differing methodology and assessment 
techniques, estimating an actual incidence or risk factors for developing cognitive 
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impairment is difficult.140 Weight gain is common in women receiving adjuvant 
chemotherapy.  The mechanism is not known but it has been shown not to be the result of 
excess caloric intake, although, the gain is from fat weight alone without proportional 
gain in lean body mass (sarcopenic obesity). It has been suggested that this may be due to 
decreased physical activity. 141 
Side effects of endocrine therapies vary depending on the specific agent given. 
Tamoxifen usage has a number of side effects that are attributed to a mixed estrogen 
agonist/antagonist activity. These include menopausal symptoms (night sweats, hot 
flashes, vaginal dryness, and irregular menses), thromboembolic events (DVT), 
thrombocytopenia or leucopenia, ocular toxicity, risk of endometrial cancer, and risk of 
teratogenicity.  Although there is an increase in risk in endometrial cancer with tamoxifen 
use, the risk is half when compared to the absolute decrease in contralateral breast cancer. 
142 
Aromatase inhibitors have several side effects in common with tamoxifen, 
however, in lower frequencies. Those include hot flashes, venous thromboembolic 
events, endometrial cancer and vaginal bleeding. Anastrazole does have additional side 
effects, those include: increased rate of bone fractures, development of benign ovarian 
pathologies, osteoporosis and musculoskeletal symptoms. 143 
Targeted agents are used in specific patients with breast cancer based on specific 
genetic parameters. Trastuzumab adverse effects include infusion reactions (fever, chills, 
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rash), headache, diarrhea and cardiac toxicity.  Infusion reactions are usually prevented 
with pre-treatment with corticosteroids and antihistamines. 144 
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Table 1.17 Common Consequences of Systemic Breast Cancer Therapy with Corresponding Risk Factors and 
Interventions 145 
 
Symptom Risk Factors Screening Interventions 





Chemotherapy, Menopause or Altered 




Non-Hormonal Products for 
Dyspareunia 
Arthralgias or 
MS Symptoms Tamoxifen or Aromatase Inhibitors History 
APAP 
NSAIDS 
Cognitive Dysfunction Chemotherapy, Tamoxifen or Aromatase Inhibitors History 
If Progressive, Evaluate for 
Alzheimer’s Disease 
Fatigue Chemotherapy, Tamoxifen or Aromatase Inhibitors History 
Rule-Out or Treat Psychiatric or 
Biologic Cause (Depression, 
Anemia, Hypothyroidism) 
Weight Gain Tamoxifen or Aromatase Inhibitors History Usual Management 
Osteoporosis/Osteopenia Chemotherapy- Induced Menopause, Tamoxifen or Aromatase Inhibitors 
Bone Density Testing Prior to 
Initiation and Every 1 - 2 Years 
Thereafter 
Usual Management 
Thromboembolic Events Treatment with Tamoxifen History 
No Proven Prophylaxis, 
Appropriate Medical Management 
if Present 
SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Serotonin-Norepinephrine Reuptake Inhibitor;   APAP: Acetaminophen; NSAIDS: Non-
Steroidal Anti-Inflammatory Drugs; MS: Musculoskeletal 
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1.3.11 OUTCOMES/MORTALITY/ PROGNOSIS 
 
Breast cancer is the second most deadly cancer in women (second to lung cancer); 
however, with increased screening, which had led to earlier diagnosis, mortality is 
decreasing. 146 The overall five-year survival for women with cancer of any type is 80%; 
in contrast, 88% of women with breast cancer will survive ten years or more. 147 The 
clinical course of breast cancer varies widely between patients, so the prognosis of 
patients is an important part of the decision-making process regarding therapeutic 
options.   
There have been several prognostic or predictive factors that have been identified; 
these are useful in determining outcomes such as recurrence or death, and can give 
information about how well patients will respond to specific therapies.  148 There are 
predictive and prognostic factors in each of three categories which are patient 
characteristics, disease characteristics, and biomarkers. These can include location of the 
tumor and how far it has spread, hormone receptor status, tumor markers, gene 
expression, tumor size and shape, and rate of cell division. 149 Disease characteristics that 
affect prognosis include tumor size, lymph node status, histological subtype, nuclear or 
histologic grade, lymphatic or vascular invasion, and proliferation indices. Both the 
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Table 1.18 Breast Cancer Five-Year Survival Rates (%) Based on Tumor Size 
 and Axillary Lymph Node Status151 
 
 
Tumor Size: < 2cm 2 - 5cm > 5cm 
Negative 96 89 82 
1 – 3 Positive 87 80 73 




Patient-related factors are independent of disease. Those affecting prognosis 
include age and race. Younger patients, especially those under the age of 35, typically 
present with more aggressive disease and have a poorer prognosis. African-American 
women have a higher mortality when compared to whites, which is usually attributed to 
decreased access to care, resulting in presentation at a more advanced disease stage, 
which subsequently affects the success of treatment.  Additionally, black, American-
Indian, or Hispanic women are often diagnosed with more advanced disease which also 
has a negative effect on mortality. 152 
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Table 1.19 Breast Cancer Mortality Rates in Females by Race from 2002 to 2006153 
 
 




Asian/Pacific Islander 12.5 
American Indian/Alaska Native 17.6 
Hispanic 15.5 




Table 1.20 Five-Year Relative Survival Rate by Estimated Stages at Diagnosis 154 
 
 
Stage Percentage of Cases 5-Year Survival 
Localized  (I and II) 60 98.3 
Regional  (II and III) 33 83.5 
Distant  (IV) 5 23.3 
Un-Staged 2 57.7 
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Hormone receptor status is not thought of as a prognostic factor, but usually, this 
is used for gauging response to hormone manipulation therapy, therefore is indirectly 
related to prognosis. Approximately 75% of breast cancer tumors are estrogen receptor 
positive, and about 65% of these are progesterone receptor positive. Cells that are 
positive to either one or both are considered hormone-receptor positive.  If tumors are 
hormone-receptor positive, they are considered hormone sensitive since they respond to 
hormone therapy.  Women with hormone-sensitive tumors have a better prognosis 
because these tumors grow more slowly than hormone-receptor negative tumors. The 
largest decline in mortality rates are seen in women with HR positive tumors due to the 
addition of hormone therapy. 155 HER-2 over-expression, in contrast to hormone receptor 
status, does give an indication of prognosis. HER-2 is often associated with more 
aggressive disease, higher rates of recurrence and mortality. 156 
Overall, lymph node status and tumor size are the two most important prognostic 
and predictive factors to assist in therapy decisions.  There are computer-aided models 
(e.g., adjuvantonline.com) that can incorporate the individual factors with tumor related 
variables to assist in predicting prognosis and help in the selection of therapy for early 
stage disease. 157 
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1.4 Heart Failure 
Generally speaking, heart failure is a clinical syndrome in which the heart is 
unable to pump a sufficient amount of blood to the rest of the body to meet metabolic 
needs. This can result from any condition that reduces ventricular filling or myocardial 
contractility (ventricle is either unable to fill with or pump blood), however common 
causes are hypertension and coronary artery disease.  Therefore, heart failure can be 
considered an end to a number of pathways from other cardiac disorders that affect 
valves, pericardium and myocardium. Heart failure can result from any disorder that 
affects the heart’s ability to contract or relax, and these can be disruptions of filling, 
contraction or both. The syndrome is progressive and its primary symptoms include 
dyspnea, fatigue and fluid retention. 158  
 
 
1.4.1 DISEASE PROCESS 
 
Heart failure usually begins with a myocardial injury; this can be an acute event 
such as a myocardial infarction or could be the result of a chronic disorder such long-
term uncontrolled hypertension. Whether acute or chronic, the decreases in cardiac output 
causes activation of compensatory mechanisms, which attempt to maintain normal 
cardiac output. One compensatory mechanism includes activation of the sympathetic 
nervous system and this is meant to increase heart rate and contractility. Additionally, the 
Frank-Starling mechanism compensates for decreased cardiac output by increasing stroke 
volume. The increased stroke volume results in vasoconstriction and ventricular 
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hypertrophy, subsequently leading to cardiac remodeling. The compensation is meant to 
be short term; however, the sustained activation of these systems is what causes the 
progression of the disease.  159 
The signs and symptoms of heart failure are a result of the activation of all of the 
compensatory mechanisms. However, ventricular hypertrophy and remodeling are 
considered the cause of disease progression. Ventricular hypertrophy basically means that 
there is increased muscle mass and remodeling refers to alterations in cellular structure of 
the myocardial and extracellular matrix which result in changes to size, shape, structure 
and function of the heart. This occurs as a result of any condition that can cause 
myocardial injury including, but not limited to, myocardial infarction, hypertension, 
valvular disease and cardiomyopathy.  Remodeling starts before the manifestation of 
symptoms, it continues after symptoms develop, and usually is responsible for the 
progression of symptoms. 160 
Remodeling occurs at many levels in the heart and is an extremely complex 
process (Figure 1.1) The progression of the process leads to additional compensation, 
which results in greater reductions in myocardial systolic and diastolic dysfunction, 
which causes greater injury, which leads to further compensatory activation.  Systemic 
and local release of endogenous neurohormones such as vasopressin, norepinephrine, 
angiotensin II, aldosterone, and pro-inflammatory cytokines are considered the key 
elements in the ventricular remodeling process. 161  
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Heart failure is a progressive condition and there are a number of classification 
systems that outline this progression, these typically begin with risk factors and progress 
through worsening of symptoms. The American College of Cardiology (ACC) and the 
American Heart Association (AHA) have a grading system with four stages progressing 
from A to D. 163 These illustrate the progression of disease from risk factors to end-stage 
refractory disease. In contrast, the New York Heart Association (NYHA) has a 
classification system that is widely used and familiar to most clinicians. The NYHA 
classification essentially stratifies patients on their functional ability or level of 
symptoms. 164 Similar to the ACC/AHA system there are four categories from ranging 
from I to IV. The ACC/AHA classification is meant to supplement, not replace the 
NYHA heart failure classification. Since the NYHA classification is based on symptoms, 
patients in all four NYHA functional classes would correspond to ACC/AHA Stage C or 
D.  165 
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Table 1.21 ACC/AHA Heart Failure Classifications 166 
 
Stage Characteristics 
A High risk for heart failure without structural heart disease or symptoms 
B Heart disease with asymptomatic decrease in left ventricular ejection fraction 
C Prior or recurrent symptoms of heart failure 
D Refractory end stage heart failure 
 ACC: American College of Cardiology; AHA: American Heart Association 
 
Table 1.22 NYHA Heart Failure Classifications 167 
 
Class Symptoms 
I Patients with cardiac disease but without limitations of physical activity, ordinary physical activity does not cause dyspnea, fatigue, or palpitations 
II 
Patients with cardiac disease that results in slight limitations of physical 
activity, ordinary physical activity results in dyspnea, fatigue, palpitations or 
angina 
III 
Patients with cardiac disease that results in large marked limitation of physical 
activity, although patients are comfortable at rest, less than ordinary will lead 
to symptoms 
IV 
Patients with cardiac disease that results in the inability to carry on physical 
activity without discomfort, symptoms of heart failure are present at rest, with 
any level of physical activity symptoms is experienced  
 NYHA: New York Heart Association 
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Treatment choices often depend on the etiology and stage. (Figure 1.2) Prior to 
initiation of drug therapy, it is important to remove any precipitating factors and identify 
risk factors. Those with causes such as hyperthyroidism, often do not need traditional 
heart failure therapies after the underlying condition is resolved. Similarly, those patients 
with correctible mechanical issues such as valvular disorders can often have heart failure 
corrected with valve replacement surgery, if diagnosed early enough.  
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Figure 1.2 Stages and Corresponding Interventions in the Development of Heart Failure168 
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Symptomatic improvement is seen with the use of diuretics to decrease the 
volume overload, and nitrates, hydralazine or calcium channel blockers to reduce angina.  
Remodeling is addressed at a number of junctures in the pathway with the use of 
angiotensin-receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACE 
inhibitors), beta blockers, aldosterone receptor antagonists and digoxin (use of digoxin, 
although historically important, has fallen out of favor because of the substantial number 
of drug interactions, risk of toxicity and lack of mortality benefit). Each medication has 
specific indications for use, as well as contraindications, according to available published 
guidelines. Therapy needs to be individualized for each patient. Although use of these 
therapies has been shown to slightly decrease mortality and improve symptoms, 
progression of disease is inevitable. In patients with refractory disease, transplantation or 
mechanical circulatory assist devices (e.g., LVAD, left ventricular assist device) may be 
considered. LVAD therapy is occasionally used as a type of bridge to transplantation.  
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Table 1.23 Indications for Cardiac Transplantation Stratified by Levels of Evidence170 
Absolute 
For Hemodynamic compromise due to HF 
Refractory Cardiogenic Shock 
Documented dependence on IV Inotropic support to maintain adequate organ perfusion 
Peak VO2 less than 10 mL per kg per minute with achievement of anaerobic metabolism 
Severe symptoms of ischemia that consistently limit routine activity and are not amenable to CABG or PCI 
Recurrent symptomatic ventricular arrhythmias refractory to all therapeutic modalities 
Relative 
Peak VO2 11-14 mL per kg per minute (or 55% of predicted) and major limitations of ADL’s 
Recurrent unstable ischemia not amenable to other intervention 
Recurrent instability of fluid balance or renal function not due to patient non-compliance with medication regimen 
Insufficient 
Low LVEF 
History of NYHA Functional Class III or IV symptoms 
Peak VO2 greater than 15 mL per kg per minute (and greater than 55% predicted without other indications) 
HF: Heart Failure; IV: Intravenous; kg: kilogram; CABG: Coronary Artery Bypass Graft; PCI: Percutaneous Coronary Intervention;      
ADL’s: Activities of Daily Living 
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Therapy goals and choices in medications are aimed at decreasing symptoms, 
reversing the ventricular remodeling process and controlling co-morbid conditions such 
as hypertension, diabetes, angina and arrhythmias. (Table 1.24)  171 
 
Table 1.24 Treatment Objectives for Chronic Heart Failure172 
 
Goal Potential Outcomes 
Improve Prognosis Reduction in Mortality 
Reduce Morbidity 
Relieve Signs and Symptoms 
Improve Quality of Life 
Eliminate edema and fluid retention 
Increase exercise capacity 
Reduce Fatigue and Breathlessness 
Reduce Need for Hospitalizations 
Provide for end of life care 
Increase Prevention 
Decrease Occurrence of Myocardial Damage 
Prevent Progression of Myocardial Damage 
Reverse Remodeling of the Myocardium 
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1.4.4 OUTCOMES/ ASSESSMENT OF THERAPY 
 
There are three main monitoring parameters needed in the ongoing assessment of 
heart failure patients. Those include periodic monitoring of 1) functional capacity, 2) 
volume status and 3) laboratory evaluations. Functional capacity is usually determined by 
the reporting of the presence and severity of symptoms by the patient. When assessing 
patient reports of symptoms it is important to ask specific pointed questions regarding 
what symptoms they are experiencing (i.e., “are you experiencing shortness of breath”) as 
opposed to asking in general, if they are/are not experiencing symptoms. 173 
Volume status is controlled by the appropriate use of diuretic therapy and directly 
affects the hallmark signs and symptoms of heart failure. There are objective measures 
performed during a routine physical exam that can be used to assess volume status, those 
measures include: patient weight, jugular venous distention (JVD), presence of 
hepatojugular reflex, presence of pulmonary congestion and peripheral edema. Symptoms 
suggestive of volume overload include increasing dyspnea with or without exertion, 
nocturia, and paroxysmal nocturnal dyspnea. Blood pressure is an indirect indicator of 
volume overload and should be monitored in patients with or without underlying 
hypertension. 174  
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Laboratory monitoring should include regular serum electrolytes and renal 
function (including BUN). Elevated potassium levels may occur with the use of 
aldosterone receptor antagonists, ACE inhibitors and ARBs, which subsequently can 
predispose patients on digoxin to toxicity. Renal function is an additional monitoring 
parameter important in diuretic use and can be used indirectly to assess the efficacy of 
ACE inhibitors or ARBs, which are often used to preserve renal function.175  
 
Table 1.25 Important Assessment Criteria During Routine Follow-Up176 
 
Clinical Parameters Educational Parameters 
Functional Capacity and Activity Level Patient’s Understanding of/Compliance with Dietary Sodium Restriction 
Changes in Body Weight Patient’s Understanding of/Compliance with Medication Regimen 
History of arrhythmia, syncope, pre-syncope, 
palpitations 
Adherence and response to therapeutic 
interventions 
The presence or absence of exacerbating 
factors for HF  
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Heart failure is usually associated with a disease course that involves frequent 
hospitalizations (risk for readmission is highest immediately following prior admission), 
poor prognosis, a complex medication regimen and diminished quality of life.  Because 
HF is a syndrome as opposed to a primary diagnosis, there are often co-morbid 
conditions that can complicate treatment, or worsen prognosis, even if LV dysfunction 
has remained clinically stable or slightly improved. Co-morbidities are extremely 
important to consider when treating heart failure patients, both coronary artery and 
diabetes are well studied co-morbidities that have been shown to increase mortality in 
heart failure patients. 177 
The ability to accurately predicting prognosis would not only useful to the 
clinician but also to patients and their caregivers, unfortunately, this is difficult and 
unreliable. In attempting to determine a patients prognosis one must consider disease 
etiology, rate of disease progression and co-morbidities. Benefits of using a prediction 
model could include: communicating realistic expectations to patient and/or 
family/caregivers regarding disease progression, goals of therapy and prognosis, assist in 
making decision regarding the use of devices and/or transplantation/surgical options, 
potentially assist in selecting therapies to positively enhance HRQOL and mortality. 178 
The flip side is that the models were developed in specific study populations and 
care must be taken when using to make patient level predictions- this may be difficult for 
providers to communicate the uncertainty involved to patients and their families and/or 
caregivers, patient specific behaviors like regimen compliance, preference and patient 
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attitudes are not incorporated, as newer therapies become available-models may become 
obsolete. 179  
Models are meant as a supplement, and never a replacement for the judgment of 
the specialist or management team. 180 From the available models, there have been a 
number of variables that can be used as surrogates to assist in predicting prognosis. 
Variables that have been described as correlating with prognosis include progressing 
NYHA functional status; decreasing LVEF, anemia, and resistance to therapy (Table 
1.26) 181 High levels of circulating neurohormones (norepinephrine and endothelin) are 
highly correlated with increased mortality; however, they are not easily measured and are 
more applicable to the research setting. 182 
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Table 1.26 Key Prognostic Parameters and Mode of Assessment in Heart Failure 183 
 






Hyponatremia Decreasing LVEF 
Intolerance to 
Conventional Therapy Resting Tachycardia 
Decreasing 
Hematocrit Widened QRS 
Refractory Volume 




NYHA: New York Heart Association; LVEF: Left Ventricular Ejection Fraction    
 
There are a number of examples of prediction models that can be used in patients 
with heart failure. Models commonly seen in the literature include The Effect Model 
(also known as the Heart Failure Risk Scoring System), The Seattle Heart failure model 
(SHFM), and the Heart Failure Survival Score (HFSS). When using models, clinicians 
must remember that these variables were derived statistically from larger heart failure 
populations, which may have included specifically recruited study participants, and must 
use care in using these to predict outcomes for individual patients. 184 
The EFFECT Model (or heart failure risk scoring system) was developed from a 
population of hospitalized patients and its use is intended as such.  This model uses a 
number of variables to predict 30-day and one-year mortality. Those include both heart 
failure related and co-morbidity data. Each predictor is assigned points and points are 
then summed. The sum corresponds to categories of risk that range from “very low”      
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(< 60 points) to “very high” (> 150 points). There is an online calculator for the Effect 
Model available at www.ccort.ca/CHFriskmodel.aspx that is supported by the Canadian 
Cardiovascular Outcomes Research Team (CCORT). When using the online calculator, 
the user needs to select whether they are using U.S. or S.I. units, enters the patients age,  
RR and SBP at presentation, BUN, whether serum sodium is < 136 mEq/L (yes or no),  
select whether there are co-morbidities present such as dementia, cerebrovascular disease, 
malignancy, COPD, anemia, or hepatic cirrhosis. Once calculated the uses then refers to 
the corresponding tables for 30-day and one-year risk.  185 
The Heart Failure Survival Score was developed and validated in ambulatory 
patients, all of which were in NYHA stages III or IV and being considered for cardiac 
transplantation. Variables used to derive the score include LVEF, peak VO2, resting HR, 
mean arterial blood pressure, presence or absence of CAD, presence or absence of 
interventricular conduction delay on ECG, and serum sodium (there is an invasive 
version that includes PCWP in the calculation). The sum is multiplied by a defined 
coefficient and the result ranks patients into low, medium and high risk categories.  The 
HFSS was meant to assist in selecting patients for transplant; however, it was developed 
long before many current therapies were developed that improve survival. 186 
The Seattle Heart Failure Model (SHFM) has benefits over the previous two 
models in that is was developed and validated in a broader population and includes more 
readily available variables such as medications and devices. The SHFM is available 
online for use by healthcare professionals (www.seattleheartfailuremodel.org).  The user 
enters baseline demographics of the patient such as age, gender, NYHA functional class, 
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weight, systolic blood pressure, ejection fraction. There are check boxes to indicate 
whether the patient has HF due to ischemic causes, which medication classes they are 
receiving, whether they have a prolonged QRS interval and whether they have any 
devices placed. There are also fields to enter particular lab values of interest such as H/H, 
uric acid, sodium, total cholesterol and lymphocytes and if the patient is taking a diuretic, 
the particular dose they are receiving.  This calculator can also estimate potential gains 
from adding additional interventions (i.e. adding an ARB to existing ACE inhibitor 





Mortality due to heart failure after the onset of symptoms is extremely high, 
although there is a range of actual number reported which usually differ based on the 
baseline characteristics of the study population and medications under study. Data from 
the Framingham study have demonstrated that there has been a slight decline in mortality 
from heart failure. The one-year mortality decreased from 30% to 28% in men and from 
28% to 24% in women. This decline was seen from data collection periods which 
included 1950-1969 and 1990-1999. 188 The five-year mortality decreased from 70% to 
59% and 57% to 45% in men and women respectively.  The overall trend demonstrates a 
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mortality decrease of approximately 12% per decade, while most of the decline was seen 
after 1980; almost all of it was after 1990.189  
There was a consistent change in mortality seen in a similar study conducted by 
the Mayo Clinic. The data collection periods for the Rochester study included 1979 to 
1984 and 1996 to 2000. Mayo observed decreases in one-year mortality of 30% to 21% 
and 20% to 17% in men and women respectively. Five year mortality showed a similar 
trend 65% to 50% and 51% to 46% in men and women respectively, improving most in 
younger men and least in older women. 190 Contributions to the change in mortality (and 
reduction in hospitalizations) are attributed to advances in drug therapy, increase in 
specialist/sub-specialist care and multi-disciplinary management. 191 
Drug therapy has been given partial credit for improvement in heart failure 
mortality. Drug classes that have been shown to improve mortality in heart failure 
patients include ACE inhibitors, ARB’s, beta blockers and aldosterone antagonists. These 
therapeutic advances in addition to newer medications for treatment of co-morbid 
conditions (such as statins for hypercholesterolemia) and those that treat conditions 
considered as risk factors (medications for better blood pressure control) contribute to a 
slight decline in mortality.  192 
There are non-modifiable patient-related factors that contribute to mortality. 
These include age and gender.  There are a number of studies that demonstrate a positive 
correlation between age and mortality. Although, there is an increase in mortality as 
patients’ age, the Framingham investigators did note that mortality in advanced age 
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groups decreased between the two observation periods. Patients between the ages of 65 
and 74, who survived at least 30 days after disease onset, saw a mortality decrease from 
66 to 54% and 47 to 40% in men and women respectively. 193 These results also show a 
lower mortality for women than men, which is consistent with the results seen in the 
Mayo study and a number of other trials.194195 A pooled analysis of five trials sought to 
examine specifically if there were survival differences between genders  reported an 
overall hazard ratio for women of 0.77 when compare to men. 196 
Ultimately, sudden cardiac death or progressive decompensation of heart failure is 
the reported cause of death in heart failure patients. 197 Although some may argue that 
distinction is difficult, heart failure trials often have differing criteria on how they define 
cardiac death as sudden or progressive. 198 A proposed standardized classification system 
called ACME was developed in response to inconsistent reporting of the cause of death in 
heart failure patients. ACME stands for activity, cause, mode and event. These authors 
propose that if a more precise cause of death is known, more productive research can be 
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1.5 Summary of Chapter One 
 
Breast cancer and heart failure are both complex diseases. Either disease alone 
has the potential for grim outcomes, for patients burdened with both conditions, outcomes 
are especially poor.  Breast cancer, if discovered early, can be curable. In contrast, heart 
failure cannot. To be cured of cancer and subsequently be diagnosed with heart failure 
caused by the chemotherapy is a devastating consequence of treatment.  The following 
literature reviews will examine the cardiovascular consequences of breast cancer therapy 
and monitoring strategies.  
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CHAPTER TWO: CARDIOVASCULAR COMPLICATIONS OF 




Diagnosing patients with heart failure is an extremely complex process and trying 
to determine if heart failure is a consequence of cancer therapy can be even more 
difficult. Reasons for this include that the signs and symptoms of cardiovascular disease 
and cardiac-related drug toxicity are essentially indistinguishable and the cardiac effects 
from cancer therapies are extremely diverse. 200 Cardiac side effects that can result from 
chemotherapy can include arrhythmias, ischemia, peripheral vascular disease, pericardial 
disease and left ventricular dysfunction.201 Each can be caused by a number of agents or 
combinations of agents used for a variety of tumor types. This can include treatment with 
chemotherapy, biological response modifiers and radiation. 202 
An additional confounding factor that makes diagnosis difficult is cardiovascular 
effects from cancer therapies may not become apparent until many years after treatment 
is concluded. This is true for both adult and childhood cancers. 203 In fact, in childhood 
cancers, cardiovascular effects may arise from manifestations of thyroid abnormalities, 
growth hormone dysregulation, obesity, pulmonary fibrosis, and renal dysfunction 
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resulting from cancer treatment. 204 These may present as mildly symptomatic changes in 
regular function such as decreased exercise tolerance and shortness of breath to overt 
heart failure and reduced left ventricular ejection fraction. 205 
 
2.2 Mechanism of Cardiotoxicity 
 
Complex interactions occur between treatments/agents that cause damage through 
several different mechanisms such as ischemia, free radical myocardial damage, radiation 
damage, alteration in conduction, and factors that increase myocardial stress such as 
increased work load, wall stress and underlying ischemia.  Specific mechanisms differ 
depending on the treatment or drug class and whether radiation therapy was received. 206 
A classification scheme was developed by Ewer and Lippman that characterizes 
the types of cardiac effects seen from different agents (See Figure 2.1). Types I and II, 
involving anthracyclines and trastuzumab respectively, are specifically relevant to 
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For breast cancer patients that require chemotherapy for either adjuvant treatment 
or palliation, anthracyclines are often used. Anthracyclines are some of the most active 
cytotoxic agents and were discovered in the 1960’s; they include doxorubicin, 
                                                 
208 Ibid. 
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daunorubicin, idarubicin, epirubicin and mitoxantrone. 209 Anthracyclines have three 
mechanisms of actions and those include: inhibiting DNA and RNA synthesis via 
intercalation between base-pairs preventing replication of cancer cells; inhibiting 
topoisomerase II, preventing the relaxation of the super coiled DNA which inhibits DNA 
transcription and replication; and creating iron-mediated free-oxygen radicals that 
damage DNA and cell membranes. (Figure 2.2) 210  
 Anthracycline toxicity is a result of repeated injuries to the myocardium that 
gradually effect cellular defenses, damaging cells that cause myocardial wall stress and 
eventually leading to cell death. There are several proposed mechanisms that may lead to 
cardiac toxicity, including: lipid peroxidation, inhibition of nucleic acids and protein 
synthesis, release of vasoactive amines, changes in adrenergic function and adenylate 
cyclase, inhibition of spontaneous or caffeine induced sarcoplasmic reticulum calcium 
release, and free radical generation. 211 
Those most widely accepted mechanism is free radical generation via a reduction 
reaction of the drug structure with oxygen which undergoes further reduction leading to 
an (–OH) free radical. This can occur as either an iron dependent or iron independent 
reaction. If iron creates a complex with the reduced drug, this often increases the amount 
of cell damage. Free radicals affect cells in a number of ways; they can cause damage 
directly to the sarcoplasmic reticulum, DNA, mitochondria, cell membrane and nuclear 
envelope. Damage to the sarcoplasmic reticulum can cause an increase in free calcium, 
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2 (2004): 185–229. 
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which in turn can damage myofibrillar elements. There are specific features that 
characterize cardiotoxicity of anthracyclines and those include the loss of myofibrils, 
dilation of the sarcoplasmic reticulum, cytoplasmic vacuolization, swelling of the 
mitochondria and an increased number of lysosomes.  212  
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2.3.2 OTHER CHEMOTHERAPY AGENTS 
 
Anti-metabolites such as fluorouracil (5-FU), capcitabine, and fludarabine can 
also cause cardiotoxicity. 5-FU is widely used in a number of regimens treating a variety 
of different cancers; it is considered the second most common cause of chemotherapy-
related cardiotoxicity after anthracyclines. The proposed mechanisms include coronary 
artery vasospasm, myocarditis and a thrombogenic effect leading to endothelial 
cytotoxicity. Vasospasm is the most widely accepted mechanism.  Patients present with a 
variety of symptoms ranging from angina, myocardial infarction and arrhythmias to acute 
pulmonary edema and cardiac arrest. Reported incidence ranges from 1 - 19%, but a 
commonly reported number is around 8%. Like anthracycline cardiotoxicity, the wide 
range can be attributed to the differing reporting criteria used in trials. Risk factors 
include the method of administration, concurrent or prior anthracycline use or radiation, 
and the presence of coronary artery disease. 214 
Capcitabine is an oral analog of 5-FU, with a reported incidence of cardiotoxicity 
that ranges between 3% and 9%. The cardiotoxic mechanism is assumed to be similar to 
that of 5-FU, as patients often present with similar symptoms (i.e., chest pain, MI or 
arrhythmias). The use of fludarabine has been associated with transient chest pain and 
hypotension; however, there have been seven case reports of severe cardiotoxicity when 
used in combination with melphalan. Nonetheless, routine use of high doses of either 
agent alone has not been associated with cardiotoxicity. 215  
Microtubule targeting agents, such as vinca alkaloids and taxanes, exhibit some 
cardiac effects. Vinca alkaloids have been implicated in a number of vaso-occluding 
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events such as hypertension, MI, and infarction; this is most commonly reported in 
vinblastine. With taxanes, paclitaxel most commonly can cause bradycardia and heart 
block. The use of paclitaxel or docetaxel in a breast cancer regimen is implicated in heart 
failure and the incidence increases up to approximately 20% when these agents are used 
together. It is hypothesized that taxanes potentiate the cardiotoxicity of the 
anthracyclines.  216 
Alkylating agents, such as cyclophosphamide, are associated with 
cardiomyopathy in higher dose protocols; however toxicity is not considered related to 
the cumulative dose administered. Platinum agents, such as cisplatin, have several cardiac 
effects; however, these are typically considered secondary to the renal toxicity caused by 
these agents. 217 
 
2.3.3 TRASTUZUMAB  
 
Monoclonal antibodies and other targeted agents such as trastuzumab, rituximab, 
and bevacizumab have varying degrees of cardiac effects and toxicities that are related to 
the receptors to which they bind. Trastuzumab and bevacizumab can cause 
cardiomyopathy and reductions in LVEF related to cellular events arising as a function of 
the drug’s mechanism of action. Whereas, rituximab can cause arrhythmias or angina, 
and this is usually considered an infusion-related reaction that is transient. 218 
The specific mechanism of trastuzumab cardiotoxicity stems from the specific 
inhibition of cardioprotective factors in normal repair pathways. The complex created by 
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binding of the drug to the targeted receptor creates a complex that specifically inhibits 
cardiac repair. This complex has multiple activation steps down steam that result in 
hypertrophy of cardiac myocytes. 219 
  
                                                 
219 Evandro de Azambuja et al., “Cardiac Toxicity with anti-HER-2 Therapies: What Have We Learned so 
Far?,” Targeted Oncology 4, no. 2 (April 2009): 77–88. 
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Table 2.1 Classes of Chemotherapeutic Agents and Corresponding Cardiotoxic 
Effects 220 
 






Arrhythmias, pericarditis, myocarditis, 
HF, LV dysfunction 
Alkylating 
Agents 
Busulfan, Chlormethine, Cisplatin, 
Cyclophosphamide, Ifosfamide, 
Mitomycin 
Endomyocardial fibrosis, pericarditis, 
tamponade, ischemia, MI, HTN, 
myocarditis, HF, arrhythmias 
Anti-Metabolites 
Capcitabine, 5-Fluorocuracil  
(5-FU), Clofarabine, Carmustine, 
Cytarabine 
Ischemia, chest pain, myocardial 
infarction, HF, arrhythmias, pericardial 




Etoposide, Teniposide, Vinca 
Alkaloids, Taxanes (Paclitaxel) 
Hypo- or hypertension, ischemia, angina, 
myocardial infarction, bradycardia, 






Hemodynamic abnormalities, LV 
dysfunction, HF, thromboembolism, 
angioedema and arrythmias 
Interleukins Denileukin, IL-2, IFN-α 
Hypotension, capillary leak syndrome, 
arrythmias, coronary artery thrombosis, 
ischemia and LV dysfunction 
Tyrosine Kinase 
Inhibitors 
Imatinib Mesylate, Sorafenib, 
Sunitinib, Dasatinib, Relotinib, 
Gefitinib, Lapatinib 
HF, edema, pericardial effusion, 
pericarditis, hypertension, arrythmias, 





Asparaginase, ATRA, Arsenic 
Trioxide, Pentostatin, 
Lenalidomide, Thalidomide 
ECG changes, prolonged QT interval, 
torsade’s de pointes, other arrythmias, 
ischemia, angina, MI, HF, edema, 
hypotension, bradycardia, 
thromboembolism and retinoid acid 
syndrome  
LV: Left Ventricular, HF: Heart Failure, MI: Myocardial Infarction, HTN: Hypertension, IL: 
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2.4 Toxicity Criteria 
 
The most prominent guideline for evaluating toxicity to cancer treatment is the 
National Cancer Institute’s (NCI) Common Toxicity Criteria (CTC) which lists possible 
toxicities and/or adverse events for each organ system. These are given a grade which 
ranges from zero (which usually means absent or normal function) to four.  
Cardiovascular toxicity is split between arrhythmias and general events. A portion of the 
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Event: 0 1 2 3 4 
LVEF Normal 
Asymptomatic decline 
of resting EF ≥10% but 
<20% of baseline; FS 
≥24% but < 30% 
Asymptomatic but 
resting EF below the 
LLN, or decline of EF 

















cTnT Normal ≥0.03 - <0.05† ≥0.05 - <0.1† ≥0.1 - <0.2† ≥0.2† 
†measured in ng/mL, * as defined by manufacturer; CHF: Congestive Heart Failure; cTnI/ cTnT: Cardiac Troponins I and T; EF: Ejection Fraction; FS: 
Fractional Shortening; LLN: Lower Limit of Normal; LVEF: Left-Ventricular Ejection-Fraction; MI myocardial infarction; TX: Treatment  
                                                 
222 Ibid. 
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The NCI also has common terminology criteria for adverse events (CTCAE), and 
differentiates the effect of chemotherapy on left ventricular ejection fraction (LVEF) 
from overt heart failure. For purposes of the CTCAE, the term adverse event refers to 
“any unfavorable or unintended sign, symptom or disease temporarily associated with the 
use of a medical treatment or procedure that may or not be considered related to that 
treatment or procedure”.  223 
The criteria of adverse events, like that of the toxicities, list each organ system 
and grades events. However, in the adverse event criteria, the grades range from 1 to 5. 
Grade 1 is considered of mild severity, where the patient may be experiencing mild 
symptoms or no symptoms at all by which only an observation is made and no 
intervention is indicated. Grade 2 is a moderate grade where the patient may be 
experiencing moderate symptoms that may indicate a non-invasive intervention and there 
may be some limitation of age-appropriate instrumental activities of daily living. Grade 3 
is severe, is not considered life threatening, but often hospitalization is required and 
typically patients are experiencing some limitation of self-care activities of daily living.  
Grade 4 is considered life threatening and Grade 5 is defined as death attributed to 
adverse event.  The common terminology criterion for adverse events that is relevant to 










Table 2.3 NCI Common Terminology Criteria for Reporting of Adverse Events (Version 3.0) 225 
 
 Grade 
Adverse Event: 1 2 3 4 5 
Heart Failure 
Asymptomatic 









symptoms at rest  
Life-threatening 
consequences Death 
Ejection Fraction - - 
Symptomatic 
due to drop in 
ejection fraction 
Refractory or poorly 
controlled heart failure due 
to drop in ejection fraction  
Death 
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2.4 Heart Failure in Breast Cancer 
 
Dilative cardiomyopathy and CHF develop after completion of cumulative 
anthracycline regimens usually within a year but very late forms of cardiac dysfunction 
have been experienced by some patients. 226  Toxicity can manifest as either sub-clinical 
or clinical heart failure. Sub-clinical is detectable heart damage that does not result in any 
symptoms.  
Three distinct types of cardiotoxicity have been described and these types are 
determined by the amount of time that had lapsed between drug administration and 
symptom development. 227 The first type includes the acute or sub-acute injury which 
occurs during or immediately after the infusion. This type of toxicity is rare and can 
result in a transient arrhythmia, pericarditis or myocarditis syndrome or acute left 
ventricular dysfunction. The most common manifestation of immediate toxicity is non-
specific ECG repolarization abnormalities which are reported in approximately 40% of 
patients.  228 Symptoms resolve after discontinuation of treatment, however, some 
patients do suffer permanent cardiac damage, especially when higher cumulative doses 
are received. The second type is a chronic progressive cardiotoxicity that results in 
cardiomyopathy. This is the most common type of cardiotoxicity and it usually manifests 
within the first year after treatment has concluded. The third type is also chronic; 
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however the onset involves the development of symptoms years to decades later (this 




The earliest reports of doxorubicin-related cardiotoxicity are in either reviews or 
retrospective analyses. When the drug first was used in breast cancer; heart failure was an 
anecdotal finding and routine monitoring was not always conducted, which may have led 
to an under-reporting in earlier literature. Retrospective studies have reported a wide 
range of incidence values for anthracycline-induced cardiotoxicity.230 This is primarily 
because reporting is not standardized. Patients tend to be monitored more closely when 
participating in clinical trials; however, monitoring usually consists of MUGA or ECHO, 
neither of which are sensitive to slight changes in cardiac function.231 Reports of 
cardiotoxicity in the publications resulting from phase II or III trials is typically reserved 
to patients in NYHA class III or IV heart failure (i.e., patients with complaints of 
symptoms). Patients not participating in trials could get an ECHO or MUGA scan but 
usually not as frequently; barriers include the high cost and extensive resource utilization 
involved in radiological tests. Patients may not be monitored at all until they report 
symptoms requiring further investigation.  232 
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In a systematic review of 25 studies involving pediatric patients, there was a 
frequency range of 0% to 57.4% reported cases of subclinical cardiotoxicity. 233 These 
authors noted that of the 25 included studies, 14 had serious methodological flaws or 
limitations. The definition of sub-clinical cardiotoxicity used in the meta-analysis was 
abnormal systolic function and/or afterload judged from values of either fractional 
shortening, ejection fraction, velocity of fiber shortening corrected for heart rate, or the 
stress-velocity index (all of which were measured via ECHO or radionuclide 
angiography). These results illustrate that there is a lack of standardized reporting, and 
when sub-clinical toxicity is considered, the incidence rises dramatically.  234  
 
 
2.4.2 RISK FACTORS 
 
The risk in anthracycline cardiotoxicity is often magnified by an overlap of 
anthracycline exposure and subsequent sub-clinical damage. There are both drug-related 
and patient-related risk factors that contribute to cardiotoxicity of cancer treatment. Drug 
related factors include: the dose administered at each session, the cumulative dose 
administered, length of infusion, the combination of drugs given, dosing schedule, and 
sequence of combination therapy. 235 
Patient-related factors include age (especially patients < 4 or > 70), female 
gender, previous therapies, underlying cardiac disease, hypertension, metabolic 
abnormalities, liver disease, chromosome abnormalities and hypersensitivity to drugs 
given. Co-morbidities and unfavorable lifestyle choices such as physical inactivity can 
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also contribute to the potential for cardiotoxicity; these risk factors may affect therapy 
choices or even exclude the use of anthracyclines from treatment plans particularly in 
older patients. 236 
Proposed risk factors for anthracycline-induced cardiotoxicity include: higher 
rates of drug administration, mediastinal radiation, advanced age, younger age, female 
sex, pre-existing heart disease, and hypertension. 237 Although, the hypothesized risk 
factors that have the most evidence include cumulative dose, advancing age, and 
combination therapy (including sequencing of medications). 238 One of the earliest 
reports of cardiotoxicity was by Von Hoff and colleagues where these investigators 
observed an increasing incidence of CHF with increasing age and also observed a 
difference in cases between dosing regimens. There were fewer cases in those patients 
who received a single dose every week when compared with patients who either received 
a single dose every three weeks or three consecutive daily doses every three weeks. 239 
In a retrospective study using SEER data for patients who received anthracycline 
therapy, the authors found an association of CHF with advancing age, black race, other 
co-morbid conditions or cardiac history. This study, because of the nature of the data, had 
ten years of follow-up information available. However, the dose of anthracycline 
received was not reported, and outcomes were dependent on what was reported in the 
billing claims. 240 
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Cardiac risk factors (e.g., hypertension) predispose patients to heart failure 
independent of receiving anthracycline therapy. Numerous studies suggest that patients 
with a cardiac history are at increased risk. In one study by Ryberg et al, the authors 
found that there was a three-fold increase in cardiotoxicity in patients with cardiac risk 
factors (i.e., hypertension, diabetes, obesity, COPD and thyrotoxicosis) independent of 
the dose of drug received. 241 However, few demonstrate that in patients with cardiac risk 
factors (with the exception of hypertension) there is an increased association between the 
development of CHF and treatment. In a SEER investigation of NHL patients who 
received anthracyclines, hypertension is the only cardiac risk factor that showed an 
association with heart failure.  242 
In a retrospective study utilizing the SEER database, Doyle and colleagues 
evaluated chemotherapy use and cardiotoxicity among elderly women in the general 
population diagnosed with early-stage breast cancer. The authors hypothesized those 
elderly breast cancer patients who received chemotherapy, especially doxorubicin-based 
regimens, would experience higher rates of cardiotoxicity than patients who did not 
receive chemotherapy. Data were collected for each patient beginning 12 months prior to 
diagnosis, continuing to death censoring on December 31, 2001. 243 
The following outcomes were measured: cardiomyopathy, CHF, heart disease 
(HD) and myocardial infarction. Heart disease (HD) was a composite that included 
diagnosis codes for cardiomyopathy, acute myocarditis, CHF, acute MI, arrhythmias, 
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ventricular dysfunction, ischemic heart disease and sudden death. The authors concluded 
that even when accounting for any baseline heart disease, patients who receive the 
anthracycline-based regimen had a higher risk of cardiomyopathy. 244 
 
2.4.2.1 Combination Therapy 
 
Certain combination therapies such as treatment with radiation, trastuzumab or 
taxanes may increase the risk of heart failure.245 In a meta-analysis by the Early Breast 
Cancer Trialists’ Group, the investigators found an increase in vascular mortality 
associated with radiation therapy, and this risk increased with advancing age. 246 Smaller 
studies have suggested that left-sided radiation with higher cumulative doses of 
anthracyclines may exacerbate the drugs cardiac toxicity, although recent studies have 
not found that association when standard dose doxorubicin is given for four or fewer 
cycles.  247 
Amplification and over-expression of HER-2 is seen in 20 – 30% of breast cancer 
patients and leads to less favorable outcomes. 248Trastuzumab is a monoclonal antibody 
that targets the extracellular domain of HER-2 and improves the outcome in patients who 
have over-expression of this receptor.249  During the drug approval trials for trastuzumab, 
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there was a significant increase in heart failure (either symptomatic or asymptomatic) in 
patients who received trastuzumab with anthracyclines when compared to trastuzumab 
alone or paclitaxel. Later trials avoid the concomitant use of the two as it is believed that 
trastuzumab somehow potentiates the cardiotoxicity of the anthracycline. 250 
The Cardiac Evaluation and Review Committee (CREC), which is part of FDA, 
reviewed all trials in which trastuzumab was being evaluated, to determine criteria for 
diagnosis of a cardiac dysfunction. The established criteria used to evaluate trastuzumab 
cardiotoxicity includes: cardiomyopathy characterized by global decrease in LVEF, signs 
or symptoms of heart failure, decline of LVEF of at least 5% to less than 55% with signs 
and/or symptoms of heart failure, or decline of LVEF of at least 10% to less than 55% 
without signs and/or symptoms of CHF. 251 
A prospective study by Tan-Chiu and colleagues was designed to determine the 
increase in cardiac dysfunction when trastuzumab is added to a standard regimen of AC 
plus paclitaxel.  Episodes of cardiac dysfunction were classified using the NYHA 
classification system and only NYHA class III or IV were considered to be CHF. Both 
arms received AC plus paclitaxel and the study arm received trastuzumab. Cardiac 
monitoring included a cardiac history form submitted at enrollment, every six months for 
five years and then annually thereafter.  MUGA scans were done at study entry, after AC, 
and at six, nine and 18 months. Additional scans were allowed at the discretion of the 
investigator. 252 
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Trastuzumab was started in the study arm patients if their LVEF did not drop 
more than 15 % below the pre-entry level or was still above the lower limit of normal 
(LLN). The study protocol included explicitly stated criteria on whether to continue or 
suspend use of trastuzumab. Criteria used by the review panel were similar to the CERC, 
and included NYHA class III or IV symptoms with a decrease of LVEF of  > 10% to 
lower than 55%, or a decrease of 5% to less than the lower limit of normal (LLN). 
Patients with reported cardiac dysfunction continued to be monitored via MUGA scans. 
253 
The primary end point was the difference in cardiac dysfunction between study 
arms (reported cardiac dysfunction or death). These authors concluded that the reduction 
in recurrence and mortality that trastuzumab gave patients was an acceptable risk in 
patients with HER-2 positive, node positive disease. However, in older patients with 
cardiac risks or who have LVEF decline after administration of AC to the LLN, the risk 
may be too great. 254 
Taxanes also are believed to potentiate the cardiotoxicity of anthracyclines by 
possibly stimulating the conversion of doxorubicin to its more cardiotoxic metabolite in 
the myocardial tissue. However, an increase in heart failure incidence is only seen at 
higher cumulative doses of doxorubicin and in combination therapy, but not when 
taxanes are given in the adjuvant setting. 255 
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There is a consensus that the incidence of chemotherapy-induced cardiotoxicity is 
dose-dependent. 256 Published results report a wide range regarding anthracycline-
induced heart failure incidence. This can be attributed to differences in how the authors 
defined “low”, “medium” or “moderate”, or “high” doses, as well as how heart failure 
was defined (whether studies reported only symptomatic dysfunction). Values reported in 
literature can range from, for example, > 4, > 18 or > 36% in patients receiving 
cumulative doses of 500-550 mg/m2, 551-600 mg/m2 or > 600 mg/m2 respectively, while 
other reviews report cardiotoxic incidence of 0.14%, 7% and 18% at doses of < 
400mg/m2, 550 mg/m2 and 700mg/m2 respectively.  A study in 1979 by Von Hoff and 
colleagues reported incidences of 3%, 7% and 18% for doses of 400 mg/m2, 550 mg/m2 
and 700 mg/m2 respectively257. In a more recent study by Swain and colleagues, the 
authors suspected that previous reports were underestimated. They found incidences of 
5%, 26% and 48% with the same respective doses. 258 See Figure 2.3 for a comparison of 
these findings.   
In another retrospective study by Lefrak and colleagues which included 399 
patients, the results showed a clear association between dose and incidence of 
cardiotoxicity. The authors concluded that incidence rose to unacceptably high levels 
when the cumulative doses exceeded 500 mg/m2. The incidence values reported were > 4, 
> 18 or ~ 36% of patients who had received cumulative doses of 500 - 550 mg/m2, 551 -
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600 mg/m2 or > 600 mg/m2 respectively. 259 In a review by Shan et al. the authors give a 
dose dependent relationship as follows: at doses < 400 mg/m2 the incidence of chronic 
cardiotoxicity is 0.14%, this incidence rises to 7% at a dose of 550 mg/m2, and to 18% at 
a dose of 700mg/m2. 260 
 
 
Figure 2.3 Comparisons of Reported Incidences of Dose-Dependent, Anthracycline-
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In a prospective study to assess the cardiac effects of two different cumulative 
doses of adjuvant doxorubicin and radiation therapy in breast cancer patients, Shapiro 
and colleagues randomized patients to receive AC (n = 299) for either 5 or 10 cycles, 122 
of these patients also received radiation. Cardiac events were compared to the 
Framingham Heart Study (which served as the control). The planned cumulative doses of 
doxorubicin were 225 or 450 mg/m2. 262 Patients with CHF, history of MI or 
cardiomyopathy were ineligible. After completion of chemotherapy, there was a second 
randomization to receive RT or observation. Patients who did not participate in the 
secondary randomization also received adjuvant chest wall and regional nodal RT after 
the completion of chemotherapy. 263 
Medical records were reviewed for the development of cardiac events from the 
time of initial randomization until the most recent follow up or death. Cardiac events 
were defined as either symptomatic CHF or MI. Follow up was available in 92% of 
randomized patients.264 Verification of CHF was based on physical exam findings, use of 
heart failure treatment, or diminished LVEF. All records initially identified as having a 
cardiac event and a randomly selected group of 68 patients were reviewed by a 
cardiologist (blinded). Identification of cardiac events were concordant in 21/23 cases, 
two cases were excluded by cardiologists because of insufficient evidence. After the 
blinded review, another patient with a cardiac event was identified, bringing the total to 
22. 265 
                                                 






For purposes of analysis, the cardiac RT dose volume for primary breast cancer 
was retrospectively categorized as low (defined as the treatment of right sided breast 
cancers with tangential fields), moderate (as the treatment of left sided breast cancers 
with tangential fields) or high (treatment of right or left breast cancers with tangential 
fields and of a separate anterior field for the internal mammary nodes). 266Cardiac events 
were analyzed in two ways. The first method included cardiac events censored for 
recurrence (i.e., only cardiac events that preceded a documented breast cancer recurrence 
or a diagnosis of contralateral breast cancer). The second method included cardiac events 
uncensored for recurrence and consisted of all cardiac events irrespective of their timing 
in relation to breast cancer recurrence or contralateral breast cancer.  Results of two 
methods did not differ substantially. Cardiac events occurred in 22 of 276 patients, CHF 
in 19 and AMI in 5, two patients had CHF and AMI during the same hospitalization, no 
patient with a cardiac event had a prior history of cardiac disease except hypertension.  
Observed cardiac events in the five-cycle group were not higher than the general 
population (when comparing to the population in the Framingham Heart Study) 
regardless which radiotherapy dose was given. In the ten-cycle group, patients had a 3.4 
fold higher risk of cardiac events than the patients in the five-cycle group and a 3.6 fold 
higher risk than the general population.267 
A prospective study, by Ryberg and colleagues, was designed to evaluate 
cumulative dose, dose intensity, single dose level and schedule of epirubicin on the 
development of CHF in breast cancer patients. The sample included 469 patients, and 
only patients that were in NYHA class II-IV were classified as having heart failure. 
Patients could not have had prior anthracycline therapy before epirubicin therapy and 




patients with evidence of cardiac dysfunction (CHF, MI or arrhythmia) were excluded.  
The primary end point of this trial was clinical CHF as defined by reported history of 
breathlessness, clinical signs of CHF (dyspnea/congestion on x-ray, peripheral edema), 
an X-ray showing cardiomegaly with or without pulmonary congestion or pleural 
effusion, an abnormal LVEF (LVEF < 46% absolute value or a decrease of >15% from 




2.4.3 PREVENTIVE STRATEGIES 
 
There are a number of strategies that have been used in an attempt to decrease the 
incidence of treatment-related heart failure. Such strategies include increasing the 
infusion time, changing administration schedule, limiting the cumulative dose to ≤ 300 
mg/m2, using anthracycline analogs (e.g., epirubicin, idarubicin and mitoxantrone), 
liposomal or pegylated-liposomal formulations and protective agents. Other strategies 
such as dietary supplements and nutrients have demonstrated some benefit in animal 
models but have not translated to productive use in humans. 269 Table 2.4 lists the 
potential strategies to prevent treatment-related heart failure, how each strategy is 
classified and the proposed mechanism for cardioprotection.  
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Table 2.4 Proposed Anthracycline Cardiotoxicity Prevention Strategies 270 
 
Agent Class Mechanism 
Dexrazoxane Chelating Agent Binds to Iron; Prevents Free Radical Formation; Inhibits DNA Topoisomerase 
NAC Mucolytic Promotes Endogenous Antioxidant Synthesis 
Carnitine Dietary Supplement Antioxidant; Transfer of Long-Chain Fatty Acids into Mitochondria 
Probucol Lipid-Lowering Drug Promotes Endogenous Antioxidant Synthesis 
Amifostine Cytoprotective Agent Scavenges Free Radicals 
Carvedilol Beta-Adrenergic Antagonist 
Prevents Free Radical Formation; Prevents 
Depletion of Endogenous Antioxidants 
Vitamins A,E, and C; 
Carotenoids Nutrient Antioxidant 
Selenium Trace Element Antioxidant; Anti-Carcinogenic Action 
Glutathione Tri-Peptide Thiol Antioxidant 
Coenzyme Q10 Dietary Supplement Antioxidant 
NAC: N-Acetylcysteine 
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There are conflicting opinions as to whether increasing the infusion time is 
beneficial, some think that giving a slower infusion over longer periods decreases the 
peak anthracycline level, however, it also prolongs the exposure of myocytes to the drug. 
There is evidence that the longer infusion times prevents the immediate cardiotoxic 
effects, however, no differences have been noted in late cardiac manifestations. 271 While 
there is evidence that schedules with extended infusions have fewer cardiotoxic events 
than bolus dosing, there are disadvantages to this dosing strategy. The extended infusions 
usually require the placement of a central line which can increase costs either directly if a 
hospital stay is required or indirectly through increased complications such as infection or 
thromboembolism. 272 The weekly administration schedule has also been shown to 
slightly decrease the incidence of cardiotoxic events273; however, this brings patients 
back to the clinic every week, increasing inconvenience to both them and the physician, 
and could potentially overlap other drugs in the regimen which could increase side effects 
(e.g. myelosuppression). 274 
 
2.4.3.1 Pegylated/Liposomal Anthracycline Formulations 
 
The purpose of the liposomal formulations is to maintain the anti-tumor effect of 
the drug while reducing toxicity, there are several proposed ways that this is made 
possible. Human vasculature has walls that are made of endothelial cells and between 
those cells are tight junctions. The tight junction prevents leakage of larger particles into 
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the extravascular space keeping them in circulation. This anatomical phenomenon 
theoretically can achieve both goals. Liposomes have larger structures than the regular 
drug making it impossible for the escape through the capillary junctions in the heart and 
GI tract, thereby keeping them in the vascular space increasing delivery to the tumor 
itself. Tumor cells lack tight junctions; therefore drugs that are encapsulated in liposomes 
get higher concentrations to the intended site of action (and conversely lower 
concentrations where problematic adverse events occur such as cardiac tissue). 275 
The decreased leakage into the extravascular space can hypothetically grant the 
ability to administer the encapsulated drug at much higher doses than the conventional 
formulation because of the proposed lower toxicity potential. Two additional advantages 
of these drug formulations include, 1) formulating the drug within liposomes slows 
release, keeping peak levels lower, which should decrease toxicity, 276 and 2) the addition 
of pegylated (polyethylene glycol) encapsulation gives the drug a much longer half-life 
than liposomal formulations (> 55 hours compared to two to four hours) which is 
attributed to the decreased degradation and uptake by the mononuclear phagocyte system.  
277  
In a prospective, multi-center trial, 224 patients were randomized to receive 
liposomal doxorubicin (n = 108) or conventional doxorubicin (n = 116) in the first-line 
treatment of metastatic breast cancer. The primary efficacy end point was response rate 
(RR) and a primary safety end point of cardiotoxicity.  Patients were excluded if their 
only site of metastasis was bone; prior chemotherapy was received in the six months prior 
to randomization, patients with brain metastasis, radiation to more than 50% of the bone 
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marrow or mediastinal radiation greater than 3500 cGy, women who were pregnant or 
lactating, or patients with congestive heart failure, arrhythmia or myocardial infarction in 
the six months prior to enrollment. 278 
In the analysis for efficacy, the time to progression (TTP) and time to treatment 
failure (TTF) were similar among the treatment groups. There was a slight trend toward 
increased survival in the conventional doxorubicin group, however, this was not 
statistically significant (p = 0.09). Cardiac events of severity sufficient for removal from 
the study were 29% versus 13% in the conventional and liposomal groups respectively (p 
= 0.0001). Congestive heart failure developed in two patients (2%) in the liposomal 
doxorubicin group compared to nine patients (8%) in the conventional doxorubicin 
group, three of which developed CHF within 30 days of their last dose.  These authors 
concluded that their findings of reduced cardiotoxicity support the use of the liposomal 
formulation. 279 
A phase II study designed to examine the response rate and toxicity of liposomal 
doxorubicin found conflicting results. The study enrolled 52 patients that had not 
received prior treatment for metastatic disease. Response was categorized as one of the 
following: complete response (CR), partial response (PR), stable disease (SD) or 
progressive disease (PD).  Almost half of the patients had received chemotherapy in the 
adjuvant setting (42%), 12 of these received anthracyclines. 280 
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Twenty patients (38%) experienced cardiotoxicity, (grade three toxicity [n = 4], 
grade four toxicity [n = 3]). The only risk factors that were significant in the authors 
logistic regression model were the prior cumulative doxorubicin dose (p = 0.007) and the 
cumulative dose of liposomal doxorubicin (p = 0.032).  The overall response rate 
observed in this study was 46% (CR in three patients [6%], PR in 20 [40%]). The authors 
compared this finding to that of four trials of single agent conventional doxorubicin that 
yielded response rates between 27% and 36% and concluded that their results were only 
marginally better and hardly justified the increased toxicity. 281 
 
2.4.3.2 Anthracycline Analogs 
 
While doxorubicin is the most common anthracycline used is breast cancer 
regimens, there is evidence that supports the substitution of epirubicin into similar 
chemotherapy regimens (i.e., using epirubicin instead of doxorubicin with 5FU and 
cyclophosphamide FEC instead of FAC). However, these substitutions are not without 
cardiac risk, in fact, dose-dependent cardiotoxicity is also observed when other 
anthracycline agents are used.  For trials that report a lower incidence of cardiotoxicity 
when epirubicin is substituted for doxorubicin, the protocols are often using mg per mg 
substitution. The NCCN guidelines for the treatment of breast cancer recommend 
protocols where doxorubicin is typically dosed at 50 or 60 mg/m2, the corresponding dose 
of epirubicin to be used is 90 or 100 mg/m2. Therefore, the dose used in the trial needs to 
                                                 
281 Ibid. 
 114 
be considered when evaluating the cardiotoxicity of epirubicin or other anthracycline 
analog. 282 
In a prospective study by Gennari  and colleagues designed to determine the role 
of cardiac risk factors in cardiotoxicity, the investigators  enrolled 105 patients who were 
to receive epirubicin/paclitaxel treatment either with (n = 76) or without (n = 29) 
gemcitabine. Patients with a prior history of cardiac disease or signs of cardiac 
dysfunction were excluded, however, prior adjuvant therapy was allowed if completed 
more than six months before enrollment. The use of prior hormone therapy was allowed, 
and prior anthracycline therapy was allowed if the total cumulative dose was < 180 
mg/m2 for doxorubicin and < 360 mg/m2 for epirubicin. 283 
Pre-existing cardiac risk factors that were considered included: hypertension, 
diabetes, and chest wall irradiation on either the right or left.  The primary endpoint of the 
study was cardiac failure defined by NYHA classification. There were nine patients that 
experienced CHF during follow up, five of which received cumulative epirubicin doses 
between 450 and 720 mg/m2, and the remaining four patients received the maximum dose 
allowed per protocol of 1,080 mg/m2. While there was no clear relationship demonstrated 
between the risk factors and heart failure, seven of nine patients who developed heart 
failure received chest wall irradiation. 284 
The authors calculated cumulative probabilities of developing heart failure and 
concluded that those patients with one risk factor a had similar probability to those 
without any risk factors up to cumulative dose of 990 mg/m2 (cumulative risk 10% and 
12% respectively). After adjustment for cumulative dose, there was no difference in the 
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incidence in CHF between those with risk factors and those patients without. Of note, 
none of the patients who received gemcitabine developed heart failure. Of those patients 
who had consolidation and subsequent BMT, only one developed heart failure.285 
The authors concluded that the substitution of epirubicin for doxorubicin had a 
lower incidence of heart failure, and that the substitution is acceptable up to doses of 990 
mg/m2. These authors suggest that this may be more clinically evident in patients who 
have received prior chest wall irradiation; however the small number of observations in 
the study makes definitive conclusions impossible.  The authors also suggest that if 
patients have a risk factor or have had epirubicin adjuvant therapy in the past, a reduction 
from eight cycles to six may be possible. 286 
In another prospective study by Nielson and colleagues that was specifically 
designed to assess the cardiac toxicity of epirubicin in patients with advanced breast 
cancer, heart failure was assessed with advanced LVEF methods. Inclusion criteria for 
the study were patients admitted with metastatic or unresectable progressive breast 
cancer, age < 70, WHO performance status ≤ 3, no concomitant cancers, no brain or 
leptomeningeal involvement, no previous treatment with anthracyclines or vinca 
alkaloids, and no clinical evidence of cardiac disease defined as CHF, MI or 
arrhythmia.287 
Pretreatment evaluation of cardiac function included physical exam, chest x-ray, 
ECG and LVEF. The exam was repeated prior to each dose, the ECG was repeated every 
1 to 3 months and LVEF was obtained at cumulative doses of 300, 600 and 900 mg/m2 
and each subsequent 100 mg/m2 thereafter. Cardiac toxicity was defined as LVEF ≤ 45% 
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or a decrease of ≥ 15% from pretreatment level; only patients in NYHA classes II - IV 
were considered having heart failure.  Of the 11 patients who received doses > 1000 
mg/m2, seven developed CHF and four subsequently died. There were six patients who 
received doses between 500 and 1000 mg/m2, of those, one patient developed CHF.  
Overall, this study reported a 6% total incidence of CHF.  These authors concluded that 
epirubicin in cumulative doses > 1000 mg/m2 increased cardiac risk and death from heart 
failure, and doses between 500 - 1000 mg/m2 increased risk of heart failure. They also 
concluded that LVEF is not a valuable predictor of heart failure and should only be 
measured as part of the work-up. 288 
Prior to the beginning of this trial there was not an established maximum dose of 
epirubicin, there were four patients who had fatal cases of CHF who received doses of 
1,081, 1,094, 1,211, and 1,317 mg/m2. 289 Following this trial the maximum 
recommended dose was reduced to 1000 mg/m2. 290  The authors used Kaplan-Meier 
estimates and logistic regression to determine risk where an event was defined as the 
development of CHF. There were 34 patients (7.2%) that developed CHF. Results 
showed an association of heart failure to the cumulative dose received, patients who 
received higher cumulative doses were more likely to develop heart failure (p = 0.001). 
The authors also listed schedule, mean dose intensity, mean single dose level and prior 
radiation therapy as possible risk factors but did not find a significant difference in heart 
failure incidence. Additionally, previous treatment with CMF was not found to be a risk 
factor. These authors concluded that epirubicin was cardiotoxic, and that the maximum 
                                                 
288 Ibid. 
289 Ibid. 
290 Ryberg et al., “Epirubicin Cardiotoxicity.” 
 117 
dose should be 900 mg/m2.  They also stated that radiation against the heart leads to an 
increased risk of developing heart failure and an accelerated death. 291  
 
2.4.3.3 Protective Agents 
 
Dexrazoxane (DZR) is a protective agent that is a derivative of EDTA; it can 
reduce the amount of free iron in the myocytes by producing its own free radicals that 
decrease the oxidized iron levels during the anthracycline infusion.  DZR is usually 
reserved for patients with metastatic disease who have received over 300 mg/m2 of 
doxorubicin. It is typically not recommended at the beginning of therapy because there is 
a possibility it may decrease the anti-tumor effect of the doxorubicin.  Dose-limiting 
strategies have reduced the reported incidence of heart failure (i.e., doses in the range of 
240 - 360) to 1.6%; however incidence increases to 2.1% in those patients receiving 
subsequent paclitaxel and the newer targeted drugs such as trastuzumab. While dose-
limiting strategies have decreased heart failure incidence, they also appear to negatively 
affect outcomes such as survival and cure. 292  
A retrospective analysis of three studies sought to determine whether heart failure 
was under-reported. To determine this, they analyzed data from the placebo arms of three 
trials, which included two breast cancer trials and one lung cancer trial. The studies 
included were placebo controlled trials to examine the protective effect of dexrazoxane 
(DZR) on development of heart failure.  The primary objective of the analysis was to 
                                                 
291 Ibid. 
292 L. Gianni et al., “Paclitaxel by 3-hour Infusion in Combination with Bolus Doxorubicin in Women 
with Untreated Metastatic Breast Cancer: High Antitumor Efficacy and Cardiac Effects in a Dose-finding 
and Sequence-finding Study,” Journal of Clinical Oncology 13, no. 11 (1995): 2688; Shan, Lincoff, and 
Young, “Anthracycline-Induced Cardiotoxicity.” 
 118 
examine the relationship between the cumulative doxorubicin dose and the cumulative 
probability of developing doxorubicin related CHF. 293 
The three studies were all randomized, double-blind, multicenter studies 
evaluating cardiotoxicity in patients receiving dexrazoxane in combination with a 
doxorubicin containing regimen. None of the trials established a maximum dose for 
doxorubicin and none of the patients had prior anthracycline therapy. The two breast 
studies had identical protocols, and the lung protocol was similar to the protocols of the 
other two studies. All three studies showed clear evidence of significant cardioprotection 
of dexrazoxane, so all patients randomized to receive placebo were switched to receive 
DZR with the seventh cycle of treatment. All patients randomized to received placebo 
were included in the analysis (N = 630). Of these, 168 were switched to open label DZR. 
294 
The incidence of doxorubicin-induced heart failure in the study was compared to 
a previous retrospective analysis by Von Hoff et al. These authors  observed estimated 
cumulative percentage of 5% of patients at 400 mg/m2, increasing to 26% at 550 mg/m2, 
48% at 700 mg/m2 compared to 3%, 7% and 18% reported in the Von Hoff et al. review.  
The authors concluded that doxorubicin-related heart failure occurs more often than 
previously thought. Additionally, they concluded that LVEF is not a sensitive test for 
predicting CHF, and laboratory tests, such as cardiac troponins might be better able to 
detect heart failure than using LVEF. 295  
 
 
                                                 




2.4.4 MANAGEMENT OF CARDIOTOXICITY 
 
Treatment options for drug-induced heart damage are similar to that of other 
etiologies, consisting of medical management and surgical therapy.  Anthracycline-
induced heart failure, whether the patients are experiencing symptoms or not, is related to 
high mortality rates and low quality of life.  The one- and two-year mortality for patients 
in NYHA classes III or IV is 40% and 60% respectively. Adults without symptoms (i.e., 
NYHA classes I or II) have a 50% mortality rate within 7 years. 296 This illustrates the 
importance of early detection and prevention of further deterioration of cardiac function.  
Heart failure treatment typically includes medications such as ACE inhibitors, 
beta-blockers, diuretics and aldosterone inhibitors; however, these patients do not 
typically see the same response from medication as heart failure patients with typical 
etiologies. 297 Therapy in later stage patients may require more invasive interventions; 
these can be experimental procedures such as cardiomyoplasty, ventriculectomy and cell 
transplantation, or procedures that are common in clinical practice like transplantation or 
insertion of ventricular assist devices (including artificial hearts). A proposed graphic for 
management is illustrated in Figure 2.4.  298 
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Figure 2.4 Proposed Strategies for Management of Patients with Doxorubicin-












As previously discussed, there are a number of medications that have been shown 
to improve morbidity and mortality in heart failure; however, guidelines do not yet exist 
for patients specifically with chemotherapy-induced heart failure. Patients with this type 
of heart failure have not been shown to experience the same improvement from 
medication therapy.  
An early observation by Lefrak and colleagues noted that this type of 
cardiomyopathy does not respond as well to typical medication therapy. 300 Although, 
that observation was made in 1973, most experts continue to agree. 301 Contrary to those 
findings, in a retrospective review by Haq and colleagues designed to look at mortality, 
these authors concluded that patients did respond well to medication therapy (which 
included digoxin and diuretics at the time of publication). 302  
Most of the prospective trials examining effects of medication on chemotherapy-
induced heart failure have been conducted in survivors of childhood cancers and have 
extremely small sample sizes. A small observational study (n = 3) which included 
pediatric patients, found that the addition of metoprolol to standard medications (i.e., 
digoxin, furosemide, captopril) improved symptoms within two months. Additionally, 
these investigators found that indices such as ejection fraction also improved over the 
follow-up period which was five to 30 months. However, long-term outcomes were not 
available. 303  
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In a randomized, double-blind, placebo-controlled trial, 135 survivors of 
childhood cancer were identified that had at least one cardiac abnormality after exposure 
to anthracyclines. The study was designed to test an intervention to prevent or slow 
progression. The outcomes in this study included maximal cardiac index (MCI), left 
ventricular end-systolic wall stress (LVESWS), shortening fraction (SF), and stress-
velocity index (SVI). There was an initial drop in LVESWS in the first year of treatment 
and this improvement was maintained throughout the follow-up period, however, it was 
not statistically significant when compared to the placebo group. The other outcome 
indices also did not yield statistically significant improvements, even after the prediction 
model was corrected for anthracycline dose received, female gender, treatment with 
radiation, if age of cancer diagnosis was ≤ 3, and years since treatment with anthracycline 
≥ 10. The study had a three-year follow-up period and the authors concluded that the 
short follow-up may be the reason for the lack of statistically-significant improvement in 
the treatment group.304  
In a retrospective study examining the potential long-term benefit of enalapril, the 
investigators reviewed the charts of 18 survivors of childhood cancer. For inclusion into 
the study, patients were exposed to anthracyclines, had received enalapril, and had 
records of ECHO’s during therapy. Outcome criteria included both systolic and diastolic 
blood pressure and ECHO measurements (LV end-diastolic dimension, LV end-diastolic 
posterior wall thickness, LV afterload [end-systolic wall stress], LV contractility [stress-
velocity index], LV fractional shortening, and LV mass). 305 
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These investigators found that there appeared to be improvement in the first 
several years of follow-up, but any beneficial effect was temporary. Patients initially with 
asymptomatic disease (n = 12) trended back to baseline after six to ten years of drug 
therapy; for symptomatic patients (n = 6), improvements lasted two to six years. These 
authors did find that those patients with CHF when starting on medication were more 
likely to show initial improvements. After six years of follow-up, nine patients either died 
or were referred for transplant; this included all six patients that began the study period 
with symptomatic disease and three patients who were initially asymptomatic. The 
authors concluded that enalapril did not appear to prevent progression of advanced 
disease, and select patients may benefit from enalapril therapy such as intermediate 
follow-up of asymptomatic patients or short-term treatment in patients with dilated 
cardiomyopathy. 306 
To determine the effect of traditional medication therapy on doxorubicin-induced 
heart failure, a prospective study was conducted by Tallaj and colleagues. Investigators 
enrolled 25 patients that were referred to their center from 1990 to 2003 with a diagnosis 
of doxorubicin-induced cardiomyopathy. Patients were grouped based on therapy 
received (ACE inhibitors (n = 23) or ARB (n = 2) ± Beta Blockers (n = 15)), with the 
majority (88%) in NYHA classes III or IV. With drug therapy, both LVEF (p = 0.022) 
and NYHA class (p < 0.003) improved over the follow-up period. When comparing the 
different treatment groups, the combination therapy group had a significantly greater 
improvement in LVEF than the mono-therapy group (p = 0.028). Four patients died, three 
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were in the combination therapy group and two deaths were attributed to progressing 
heart failure. 307 
These authors concluded that the outcomes may not be as grim as previously 
thought, based on their study’s results showing a ten-year survival greater than 60%. 
However, the total cumulative dose of doxorubicin was only known in ten patients and 
potential use of combination therapy was not known for any of the study participants. 
The authors conceded that their small sample was a limitation and recognized that more 
studies would have to be conducted, but that their results did show that medication 
therapy could be useful. 308 
 
2.4.4.2 Surgical Options 
 
Transplant was once considered the only therapeutic option for cardiac functional 
improvement in heart failure patients. There is a common limitation- the shortage of 
organs (a barrier for all heart failure patients). The use of transplantation in cancer 
patients elicits unique challenges. Typically, the most frequently encountered barrier to 
transplantation is the requirement that patients have evidence of cure or remission of the 
disease for at least five years. 309 An additional barrier unique to cancer patients is that 
anti-rejection agents have the potential to increase the possibility of recurrence or 
development of second malignancies. Therefore, because of the challenges to receiving 
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this intervention, in patients with or without cancer, other therapeutic modalities in late- 
or end-stage disease are needed. 310 
As a result of the continually evolving criteria for selection for organ 
transplantation, transplants have been successfully performed in cancer survivors. A 
retrospective study was conducted to determine outcomes in cancer patients who 
subsequently developed cardiomyopathy in a single transplant center. That facility had 
performed heart transplants in nine patients who developed cardiomyopathy post 
chemotherapy during the data collection period. Three patients died during the follow-up 
period, causes of death were sepsis, graft failure and recurrence of malignancy. The six 
remaining patients achieved survival similar to patients who had undergone transplant 
without a prior history of malignancy. 311 However, since the mean age of these patients 
was about 30 years old and the sample was extremely small, it may be unrealistic to 
expect similar outcomes in a larger study from multiple centers.  
There are other surgical procedures that could be used, including ventricular assist 
devices (VASD) and ventricular restoration procedures. Either could be used as a bridge 
to transplant or as destination therapy.  The goals of ventricular restoration surgery are 
typically to reduce the chamber volume and attempt to restore the shape/geometry of the 
ventricle. The technique shows increases of LVEF of 29.6% to 39.5% and a 
corresponding decrease in left ventricular end diastolic volume. Additionally, the five-
year survival of patients after this procedure is almost 70%. 312 
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The use of ventricular assist devices and heart transplantation are common 
procedures for patients with late- or end-stage disease. Ventricular assist devices are 
typically used for one of three reasons, as a “bridge” to transplant in patients who qualify 
for an organ but would not survive the wait otherwise, as a “bridge” to recovery in 
patients who are expected to recover ventricular dysfunction after resolution of another 
disorder such as myocarditis, and as an alternative to transplant (i.e., destination therapy) 
in patients who do not qualify for a new organ. 313 
Additionally, now, there are two types of “artificial hearts” available for use in the 
place of VAD therapy. The CardioWest® requires the patient to stay at the hospital 
because of the size of the control panel and the external power source. The AbioCor® is 
an entirely implantable device with a small battery that provides power through the skin 
and was designed as an alternative to transplant with the goal of becoming an effective 




The mortality of chemotherapy-induced heart failure appears to display a similar 
trend to heart failure of other etiologies; patients that are symptomatic at the time of 
diagnosis realize worse outcomes than those patients that are asymptomatic at time of 
diagnosis.  Haq and colleagues performed a retrospective chart review of adult patients 
diagnosed with heart failure subsequent to exposure to doxorubicin therapy. All patients 
that met inclusion criteria were in NYHA classes II – IV and were split into two groups 
                                                 
313 John G.T. Augoustides and Hynek Riha, “Recent Progress in Heart Failure Treatment and Heart 
Transplantation,” Journal of Cardiothoracic and Vascular Anesthesia 23, no. 5 (October 2009): 738–748. 
314 Nicolini and Gherli, “Alternatives to Transplantation in the Surgical Therapy for Heart Failure.” 
 127 
depending on whether CHF was controlled at time of death (group I (n = 18), group II (n 
= 25)) and group I was further subdivided into three groups based on the patients’ 
response to heart failure therapy. There were 43 patients included in the study, all but 
four patients developed symptoms of heart failure within six months of their last dose of 
doxorubicin. Of the included patients, 18 died as a result of heart failure (group I = 12, 
group II = 6). 315 
These authors concluded that symptom severity is a predictor of poorer prognosis, 
patients in NYHA classes III or IV had significantly worse survival than those patients in 
NYHA class II (p = 0.05). The authors also mention that patients may recover some 
cardiac function with appropriate drug therapy, although damage is not considered 
reversible. 316 These results support the idea that monitoring and prevention is a 
worthwhile strategy to improve outcomes.   
In another retrospective chart review of nineteen patients diagnosed with 
anthracycline-induced heart failure, Moreb and Oblon sought to examine long-term 
outcomes. The authors divided the patients into two groups; those who died from CHF 
were in group one (n = 7), those who survived in group two (n = 12). Response was 
defined using the NYHA classification system. Of the patients in group two, three had a 
complete response, eight patients improved and one had stable CHF with follow-up time 
ranging from two to eight years. The authors found a statistically significant association 
between NYHA class and mortality, patients in class III or IV tended toward worse 
outcomes (p = 0.065). 317 
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 The authors also noted that all of the patients in group one received cumulative 
doxorubicin doses ≥ 300 mg/m2, however, five of the patients in group two received 
cumulative doses less than 300 mg/m2 indicating that although cumulative dose is 
considered the most significant risk factor, heart failure can occur at a wide range of 
doses.  These authors did not find a significant association with any other factors, 
although, they do suggest that larger studies may be better able to explore those factors. 
318 
Since treatment of early, asymptomatic disease has been shown to improve long 
term outcomes in heart failure patients, a study was conducted to determine whether 
outcomes differed between patients with class I heart failure and patients with 
asymptomatic LV dysfunction.  Those with class I heart failure must have had prior 
history of congestive symptoms for inclusion. It was found that for those patients with 
asymptomatic LV dysfunction, short-term outcomes were better (100% survival at two 
years), however, long-term survival was not significantly different in the class I heart 
failure group with seven year mortality ~50%. 319 
 
2.4.6 ECONOMIC IMPLICATIONS 
 
A recent retrospective chart review by Choi and colleagues examined the risk and 
cost of anthracycline cardiotoxicity. There were three patient groups, those patients who 
received anthracycline chemotherapy (ACC) (n = 3,428), patients who received a non-
anthracycline chemotherapy (NACC) regimen (n = 7,125) and a control group who did 
not receive chemotherapy (n = 10,553). The authors used the first chemotherapy claim as 
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the index date and patients were followed for 24 months, cardiac event (CE) was 
determined using ICD-9 codes. 320 
The investigators found that the ACC group had higher rates of CE over the 
follow-up period starting as early as month three. At 12 months, the ACC group had 485 
patients with a cardiac event (14%), the NACC group had 381 (5%) and the control group 
had 310 (3%). This gave an OR of 3.98 and 1.31 for the ACC and NACC groups 
respectively.  The mean costs for each group were $59,287, $20,528, and $11,600 for the 
ACC, NACC and controls respectively, showing that groups with higher numbers of 
cardiac events incur greater cost to the health system. 321 
In a much older economic analysis of the toxicity secondary to anthracyclines, the 
authors compared the number of cardiotoxic and febrile neutropenia events, 
hospitalizations and utilization of resources between patients receiving doxorubicin 
(FAC) and epirubicin (FEC) for the treatment of breast cancer.  The study was a 
retrospective chart review, data for cardiotoxic events included the number of monitoring 
procedures that were ordered, occurrence of an event requiring a hospitalization, length 
of hospital stay, supportive care required, number of cardiology consultations. Patients 
with previous cardiovascular event (CHF or MI) were excluded. 322 
The economic analysis was performed from the institutional perspective, the 
study was conducted in Canada using the incidence method and results were reported in 
Canadian dollars. The resultant costs were reported as overall cost per incident and costs 
per cycle of therapy. For medication costs, the authors used the hospital’s ordering cost 
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plus the estimate of personnel cost of medication preparation and/or administration 
(excluding the costs of the chemotherapy regimens because they were considered 
equivalent). The costs for daily hospitalization were obtained from the Ontario Hospital 
Association and the costs for laboratory and diagnostic tests were obtained from their 
respective departments. The authors found that the costs of cardiotoxic events per episode 
were $4,268.08 and $2,447.28 for the FAC (n = 5) and FEC (n = 2) groups respectively. 
When the costs for cardiotoxic events were adjusted for the difference in the number of 
courses received, those costs were $80.77 and $51.90 for the FAC and FEC groups 
respectively (p = 0.68). 323 
 
2.5 Summary of Chapter Two 
 
An unfortunate consequence of cancer treatment is the possibility of long-term 
effects from the therapy.  This is often seen in patients treated for breast cancer with 
anthracyclines and/or trastuzumab. A continuing challenge is that toxicity cannot be 
accurately predicted and since the exact mechanism of cardiotoxicity subsequent to 
anthracycline or trastuzumab is not known it cannot be effectively prevented.  
Clinical practice has attempted to be proactive regarding the issue of 
cardiotoxicity through the development of preventive or protective strategies, however, 
patients still develop this condition. There are data that suggest anthracycline analogs, 
liposomal or pegylated formulations and protective agents can be useful in the prevention 
of heart failure secondary to cancer treatment, however, even when treated with these 
agents, patients still have a risk of heart failure. Additional strategies such as limiting 
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cumulative dose, increasing infusion time, and changing dosing schedules have also 
failed to eliminate this problem.  
Patients that develop heart failure are typically diagnosed in the clinical or 
symptomatic stages and are prone to higher mortality rates than patients who are 
diagnosed in earlier stages. More efficient strategies for long-term monitoring are needed 
to enable earlier detection and diagnosis.    
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Improvements in technology have afforded earlier detection of cancer which 
increases success of treatment thus improving overall survival. The age-adjusted ten-year 
survival for breast cancer, lymphoma and testicular cancer is 70%, 80% and 90% 
respectively. 324 Monitoring for adverse events has become increasingly important as 
improvements in therapy and screenings are realizing higher survival rates. Addition of 
several monoclonal antibodies can increase the cardiotoxicity of several regimens and the 
use of anthracyclines with platinum agents also increases toxicity, whereas platinum 
agents alone have very low cardiotoxicity. 325  
It is recommended that close monitoring of these patients be performed, however, 
concrete guidelines have yet to be developed. It is also recognized that monitoring is 
especially important in patients who have received agents that are known to cause cardiac 
dysfunction, such as anthracyclines, trastuzumab and radiation, or the combination of all 
three. Again, current treatment and surveillance guidelines do not give specific 
recommendations on the best techniques. Monitoring during therapy can assist in 
decisions as to whether to continue chemotherapy to maximize efficacy to eradicate 
tumor burden. 326  
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There are a handful of guidelines that recommend monitoring cardiac function of 
patients receiving cardiotoxic therapy. Available guidelines do not necessarily include all 
of the elements needed to guide monitoring and often do not include recommendations 
for long-term follow-up. 327 Since toxicity has a strong relationship to cumulative dose, 
the recommended monitoring frequencies are often dose-driven.  There appears to be 
differences in sensitivities between patients with regards to the cumulative dose that is 
tolerated, therefore, there is no minimum dose anthracyclines that prevents cardiotoxicity 
for all patients.  
When monitoring for anthracycline-induced cardiotoxicity, it is typically 
recommended at the beginning of therapy, after administration of half the total 
anthracycline cumulative dose, and before every subsequent dose. It is also recommended 
that during follow-up, left ventricular ejection fraction (LVEF) evaluation occur at three, 
six, and 12 months after the end of treatment. 328 The generally accepted “rule-of-thumb” 
for when treatment should be suspended is if there is a decline of LVEF by more than 
10% associated with an absolute LVEF value of less than 50%. 329 However, when 
monitoring cardiac function via LVEF, toxicity may not be apparent until almost 2/3 of 
what is considered the recommended safe dose (RSD) has been received (the RSD for 
doxorubicin is 450 mg/m2). 330 
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Schwartz and colleagues conducted an investigation in which guidelines for 
monitoring patients receiving doxorubicin were developed, patients were categorized 
based on whether follow-up was conducted in concordance or discordance with the 
guidelines and cardiac outcomes were subsequently compared.  The monitoring 
parameters were based on published research and clinical experience. The guidelines 
used in the study included baseline (prior to receiving doxorubicin dose of 100 mg/m2) 
evaluation of LVEF using radionuclide angiocardiography (RNA), this result determined 
the schedule of the subsequent scans (LVEF ≥ or < 50%). For the patients with a normal 
baseline LVEF ( ≥ 50%), the second study was performed after 250 – 300 mg/m2, 
repeated after 400 mg/m2 or 450 mg/m2  in patients with risk factors or without risk 
factors respectively and prior to each dose thereafter. Doxorubicin was to be discontinued 
if LVEF decreased > 10% to value ≤ 50%. For patients with baseline LVEF ≤ 30%, 
doxorubicin should not be started, for LVEF between 30 - 50%, patients received a scan 
prior to each dose, doxorubicin was discontinued if LVEF decreased > 10% to value ≤ 
30%. 331  
Patients were considered high-risk (n = 282) if they met one of three criteria, if 
their LVEF declined by more than 10% to an absolute value of ≤ 50%, cumulative dose 
of doxorubicin of ≥ 450 mg/m2, or abnormal baseline LVEF. Heart failure developed in 
16% (n = 46) of high-risk patients with 21 (46%) mild, 19 (41%) moderate, and five 
(11%) severe cases; there was one death attributed to heart failure (cardiogenic shock). 
Development of heart failure did not differ between patients with or without abnormal 
baseline LVEF. Authors considered heart failure “predicted” if LVEF decreased ≥ 10% 
to a value of ≤ 50% and heart failure resulted after the administration of doxorubicin that 
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followed that decrease. High-risk patients were categorized based on adherence to the 
prescribed guidelines and outcomes were compared between groups.  Group A (n = 70) 
had follow-up that was in accordance with guidelines and had two patients that developed 
heart failure, both were mild cases, whereas Group B (n = 212) had 44 (20.8%) patients 
that developed heart failure (p < 0.001). The authors concluded that these results suggest 
serial RNA has utility in monitoring and preventing heart failure and that guideline 
adherence was effective for prevention and limiting severity in high-risk patients. 332 
When HER-2 positive patients are to receive trastuzumab therapy, there are 
additional recommendations for monitoring developed as a result of findings from the 
HERA Trial.333 There is a baseline evaluation similar to all patients and assessment of 
LVEF by either MUGA or ECHO. It is recommended that LVEF be measured after the 
completion of chemotherapy and before the initiation of trastuzumab. The patient must 
have LVEF above the lower limit of normal (LLN) of the institution for trastuzumab to 
be started. For patients who start trastuzumab, LVEF is re-evaluated at four and eight 
months, and at the conclusion of therapy for any patient who required any cardiovascular 
treatment during therapy. For those who needed therapy postponed, LVEF is re-evaluated 
in three months. If at any time during treatment, the patient develops symptoms 
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Both ASCO and the ACC/AHA have guidelines that mention monitoring cardiac 
function in patients receiving doxorubicin, however, in the case of ASCO, it is only with 
respect to patients already receiving dexrazoxane for cardioprotection. ASCO does not 
make any mention of monitoring strategies in patients who are not receiving 
dexrazoxane. 336 The AHA/ACC guidelines for diagnosis and management of heart 
failure lists anthracyclines as a risk factor, thus these patients would classify as stage A. It 
also states that these patients should be monitored closely and that the use of dexrazoxane 
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could potentially be beneficial. 337 There are guidelines for the use of RNA and ECHO 
developed by the American Society of Nuclear Cardiology and American Society for 
Echocardiography respectively.338 These guidelines provide recommendations for the 
frequencies of scans; however, there is little information given on the course of action to 
take when tests are abnormal.  
Monitoring is important since the earlier left ventricular dysfunction is 
discovered; the sooner patients can begin drug therapy to reverse the remodeling process. 
339 This is true for patients with symptomatic or asymptomatic dysfunction and it has 
been shown that patients who are symptomatic would benefit from receiving 
conventional heart failure therapies such as ace-inhibitors and beta blockers 340 There are 
a number of barriers that potentially inhibit the suggested frequency of monitoring of 
patients in routine clinical practice (outside of a trial setting). The costs of monitoring 
utilizing “preferred” or common methods are high; as a result, patients may not receive 
routine monitoring at regular intervals (if at all).  Therefore, it is necessary to explore 
other options in monitoring of cardiac function; one algorithm was proposed by Clerico 
and colleagues (Figure 3.2).  
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3.2 Methods of Detection 
 
Early detection and treatment of heart failure from chemotherapy or other 
etiologies can reduce development of clinical manifestations. There are a number of 
different methods that could be utilized to monitor patients for the development of 
cardiotoxicity; these include invasive methods such as biopsies, radiological methods 
such as echocardiograms (ECHO) and multiple-uptake-gated acquisition (MUGA) 
scanning (multi-gated acquisition scan), electrocardiograms (ECG’s), and laboratory 
values such as cardiac troponins and natriuretic peptides.342 The table below lists the 
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Table 3.1 Advantages and Disadvantages of Methods to Detect Cardiotoxicity343 
Method Advantages Disadvantages 
Biopsy 
Provides Histological Evidence  Invasive 
Requires specialist  
Small sample is tested 
ECG 
Highly Available/ Non-Invasive 
Computerized analysis  
Prolonged QTc interval possible marker of cardiotoxicity 
Doesn’t provide information on LV function 
QTc interval is the only investigated marker 
Variation in intra-observer interpretation 
Timing of ECG changes is not known 
MUGA 
Well established/ validated method 
Assesses regional wall motion and diastolic function 
Low  intra-individual and intra-observer variability 
High Sensitivity to anthracycline damage 
Exposes patient to radiation 
Not sensitive to early changes in LVEF 
No information on valve function 
Low spatial resolution, High cost 
Limited information on diastolic function 
ECHO 
Provides wide spectrum of information  
Does not expose patients to radiation  
Tissue Doppler imaging may improve detection of 
dysfunction 
Image quality limits use in some patients 
LVEF not sensitive for detection of early disease 
Time consuming, High intra-individual and intra-observer 
variability; Some parameters are dependent on preload  
Biomarkers 
Highly Available; Minimally Invasive 
Easy Analysis/Interpretation 
Low Intra-observer variability 
Data regarding clinical use is limited 
Exact Predictive Value Not Certain 
Positive/Negative Values not yet defined 
MRI 
Can assess myocardial damage and function 
Gives high-quality, detailed image  
Reliable calculation of LVEF 
Limited availability, High cost 
Unknown whether early damage can be visualized 
Contraindicated in those with metal implants 
CT Image quality similar to MRI Low temporal resolution 
High radiation dose 
Limited availability 
LV: Left Ventricular; LVEF: Left Ventricular Ejection Fraction; MRI: Magnetic Resonance Imaging; CT: Computed Tomography; ECG: 
Electrocardiogram; ECHO: Echocardiogram; MUGA: Multi-Gated Acquisition Scan; QTc: Corrected QT interval duration 
                                                 




Biopsies were used in the past and are considered the “gold standard” in 
monitoring of cardiotoxicity as it is often considered the most reliable and specific means 
of detection. Anthracyclines in particular, cause a specific histological pattern of damage 
to myocytes, and these patterns have been shown to mirror clinical findings in animal 
models and in practice. 344 Biopsy provides histological evidence that cannot be provided 
through any other means. However, because of the nature of the sampling (damage is 
typically not uniform throughout myocardium); there is potential for a negative biopsy 
when there is damage present. Additionally biopsies lack any indication of the patients’ 
clinical status or myocardial function. These limitations decrease the utility of biopsy in 
this setting, as well as the resources required and invasiveness of the procedure. 345 
Benefits to biopsy include that it is very specific and sensitive to changes and is 
considered to be the most reliable method, however there are high costs associated with 
this test since the procedure is done through a cardiac catheter and involves interpretation 
by a specialist. Additionally, the use of biopsy to detect changes in this patient group has 
had reports of false negative result. One study found negative results in about 1/3 of 
patients (7 of 20) with clinical symptoms of heart failure; these investigators also found 
that of the 44 patients that did not have clinical signs of toxicity, 23 had histological signs 
of toxicity. These authors calculated a sensitivity and specificity of histological 
evaluation of 65% and 48% respectively and concluded that although their study 
confirmed previous results regarding the risk factors of anthracycline use and 
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cardiotoxicity, monitoring patients with biopsy has limited utility since toxicity could not 
be accurately predicted with histological changes. 346 
Ideally, a monitoring method would be able to detect cardiac changes early 
enough that intervention could provide benefit and this is not true of biopsy, as 
histological changes are often visible late and therefore remodeling would be difficult to 
reverse. 347 Although biopsy results have been shown to correlate well with left 
ventricular function measured by other methods such as ECHO, and has been shown to 
detect damage; it has not been able to predict which patients would experience toxicity.  
Additionally, considering the risk involved with repeated testing and concerns with 
safety, biopsy has had limited utility as a monitoring tool. 348 
There are guidelines in place for interpretation of biopsy results with regard to the 
degree of heart failure (Table 3.2) and the scale has been shown to correlate well with 
dose-dependent damage and left ventricular function as measured by other methods. 349. 
Currently, biopsy is rarely done in favor of less invasive monitoring methods (such as 
radiological procedures or lab tests) that do not require the same level of specialist input 
in performing the procedure and interpreting the results. 350 Current ACC/AHA 
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guidelines do not recommend the use of biopsy in the diagnosis or monitoring of heart 




Table 3.2 Histopathologic Scale of Anthracycline-Induced Cardiac Toxicity352 
 
Grade Features 
0 Within normal limits 
1 
Minimal number of cells (< 5%) showing change  
(such as early myofibrillar loss or distended sarcoplasmic 
reticulum) 
1.5 
Small group of cells involved (5 - 15%) some of which have a 
definite change 
(such as marked myofibrillar loss or cytoplasmic vacuolization) 
2 Group of cells (16 - 25%) some of which have a definite change (such as marked myofibrillar loss or cytoplasmic vacuolization) 
2.5 Group of cells (26 - 35%) some of which have a definite change  (such as marked myofibrillar loss or cytoplasmic vacuolization) 
3 
Diffuse cell damage ( > 35% of cells) with marked change 
(total loss of contractile elements or organelles; mitochondrial 
and nuclear degeneration) 
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Electrocardiogram (ECG) is a recording of electrical activity within the heart and 
the leads attached to patients’ extremities and chest wall are able to detect instantaneous 
differences in electrical potentials. ECG can provide information that is essential to the 
diagnosis and treatment of many cardiac problems, and is the most widely used test in 
cardiac screening. The advantages of this test as a screening/monitoring tool lie in its 
wide availability and low cost. 353 
A variety of ECG changes have been reported with anthracycline use. These can 
include non-specific T- wave or ST-wave changes, low QRS voltage, prolongation of QT 
interval or ventricular arrhythmias. 354 The QT interval is the most often studied 
parameter with respect to anthracycline cardiotoxicity. ECG values automatically print 
out and display with currently available technology, which is a feature that also makes it 
easy to compare to previous testing 355 Patients with early ECG changes usually only 
suffer from acute and sub-acute symptoms that are transient in nature. 356  
Anthracyclines, however, can cause arrhythmias in the chronic toxicity time period. It is 
not known if ECG monitoring would provide improved outcomes for these patients. 
However, prolonged QT-interval dispersion has been shown to predict heart failure in 
patients receiving cyclophosphamide. 357 QT dispersion is defined as the difference 
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between the longest and shortest QT interval in an ECG. Nakamae and colleagues 
conducted a study specifically aimed at determining if there were relationships between 
QT dispersion/corrected QT (QTcD) dispersion and diastolic and systolic parameters as 
measured by ECHO. 358 
The investigators enrolled 79 patients receiving anthracycline therapy for 
hematologic malignancies and along with 44 healthy controls. QT dispersion was 
measured both automatically and manually. Additionally, to assess reproducibility of the 
automatic measure of QTcD, five of the healthy controls had ten automatic measurements 
of QTcD; this yielded a coefficient of variance (CV) of 5.2%. There was a significant 
relationship between automatic and manual measures of both QT dispersion (r = 0.82, p < 
0.001) and QTcD (r = 0.81, p < 0.001). 359 
There were significantly higher QTcD values in the anthracycline group when 
compared to the healthy controls (52.2 ± 14.9 vs. 43.7 ± 10.1 msec. p = 0.001) and there 
was a significant correlation found between QTcD and cumulative dose (r = 0.28, p = 
0.02). Additionally, there were significant correlations found between QTcD and mean 
LV end-diastolic (r = 0.35, p < 0.01) and systolic diameters (r = 0.43, p < 0.01). 
However, when compared to specific measures of systolic or diastolic function, QTcD 
only had significant relationships with LVEF (r = -0.46 p < 0.001) and FS (r = - 0.27, p = 
0.02), which are both measures of systolic function. These authors concluded that 
although their results did not confirm relationships with any diastolic functional 
parameters, they believe that these results cannot necessarily deny relationships between 
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these parameters since ECHO is a poor measure of early diastolic dysfunction. They 
therefore concluded that further study was required. 360 
In a small study of 26 leukemia patients who received anthracycline therapy, ECG 
and ECHO findings were compared. All patients received an ECG at baseline, after the 
first chemotherapy dose, after the last dose and six months after the conclusion of 
therapy. Parameters documented by the researchers included: heart rate, RR interval, PQ 
interval, QRS duration, and QT interval, total QRS voltage in limb leads, presence of 
repolarization changes, arrhythmias or other abnormalities. Each ECG was performed 
and read by two physicians and ECHO’s were done at the same times the ECG’s were 
performed. The authors found a significant correlation between QRS voltage and both 
systolic (r = 0.66, p < 0.001) and diastolic (r = 0.592, p < 0.01) LV dysfunction shown on 
ECHO. There were also significant correlations between QT prolongation and both 
systolic (r = 0.246, p < 0.01) and diastolic (r= 0.257, p < 0.01) LV dysfunction shown on 
ECHO. Additionally, patients with prolonged QTc were at risk for ventricular 
arrhythmias and sudden death. The authors concluded that larger studies would need to 
be conducted to examine the utility of ECG monitoring.  361 
In a slightly larger, yet much older, study enrolled 49 patients who received 
doxorubicin and 20 control patients who had cancer but were treated with other 
chemotherapy regimens. A minimum of four ECG’s were evaluated for each patient. An 
ECG recorded within one month prior to starting doxorubicin was considered the baseline 
in the study group and ECG prior to chemotherapy was baseline for the controls. 
Doxorubicin patients were stratified based on the cumulative dose received. Changes in 
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QRS duration and ventricular conduction patterns were not significantly different 
between groups. These authors therefore concluded that ECG had limited utility in 
screening patients in this setting and that screening should include better tests of 
ventricular function. 362  
There was a recent meta-analysis of four studies examining the use of ECG in 
patients suspected of HF (non-cancer patients) referred for ECHO (n = 1419). The 
authors calculated the sensitivity and specificity of abnormal ECG to identify LV systolic 
dysfunction for each study. The sensitivity for the four studies ranged from 73 to 94% 
and failure to detect patients with LV systolic dysfunction ranged from 6% to 27% 
(average of 16%).  The authors extrapolated an ROC value of 0.84 for the four studies, 
which is the true positive rate. The authors concluded that their results confirmed 
previous results that ECG in inadequate when used as a screening tool in patients who are 
suspected of having heart failure and are referred for an ECHO. 363 
 Since it is primarily non-specific ECG changes seen in anthracycline use, the test 
is non-specific , the false negative rate is high, and a predictive role has yet to be 
established, Therefore, using ECG has not proven to be useful for monitoring/screening 
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3.2.3 RADIOLOGICAL PROCEDURES 
 
Radiological procedures are less-invasive methods for monitoring. These can 
include radionuclide ventriculography or multiple uptake gated acquisition scan 
(MUGA), echocardiography (ECHO), more advanced ECHO procedures like two-
dimensional ECHO with Doppler and stress echocardiography, CT scan, MRI and 
scintigraphy.  These procedures typically are performed to provide information regarding 
the patients LVEF, which is considered the parameter of choice since HF patients’ 
mortality is inversely proportional to LVEF.  Radiological procedures are popular choices 
for monitoring patients because of accessibility, availability of scans and familiarity with 
the procedures; however, these tests tend to be more expensive than laboratory 
monitoring techniques and more resource intensive with respect to scheduling and 
interpretation. Additionally, they are used more often in the trial setting than in regular 
clinical practice. Serial measurements are necessary and have to be compared to baseline 
values to determine if there are clinically relevant changes after therapy. 365 
Typically when utilizing radiological procedures for monitoring or screening the 
LVEF is the most common parameter used to assess cardiac function during cancer 
therapy. LVEF is a ratio of the stroke-volume (which is the difference between the LV 
end-diastolic and end-systolic volumes) to the end-diastolic volume, [SV/EDV] 
multiplied by 100 to yield a percent. LVEF is a measure of systolic function and 
considered the best global indicator of such. LVEF can underestimate the actual damage 
because there is a compensatory mechanism in early dysfunction via a reserve in the 
myocardium that can maintain output although there are damaged myocytes. This can be 
problematic if LVEF is the only parameter used to assess cardiac function as a normal 
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LVEF can mask actual damage as diastolic dysfunction can be present without systolic 
dysfunction and as many as 30 - 40% of patients presenting with heart failure have 
normal LVEF. 366  In addition, research has shown that determination of LVEF is not 
sensitive or specific enough to predict heart failure post-chemotherapy; there are data that 
suggests that drops in LVEF shown on ECHO or MUGA scans are indications of later, 




Echocardiography is a safe and widely available procedure for use in patients with 
known or suspected heart failure. There are a number of different types of 
echocardiography procedures that can be used in diagnosing or monitoring heart failure, 
those include two- and three- dimensional scans, Doppler and stress ECHO’s. The table 
below illustrates the different types of ECHO’s and what each type is used for. 368  A 
benefit of using ECHO instead of methods such as radionuclide ventriculography is that 
ECHO does not utilize radiation in the scan and gives a number of functional parameters 
(both systolic and diastolic) that are not available with radionuclide ventriculography. 
While ECHO can give measures of diastolic and systolic function, diastolic measures are 
more sensitive to early changes in cardiac function.  369  
Expansion of the technology has made ECHO useful in a number of applications 
and there are now several types of ECHO scans that can be performed. These include: 
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two-dimensional trans-thoracic ECHO, Doppler interrogation, Trans-esophageal echo, 
three-dimensional ECHO, and contrast ECHO. The basic two-dimensional ECHO utilizes 
ultrasonic reflections to visualize the structure of the heart. In trans-thoracic (TTE) 
ECHO, the principle is the same, and the transducer is placed on the chest wall. The 
images produced are immediate, which gives ECHO a distinct advantage over other 
imaging techniques, however, with the immediate images comes poor quality creating a 
major limitation. Doppler ECHO also uses the same type of ultrasound technology but 
the reflections are from blood cells instead of the heart itself, in order to measure blood 
flow/velocity. Tissue Doppler ECHO measures the velocity of myocardial motion which 
gives a type of measure for contraction and relaxation. 370 A benefit of three-dimensional 
over two-dimensional ECHO is the ability to depict cardiac structures as they exist in 
three-dimensional space, therefore eliminating the need for modeling and the use of 
assumptions to determine the functional parameters of interest. 371 
While ECHO is a non-invasive procedure, widely available and accessible, and 
often able to detect etiologies of heart failure, there are limitations to the use of ECHO in 
diagnosing patients with HF, which include the dependability of the operator and 
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Table 3.3 Types of ECHO and Uses in Heart Failure373 
 
Type of ECHO Used to Detect 
Routine Use  
Two-Dimensional Anatomical and/or functional cardiac abnormalities 
Doppler Valvular or diastolic function, shunts, intracardiac gradient assessment 
Trans-Esophageal 
Visualize cardiac structures when transthoracic ECHO is 
limited, used when visualization of posterior of heart and 
great vessels is needed 
Stress 
Exercise: assessment of ischemia 
Dobutamine: viability: evaluation of contractile reserve, 
ischemia assessment, stunned and/or hibernating 
myocardium 
Doppler: physiologic information related to symptoms in 
patients with concomitant valvular disease 
Experimental Use  
Three-Dimensional More accurate assessment of cardiac structures; removes geometric assumptions required for 2-D ECHO  
Tissue Doppler Able to detect abnormal patterns to mitral inflow velocities 
Contrast Able to detect perfusion 
 
 
Two-dimensional ECHO (trans-thoracic) is widely used to monitor cardiotoxicity. 
LVEF and fractional shortening (FS) are parameters obtained via two-dimensional ECHO 
that are used to evaluate systolic function. It has been shown that substantial damage is 
possible (i.e., diastolic dysfunction) before there is a notable decline in either FS or 
LVEF. 374 Other parameters that can be obtained via ECHO and used for monitoring 
include endocardial wall thickness, increasing isovolumic relaxation period, reduction in 
peak flow velocity  which are diastolic parameters, all of which manifest sooner than 
changes in FS or LVEF. 375 
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Parameters of interest includes the left ventricular ejection fraction [LVEF], two-
dimensional ECHO can determine ejection fraction from modeling techniques using 
values for end systolic and diastolic volumes. This has shown to be consistent with other 
methods of determining LVEF. A normal value is considered to be ≥ 55 – 60%; and 
values ≤ 40% would warrant drug therapy according to current treatment guidelines. 
Diastolic parameters of interest include the E/A ratio which is a ratio of early to late peak 
atrial velocities. This is important because it has been shown that diastolic impairment is 
more evident in early toxicity, usually before systolic dysfunction can be detected. 376 
ECHO with Doppler imaging is able to detect changes in diastolic function before 
the overt symptoms of systolic dysfunction manifest themselves. 377 Doppler imaging 
gives the ability to visualize flow and therefore, adds the measurement of parameters 
other than those which simply quantify anatomy.  Flow velocity is the most common 
method to evaluate diastolic compliance. The trans-mitral velocity profile provides two 
waves which correspond to the early phase of filling (E-wave) and the atrial contraction 
contribution to filling (A-wave), these values are represented by a ratio of E-wave to A-
wave (E/A) and a normal value is ≥ 1.6. With normal function the E-wave is much larger, 
as the ability of the heart to pump normally becomes impaired, the value for E decreases 
and the pressure in the atrium increases, any value for the E/A Ratio that is < 1 is 
considered abnormal.  378 
Tissue Doppler Imaging (TDI) is a newer technique which permits an assessment 
of myocardial wall motion similar to traditional Doppler ECHO, however this technique 
is able to detect lower velocity frequency shifts. TDI also offers more objective measures 
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of function when compared to traditional ECHO which relies on a visual determination of 
parameters. TDI obtains parameters such as the velocity from early diastole, strain and 
strain rate which are all measures of diastolic function and less susceptible to intra-
observer variability than the E/A ratio. 379  The addition of TDI could potentially add to 
the utility of ECHO in detection of clinical LV dysfunction, the use of ECHO to monitor 
cardiac toxicity is primarily during treatment and while TDI can detect the small changes 
in function, predictive value for heart failure after therapy has been concluded is not 
known. 380 There is increasing evidence that using ECHO to detect chemotherapy-
induced heart failure has low sensitivity in the early stages when drug therapy can be 
most useful in reversing remodeling.  
 
3.2.3.2 Other Imaging Procedures 
 
Multi-gated Acquisition scanning (MUGA) is also known as radionuclide 
ventriculography, radionuclide angiography, and equilibrium radionuclide angiography. 
The procedure involves labeling the patients red blood cell pool with Tc-99m and 
imaging the movement of these cells through the chest as radioactive blood passes 
through the heart and vessels. Cells can be labeled by either injecting them directly or by 
“incubating” cells with the tracer then injecting them into the circulation. MUGA has 
shown to correlate well with LVEF obtained via catheterization (r = 0.94) 381 
MUGA is considered the “gold-standard” for evaluating LVEF, and with ECHO, 
are the most accepted methods of monitoring during therapy. Advantages include high 
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reproducibility and low intra- or inter-observer variability. Disadvantages include the 
exposure to radiation and low sensitivity to small changes that could be present in 
asymptomatic patients with early toxicity. 382 
Cardiovascular MRI or CT scanning are additional alternatives and can be 
performed to assess ventricular function. Cardiovascular MRI is considered the most 
accurate and precise non-invasive imaging technique to assess ventricular dysfunction. 
Some advantages of this technique include: a high resolution of the images, an ability to 
obtain images from any plane/orientation, an image not affected by patient’s body 
habitus, no radiation or contrast needed, all aspects of anatomy and function can be 
evaluated, and consistent values for LVEF can be calculated. However there are 
disadvantages as well to the cardiovascular MRI; the test is not widely available, manual 
tracing of borders increases evaluation time and perhaps bias, artifacts may be created by 
any motion during imaging, it is uncomfortable for claustrophobic patients, and it cannot 
be performed at the bedside (unlike ECHO which can provide similar information). 383  
When combined with contrast, the cardiac MRI has been shown to detect subtle 
areas of myocardium with irreversible damage, however, evidence is lacking that would 
suggest this method has any gains over currently available technology. 384 CT scanning is 
widely available, reproducible and produces images with good delineation of myocardial 
borders. When compared to other methods such as cardiovascular MRI or MUGA, there 
have been mixed results, where some studies show good agreement in measurement of 
left and right ventricles, while other studies conclude that CT scanning overestimates 
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LVEF.  CT is usually not considered an optimal method to determine LVEF as patients 
are exposed to radiation during the procedure. 385 
The choice of scan is dependent on what the scan is meant to look for, as each has 
its own advantages and disadvantages. When measuring LVEF, the indication for testing 
is important as are the needs of the specific patients (i.e., importance of detecting even 
slight changes in LVEF). With regard to imaging, if it is critical to detect slight changes, 
serial measures using cardiac MRI or MUGA scanning are considered optimal. This is 
applicable to cancer patients, pre- and post-transplant patients and patients enrolled in 
clinical trials. 386 
 
3.2.4 LABORATORY PROCEDURES 
 
Laboratory tests can be useful as they provide a non-invasive and inexpensive 
way to quantify a number of different processes with respect to cardiac function. 
Consequently, there are a number of laboratory tests that have been tested for use in 
monitoring cardiac function in cancer patients. The tests that have received the most 
study have been cardiac troponins and natriuretic peptides; however, there are others that 
have been proposed for use. These include serum lipid peroxide, serum carnitine, TNF-α, 
IL-6, IL-2, CA-125 and CRP. Utilizing laboratory methods in place of other more costly 
alternatives can potentially increase efficiency and cost-effectiveness of 
screening/diagnosis of heart failure. 387 
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A biomarker is “a characteristic that is objectively measured and evaluated as an 
indicator normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention”. 388 Biomarkers have proven to be valuable in a 
number of settings and can indicate a variety of health or disease characteristics such as 
genetic susceptibility or response likelihood, exposure types or levels, or subclinical or 
clinical responses to therapy. 389 Therefore, biomarkers have several different ways to 
provide utility in clinical practice, such as diagnosis and staging of disease, prediction of 
prognosis and monitoring responses to therapy. 390  As a result, they have a number of 
categories or classifications. These include antecedent, screening, diagnostic, staging, 
prognostic or therapeutic monitoring. 391  
Some characteristics of useful biomarkers are: they must be accurate, serial 
testing should be inexpensive and timely, they should provide information that would not 
be obtained from routine assessment, and the resulting value should assist in the 
subsequent care of the patient (Table 3.4). 392 Thus, no matter how markers are being 
used, if they are not affecting the management of the patient, they will not improve 
outcomes and will not likely be cost-effective. 393 Biomarkers can be measured from a 
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sample such as blood, urine or tissue, they can be recorded (ECG, BP, Holter monitor), or 
obtained via radiological procedures. 394 
 
Table 3.4 Characteristics and Corresponding Benefits of Ideal Biomarkers395 
 
Administration Interpretation 
Accessible to patient Adequate Analytical Sensitivity 
Easy to Perform High Degree of Diagnostic/Prognostic Accuracy 
Automated High Degree of Reproducibility  
Low Cost International Standardization 
Favorable Cost-Benefit Ratio Low Biological Variation  
 Stability (both in vivo and in vitro) 
      
 
When considering use of biomarker assays, one must consider the specific test 
characteristics such as the assay type, precision and performance relative to other means 
of detection and/or diagnosis. Assays can be point-of-care testing (POC) or rapid testing 
which may have different cut-off values from laboratory tests. 396 Desirable qualities of a 
marker will depend on why it is being measured. Markers used for screening need to have 
low costs, high sensitivity and specificity, high predictive values, and large likelihood 
ratios. On the other hand, when monitoring progression or response to therapy, sensitivity 
and specificity are not priorities since the resultant values are compared to previous 
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results not to population cut-off values and for prognostic markers. In addition, cost is not 
usually as important since only those with the condition are tested. 397  
The need to detect subclinical damage early with economically feasible methods 
has increased the interest in using cardiac biomarkers in screening and monitoring. 
Biomarkers have become a proposed way to monitor cardiac function in cancer patients, 
which could be more cost-effective and less resource-intensive when compared to 
radiological procedures or biopsy. Additionally, biomarkers are typically more sensitive 
to small changes in cardiac function, and have improved diagnostic sensitivity and 
predictive values when compared to traditional methods. 398  
In heart failure, effective biomarkers should provide information regarding 
pathogenesis of heart failure, identify patients at risk, and assist in diagnosis and 
monitoring. Some biomarkers can also serve as therapeutic targets. 399 Each cardiac 
biomarker has characteristic release and clearance kinetics and these patterns can assist 
clinicians in diagnosis and monitoring. 400 There have been a number of markers that 
have been suggested for heart failure, including markers of inflammation (CRP), myocyte 
injury (cTnI) or stress (BNP), neuroendocrine hormones (endothelin), oxidative stress 
(oxidized LDL), and extra-cellular matrix remodeling (collagen pro-peptides).401 
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Examples of potential biomarkers in heart failure with their mechanisms are illustrated in 
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Table 3.5 Reference Ranges for Biomarkers Used in Cardiac Dysfunction 404 
 
Biomarker Reference Range Negative Positive 
BNP < 100 pg/mL ≥ 100 pg/mL 
NT-pro-BNP < 125 pg/mL (< 75) < 450 pg/mL ( ≥75)  
CRP < 0.8 mg/dL  
CRP High-Sensitivity < 0.5 mg/dL  
Heart-Type FABP < 6.2 μg/L  
IL-6 < 5 pg/mL  
Myeloperoxidase < 539 pM  
Myosin Light Chain-1 < 2.5 μg/L  
Plasma Norepinephrine 112-658 pg/mL  
TNF-α < 20 pg/mL  
TNF-receptor I < 0.3 ng/mL  
TNF-receptor II < 1.0 ng/mL  
Troponin T < 0.10 ng/mL  
Troponin I < 0.10 ng/mL > 0.25 ng/mL 
BNP: B-Type Natriuretic Peptide; NT-pro-BNP: N-Terminal – Pro-BNP; CRP: C - 
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Markers of inflammation were shown in the Framingham heart study to identify 
asymptomatic patients that were at risk of the development of heart failure. 405 In animal 
models it has been shown that increased levels of TNF-α have resulted in LV dysfunction 
and examination of tissue from explanted hearts have shown higher myocyte mRNA 
expression of inflammatory markers such as  TNF-α signifying local activation in 
patients with end-stage disease suggesting possibly utility as a marker. Unfortunately, 
markers for inflammation or oxidative stress these are not specific for heart failure which 
reduces their utility in routine clinical use. 406 
Elevated levels of markers for extracellular matrix (ECM) remodeling are 
associated with left ventricular dysfunction and could potentially serve as a target of 
therapy since degradation of the ECM has been shown to contribute to left ventricular 
remodeling. 407 However, since there have been over 15 markers of ECM degradation 
identified and it is not yet known which would provide the most useful information, these 
are not routinely used in clinical practice.  408  
Neurohormones are activated and circulate in response to a reduction in cardiac 
output. This compensation is effective in the short-term, however after long-term 
activation, this can worsen LV function. A number of neurohormones have been shown 
to predict hospitalizations and mortality in heart failure patients and can also serve as a 
therapeutic target. Additionally, markers of endothelial dysfunction have shown similar 
relationships with heart failure as elevated levels of makers for inflammation, oxidative 
stress or ECM degradation. Higher plasma levels of endothelin or endothelin-1 
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correspond to higher mortality in heart failure patients, although blocking the action of 
these substances does not confer improved outcomes. 409 Since neurohormones are not 
stable in plasma, measurement is difficult and although, neurohormones may serve as a 
predictor of outcomes, data are lacking that suggests these markers could be useful in 





Troponins (Tn) are proteins found in striated muscle. There are three subunits that 
regulate the calcium-dependent interaction between actin and myosin, which, in turn, 
forms complexes that regulate muscle contraction. (Figure 3.4) 411 The three subunits 
include the tropomycin binding subunit (T), the inhibitory subunit (I) and the calcium 
binding subunit (C). All three subunits are found in both cardiac and skeletal muscle, 
however, the calcium binding subunit is identical in both, therefore, it is not considered 
useful as a marker. 412 Currently available assays are able to detect levels of the cardiac 
specific isoforms of cTnT and cTnI and both are considered clinically equivalent in the 
detection of cardiac necrosis. 413 
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TnC: Calcium-Binding Subunit; TnI: Inhibitory Subunit;  
TnT: Tropomycin Subunit 
 
Traditionally, the cardiac specific troponins are used to detect damage during or 
after acute coronary syndromes (ACS) such as myocardial infarction (MI). Cardiac 
troponins have been used as a screening tool in this patient population, although, using 
the test in those with a low suspicion of ACS decreases the sensitivity and positive 
predictive value (PPV) to 47% and 19% respectively. 415 Troponins are able to diagnose, 
contribute to risk stratification and assist in designing appropriate care for patients with 
ischemic injury. They are now considered the “gold standard” biomarker in this 
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setting.416 The cardiac specific troponins I and T are considered similar with respect to 
utility in diagnosis and prognosis as well as kinetics in acute coronary syndromes. 417 
Typically, cardiac troponins are first detectable within two hours of the onset of 
symptoms, are considered maximally sensitive 8 - 12 hours later and peak 10 - 24 hours 
later, and are usually detectable for up to seven days but may persist for 14 days. 418  
In diagnosing ACS, the initial troponin has low sensitivity if drawn less than six 
hours after the onset of symptoms and needs to be redrawn in eight to twelve hours if 
negative. However, it can detect an MI up to two weeks after infarction and can be used 
for risk stratification and therapy selection. In addition, it has greater selectivity than 
prior markers (CK-MB) and can detect reperfusion. 419 There are other cardiac conditions 
besides ACS or MI that may show elevations in troponin measurements; these include 
myocarditis, pericarditis, CHF, LV dysfunction and cardiac trauma. There are non-
cardiac conditions that also may show elevations in troponins (usually cTnT); these 
include renal disease (usually later stages), pulmonary embolism (PE), chronic muscle 
disease (muscular dystrophy), and sepsis.  420  
The serum half-life of cTnT is 120 minutes and it is highly sensitive for 
myocardial injury in the first 48 hours (with respect to the onset of symptoms). The level 
of cTnT can remain elevated for five to seven days, but can be detectable for up to 21 
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days. In patients with reduced renal function, cTnT more than cTnI can show false 
positives, therefore, cTnI is sensitive and considered more specific for myocardial injury; 
the level is elevated the first 8 hours, peaks in 24 hours and is detectable for up to seven 
days. Values for cTnI levels have a positive correlation with mortality as higher levels are 
suggestive of more extensive damage.  421 The normal range for cardiac troponins is        
< 0.04 ng/mL; a level within this range is considered a negative result and this is often 
reported as undetectable. The indeterminate range is from 0.05 to 0.49 ng/mL; levels 
within this range suggest additional testing if MI is in the differential diagnosis. 
Additionally, levels of Troponin I in this range are considered at risk for cardiac events in 
the near future. A level greater than 0.5 ng/mL suggests there is a strong probability of 
MI.  422  
 
3.2.4.2.1 Use of Troponins in Heart Failure 
 
Since troponins can detect myocardial cell death, several recent investigations 
have shown increased interest in studying troponin levels in patients with heart failure. 423 
There can be mild elevations in troponins seen in patients both with acute decompensated 
and chronic heart failure (without evidence of ischemia). 424 Additionally, it has been 
suggested that cardiac-specific troponins may provide additional information regarding 
the prediction of prognosis, mortality, and re-hospitalization in heart failure patients and 
could serve as a tool for risk stratification and as a potential therapeutic target. 425 
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In a recent retrospective investigation by Peacock and colleagues utilizing 
ADHERE data (Acute Decompensated Heart Failure National Registry), the investigators 
examined patients who were hospitalized for acute decompensated heart failure who had 
troponins measured on admission. The sample included 84,872 patients over a four-year 
period (2001 - 2004). It was found that patients with a positive troponin test for either 
cTnI or cTnT (n = 4,240), had significantly higher in-hospital mortality (8% vs. 2.7%,     
p < 0.001). The adjusted odds-ratio for death in patients with a positive troponin result 
was 2.55 (2.24 to 2.89, p < 0.001) and when examined on a continuous scale, higher 
troponin levels were associated with higher mortality. Other notable differences were the 
positive troponin group was significantly more likely to receive inotropes (18% vs. 9%, p 
< 0.001) and vasodilators (28% vs. 18%, p < 0.001) when compared to the negative 
troponin group and had a longer time to first diuretic dose (2.4 hrs. vs. 2.2 hrs. p < 0.001). 
426  
The authors adjusted the odds-ratios for mortality for treatment with vasodilators 
or inotropes, the odds-ratios were and 1.84 (95% CI: 1.37 to 2.81) and 1.96 (95% CI: 
1.43 to 2.36) respectively when comparing the troponin-positive versus the troponin-
negative groups. When comparing treatment with inotropes versus vasodilators within 
each group, the adjusted odds-ratios for death were 4.44 (95% CI: 2.90 to 6.81) and 4.54 
(95% CI: 3.75 to 5.49) for the positive and negative groups respectively. These authors 
do propose utility for troponins in this patient population for outcome prediction, 
however, they also stipulate that their study is retrospective and lacks the ability to 
establish cause and effect. 427  
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Two studies were conducted by Missov and colleagues. The earlier of the two 
studies sought to determine whether cTnI was elevated in later stage heart failure 
patients, this was later extended to cTnT measurement in heart failure patients from all 
NYHA classes.  In the first study investigators sought to determine if troponin I was a 
sensitive and specific marker for heart failure in patients with advanced disease. The 
study population consisted of 115 patients, 35 heart failure patients in NYHA classes III 
or IV, 55 patients that were healthy blood donors and 25 patients with hematological 
malignancies (without evidence of cardiac disease) to serve as hospitalized controls. 
Measurements were assessed both with a high sensitivity and the standard assay that have 
a lower limit of detection of 3 pg/mL and an upper reference limit of 1 ng/mL 
respectively. The use of the higher sensitivity assay provided detectable results from the 
control patients, the mean for the entire control population (n = 80) was 25.4 ± 2.9 pg/mL 
(20.4 ± 3.2 for healthy controls and 36.5 ± 5.5 for hospital controls).  The mean cTnI 
level for the heart failure group was 72.1 ± 15.8 pg/mL; this was found to be significantly 
higher than the pooled, healthy, and hospitalized control groups (p < 0.01). Additionally, 
the authors were not able to demonstrate a difference between ischemic and idiopathic 
dilated cardiomyopathies or between NYHA classes III or IV. 428 
However, when the standard assay was used, only one patient had a level that was 
greater than the 1 ng/ml upper reference limit. Eight heart failure patients did not register 
a detectable level and the remaining 26 had levels that were below the upper reference 
limit. The authors concluded that these results provide strong evidence that the number of 
patients with positive tests depend on the sensitivity of the assay. They also conclude 
more work needs to be done in a larger population that includes heart failure patients 
                                                 
428 Missov, Calzolari, and Pau, “Circulating Cardiac Troponin I in Severe Congestive Heart Failure.” 
 168 
from all functional classes and examination of the possible implications of targeting 
levels as therapeutic outcomes. 429 
A second study conducted by Missov and Mair that looked at troponin T levels in 
heart failure patients. In the troponin T study, 33 consecutive patients with what was 
considered stable heart failure were enrolled for evaluation, 10 patients (30%) were in 
NYHA classes I or II and 18 patients (55%) had heart failure resulting from an ischemic 
etiology. The control group (n = 47) included age and gender matched healthy blood 
donors. The assay used in the study was a second generation assay that utilized 1 ng/ml 
as the diagnostic upper reference limit. 430 
The measured cTnT was significantly higher in the study population (0.140 ± 
0.439) versus the controls (0.0002 ± 0.001) (p = 0.0001). There was also a statistically 
significant difference in cTnT between patients stratified on heart failure severity. 
Patients in NYHA classes III or IV (0.163 ± 0.50) had a significantly higher cTnT than 
those in NYHA class I or II (0.007 ± 0.01) (p = 0.04). The authors state that the increase 
in cTnT parallels the disease severity and the decline of left ventricular function             
(R = - 0.41, p = 0.01).431 The authors did not find a significant difference between 
patients with ischemic cardiomyopathy and those with idiopathic dilated cardiomyopathy.  
The authors concluded that these results suggest that cTnT would be a viable, low-cost 
option in screening asymptomatic patients. 432 
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In a more recent study by Latini and colleagues, the investigators also examined 
troponin T with both the standard assay and a high-sensitivity assay to determine if there 
was a relationship between the detected level and patient prognosis. The authors intended 
to confirm previous findings in smaller studies which indicated that elevated troponin 
levels can predict adverse outcomes in heart failure.  At the time of publication, the high-
sensitivity assay was not commercially available. 433 
The Valsartan® Heart Failure Trial (VAL-HeFT) population included 5,010 
patients, all of which had a LVEF of < 40% and were currently receiving heart failure 
pharmacotherapy. Troponin measurements were assessed at baseline (n = 4,053) and at 
follow-up four months later (n = 3,474) using both assays. The lower limits of detection 
for the standard and higher sensitivity assays were 0.01 and 0.001 ng/mL respectively. 434 
Of the 4,053 patients with troponin measurements, 420 (10.4%) had detectable 
values with the standard assay (median 0.027 ng/mL) compared to 92% of patients with a 
detectable level using the high sensitivity assay (median 0.012 ng/mL). Patients with 
elevated levels were more likely to be male, non-white, diabetic, and older, have a lower 
ejection fraction, and be classified in NYHA class III or IV. They were more likely to be 
treated with digoxin and diuretics, but less likely to have been receiving beta-blockers at 
study entry. Those patients also had elevated levels of neurohormones associated with 
poor prognosis. Of those patients from the placebo arm of the trial, disease was 
considered stable if the patients had < 2 kg change in body weight, < 5% change in 
ejection fraction, and unchanged NYHA functional class. There were 670 patients that 
met these criteria. 435 
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The two main outcomes of interest were all-cause mortality and hospitalizations. 
Of the original patients, overall mortality was 16.5% and 43.3% for patients without and 
with detectable cTnT levels respectively (p < 0.0001). Mortality was 7.8% and 35.6% for 
the lowest and highest quartile of high sensitivity cTnT respectively. There was a similar 
trend in heart failure-related hospitalizations.  In a separate Cox Multivariate analysis 
where cTnT was dichotomous (detectable vs. undetectable), the authors reported that 
detectable levels had the strongest association with all-cause mortality, reporting a hazard 
ratio of 2.08 (95% CI: 1.72 to 2.52). In a model substituting high sensitivity troponins, 
detectable levels were also the strongest predictor of mortality. In the model predicting 
hospitalizations, the standard and high sensitivity assays ranked sixth and seventh 
respectively. The authors then explored using both troponins and BNP as predictors. The 
VAL-HeFT data demonstrated a moderate correlation between the higher sensitivity 
assay and BNP (r = 0.441 p < 0.0001). In a prediction model, each predictor was added 
separately then together. BNP, and both high sensitivity and standard troponins, all were 
statistically significant predictors for both mortality (p < 0.001) and hospitalizations       
(p = 0.025). 436 
The authors concluded that troponin values which would be considered irrelevant 
clinically in the context of acute coronary syndromes appeared to be a valuable outcome 
prediction measure in stable heart failure patients. The addition of troponin, specifically 
the high sensitivity assay, adds to prognostic information and risk stratification for 
patients with stable heart failure. The authors also maintained that serial measurements 
can be clinically relevant and suggested that future studies focus on two or more markers 
as it appears BNP and troponins contributed unique information to the clinical picture. 437 




3.2.4.2.2 Troponins in Cardiotoxicity 
 
To date, there have been a number of studies that examined the use of troponins to 
monitor cardiac function in cancer patients with a total of approximately 1,500 patients. 
The bulk of the evidence provided in favor of the use of troponins, are four studies that 
are from the same group of investigators. In two of those studies, troponins were 
measured using an assay that is no longer commercially available (Dade Stratus II). 
Patients on cardiotoxic chemotherapy with positive troponins ranged from 30% to 38%, 
therefore the authors concluded that troponins were able to detect some level of 
myocardial injury in about one-third of patients receiving cardiotoxic chemotherapy.438; 
Cardinale et al 2002)  
In the first of four studies, cTnI measurement was essentially identical for each 
protocol, values were evaluated immediately before, immediately after, and at 12, 24, 36, 
and 72 hours after receiving the drug (i.e., each patient had six measures per infusion), 
and only the highest values were considered. Patients were followed for ten months to 
determine if cardiotoxicity developed. All patients had values within normal limits at 
baseline and at each subsequent measurement (i.e., each measure would be considered 
negative using threshold criteria for ACS).  439 
Patients were classified as positive if levels were detectable, this occurred in 65 
patients (32%), 59 (53%) of these patients had detectable levels immediately following 
drug administration, 10 (9%) at 12H, 21 (19%) at 24H, 8 (7%) at 36H, and 14 (12%) at 
72H. Of those with detectable troponins, 19 (29%) had a measured LVEF < 50% at any 
time during follow-up compared to zero in the other group (p < 0.001). Three patients 
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developed symptoms of heart failure, all of which had detectable troponin levels, as well 
as a positive CK-MB and LVEF < 30% at the last evaluation prior to symptom onset. The 
maximal percentage change from baseline of end-systolic (ESV) and end-diastolic 
volumes (EDV) were calculated and found to be significant for both groups. The authors 
however, state that the changes were greater in the troponin-positive group. Additionally, 
the authors found that there was a significant relationship between the maximum troponin 
value and maximum LVEF reduction (r = - 0.87, p < 0.0001). Therefore, they concluded 
that positive troponin measurements could serve as a prediction tool for future systolic 
dysfunction. 440 
In a 2002 study these same investigators conducted essentially the same study 
with a longer follow-up (14 months instead of 10), except this study population was 
entirely breast cancer patients (n = 211). Patients were treated with one of four different 
regimens, two of which were anthracycline-based (n = 136), and all of the patients who 
received non-anthracycline regimens in this study had received anthracyclines in the neo-
adjuvant setting. This study used the same assay, identical limits of detection for positive 
values and measurements were taken at the same times relative to drug dosing.  441 
Ten (4.7%) patients developed symptoms of heart failure during follow-up (LVEF 
range from 30 - 45%), three of which developed overt heart failure (LVEF < 30%), cTnI 
was within normal limits (WNL) at baseline and for each of the subsequent measures for 
all patients. A detectable value was reported in 33% of patients (n = 70) and in 120 cycles 
(19%) of chemotherapy. Patients with detectable levels were then categorized based on 
maximal troponin as either positive (≥ 0.05 ng/mL) or negative (< 0.5 ng/mL). In the 
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troponin-positive group, 17/75 (23%) previously received anthracyclines. In the troponin-
positive patients, LVEF decline was observed after one month of follow-up and 
continued over the duration of follow-up, whereas, the troponin-negative group did not 
have a significant decrease in LVEF.  442 
Similar to the previous study, these authors found a significant relationship 
between the maximal troponin value and the maximal LVEF decline over the follow-up 
period (r = - 0.9, p < 0.0001), and between the number of positive assays (for each 
patient) and LVEF decline (r = - 0.93, p < 0.0001). Of the ten symptomatic patients, all 
had multiple detectable levels ranging between five and seven positives per patient (of 18 
measurements). Conclusions were similar to the prior study. 443 
The 2003 study had a similar protocol to the previous two studies; however, a 
different assay was utilized.  The population included 179 patients with varying 
diagnoses; this included nine patients from a previous pilot study. Troponins were 
measured at the same times as previously described and were interpreted in a similar 
fashion. However, the 99th percentile was obtained from testing 99 healthy individuals 
and the threshold value was determined to be ≥ 0.08 μg/L. An ECHO measurement was 
conducted at baseline and at 1, 2, 3, 4, 7, and 12 months. 444 
Patients were categorized as per the previous study protocols.  Patients with 
positive results (n = 57) had an average of 2.7 positives per patient, detectable levels were 
spread homogenously among collection times with the exception of the final measure at 
72 hours, which resulted in fewer positives. There was a trend toward an increasing 
number of positive values with the number of cycles. Patients in the positive group were 
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more likely to have received anthracyclines in the past (72% vs. 45%, p < 0.05), groups 
were balanced on all other characteristics at baseline including LVEF. Patients with 
positive troponins had an average decrease in LVEF of 6.8% after one month of follow-
up, which progressively worsened over the evaluation period (at 12 months, the mean 
decrease was 18.2%). 445 
In comparison, the negative group had a mean LVEF decrease of 1.5% at one 
month and 2.5% after 12 months, which was statistically significant at each interval. 
Conclusions for this study were similar to previous studies, that measurement of 
troponins could provide a reliable early marker for myocyte damage secondary to 
chemotherapy and potentially identify “at-risk” patients. Furthermore, they speculated 
that although there were twenty patients with elevated levels that did not experience 
decreases in LVEF, this might be explained this by the short follow up period. 446 
In 2004, the same authors conducted a study including 703 patients with various 
malignancy types, during this study, the investigators gathered troponin values at the 
same times surrounding each dose of the drug. However, they also obtained cTnI levels 
one month after the conclusion of therapy and this was considered the late or L-cTnI 
level. Patients were categorized as to whether they had detectable levels in early 
measurements only (TnI +/-), early and late   (TnI +/+), or neither (TnI -/-). Troponin 
values in 70% (n = 495) of patients were below the cutoff in both early and late 
measurements and were categorized as TnI -/- . Of the remaining, 145 (70%) had 
detectable troponins in the early phase only and were categorized as TnI +/- and 63 
(30%) continued to have detectable levels in the late phase and were categorized as      
TnI +/+.  Of 111 patients that experienced cardiac events, there were significant 




differences found when comparing patients who had late detectable values and those 
without (p < 0.001) and comparing patients with early positives and those without          
(p < 0.001).447 
Additionally, from these studies, the authors concluded that troponins are able to 
predict clinically significant dysfunction up to three months in advance and that an early 
increase in troponins can predict the degree and severity of dysfunction. It must be noted 
that the dysfunction was detected using ECHO or MUGA scanning. It was determined 
from these trials that a persistent increase in troponins up to one month after 
chemotherapy is associated with greater cardiac dysfunction and an increased risk of 
cardiac events within the first year of follow-up than patients with only a brief increase. 
The negative predictive value was reported as 99% for patients who continually have 
negative troponins. 448 
A limitation to the use of cardiac troponins in monitoring is that peak levels are 
not seen consistently or in predictable patterns around chemotherapy administration. In 
the above listed trials, there were six measures taken for each administration of drug and 
the highest was considered for analysis, therefore it may be necessary to obtain serial 
measurements to provide useful information. 449 Multiple blood draws may make this 
unattractive in routine outpatient clinical practice. The authors of these studies justify the 
use of troponins by concluding that although multiple measures may be necessary, the 
cost of the test is low and negative values would exclude those patients from further 
expensive radiological procedures. However, they do not mention or allude to costs that 
would be involved in bringing the patient back to the clinic several times after drug 
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administration to obtain these values, and although, the authors conclude the cost is 
justified and the method is cost-effective, no analysis is presented to support this 
conclusion. 450 
 
3.2.4.3 Natriuretic Peptides 
 
Natriuretic peptides levels could also be obtained from relatively non-invasive 
blood draws and could provide another attractive alternative to traditional monitoring 
with ECHO or MUGA. Natriuretic peptides are neuro-endocrine hormones whose 
function in heart failure is to assist in fluid regulation (increasing urine volume and 
sodium excretion). BNP levels are known to increase proportionally with an increase in 
fluid volume and ventricular dysfunction.451 The mammalian natriuretic peptide system 
involves three different substances; those are ANP (atrial natriuretic peptide), BNP (b-
type natriuretic peptide) and CNP (c-type natriuretic peptide). The three peptides share a 
17 amino acid ring. 452 
ANP was the first of the three to be described in 1983. ANP is synthesized and 
released into the atrium and its secretion is stimulated by stretch. ANP can also be found 
in ventricular tissue in patients with left ventricular hypertrophy but is not found in 
healthy ventricular tissue. ANP has an extremely short half- life lasting only one to two 
minutes in plasma, making measurement difficult. Therefore, for clinical purposes, NT-
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ANP is measured in lieu of ANP since it is released in equal amounts and is not degraded 
as quickly. 453 
B-type natriuretic peptide (BNP) was formerly known as brain natriuretic peptide. 
It was initially called brain natriuretic peptide because it was originally identified in 
porcine brain in 1988. It consists of 32 amino acids, found in highest concentration in the 
atria, but because of the larger size of the ventricles, it is released in greater amounts from 
the ventricles. Both ANP and BNP have similar hemodynamic effects, which include 
increasing urine output and sodium excretion, decreasing systemic vascular resistance 
and central venous pressure, increasing cardiac output and decreasing blood volume. 
These actions subsequently cause arterial and venous dilation leading to reduced blood 
pressure and ventricular preload and are the exact opposite effects of the renin-
angiotensin-aldosterone system (RAAS).  454  
 ANP and BNP also have important central and peripheral sympathomimetic 
effects which include blocking cardiac sympathetic nervous system activity- even when 
cardiac filling pressures fall. They both also inhibit the renin-angiotensin-aldosterone 
axis; ANP infusion directly blocks secretion of renin and aldosterone and further inhibits 
the stimulatory effect of angiotensin II on release of aldosterone. BNP has direct relaxing 
properties in the myocardium and might have anti-proliferative and anti-fibrotic effects in 
vascular tissues. CNP does not act as a circulating hormone; it acts locally in vasculature 
as a vasodilator and inhibitor of vascular proliferation. 455 
BNP gene expression is induced within one hour of overload, which is one quality 
that makes it a good clinical marker. Chronic overload causes levels to be constantly 
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increased. It is secreted by both ventricles of the heart in response to stretching of the 
myocytes, and has a half-life of 20 minutes. 456 BNP is secreted with an N-Terminal 
fragment called NT-pro-BNP which is biologically inactive but has a longer half-life of 
one to two hours. Both have uses in screening and diagnosis and are also useful in 
determining prognosis, as those with higher levels experience worse outcomes. Both 
BNP and NT-pro-BNP are measured in pg/mL in U.S. assays.457 Figure 3.5 illustrates the 
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The stimulus for release for both ANP and BNP is myocyte stretch and both are 
synthesized as precursors and undergo intracellular modification to prohormones.  ANP 
is sequestered in atrial storage granules and cleaved into a 98 amino acid (AA) N-
terminal fragment. The 28 AA active hormones are released into the circulation and 
regulation occurs at the level of release from storage. BNP regulation takes place at the 
level of gene expression. BNP is synthesized in bursts and released from ventricular 
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myocytes as a 76 AA N-terminal fragment and a 32 AA active hormone. The expression 
of BNP can increase very rapidly in response to stimulus.  In addition to primary 
regulation via myocyte stretch, synthesis can by augmented by tachycardia, 
glucocorticoids, thyroid hormones and vasoactive peptides such as endothelin-1 and 
angiotensin II independent of the hemodynamic effects of these factors. 460 
A third natriuretic peptide, CNP, was also found in porcine brain in 1990 and it 
was thought to be mainly a regulator, with actions primarily in the brain. CNP, however, 
also resides in vessels and can cause vasorelaxation of vascular smooth muscle. The 
plasma concentrations of CNP are extremely low and cause minimal diuresis and 
natriuresis. Most of the biological effects of all three natriuretic peptides occur via a 
second messenger system via guanosine monophosphate. There are three receptors 
identified which are NPR-A, NPR-B and NPR–C. NPR-C is a clearance receptor for 
ANP and BNP, the lower affinity of the NPR-C for BNP gives it a longer plasma half-life 
and thus, greater utility as a marker. 461  
 BNP and NT-pro-BNP are well established markers for left ventricular 
dysfunction but are still seeing resistance to their routine use. Since it has been known 
since the 1950’s that the heart was an endocrine organ, increased levels of such 
vasoconstrictors neurohormonal factors such as norepinephrine, renin, and enodthelin-1 
have been found to be significant prognostic predictors in heart failure.  Antagonizing 
these same neurohormonal factors has led to improvements in cardiac function. However, 
monitoring these factors is impractical because of instability, difficult assay 
characteristics with wide ranges and overlapping values, thus making natriuretic peptides 
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better candidates for monitoring.462 In a recent review, the authors suggest clinical trials 
should include rather than exclude patients that have cardiac risk factors in order to study 
new methods of monitoring and treatment. 463 
 
3.2.4.3.1 Available Assays 
 
BNP can be measured using either traditional laboratory techniques or a bedside 
assay that has recently become available.  The Triage® BNP test, according to the 
manufacturer Biosite®, is the only point of care assay available that is a CLIA waived 
blood test for BNP. The assay needs to be used with the Triage® meter. The Triage® BNP 
test is a fluorescent immunoassay that quantitatively measures BNP in whole blood or 
plasma using only EDTA as the anticoagulant.464 Samples collected are stable for four 
hours. The test kit must be refrigerated and once opened, is stable at room temperature 
for 14 days. (http://www.alere.com/EN_US/index.jsp) The assay can detect values 
between 5 pg/mL and 1,300 pg/mL; however, the actual value can potentially be up to 
3500 pg/mL.465 The accepted upper limit of normal for BNP is 100 pg/mL. The Triage® 
BNP test gives results in 15 minutes, with a specificity of 98% and > 98% negative-
predictive value with a cut-off of 100 pg/mL.466   This study used the 2002 cost of the test 
kit for analysis, which was $26.  
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To be useful as biomarkers, peptides must be able to be measured rapidly and 
accurately at a reasonable cost, add diagnostic or prognostic information and help guide 
patient management. BNP and NT-pro-BNP fit most of these criteria in patients with 
heart failure, both BNP and NT-pro-BNP provide similar information and assays are 
available for both. 467 Candidates for assay use would be patients who present to an acute 
care setting with signs and/or symptoms suggestive of heart failure but in whom a 
diagnosis is in question. The assay can assist in distinguishing heart failure from 
respiratory reasons for dyspnea or renal reasons for edema. 468 
While high BNP is specific to heart failure, it does not preclude the existence of 
other disease states creating a potential limitation for use. Other limitations may include 
that patients with chronic heart failure may test with persistently high BNP values - so in 
determining their clinical status - comparison to their baseline value may be necessary. 
469 Additionally, there are several disorders corresponding to small or intermediate 
increases in BNP, including right ventricular dysfunction or left ventricular hypertrophy 
(LVH). This would have to be considered when using the assay as a screening tool. 
Normal values have yet to be established, although levels are known to be affected by 
age, gender, renal failure and medication use (such as diuretics and beta-blockers). These 
factors need to be considered before use.470 
With a number of limitations, the assay still has utility in diagnosis, screening, 
risk stratification, monitoring and tailoring therapy.  471 A recent paper by Cowie and 
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colleagues describes two available assays, the first is a point-of-care rapid fluorescence 
immunoassay for BNP, which provides results in about 15 minutes and produces results 
that appear to correlate well those from radioimmunoassay. The second assay is an 
electrochemiluminescent assay available for measuring NT-pro-BNP and this yields 
results in about 18 minutes. The reference ranges for both assays vary depending on the 
assay method and the nature of the control population. In general, values rise with age 
and are higher in women than in men for matched ages. The suggested normal range for 
BNP is 0.5 – 30 pg/mL (0.15 – 8.7 pmol/L) and for NT- pro-BNP is 68-112 pg/mL (8.2 – 
13.3 pmol/L). The suggested cut-off point for detection of heart failure is 100 pg/mL in 
those patients older than 55. For NT-pro-BNP the cut-off points in Europe are gender-
specific with a cut-off of 100 for men and 150 for women. The cut-off is 125 for both 
genders in the US. 472 
The authors concluded that BNP testing is most valuable to non-specialist 
physicians in the diagnosis of heart failure. In practice, the assay should be used as a rule-
out test, but for cardiologists, the assay does prove useful for monitoring outcomes and 
tailoring existing therapy. These authors also suggest there may be value in monitoring 
BNP values in selecting patients for transplant. Additionally, ejection fractions were 
noted if assessed within twelve months of the physical exam. The protocol defined 
systolic dysfunction as ejection fraction (EF) ≤ 45% and diastolic dysfunction as EF > 
45%. Using these criteria, 231 patients had systolic dysfunction and 71 patients had 
diastolic dysfunction.  473 
A prospective multicenter study by Wieczorek and colleagues was designed to 
assess the use of a point-of-care assay to diagnose and evaluate heart failure severity 




using NYHA classification. The design categorized patients into three groups, the CHF 
group (n = 409), the control group (n = 473) and a second control group of patients with 
hypertension (n = 168). The CHF group included patients in all four functional classes of 
heart failure (the CHF group), the first control group included patients without heart 
failure or other cardiovascular disease, and the additional control group included patients 
with hypertension but without other cardiovascular disease. Samples were drawn from 
the hypertension group, when it was determined that their BNP levels were not 
significantly different than the control group, these groups were combined. Of the 
patients with heart failure, 28% were diagnosed with idiopathic heart failure, 43% were 
diagnosed with ischemic heart failure, 19% had other causes such as hypertension or 
alcoholism, and 10% had an unknown cause.  474 
Samples were drawn and examined in triplicate using the Triage® assay. 
Measurements were made using whole blood and plasma and there were no significant 
differences found. The findings for non-cardiac patients were inconsistent. The BNP 
levels were higher in women than in men and increased with age; this difference did not 
becoming significant until patients were over the age of 55. 475 
In the CHF groups, the circulating BNP increased with disease severity; however 
it was not possible to predict class because of the overlapping confidence intervals. The 
authors attributed this degree of overlap to the subjective nature of the classification 
system. The investigators also found a negative linear relationship between BNP and 
systolic ejection fraction. 476 The sensitivity and specificity of the assay was also tested in 
these patients.  Using a cut-off of 100, the specificity was 97% and the sensitivity was 
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82%. Using a ROC for each class plotted against BNP; BNP was able to separate normal 
patients from those in each class. Confidence intervals got wider as disease severity 
increased. The assay had the highest sensitivity and specificity when comparing the 
control to those patients in class four and had its lowest values when comparing the 
controls with the patients in class one. 477 
 The authors concluded that BNP concentrations taken with bedside assay 
increased with CHF severity, differences were only seen between individuals with and 
without CHF.  With a decision threshold equal to 100 pg/mL, this assay demonstrated 
82% sensitivity and 99% specificity for distinguishing patients with CHF. These authors 
suggested that a lower threshold (such as 50 pg/mL), might also be useful as a negative 
predictive value.  478 
As previously discussed, there are several properties that would make any 
biological marker assay useful. BNP levels should be measured accurately and rapidly, 
and this is met by the currently available bedside assay where results are available in 15 
to 30 minutes. Levels should not be changed by any property that does not change the 
state of cardiac compensation, which is the case of the Triage® assay; the results are not 
affected by any major class of cardiac drugs.  Changing levels should be indicative of 
either de-compensation or improvement in function, which had been demonstrated in a 
number of studies. And, lastly, the assay should be able to be used to tailor therapy. 479 It 
has been shown that BNP levels correlate to elevated end diastolic pressure which in turn, 
correlates closely to the chief symptom of CHF which is dyspnea. The BNP levels 
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correlate closely to NYHA classification, which would make it useful in tailoring 
therapy. 480  
A threshold of 100 pg/mL has been suggested to allow for the increased levels 
seen with advancing age and provides the ability to discriminate patients with CHF from 
patients without CHF. This level shows sensitivity from 82.4% for HF in general and 
increases to 99% for CHF in NYHA Class IV. Specificity exceeded 95% when 
comparing patients without HF with all patients with HF, and 93% in all subsets studied. 
It has been suggested by a number of researchers that a lower cutoff may be practical for 
screening large populations for LV dysfunction. 481 There is strong evidence suggesting 
that levels below 100 pg/mL have a strong negative predictive value for heart failure. 
Monitoring levels during acute decompensated states can be useful in gauging effects of 
short-term treatment. 482 
Maisel suggests that since heart failure affects 2% of the US population, is the 
fourth leading cause of adult hospitalizations, and is the most frequent cause of 
hospitalization in patients older than 65, finding a blood test to aid in diagnosis and 
management of heart failure clearly would have a favorable impact on the costs 
associated with the disease. Maisel cited direct costs of heart failure exceeding $38 
billion, which accounts for over 5% of total health care costs. 483 When screening 
asymptomatic patients, it is important to consider the value used for a lower cut-off for 
negative predictive value. It has been suggested that a much lower value (such as 20 
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pg/mL), be used when screening asymptomatic patients. 484 The half-life of BNP is about 
20 minutes which suggests that it can accurately detect a change in pressure every two 
hours, whereas NT-pro-BNP has a half-life of about two hours which suggests that 
meaningful hemodynamic changes could be detected about every 12 hours. 485 
Like BNP, NT-pro-BNP is secreted from the ventricles as a result of increased 
stretch or tension and has been shown to correlate well with NYHA class. Concentration 
in plasma is about the same for BNP and NT-pro-BNP in healthy patients; however, for 
patients with heart failure, NT-pro-BNP can exceed BNP concentration by two to ten 
times, the mechanism of this difference is not yet know. It has been shown in animal 
studies that the half-life of NT-pro-BNP is much longer and this is often credited for the 
difference in concentrations.486 The assay for the measurement of NT-pro-BNP can be 
conducted with several different analyzers, including the Roche Elecsys 1010®, 2010® 
and E170®; all of which use the same detection technology (chemiluminescence) and 
analytical range (5 – 35,000 ng/L). 487  
A study to determine the precision and comparability of the assay was performed 
using samples with concentrations representing the entire analytical range, thus including 
healthy subjects and known heart failure patients (n = 1,205). Each subject had a full 
evaluation of risk factors, blood work including full biochemical profile (LFT’s, lipid 
profile), and ECHO for measurement of LFEF. Patients were then categorized based on 
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risk factors and LVEF. Results from NT-pro-BNP were compared to both BNP and NT-
pro-ANP. 488  
Of the study population, it was determined that 290 patients were without risk 
factors therefore patients represented the healthy population. The results from the healthy 
population demonstrated that NT-pro-BNP increases with age and with female gender. 
To determine the ability of the assay to detect LV dysfunction, patients were categorized 
on LVEF greater or less than 40%. The ROC curves for the 1) entire population, 2) low-
risk patients and 3) high-risk patients were 0.913, 0.974, and 0.832 respectively. These 
authors concluded that the assay performed well and met criteria typically used to 
determine if an assay could be useful in practice. They also stated that further work was 
required but their preliminary data demonstrated that NT-pro-BNP was able to detect LV 
dysfunction. 489 
 A study by Gustafsson and colleagues sought to determine the sensitivity and 
specificity of the NT-pro-BNP assay to detect LV systolic dysfunction in primary care 
patients and to predict death in these patients.490 The sample included patients who were 
referred by their general practitioner to receive an ECHO because of suspected heart 
failure (n = 367). As a result of the ECHO, patients were categorized into three groups 
based on their ejection fraction, 1) > 40%, 2) > 30 but ≤ 40%, 3) ≤ 30%. The 
corresponding mean NT-pro-BNP levels were 136 pg/mL, 1,643 pg/mL, and 4,314 
pg/mL respectively. The NT-pro-BNP levels were significantly higher in the LVEF ≤ 
30% when compared to patients with LVEF > 30% (p < 0.0001), additionally, patients 
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with LVEF ≤ 40% had significantly higher levels when compared to those with LVEF > 
40% (p < 0.0001). The assay proved to be reasonably sensitive for patients with LVEF ≤ 
40%; the sensitivities were 91% and 97% both with and without utilizing age-specific 
cut-off values respectively. While for patients with LVEF ≤ 30%, the test was 100% 
sensitive with or without adjustment of the cut-off value. 491 
While assays are available for both BNP and NT-pro-BNP, there are some distinct 
advantages of the BNP assay, including: it is available at the point-of-care, it is less 
influenced by age and renal function, it has a single approved value used for diagnosis, 
and it has a documented ability to discriminate between patients both with and without 
heart failure. 492 There are a number of positive points with the NT-pro-BNP assay as 
well. The NT-pro-BNP assay includes use on large laboratory platforms for economies of 
scale; its relationship to renal function has led some investigators to suggest that NT-pro-
BNP may be an overall marker of cardio-renal function. However, a disadvantage for its 
use is that the cut-off for NT-pro-BNP is dependent on patient age. Both BNP and NT-
pro-BNP have been shown to correlate well with heart failure severity (NYHA Class) so 
they can both contribute to objective assessment of patients, however, when compared 
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3.2.4.3.2 Natriuretic Peptides in Screening 
 
In the PROBE-HF Study, investigators were attempting to determine the 
prevalence of asymptomatic heart failure in a population of patients at high risk and to 
evaluate the reliability of natriuretic peptide testing when compared to ECHO for 
diagnosis. There were 1,012 at-risk patients enrolled. Patients were considered at-risk if 
they had a diagnosis of type II diabetes or hypertension for which they had been 
receiving medication for at least the last six months- hypertensive patients had to be on at 
least two medications for six months. Systolic dysfunction was defined by ejection 
fraction ≤ 50% and categorized as mild (41 - 50%), moderate (31 - 40%), or severe (≤ 
30%). The degree of diastolic dysfunction was determined via the ECHO parameters E/A 
ratio and deceleration time, and subsequently categorized as impaired relaxation, pseudo-
normal, or restrictive pattern.  Since the specificity for mild diastolic dysfunction is low, 
investigators pooled subjects with moderate-to-severe diastolic dysfunction and systolic 
dysfunction to create a subgroup for which greater specificity could be achieved. ECHO 
results were compared with those obtained via NT-pro-BNP testing to calculate the 
positive and negative predictive values for NT-pro-BNP and see if the test detected cases 
that were missed by ECHO. 494 
In the study population there were 633 patients (62.5%) with normal ECHO 
results. Of those with abnormal ECHO results (n = 379), 368 (36.4%), and eleven 
patients (1.1%) patients showed diastolic and systolic dysfunction, respectively.  Patients 
with diastolic dysfunction (n = 368) was further classified into mild (n = 327, 32.4%) or 
moderate-to-severe (n = 41, 4%). The patients with moderate-to-severe diastolic 
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dysfunction were pooled with those with systolic dysfunction yielding a pooled subgroup 
of 52 patients. The patients with mild diastolic dysfunction were added to the group with 
normal ECHO results (n = 960). NT-pro-BNP levels were compared between the no 
dysfunction/mild dysfunction group and the moderate-to-severe systolic dysfunction 
group. NT-pro-BNP levels were significantly higher in patients with asymptomatic LV 
dysfunction than normal patients (258 pg/mL vs.74 pg/mL, p < 0.001).  
In multivariate analysis, the likelihood of LV dysfunction was independently 
associated with (log) NT-pro-BNP levels (p < 0.0001). There was a significant difference 
in NT-pro-BNP levels between sub-groups of diastolic dysfunction. Patients with mild, 
moderate, and severe diastolic dysfunction had BNP levels of 146 ± 156 pg/mL, 317 
±375 pg/mL, and 443 ± 416 pg/mL (p < 0.001) respectively. Additionally, the authors 
determined that a cut-off value of 125 pg/mL yielded the best sensitivity/specificity ratio, 
NPV and PPV for identifying patients with moderate-to-severe diastolic dysfunction 
(sensitivity 98%, specificity 80%, ROC AUC 0.93, NPV 99.8%, PPV 24%). These 
authors concluded that assessing NT-pro-BNP levels can lead to early exclusion of LV 
dysfunction in diabetic or hypertensive patients.  Although tests such as an ECHO may 
provide more detailed information, NT-pro-BNP levels below the cut-off point of 125 
pg/mL provided a high negative predictive value, whereas higher levels would warrant 
further evaluation with a test such as ECHO. Therefore, NT-pro-BNP levels could be 
used as an initial test to rule out LV dysfunction in high-risk patients. 495 
In a prospective study, Suzuki and colleagues sought to determine whether 
circulating BNP levels correlated with cardiac function while screening asymptomatic 
patients. All employees that were 55 or older working at the pharmaceutical company 
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Shionogi were included unless taking anti-hypertensives. BNP was collected, and in 
those patients where BNP was > 18 pg/mL, a subsequent ECHO was done. During the 
ECHO, ejection fraction, fractional shortening, and mitral inflow E-wave to A-wave ratio 
were assessed as primary indices representing systolic and diastolic function. Additional 
ECHO parameters that were collected included left ventricular wall thickness of the intra 
ventricular septum and posterior wall, aortic root and left atrial dimensions and the left 
ventricular diastolic and systolic dimensions, in addition to heart rate. An ECHO was also 
conducted for age- and gender-matched controls from among the patients without 
elevated BNP measurements. 496 
The study population included 294 patients, and 49 patients had a BNP of > 18.4 
pg/mL. The investigators found that BNP had significant correlations with multiple 
ECHO parameters. The authors concluded that the non-invasive nature of the test made it 
useful in screening the asymptomatic patient, with the addition of other tests such as an 
ECG and chest x-ray, to determine which patients might need more complex tests such as 
an ECHO. 497 
 
3.2.4.3.3 Natriuretic Peptides in Diagnosis 
 
BNP can be useful to diagnose patients in the acute setting, where a quick and 
accurate diagnosis is needed, and misdiagnosis could lead to adverse outcomes. 498 
Alternative tests such as ECG’s, chest x-rays and ECHOs are accessible and have been 
used to detect heart failure; however, they can give results that are non-conclusive. 
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ECHOs have additional issues including; the limited availability in the acute care setting, 
and the difficulty imaging patients with dyspnea or those who are obese. These downfalls 
decrease utility of the ECHO. 499 
A systematic review, conducted by Doust and colleagues, included 20 studies to 
determine the diagnostic accuracy of natriuretic peptides for heart failure. There were 
eight studies that measured BNP versus a criterion of LVEF of 40% or less, there were 
seven studies that compared BNP versus clinical criteria, and there were three studies that 
compared BNP versus NT-ANP. Inclusion criteria required that all studies that compared 
BNP and a reference standard have results that were reported such that a two by two table 
could be constructed. The authors excluded all case-control studies and those with 
overlapping populations (n = 6). 500 
Two reviewers extracted data and assessed the quality of each study. In the event 
of a disagreement; quality was assessed by a third reviewer.  To allow for differences in 
cut-off points between studies, the reviewers calculated a diagnostic odds-ratio, and if 
there were more than one per study, the average was used. The diagnostic odds-ratio  
 





Studies were grouped so that a DOR was calculated against each reference standard and 
if possible, positive and negative likelihood ratios were calculated where the studies had 
similar cut-off levels and reference standards. 501 
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The investigators used an unweighted least squares regression to determine if the 
odds ratio was independent of the cut-off point. An unpaired two-tailed t-test was used to 
determine if the slope of the line was significantly different from zero, which would 
imply that the diagnostic accuracy of the test varied with the cut-off point. In those 
studies that compared BNP and ANP, the area under the curve for each study was pooled 
by an inverse variance method, diagnostic accuracy was assessed by taking the 
differences of the AUC’s and dividing by the variances of the AUC. The overall quality 
of the included studies was considered good as judged by the six criteria determined by 
the authors. 502 
The authors of this paper concluded that BNP is accurate in the diagnosis of heart 
failure. Considering that the measurement of BNP is less expensive and more highly 
accessible than other choices, it is a viable alternative. One of the advantages is that the 
results can be obtained within about 20 minutes of the blood collection, which makes the 
test most useful in the ambulatory care setting to determine which patients need to be 
further evaluated. When using a cut-off level of 15 pmol/L (1 pg/mL = 0.29 pmol/L) the 
test achieves “high” sensitivity, and values below this can be excluded from diagnosis. 503 
A meta-analysis of the validity of BNP and NT-pro-BNP studies in the diagnosis 
of clinical heart failure, examined the effect of age and role in population screening for 
left ventricular systolic dysfunction.  Like the previous study, authors summarized test 
performance in each study with a calculation of the diagnostic odds- ratio (DOR) which 
was pooled for BNP and NT-pro-BNP studies for purposes of comparing the two tests. 
Forty-seven studies were identified and 27 were included for analysis.  Authors sought to 
determine: the accuracy of both BNP and NT-pro-BNP in diagnosing HF in symptomatic 




patients (inpatient or outpatient), test performance in studies where both assays are 
carried out on each study participant, effects of age or study setting on test performance, 
and the accuracy of tests to detect asymptomatic disease. 504 
The “Breathing not Properly” study included seven centers with a total of 1,666 
patients who reported to emergency departments (ED) with a complaint of dyspnea and 
were subsequently screened for HF. There were 1,586 patients enrolled in the study, 48 
patients had incomplete records and were therefore excluded. Other exclusion criteria 
consisted of advanced renal failure defined by calculated creatinine clearance (CrCl) of < 
15 mL/min, acute myocardial infarction, and overt causes of dyspnea (i.e., trauma or 
injury). Data collection in the ED included demographics, clinical history and objective 
assessment of clinical signs which were gathered by research personnel present for entire 
stay in ED. Each participant was seen by a physician, and an ECG, chest x-ray and blood 
tests were categorized via a structured checklist. The research personnel then categorized 
the physicians’ estimate of clinical probability using a visual analog scale. BNP was 
tested using the Triage® BNP assay. 505 
Thirty days after the visit, the charts without the estimate of CHF probability, 
were reviewed by two cardiologists who were not treating physicians. The Framingham 
risk scores and NHANES scores were also calculated. After all information was 
reviewed, if agreement was achieved then that case was categorized as either: group 1- 
dyspnea due to CHF, group 2 - history of CHF but dyspnea due to non-cardiac cause, or 
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group 3 - dyspnea due to non-cardiac cause. To conduct a binary analysis, groups 2 and 3 
were pooled. 506 
The cardiologists that were independent reviewers agreed 89.3% of the time, for 
the remainder of cases, additional information was requested, and if disagreement still 
existed, a decision was made by an end-points committee. Diagnosis was supported by 
Framingham (83%) and NHANES (86%) scores. 507 Diagnostic accuracy for BNP was 
81.2%, with a sensitivity of 90%, and a specificity of 73%. The positive predictive value 
(PPV) was 75%; the negative predictive value (NPV) was 90%, and the positive 
likelihood ratio was 3.4. These researchers found that BNP adds about 10% to the 
accuracy of clinical judgment, and is especially useful for those patients in the 
intermediate category.508 
In another analysis with the same participants (i.e. n = 1,586), Meisel and 
colleagues used the Triage® bedside assay for the diagnosis of HF in emergency 
department patients. The study had the same criteria for exclusion and diagnosis as 
described above. There were 452 patients who were diagnosed with CHF and returned for 
an ECHO within 30 days of their visit to the ER. Patients were categorized into two 
groups based on their LVED obtained via ECHO. Patients with LVEF > 45 were 
considered to have non-systolic dysfunction (n = 165) and patients with LVEF ≤ 45 (n = 
287) were considered to have systolic dysfunction. The BNP was measured during the 
patients’ initial visit as per above methods using the Triage® BNP assay.509 Patients 
without a diagnosis of CHF had a significantly lower mean BNP (34 pg/mL) than patients 
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with either non-systolic (vs. 413 pg/mL, p < 0.001) or systolic dysfunction (vs. 821 
pg/mL, p < 0.001). Additionally, patients with non-systolic heart failure had a 
significantly lower BNP than patients with systolic dysfunction (413 vs. 821 pg/mL;  
p < 0.001). 510 
When comparing patients with non-systolic dysfunction with those without heart 
failure, the BNP assay with a cut-off point of 100 pg/mL had a sensitivity of 86% and a 
negative predictive value of 96%. The assay had an accuracy of 75% for detecting 
abnormal diastolic dysfunction and logistic regression revealed that BNP was the 
strongest predictor to differentiate systolic versus non-systolic dysfunction. 511 These 
authors had similar conclusions to the other “Breathing Not Properly” study in that BNP 
was useful in differentiating heart failure from non-heart failure patients and may 
additionally have utility in discriminating between systolic and non-systolic dysfunction, 
which usually cannot be differentiated using clinical indicators alone. 512 
In a prospective randomized controlled trial [BASEL] of 452 patients who 
presented with acute dyspnea, 225 patients were assessed using the BNP bedside assay 
and 227 patients were assessed using the “conventional diagnostic strategy”. Time to 
discharge and total cost of treatment were the primary end points. Secondary end points 
were in-hospital and 30-day mortality. All patients underwent the same initial 
assessment; BNP was collected using the point of service assay in the study arm with a 
cut-off point of 100 pg/mL.  If patients had a BNP < 100, it was decided that HF was an 
unlikely cause of dyspnea, those with BNP > 500 were treated with HF as the diagnosis 
and were given rapid therapy with diuretics, ACE inhibitors, nitroglycerin, and morphine, 





while for those patients with levels between 100 – 500 pg/mL, further investigation was 
conducted. 513 
Time-to-discharge was defined as the difference between the time of presentation 
in the emergency department and the time of discharge; patients who died in the hospital 
were excluded from these calculations.  To avoid differences resulting from a variety of 
third-party payers, hospital charges were standardized according to actual rates for 
patients with general insurance living is Basel, Switzerland.  All endpoints were assessed 
in a blinded fashion by physicians who were not involved in patient care, but who had 
access to all medical records pertaining to each patient. 514 
The authors found that the use of the BNP assay reduced the need for 
hospitalization and an ICU stay. Additionally, the time to discharge was significantly 
shorter in the BNP group, which translated into significantly lower costs. Deaths in each 
group were not significantly different. Use of the BNP assay reduced the total cost of 
treatment by 26%. Authors concluded that the rapid measurement of BNP used with other 
clinical information in the emergency department, improves the care of patients with 
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3.2.4.3.4 Natriuretic Peptides in Cardiotoxicity 
 
It is well-documented that patients who receive cardiotoxic chemotherapy should 
be monitored closely; there are those who believe that this would ideally be with 
biomarkers such as troponins or BNP, especially when cardiac risk factors are present. 516 
Biomarkers are useful, as they are specific for overload and stretch- the primary 
pathologic changes in heart failure. In a study of 111 patients at MD Anderson Cancer 
Center, a BNP level of > 150 pg/mL was 100% sensitive and 81% specific for a cardiac 
event, while BNP levels of > 200 pg/mL had an 88-fold increase in risk for cardiac event. 
LVEF was also monitored and was not predictive of these events.  There is evidence that 
although symptoms are being reported by patients, these symptoms are not being 
evaluated or diagnosed appropriately by physicians. 517 
In a study by Lee and colleagues, which included 86 patients with hematologic 
malignancies receiving anthracycline chemotherapy, investigators sought to assess the 
correlation between BNP levels and cardiac complications. BNP and cTnI levels were 
measured in all patients prior to each chemotherapy cycle. The BNP lower limit of 
measurement was 5 pg/mL and the threshold value for normal was 100 pg/mL; the 
troponin lower limit of detection was zero and threshold value for normal was 0.2 ng/mL.  
For ECHO examination, the M-type, two-dimensional and Doppler ECHO were 
performed. 518 
During evaluation, 21 patients (24.4%) experienced some type of cardiac event. 
Cardiac events included heart failure (n = 15), heart failure with shock (n = 3), 
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arrhythmias (n = 2) and arrhythmia with heart failure (n = 1). Using univariate analysis, 
the authors found an association between the development of heart failure and several 
parameters including:  maximum BNP level measured during chemotherapy (mean 305.8 
pg/mL, p < 0.001), LVEF < 50% (mean 40.6%, p < 0.001), abnormal ECG (p < 0.001), 
and elevated cTnI (p = 0.002).  Additionally, there appeared to be an association between 
increased age and the development of events, albeit, this also did not result in a 
statistically significant difference (p = 0.066).  On multivariate analysis, elevated BNP 
(OR 1.017, 95% CI: 1.002-1.032, p = 0.029), elevated troponins (OR 52.231, 95% CI: 
1.344 – 2,030.343, p = 0.034) and abnormal ECG (OR 26.035, 95% CI: 2.071 - 327.234, 
p = 0.012) were associated with cardiotoxicity. These authors concluded that elevated 
levels of BNP or cTnI may correlate with the development of cardiotoxicity; therefore, if 
abnormal results are found then preventive strategies must be employed to prevent 
additional damage. They also suggest that additional prospective studies should be 
conducted to understand the relationship between elevated BNP and development of 
cardiotoxicity. 519 
A small Japanese study evaluated the use of biochemical and myocardial markers 
of cardiotoxicity in a population of 27 patients. The population consisted of consecutive 
patients receiving anthracycline therapy for hematologic malignancies. Basal and post-
chemotherapy levels of BNP, ANP, renin, aldosterone, angiotensin II, norepinephrine, 
epinephrine, CK-MB and  myosin light chain along with ECHO measurements of 
ejection fraction and mitral valve inflow E/A ratio were measured (the frequency of 
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measurement was not explicitly stated). The cumulative dose of anthracycline received at 
study entry was 221.4 ± 53.7 mg/m2. 520 
The investigators found that basal levels of BNP were elevated, and these levels 
increased significantly after patients received chemotherapy (31.1 ± 7.16 pg/mL to 58.1 ± 
12.8 pg/mL; p < 0.05). The BNP reference value used for this study was < 19 pg/mL.  
The post-chemotherapy increase of ANP was also found to be statistically significant 
(14.1 ± 2.21 pg/mL to 29.2 ± 6.94 pg/mL, p < 0.05), although, the authors state that this 
is considered “non-diagnostic” as the increase was still below the reference value (< 43 
pg/mL).  There was also a rise in post-chemotherapy angiotensin II (24.5 ± 16.1 pg/mL) 
which was above the reference value (< 20 pg/mL); however, this rise was not found to 
be significant.  The authors stated that the increases of BNP were transient in most 
patients lasting from three to seven days and returning to basal levels within two weeks.  
Three patients did experience persistently elevated BNP levels, two of which died from 
heart failure.  The authors conclude that transient increases in BNP suggest a type of 
tolerance, and levels that are persistently elevated could be suggestive of a 
decompensation of this tolerance creating prognostic value for serial BNP levels. They 
also stated that the elevation of ANP and angiotensin II is suggestive of cardiac 
dysfunction, but further investigation is required to elucidate the utility of their serial 
measurement. The authors state that their findings suggest a possible role for the 
measurement of BNP after anthracycline administration; however, future studies with 
larger populations are required. 521 
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Daugaard and colleagues conducted a study to evaluate potential utility of ANP 
and BNP measurements in the monitoring of patients for cardiotoxicity in order to assess 
whether ANP or BNP could replace obtaining LVEF measurements via MUGA scanning. 
Therefore, the reference standard used in this study was ejection fraction as measured by 
MUGA scans. There were 107 patients included in the study with a variety of cancer 
diagnoses and all patients had been treated with anthracyclines.  There were a total of 204 
measurements taken; there were simultaneous ejection fraction measurements and blood 
samples drawn. Pre-treatment values for either LVEF or natriuretic peptides were not 
obtained; the first measurement was taken when the patient had received 50% of the 
maximal cumulative dose. (450 mg/m2) Therefore, some patients had several measures 
while others only had one.  An ejection fraction of > 50% was considered normal; 
treatment was discontinued if patients had an ejection fraction < 50% or if their ejection 
fraction had decreased more than 10%. 522 
There were 48 patients in which multiple measures were taken, of which three 
(6%) developed heart failure (NYHA class II to IV), fifteen (31%) experienced a 
decrease in LVEF of > 10%, nine (19%) of those patients had a final measured LVEF < 
50%.  The authors found a relationship between low ejection fraction and elevated ANP 
and BNP in both the initial baseline measurements (n = 107) and all measurements (n = 
208). They found statistically significant correlations between both ejection fraction and 
ANP (r = 0.78, p < 0.001) and ejection fraction and BNP (r = 0.76, p < 0.001) when 
ejection fractions are less than 50%, however, they did not find a similar relationship for 
ejection fractions > 50%. They also did not find associations between the change in 
ejection fraction and changes in natriuretic peptides levels during the duration of 
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treatment.  These authors therefore concluded that because they did not find a 
relationship between serial natriuretic peptide and ejection fraction measurements, 
natriuretic peptides cannot replace LVEF for cardiac evaluation of patients receiving 
anthracyclines. 523  
Kouloubinis and colleagues conducted a prospective study to determine the 
sensitivity of natriuretic peptide markers to evaluate cardiac function. The study had forty 
cancer patients divided into two nonrandomized treatment groups and two additional 
control groups. The treatment groups included patients with advanced disease that were 
to receive epirubicin and paclitaxel (Group A) and patients with early stage disease that 
were to receive mitoxantrone and docetaxel (Group B). The control groups consisted of 
women with heart failure (n = 13) in NYHA classes II, III or IV and healthy women (n = 
20) without cancer or cardiac disease. Left ventricular ejection fraction, ECG, Pro-ANP 
and NT-pro-BNP were evaluated in all patients. Patients who had received chemotherapy 
with or without hormone therapy or radiotherapy within the prior six months were 
excluded.  Significant cardiotoxicity was defined as LVEF decline of > 10% from 
baseline. LVEF was determined before chemotherapy and one week after completion, the 
control group with heart failure had LVEF values between 15 and 30%, and the healthy 
control group had LVEF values > 50. A twelve-lead ECG was obtained every three 
cycles for all patients; a QT interval > 440 ms was considered prolonged.524 
Results showed a statistically significant increase in pro-ANP and NT-pro-BNP 
levels in group A (p = 0.0001), whereas the increase in group B was not significant (p = 
0.43). There was no difference in the natriuretic peptide levels prior to treatment between 
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treatment groups and the healthy control group. However after treatment, both natriuretic 
peptide levels (pro-ANP and NT-pro-BNP) were significantly elevated compared to the 
healthy controls (p = 0.0001 and p = 0.0002), and none of the factors such as age, HER-2 
status, grade, estrogen or progesterone status, or metastases were found to be 
significantly related to either pro-ANP or NT-pro-BNP. 525 
The LVEF was found to decrease significantly in the high-risk cardiotoxic 
regimen (p = 0.0001). The high-risk group had three patients experience a decrease in 
LVEF of > 10%, and three experienced a decrease resulting in an LVEF < 50 (one patient 
common to both). There was a significant correlation found between the increase in both 
natriuretic peptides and the decrease in LVEF for Pro-ANP (r = 0.8, p < 0.0001) and NT-
pro-BNP (r = 0.7, p < 0.0001). There were no significant correlations found for Group B. 
There were no significant ECG changes found in any group. In group A, 12 patients died 
from metastatic disease and two patients developed congestive heart failure.526 These 
authors concluded that even at low cumulative doses of epirubicin, cardiac dysfunction 
can present as a serious side effect of therapy; pro-ANP and NT-pro BNP might be used 
as reliable markers in the detection of both early and late cardiac dysfunction. 527  
In a study to determine any possible relationship between NT-pro-BNP and acute 
post-anthracycline cardiotoxicity, Cil and colleagues enrolled 33 newly diagnosed 
patients with early disease. Any patients who had received previous treatment with 
chemotherapy, radiation or hormone therapy were excluded. Patients had an ECHO 
determination of LVEF, in addition to ECG and the measurements of NT-pro-BNP, 
troponin I, CK-MB and myoglobin prior to and after the conclusion of chemotherapy. 





Patients were classified into either decreased or normal LVEF; those that had any decline 
in LVEF from first to last evaluation were classified into the “decreased LVEF” group. 
528 
Prior to therapy, there were no differences between LVEF, blood pressure, heart 
rate, NT-pro-BNP, troponin I, CK-MB, myoglobin between the decreased and normal 
LVEF groups. However, after treatment, the patients in the “decreased LVEF” group had 
significantly higher NT-pro-BNP (p = 0.02) and lower LVEF (p < 0.001) than the 
patients in the normal LVEF group. There continued to be no differences in blood 
pressure, heart rate, troponin I, CK-MB and myoglobin between groups and no 
significant changes in ECG readings, symptoms, or physical indications of heart failure in 
either group. Additionally, there was no association found between NT-pro-BNP levels 
and hormone receptor status, disease grade, HER-2 status or number of breast cancer risk 
factors. 529 These authors concluded that although their study size was small, they did 
find an association between higher NT-pro-BNP levels and reduced LVEF. They 
suggested that this could potentially indicate early sub-clinical cardiotoxicity secondary 
to anthracycline administration and larger studies are needed to confirm these results. 530 
A retrospective analysis by Sandri and colleagues sought to determine if there was 
a predictive role for the measurement of NT-pro-BNP in patients receiving cardiotoxic 
chemotherapy. The study included 52 patients who received high dose chemotherapy and 
had cardiac evaluations (including ECHO) prior to therapy and at four and 12 months 
post therapy for aggressive malignancies. These same authors did a number of 
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investigations using cardiac troponins in this population, and NT-pro-BNP was measured 
from stocked specimens. The measures were obtained at baseline, at the end of each 
infusion, and 12, 24, 36 and 72 hours after chemotherapy (times were determined as part 
of other protocols). 531 
Cut-off values used were those suggested by the manufacturer (153 ng/mL and 88 
ng/mL, 334 ng/mL and 227 ng/mL for women and men ≤ 50 and > 50 years old 
respectively).  After levels were determined at each time point, patients were then 
categorized into three groups based on the changes in NT-pro-BNP values. Group A (n = 
17) consisted of patients whose NT-pro-BNP values rose after the infusion and continued 
to be elevated 72 hours later (i.e., those with persistently elevated levels), Group B (n = 
19) had elevated values after 12 - 36 hours but trended back to baseline at 72 hours (i.e., 
transient increases only), and Group C (n = 16) had levels that decreased from baseline to 
72 hours post infusion (i.e., no increases). There were nine patients (17.3%) that had 
values at baseline above the cut-off, three were in each group. There were no differences 
between the three groups with respect to gender, age, or malignancy type. 532 
At twelve months of follow-up, only Group A saw a significant decline in LVEF. 
The mean LVEF measurements for Group A obtained at baseline, four, and twelve 
months of 62.8%, 54.4% and 45.6%, respectively (p < 0.0001). There were no patients in 
Groups B or C that had an LVEF of < 55% after twelve months, whereas 59% of Group 
A patients met this criterion, four of which had overt signs of heart failure. These authors 
concluded that their results confirm previously reports that there is a relationship between 
elevated natriuretic peptides and cardiac dysfunction in patients receiving anthracycline 
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therapy. Additionally, persistently elevated NT-pro-BNP is suggestive of some type of 




3.3 Comparisons of Monitoring Methods 
 
In 2009, Troughton and Richards reviewed the use of the potential of integrating 
BNP, NT-pro-BNP, and ECHO measures to assess cardiac function and clinical status 
and to provide predictions regarding outcomes.  The authors compared values of the 
natriuretic peptide assays with indices of cardiac function as measured by ECHO, both 
BNP and NT-pro-BNP correlate with dimensions, volumes, mass and pressure estimates 
of both ventricles, and are negatively correlated with LVEF. The strongest correlation 
was between BNP and LV diastolic wall stress; this was independent of ejection fraction, 
age, gender, and renal function.  Both BNP and NT-pro-BNP had high negative 
predictive values (> 90%) for diastolic dysfunction when below threshold values of < 100 
pg/mL for BNP and < 140 pg/mL for NT-pro-BNP. Additionally, in patients with normal 
ejection fractions, both are the strongest predictors of severe diastolic dysfunction when 
elevated levels are detected (i.e., BNP > 100 pg/mL and NT-pro-BNP > 600 pg/mL). 534 
When used in either the detection of diastolic dysfunction or in a screening setting 
(usually consists of patients with suspected dysfunction that have been referred for 
ECHO); BNP demonstrates a high sensitivity 85 - 90% when compared to ECHO. 535 In 
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screening studies, the prevalence of LV dysfunction is usually low (< 6%) and as the 
prevalence of dysfunction increases, so do both specificity and positive predictive value. 
Despite the low prevalence, negative predictive values remain high (93 - 99%) for 
natriuretic peptides that measure below threshold values. 536 
The Olmstead County group found that using age- and gender-adjusted cut-off 
values for diagnosis, both sensitivity and specificity range from 90 - 100% in detecting 
LV dysfunction in the general population.  537 The use of clinical presentation or tests 
such as ECG in conjunction with natriuretic peptide levels can improve positive 
predictive value and specificity, and use of an ECHO is usually recommended for a 
definitive diagnosis of heart failure when values are in the intermediate or “gray” range. 
538 
Additionally, both BNP and NT-pro-BNP are the strongest two predictors of 
events and mortality in heart failure patients, and serial levels have been shown to be 
useful in the monitoring of chronic therapy, whereas serial ECHO measurements are not 
recommended. The authors concluded that BNP and NT-pro-BNP are useful in the 
screening and evaluation of patients with asymptomatic LV dysfunction; ECHO should 
be used to evaluate patients with levels in the intermediate or “gray” range to improve 
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accuracy and provide a more powerful prediction of risk of future cardiac events or 
mortality. 539 
In a study by Feola and colleagues, the authors prospectively examined 
relationships between LVEF changes seen via MUGA scanning with biochemical 
markers in breast cancer patients who had received anthracyclines (epirubicin). Enrolled 
patients (n = 53) were categorized into two groups at the conclusion of a two-year follow-
up period. Group A (n = 13) included patients that experienced a cardiac event during 
surveillance, two of which developed symptomatic heart failure. Group B (n = 40) 
consisted of the patients who did not experience any cardiac changes during that time. 
Measurements were taken at baseline, one month (T1), one year (T2) and two years (T3) 
post-chemotherapy. Measurements included the following: a clinical assessment, 
troponin I, BNP, and radionuclide ventriculography. An event was defined as a decrease 
of LVEF of > 10% or overt HF. 540 
By T3, 13 patients (24.5%) had developed a cardiac event, two of which exhibited 
symptoms of heart failure, these patients comprised Group A while the remaining 40 
patients (75.5%) who did not experience a cardiac event during follow-up comprised 
Group B.  The investigators did find that the patients in Group A were older (p = 0.04), 
and differed in baseline, T1 and T2 BNP levels (p = 0.02), baseline heart rate (p = 0.001), 
and baseline hemoglobin levels (p = 0.007), although in multivariate analysis, the only 
parameter that showed a trend toward a relationship with T3 LVEF was baseline BNP    
(p = 0.07). Troponin measurements showed a release at T1 (p < 0.01) that disappeared at 
T2, this release was demonstrated in both groups and was not statistically different         
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(p = 0.04). These authors concluded that these results suggest that neurohormonal 
activation as measured by BNP levels could be a valuable tool to predict future LV 
dysfunction and further studies with larger samples are advised. 541 
 
 
3.4 Economic Implications  
 
3.4.1 ECONOMIC IMPLICATIONS IN HEART FAILURE 
 
BNP would be expected to have a favorable impact on costs as a non-invasive 
point-of-care tool for screening patients that present with dyspnea and those patients for 
whom a referral for an ECHO may be considered. It has been shown to correlate well 
with left ventricular pressure, the amount of dyspnea, and the state of neurohormonal 
modulation542. The assay has a reliable negative predictive value; therefore, those without 
left ventricular dysfunction have a low probability of being misdiagnosed. 543 Acute 
symptoms of heart failure overlap many other conditions such as COPD. This 
necessitates rapid diagnosis since giving sympathomimetic drugs that are routine for 
COPD, would be harmful to patients with CHF. 544 
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Studies have shown that more rapid and accurate diagnosis of heart failure results 
in a decrease in hospitalizations, time to discharge and initial treatment cost. 545 One 
investigation used data from a study that was described previously in this chapter to 
estimate costs associated with BNP testing. They assumed the cost of a BNP test was 
$47, and used hospital charges. Because of the short follow up period, neither adjustment 
nor discounting was conducted. 546 
Follow-up was completed in 451 of the patients initially enrolled. Data regarding 
hospital charges (treatment costs) were equally available in both the BNP and control 
groups. During the initial presentation to the emergency department, the use of BNP 
levels reduced the need for hospitalizations and ICU care. BNP levels also reduced the 
need for ventilator support and the number of ECHO procedures performed during initial 
presentation. At 180 days, all-cause mortality was 20% in the BNP group and 23% in the 
control group which was found to be not significant. Patients assigned to the BNP group 
spent significantly fewer days in the hospital than the control group, reducing total 
treatment costs when compared to the control group (p = 0.004).  The reduction in total 
treatment costs was mainly driven by the reduction of days spent in the hospital. 547  
These authors found that BNP testing was cost-effective and significantly reduced 
treatment costs; $5,410 vs. $7,264, (p = 0.006) for initial treatment, and $7,930 vs. 
$10,503 (p = 0.004) for BNP and control groups respectively. Sensitivity analyses 
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indicated that these results were robust to changes in all variables except re-
hospitalization with BNP guidance. 548 
A prospective screening study by Heidenreich and colleagues was designed to 
assess if BNP population screening for LV systolic dysfunction would be cost-effective. 
There were four different screening strategies examined. First, BNP testing; if result 
abnormal, the patient would get an ECHO. Patients whose ECHO showed an EF < 40 
were given an ACE inhibitor to prevent the development of HF. The second strategy used 
only BNP levels to determine which patients would be treated. The third strategy sent all 
patients for an ECHO. The fourth strategy was no screening. Each test had one of four 
results, true positive, true negative, false positive or false negative. 549 
A model was developed to determine the lifetime health and economic outcomes 
for several hypothetical cohorts. The first was of 60 year-old patients with depressed EF 
(< 40) but without history who were given treatment with ACE inhibitors. The second 
cohort included patients with depressed EF but without history and no treatment until HF 
developed. The third included patients without depressed EF. Each month, patients with a 
low EF and without a history of HF can remain asymptomatic, develop HF or die. For 
those patients developing HF, it was assumed that 33% would be hospitalized during the 
initial episode of HF. Once patients developed HF, they could remain stable, be 
hospitalized or die during each time period. The model followed patients until all had 
died. The study used a BNP cost of $30. 550 
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The authors found that in 1,000 men, using the strategy of BNP followed by 
ECHO, there was improved outcome at a cost of $22,300 per quality-adjusted life-year 
(QALY) gained when compared to no screening. If quality-of-life is ignored, then BNP 
screening costs $23,500 per life-year gained when compared to no screening.  Screening 
with ECHO alone costs more than $100,000 per QALY gained and screening with BNP 
alone was more expensive and led to worse outcomes. For women, the screening with 
BNP followed by ECHO was $77,700 per QALY, while screening with BNP alone or 
ECHO alone were both dominated by the BNP-ECHO combination. The authors 
concluded that BNP followed by ECHO was cost-effective in men and possibly for 
women aged 60 and up. 551 
In a model constructed by Zomer and colleagues, the authors evaluated the cost-
effectiveness of screening asymptomatic high-risk patients using BNP levels. The model 
included subsequent treatment with enalapril for those patients identified with left-
ventricular dysfunction. There were three health states considered: alive with 
asymptomatic LV dysfunction, alive with symptomatic heart failure and dead, probability 
estimates for each state, hospitalizations and mortality were obtained from the SOLVD 
trial. Costs were obtained from a published paper by Liao and colleagues. 552 
Calculations were conducted using three estimates of underlying prevalence of 
asymptomatic LV dysfunction (10, 20 and 30%) with a five-year time horizon. At five 
years, these authors found that for BNP screening strategies, the costs per LY gained 
were $40,306, $28,727 and $25,414 for prevalence estimates of 10, 20 and 30% 
respectively. These amounts decreased each subsequent year. These authors concluded 
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that screening with BNP and subsequent treatment with enalapril was a cost-effective 
strategy for decreasing heart failure related morbidity and mortality. 553 
An investigation by Galasko and colleagues sought to determine the most cost-
effective strategy to screen for LV systolic dysfunction.  The methods under comparison 
included traditional ECHO, hand-held ECHO, ECG and NT-pro-BNP; the traditional 
ECHO was considered the gold-standard method of evaluation for this study. Subjects 
initially either had one or a combination of tests utilizing one of eight strategies under 
study.  There were a total of 1,205 subjects, comprised of 734 from the general 
population, and 471 known to be at high risk. Upon assessment of the 734 from the 
general population, 290 had risk factors and were placed in the high-risk group (added to 
471 high-risk patients for a total n = 762). This left 444 patients from the general 
population who were without risk factors and therefore classified as low-risk. All patients 
completed a questionnaire, received an ECHO and ECG, and had their blood drawn for a 
NT-pro-BNP level. Investigators then used a series of eight strategies for the detection of 
LVSD. 554 
Results indicated that screening low-risk patients was always the least cost-
effective regardless of the strategy employed when comparing to the general population 
and high-risk groups. Strategy 7, which used a detection strategy of ECG first, then hand-
held ECHO, then traditional ECHO had the lowest cost per detected case in all risk 
groups. This strategy had costs of € 12,960, € 884 and € 649 per detected case for low-
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risk, general population, and high-risk groups respectively. Screening with a combination 
of ECG and NT-pro-BNP was always less cost-effective than using either of the initial 
tests alone, and both were less cost-effective than using a hand-held ECHO. 555 
The authors concluded that performing both ECG and NT-pro-BNP did not 
provide additional cost-savings and that utilizing the NT-pro-BNP may be preferred 
because of ease of interpretation and practicality. Additionally, these authors concluded 
that their study supports the development of community screening programs to screen 
high-risk patients (patients with ≥ 1 risk factor) for systolic dysfunction and the most 
cost-effective strategy would be a multi-step process to pre-screen using either ECG or 
NT-pro-BNP, followed by a hand-held ECHO in patients with abnormal results, in-turn 
followed by a traditional ECHO for those with abnormal hand-held ECHO results. 556 
Nielson and colleagues had similar conclusions after retrospectively examining 
the cost of using BNP to screen and detect LV dysfunction in the general population (n = 
1,257). Patients completed a self-administered questionnaire and had blood pressure 
measured.  All patients also received an ECG, an ECHO, and BNP measurement.  
Patients were categorized into three risk groups. The first group consisted of patients with 
symptomatic ischemic heart disease (IHD) (n = 140) who had either a self-reported 
history of MI and ischemic changes on ECG, or physician-diagnosed angina and were 
receiving therapy. The remaining patients were then categorized into two groups (high- 
and low-risk) where group assignment depended on the patients’ blood pressure 
measurement and ECG reading. The high-risk patients (n = 269) had a blood pressure 
measurement greater than 160/95 and /or signs of ischemia on ECG. The low-risk group 
(n = 823) were without either of those conditions. There was a total of 48 patients (3.8%) 




with LV systolic dysfunction, 6 (0.7%), 16 (6%) and 26 (19%) in the low, high, and IHD 
groups respectively. BNP was significantly associated with LV systolic dysfunction in 
both the high-risk (p = 0.023) and IHD patients (p = 0.015) but not in low-risk patients (p 
= 0.087).  557 
The authors used a cost of $100 for ECHO and the cost of BNP was varied using 
values of $5, $10 and $20. The authors compared the cost per detected case of using an 
ECHO alone for all patients in each risk group with the cost of pre-screening with BNP 
(which consisted of BNP testing and subsequent ECHO for all patients with BNP levels  
≥ 8 pg/mL).  The cost per detected case of LVSD was less in all risk groups for all three 
cost values of the BNP assay. The cost per detected case via ECHO was $13,717, $1,681 
and $538 for low-risk, high-risk and IHD groups respectively. The cost per detected case 
utilizing BNP ranged from $7,543 to $10,012 (cost-reduction range from 27- 45%) for 
low-risk, $1,243 to $1,512 (10 - 26%) for high-risk, and $442 to $529 (2 - 18%) for IHD.  
The authors did note that their proposed strategy would fail to detect LVSD for 1 in 6, 1 
in 16, and 2 in 26 patients in the low-risk, high-risk and IHD group respectively. These 
authors concluded that using BNP levels to determine which patients to refer for an 
ECHO is cost-effective and that a questionnaire and blood pressure measurements are 




                                                 
557 O. W Nielsen et al., “Retrospective Analysis of Thecost-effectiveness of Using Plasmabrain Natriuretic 
Peptide Inscreening for Left Ventricularsystolic Dysfunction in the General Population,” Journal of the 
American College of Cardiology 41, no. 1 (2003): 113–120. 
558 Ibid. 
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3.4.2 ECONOMIC IMPLICATIONS IN CARDIOTOXICITY 
 
In an early investigation of patients receiving doxorubicin, by Bristow and 
colleagues, authors compared the incidence of heart failure, heart failure mortality, and 
severity between patients receiving cardiac monitoring and those who did not. The 
monitoring protocol changed after data collection already started. The initial protocol 
included both invasive (biopsy and catheterization) and non-invasive (ECHO and systolic 
time interval via ECG) testing at mid-course with an optional measure at baseline. The 
new protocol required tests both at baseline and at regular intervals during therapy. 559 
Heart failure was defined as the development of symptoms suggestive of 
myocardial dysfunction verified via radiography or catheterization and biopsy. An 
abnormal ECHO was defined as a decrease in fractional shortening > 25% or decrease of 
> 10% to a value below 30%, abnormal septal thickening, or enlargement of either the 
left or right ventricles.  Biopsy results were graded on a scale ranging from zero (no cell 
changes) to three (diffuse cell damage). There were 206 patients enrolled, 80 received 
monitoring (Group B), the remaining 126 had therapy guided by empiric dose limitations 
of doxorubicin (Group A).  Group B (61%) had more patients with risk factors than 
Group A (46%), which included mediastinal radiation, history of hypertension, 
cardiomyopathy, coronary artery disease, valvular heart disease, age over 70 years and 
cumulative doxorubicin dose over 550 mg/m2. 560 
Of the 206 patients, 15 patients developed heart failure, twelve of whom were in 
Group A, ten (of 15) had at least one risk factor and six of which died as a result of heart 
failure related causes (five deaths were in patients with risk factors). Of the three patients 
in Group B who developed heart failure, all possessed at least one risk factor.  There was 
                                                 
559 Bristow, Mason, and Daniels, “Monitoring of Anthracycline Cardiotoxicity.” 
560 Ibid. 
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not a significant difference in the incidence or HF mortality between groups, with or 
without regard to risk factors. Cost analysis was performed for the 49 patients with risk 
factors that were monitored, costs were based on billing fees charged by the health care 
facility and included the cost of performing tests and analyzing/interpreting results. The 
fees for biopsy and catheterization were $1,753 per test, systolic time interval was $55 
per test, and ECHO was $108 per test. The authors “put these costs in perspective” by 
comparing the cost of monitoring to the cost of the actual chemotherapy, which has a 
1979 price of $1.70/mg and averaged $1,122 per patient. The cost of monitoring averaged 
$2,209 per patient which translated to a cost of $20,308 and $25,650 per case of heart 
failure prevented and heart failure death prevented respectively.  561 
There were eleven patients who had false positive results on non-invasive testing 
who had subsequent invasive tests accounting for $19, 287 (18%) of the total monitoring 
costs ($108,245).  The authors remarked that although cardiac monitoring is costly, it is a 
small fraction of the total cost of cancer care.562 These authors conclude that patients 
without risk factors have a low incidence of heart failure and monitoring in this group 
would not be justified; however, incidence is high enough in patients with risk factors to 
justify cardiac monitoring. Further studies need to be conducted to find suitable non-
invasive tests with higher sensitivity and specificity for cardiac monitoring. 563 
Shureiqi and colleagues created a decision analysis model to determine the cost-
effectiveness of MUGA monitoring in patients receiving doxorubicin therapy. These 
authors pointed out that previously accepted guidelines for monitoring LVEF failed to 
account for the dose of doxorubicin received and the age of the patient. The model 





covered five years, probabilities for heart failure with and without MUGA scanning, heart 
failure after doxorubicin therapy, five-year survival for non-Hodgkin’s lymphoma, five-
year survival for heart failure, and five-year survival from other causes were obtained 
from previously published studies. The probabilities for positive MUGA results were 
obtained from prospectively collected data from The University of Michigan. 564 
The cost of a MUGA scan used in the model was the facility charge-list price at 
the University of Michigan Medical Center in 1996, which was $751. The cost of patient 
time was estimated at three hours multiplied by the average wage of each age group as 
per a previously published population survey.  The cost of heart failure was considered 
for the five years of the model, and was obtained from a published cost-effectiveness 
analysis using standard therapy plus enalapril [the previously published study reported a 
ten-year cost of $8,117 in 1992 dollars with a 5% discount rate]. The 1996 study used a 
3% discount rate and used a five-year cost for heart failure therapy of $6,885.  The costs 
of doxorubicin and non-doxorubicin-based chemotherapy were considered equal. The 
non-doxorubicin chemotherapy regimen was estimated to have a five-year recurrence rate 
of 26%, and the cost of additional high-dose salvage chemotherapy was $45,792. There 
were 227 patients screened using MUGA scans, 47 (21%) were between 15 - 39 years 
old, 98 (43%) were between 40 and 59 years old, and 82 (36%) were 60 and older. 565 
There were only four abnormal screens; one in the youngest group [was 
considered a false-positive], one in the middle-aged group, and two in the oldest group. 
Both cost-effectiveness and the probability of five-year survival based on the cumulative 
doses of 350 mg/m2   and 500mg/m2 were calculated and dependent on age.  For the base-
                                                 




case dose of 350 mg/m2, the mortality gains were minor with survival improvements of 
less than 1.5% in each age group. The incremental mortality improvements with the 
higher dose were 0.77%, 2.12% and 2.7% for 15 - 39 years, 40 - 59 years and ≥ 60 years 
respectively. Cost-effectiveness ratios for each life-year saved for each of the three age 
groups were $425,402, $138,191 and $86, 829. 566 
The authors concluded that their findings may improve the monitoring guidelines 
regarding the use of MUGA scans. Additionally, they concluded that the cost-
effectiveness of MUGA monitoring is dependent upon patient age and the cumulative 
dose of doxorubicin received. The use of MUGA pre-screening for patients under the age 
of 40, without evidence of cardiovascular disease, who received doses less than 350 
mg/m2 provides little benefit. They commented that since cardiotoxicity can manifest 
many years after treatment has ended and MUGA has low sensitivity to detect 














3.5 Summary of Chapter Three 
 
Heart failure in breast cancer patients is a significant adverse effect of the most 
active regimens used to treat the disease. While there are conflicting estimates of its 
incidence and prevalence, heart failure as an outcome is treatable with appropriate 
medications. If HF is discovered early enough, it could potentially be reversible.  
There are many barriers to the effective monitoring of cardiac function in breast 
cancer patients who have received cardiotoxic treatments. The monitoring costs prove to 
be a significant barrier. Numerous studies have evaluated the utility of BNP levels heart 
failure assessment and treatment, and reported similar conclusions. BNP is an adequate 
tool to discriminate between patients with LV dysfunction and those without. There have 
been additional studies that suggest cardiac troponins are the blood levels that should be 
monitored with respect to chemotherapy-induced heart failure. Although the costs of 
troponin levels are in-line with the cost of a BNP test, troponins may require multiple 
draws to get a post-therapy level, which make this test a less attractive alternative when 
compared to BNP.  
There have been studies examining the cost-effectiveness of BNP in both 
population screening and in patients with cardiac known disease. While those studies 
were primarily examining heart failure independent of cancer treatment, similar 
principles would apply. If heart failure, either with or without cancer treatment is not 
diagnosed early, the patient may experience an acute decompensated episode. The studies 
reported that BNP monitoring saved resources when differentiating patients with acute 
symptoms. 
With the availability of BNP rapid assays at considerably lower costs than either 
invasive biopsies or expensive radiological procedures, guidelines for cardiac monitoring 
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can be followed in the clinical practice setting (not only in clinical trials) and could 
ultimately decrease hospitalizations and mortality in these patients.  
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CHAPTER FOUR: METHODOLOGY  
 
4.1 Introduction  
 
This chapter will provide details of the study methodology. Section 4.1 includes 
the purpose of the study and problem statement, study objectives with corresponding 
hypotheses to be tested. Section 4.2 gives an introduction to the economic evaluation in 
healthcare, welfare/extra-welfare and Pareto economics, an introduction to patient 
preferences and outcome measures, and types of analyses.  Section 4.3 discusses cost-
effectiveness analyses in more detail as well as the use of decision analysis and Markov 
analyses, including the rationale for using decision analysis/Markov modeling, and the 
strengths and weaknesses of specific modeling methods. Section 4.4 gives an 
introduction to uncertainty and sensitivity analyses and section 4.5 gives an introduction 
to utilities and health-related quality-of-life.  
Section 4.6 gives the specific estimates and parameters used for the model in this 
study. This includes the study perspective, the inclusion/exclusion criteria for the 
hypothetical cohort, details regarding costs included, sources and calculation of 
probability estimates. Additional parameters included the incidence and prevalence of 
heart failure in breast cancer patients as well as utility estimates for heart failure patients, 
these data were obtained either from previously published literature or calculated with 
estimates given by SEER. This chapter concludes with additional model considerations, 
which includes figures illustrating the proposed model structure of relevant decision and 
chance nodes as well as heart failure transition states used in the study, details regarding 
cycle length and termination conditions, and discussion of model assumptions.  
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4.2 Study Objectives and Hypotheses 
 
4.2.1 STUDY OBJECTIVES 
 
From the review of the literature, it is clear that although it has been known that 
cancer patients often develop heart failure, strategies for earlier detection and diagnosis 
are needed. Numerous studies examining the use of BNP and/or NT-pro-BNP assays for 
screening populations for heart failure suggest that both tests have the potential to fulfill 
this need and could be cost-effective for this purpose. This dissertation will evaluate the 
cost-effectiveness of these tests when compared with strategies currently employed.  
 
The objectives of the study are as follows: 
 
1. Describe current cardiotoxicity-induced heart failure monitoring strategies used in 
breast cancer patients. 
2. Estimate the current incidence of treatment-induced heart failure in breast cancer 
patients. 
3. Estimate costs of performing heart failure monitoring using B-type Natriuretic 
Peptide, ECHO, or MUGA scanning at frequencies determined by NCCN 
surveillance guidelines.  
4. Estimate average direct costs of treating heart failure in patients diagnosed as a 
result of monitoring. 
5. Estimate differences average in QALYs for each monitoring option 
6. Calculate the incremental cost-effectiveness of using BNP monitoring versus no 
monitoring, ECHO, or MUGA scanning; effectiveness will be measured as 
percent diagnosed. 
7. Calculate the incremental cost-utility of using BNP monitoring versus no 





4.2.2 EXPANSION AND HYPOTHESES 
 
The literature review suggests that although ECHO has been the more widely 
accepted method for monitoring cancer patients for the development of heart failure, the 
use of BNP may provide a more cost-effective alternative to what is currently considered 
the “gold-standard”. Expanded explanation of the objectives and specific hypotheses, 
where applicable, are outlined below.  
Objective one was to describe the currently employed strategies to monitor for 
chemotherapy-induced heart failure. Strategies used are mentioned in the NCCN Breast 
Cancer guidelines and are described in detail in the ACC/AHA Heart Failure guidelines. 
No hypothesis needs to be tested for this objective.  
Objective two was to estimate the current incidence of treatment-induced heart 
failure in breast cancer patients. The development of heart failure is known to be related 
to the regimen received, it is also known that patients receiving therapy corresponding to 
testing HER-2 positive (e.g., trastuzumab) have higher incidence of heart failure than 
patients treated with chemotherapy alone (e.g., cyclophosphamide and doxorubicin).  
Therefore, incidence of heart failure will be therefore determined from widely accepted 
values reported in the literature for a hypothetical cohort of U.S. breast cancer patients 
diagnosed and successfully treated (i.e., survived to achieve complete remission) for 
invasive disease in 2010. The estimated number of new cases of breast cancer for all ages 
and races is available from SEER; therefore, no hypothesis needs to be tested for this 
objective. 568 
 
                                                 
568 Howlader et al., “SEER Cancer Statistics Review 1975-2008.” 
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Objective three was to estimate the costs of using each monitoring strategy to be 
compared at follow-up intervals suggested by current surveillance guidelines.  
Surveillance is performed by the treating oncologist to monitor for not only cancer 
recurrence but also for late-onset adverse reactions to therapy. ASCO recommends that 
patients have a follow-up visit every three to six months for the first three years after 
adjuvant treatment, then every six to twelve months for the next two years and annually 
thereafter. 569 NCCN guidelines recommend a follow-up visit every four to six months 
for the first five years then annually thereafter. 570 There is a risk of breast cancer 
recurrence for up to fifteen years after initial adjuvant therapy, and heart failure can 
develop at any point in that period; therefore, total costs will be determined 
corresponding to that surveillance period.    
Objective four was to estimate the average direct cost of treatment of heart 
failure that is discovered and diagnosed as a result of monitoring. The treatment scenarios 
for different stages of heart failure were obtained from ACC/AHA guidelines for 
treatment. Costs will include the direct costs of medications used in both asymptomatic 
and symptomatic stages, costs of emergency care and/or hospitalizations resulting from 
heart failure exacerbation, and costs of outpatient cardiology management. Since the 
perspective of the study is the payer, MAC unit cost will be used to represent the costs of 
medications. Costs of emergency care and/or hospitalizations and outpatient management 
were obtained from published literature and/or CMS. The hypothesis tested for this 
objective is that the average direct costs of treating cardiac dysfunction as a result of BNP 
                                                 
569 Khatcheressian et al., “American Society of Clinical Oncology 2006 Update of the Breast Cancer 
Follow-Up and Management Guidelines in the Adjuvant Setting.” 
570 NCCN Breast Cancer Panel Members, “Breast Cancer Practice Guidelines V2.2011.” 
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will be greater than the strategy of doing nothing, but less than using either ECHO or 
MUGA.  
• No Monitoring direct cost < BNP direct cost 
• BNP direct cost < ECHO direct cost 
• BNP direct cost < MUGA direct cost 
 
Objective five was to estimate any differences in QALYs between each 
monitoring strategy. Utilities for patients with heart failure are readily available in 
published literature. The difference in utilities will arise from the stage of heart failure at 
diagnosis and subsequent transitioning through progressive states. The hypothesis for this 
objective is that the QALY associated with the use of natriuretic peptides is greater than 
the options being compared (i.e. doing nothing, ECHO and MUGA).  
• No Monitoring QALY  < BNP QALY 
• ECHO QALY  < BNP QALY 
• MUGA QALY  < BNP QALY 
 
Objective six was to determine the incremental cost-effectiveness of using BNP 
versus other comparators; effectiveness measured by the percent of patients diagnosed. 
The hypothesis for this objective is the percentage of patients’ diagnosed utilizing BNP 
will be greater than that of either ECHO or MUGA. Since the average costs associated 
with BNP are expected to be lower, the resulting ICER will show that BNP is the 
dominant strategy. 
• ECHO % Diag  < BNP % Diag   
• MUGA % Diag   < BNP % Diag  
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Objective seven was to determine the incremental cost-utility of using BNP 
versus other comparators as measured by QALYs.  The Hypothesis for this objective is 
the ICER resulting from the comparison of all alternatives to BNP will be below the 
WTP threshold of $50,000. 
• BNP vs. No Monitoring; ICER < $50,000 WTP per QALY 
• BNP vs.  ECHO; ICER < $50,000 WTP per QALY 
• BNP vs.  MUGA; ICER < $50,000 WTP per QALY 
 
 
4.3 Theoretical Basis of Economic Evaluation of Healthcare 
 
4.3.1 INTRODUCTION TO ECONOMIC EVALUATION IN HEALTHCARE 
 
Economic evaluation is important in healthcare as resources are finite; therefore, 
to facilitate the most efficient utilization, it is important to have analyses that evaluate all 
of the relevant choices available. Since each alternative may yield differing outcomes, it 
is imperative that analyses account for a variety of end-points. There are two 
characteristics of economic evaluation; economic evaluation considers both inputs and 
outputs, and is concerned with choices. Drummond et al. define economic evaluation as 
“the comparative analysis of alternative courses of action in terms of both their costs and 
consequences”. 571  
 
 
                                                 
571 Michael Drummond et al., Methods for the Economic Evaluation of Health Care Programmes (Oxford 
University Press, USA, 2005), http://www.amazon.ca/exec/obidos/redirect?tag=citeulike09-
20&path=ASIN/0198529457. 
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4.3.2 WELFARE/PARETO ECONOMICS 
 
There are different perspectives from which to perform economic evaluations 
including that of society, the payer, or patient. In the societal perspective, the goal is to 
improve welfare for everyone in the society. Welfare economics is described as 
“achieving a social maximum derived from individual desires” and is based on the 
assumptions that individuals will maximize preferences represented by utility functions 
and overall welfare is a function of those individual preferences. Utility is considered the 
only outcome of interest and societal welfare is the sum of all individual’s welfare and 
the affected individuals are the source of how utility is valued.  572 Preferences of 
individuals are typically determined by how those individuals prioritize health status over 
other goods and services; social utility is the synthesized composite of all the individual 
utilities. 573 
Economic analyses often take the perspective of society; Pareto economics is a 
type of welfare economics which considers those preferences and is one method to 
aggregate utilities among individuals to determine if the proposed resource allocation will 
improve social welfare. When creating an aggregate utility representing individuals, there 
are a number of states that can result depending on whether members of society gain or 
lose utility.  Resulting states include optimality, improvement, efficiency, deterioration, 
comparable, and non-comparable. 574 
Pareto optimality exists when the demands of society do not exceed supply and is 
broken down into improvement and efficiency. An improvement is when the allocation of 
                                                 
572 Werner B. F. Brouwer et al., “Welfarism Vs. Extra-welfarism,” Journal of Health Economics 27, no. 2 
(March 2008): 325–338. 
573 Michael Drummond and Alistair McGuire, Economic Evaluation in Health Care : Merging Theory 
with Practice (New York: Oxford University Press, 2001). 
574 Ibid. 
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resources improves the utilities of all, (the opposite of this would be Pareto deterioration). 
Pareto efficiency is when there is improvement in utilities for some; however, no one is 
worse off.  The status of how “well-off” someone is can be measured in either tangible 
goods or in natural units (such as life-years or health).  Pareto non-comparable states 
occur when there are some that gain utilities and some lose in re-allocation. 575 
The figure below (Figure 4.1) illustrates the comparison of utilities between two 
individuals and the gains and losses as there are transitions between states. In the figure, 
each axis represents levels of utilities with respect to two individuals, the lower case 
letters in each quadrant serve to represent the gain or losses in utilities from one level to 
another.  In the figure, point e represents the initial allocation of resources. Quadrants A 
and D correspond to Pareto non-comparable states since moving from the initial 
allocation (e) into either results in one person gaining while the other loses (i.e., a move 
to either points x or z, result in a situation where one individual clearly gains utility while 
the other loses). Whereas moving to points y or w creates a gain or loss for both 






















Not unlike welfare economics, extra-welfarism considers utilities and preferences, 
but also allows the inclusion and consideration of other outcome measures important for 
well-being such as health gained, patient satisfaction, and the burden on caregivers. As a 
result, those additional individuals such as caregivers, health care providers, experts or 
decision makers can be a source of how outcomes will be valued. Individual weights are 
assigned to outcomes of interest (such as QALYs); therefore, extra-welfarism provides a 
                                                 
577 Ibid. 
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Preferences or utilities “refer to the level of subjective satisfaction, distress, or 
desirability that people associate with a particular health state.” 579 Utilities can also be 
considered a measure of health based on how individuals prefer one health state over 
another. 580  Approaches to determine preferences typically involve a sequence of general 
steps including:  defining the health states of interest; identifying subject(s) to assign 
ranks or weights to the chosen health states; and compiling those rankings to determine 
an overall scale-value for each respective health state. 581 When measuring health states, 
it is important to determine:  which dimensions of that state will be considered relevant 
(such as physical or social functioning); which scaling method will be used; how material 
will be presented to subjects; and potential population or situational differences that may 







                                                 
578 Brouwer et al., “Welfarism Vs. Extra-welfarism.” 
579 Debra G. Froberg and Robert L. Kane, “Methodology for Measuring Health-state preferences--I: 
Measurement Strategies,” Journal of Clinical Epidemiology 42, no. 4 (1989): 345–354. 
580 Ann M. Holmes, “A Method to Elicit Utilities for Interpersonal Comparisons,” Medical Decision 
Making 17, no. 1 (February 1, 1997): 10 –20. 
581 Froberg and Kane, “Methodology for Measuring Health-state preferences--I: Measurement Strategies.” 
582 Ibid. 
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4.3.5 OUTCOME MEASURES 
 
The outcomes from a given intervention can be measured in reduced mortality or 
morbidity; these alone do not incorporate the impact the health state has on someone’s 
life. Measures which incorporate individuals’ preferences for particular health states 
include measures such as quality-adjusted life-years (QALYs) or healthy-year 
equivalents (HYEs) which incorporate quantity of life gained as well as health-related 
quality of life (HRQoL).  Quality-adjusted life-years (QALYs) are a single measure that 
represents not only the quantity of time that can be gained from reduced morbidity and 
mortality resulting from an intervention, but also how incorporates the “quality” of that 
time by accounting for patient preferences. This approach assigns a value (usually 
between zero and one, however states worse than death are also recognized, which yield a 
negative value) corresponding to the HRQoL for a given year. QALYs are obtained by 
multiplying the established utility for a particular health state by the amount of time spent 
in that state. Healthy-year equivalents (HYEs) determine how many years of perfect 
health subjects would consider equivalent to a particular health state. 583 
Other valuation methods can be used to determine patient preferences for health 
states and to quantify how individuals value the benefits gained from health care 
improvement or interventions (including monetary value). Valuation methods that can be 
used to elicit preferences include either interval or ratio scales; both are considered to add 
comparability among individuals. 584 The scaling method chosen by researchers is based 
                                                 
583 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice. 
584 Debra G. Froberg and Robert L. Kane, “Methodology for Measuring Health-state preferences--II: 
Scaling Methods,” Journal of Clinical Epidemiology 42, no. 5 (1989): 459–471. 
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on how measurements are collected from respondents (i.e., how questions are presented 
to respondents) and how the data will be aggregated. 585  
Methods with interval-level data include the standard gamble (SG), time-trade-off 
(TTO) and visual or rating scales; these methods ask respondents to assign a value on one 
health state in comparison to another. In the standard gamble (SG) method, respondents 
are asked to choose between two alternatives, with either definite or variable outcomes 
(like a wager). The subject could be given alternatives that may represent different 
therapies  where one choice would cause certain death, the other could either lead to 
absolute perfect health or a state that is considered worse than the certain outcome (in this 
case, worse than death). 586 The time-trade-off (TTO) method is similar to SG, except 
that all outcomes are certain. Respondents essentially have to quantify how much time 
they would sacrifice to be in a state that is healthier than another (i.e., respondents can 
choose to be in some chronic disease state for the typical life expectancy for that 
condition or give up some of that life expectancy to be in a healthier state).  In visual 
analog (VAS) or rating scales, the respondents are shown a line or continuum with 
definite anchors on each end, such as death and perfect health. Respondents are then 
asked to place various health states with representative differences between states. 
Subjects could also be presented with a line with existing graduations on it and asked to 
sort a group of states into categories.  587 
Valuation methods with ratio-level data ask respondents to quantify how much 
better or worse one state is compared to another. These include magnitude estimation, 
equivalence and willingness-to-pay (WTP).  In magnitude estimation, respondents are 
                                                 
585 Froberg and Kane, “Methodology for Measuring Health-state preferences--I: Measurement Strategies.” 
586 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; 
Froberg and Kane, “Methodology for Measuring Health-state preferences--I: Measurement Strategies.” 
587 Froberg and Kane, “Methodology for Measuring Health-state preferences--II: Scaling Methods.” 
 235 
first given a state that they will use as a standard for comparison purposes. They will then 
be given other states to provide a number or ratio of how much better or worse that state 
is compared to the standard.588 The equivalence method is similar to magnitude 
estimation in that respondents are given a standard health state for comparison purposes 
and a specified number of people in that state. They are then presented with other health 
states and asked to estimate how many people in that state would be equivalent to the 
number in the reference.589 For example, if the reference state is perfect health which has 
50 people, respondents could be given various states of lesser health and asked to assign a 
number ≥ 50 representing the quantity of people in each state that would be equal to those 
in perfect health.  
In the willingness-to-pay (WTP) method, respondents are asked to give either a 
dollar amount or proportion of income they would pay for a particular intervention to 
gain a certain level of improvement in health. 590 Positive aspects of the WTP method are 
that the respondents are valuing the benefits in the same units as costs and are not 
restricted in considering only the health-related benefits.  WTP can be assessed using 
contingent valuation (CV), conjoint analysis/discrete choice experiments (CA/DCE) or 
magnitude estimation. 591  
Contingent valuation (CV) specifically asks respondents to quantify the maximum 
amount they would be willing-to-pay for a particular health benefit, or the minimum 
amount they would be willing-to-accept (WTA) to forego that benefit. 592 In order for CV 




591 J. A. Olsen and R. D. Smith, “Theory Versus Practice: a Review of ‘willingness-to-pay’ in Health and 
Health Care,” Health Economics 10, no. 1 (2001): 39–52. 
592 Tapio Nousiainen et al., “Concomitant Impairment of Left Ventricular Systolic and Diastolic Function 
During Doxorubicin Therapy: A Prospective Radionuclide Ventriculographic and Echocardiographic 
Study,” Leukemia & Lymphoma 43 (January 2002): 1807–1811. 
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to be useful, it is crucial that both the hypothetical scenarios surrounding health 
states/benefits and how payments are made are carefully defined. 593 Conjoint Analysis 
(CA) (also known as discrete choice experiments) utilizes ranking, rating or pairwise 
comparisons to determine how a respondent values particular attributes of health states. 
CA can be used to determine values for both WTP and QALY depending on the 
attributes to which respondents are assigning values. 594 
 
4.4 Types of Analyses 
 
There are a number of methods which to perform such comparisons; those include 
cost-minimization, cost-effectiveness (CEA), cost-benefit (CBA), and cost-utility 
analyses (CUA).  Each technique has a distinct approach to account for the costs and 
consequences of the alternatives being compared. 595  Table 4.1 illustrates the different 
types of analyses that can be performed which are classified as either partial or full 
analyses.  A partial analysis may consider one or multiple alternatives and can describe, 
quantify or compare either outcomes or costs. Typically, partial analyses take one of the 
following approaches:  describe outcomes or costs of a single alternative; compare either 
costs or outcomes for multiple alternatives; or describe both costs and outcomes for a 
single alternative. Full analyses include comparisons of both costs and consequences of 
                                                 
593 Richard T. Carson, “Contingent Valuation:  A User’s Guide†,” Environmental Science & Technology 
34, no. 8 (April 1, 2000): 1413–1418; Richard D Smith, “Construction of the Contingent Valuation Market 
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594 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; Terry 
N. Flynn, “Using Conjoint Analysis and Choice Experiments to Estimate QALY Values: Issues to 
Consider.,” PharmacoEconomics 28, no. 9 (2010): 711–722. 
595 Drummond et al., Methods for the Economic Evaluation of Health Care Programmes. 
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multiple therapies or interventions; examples of full analyses include cost-benefit, cost-






Table 4.1 Types of Economic Analyses 597 
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CEA: Cost-Effectiveness Analysis; CBA: Cost-Benefit Analysis;  




Cost-minimization analyses (CMA) consider the outcomes to be equal among 
alternatives; therefore, the only real comparison is the cost of that intervention or therapy. 
This may, for instance, be a comparison of medications for hypertension within the same 
drug class that have both been shown have similar decreases in blood pressure.  Cost-




benefit analyses (CBA) consider the costs of the interventions being compared and also 
assign monetary values to the gains expected. These analyses can be useful to decision 
makers who are comparing programs that have very different outcomes, and because of 
budgetary restraints, resources can only be applied to the adoption of a single alternative.  
598 
 In cost-effectiveness analyses (CEA), the inputs of an intervention are assigned a 
monetary value or cost, and outcomes or consequences are expressed in units of 
improvement or gain (i.e., decrease in mmHg); the alternatives being compared must 
have similar outcome measures.  Results of cost-effectiveness analyses are expressed as 
cost-effectiveness ratios (CERs) or incremental cost-effectiveness ratios (ICERs) which 
enable the decision maker to compare alternatives to either each other or to a threshold 
value. 599  Cost-utility analyses are similar to CEA; however, the outcomes have been 
assigned a value or utility based on preferences of the patients. The outcomes of each 
alternative are often expressed in quality-adjusted life years (QALYs).  600 
 
 
4.4.1 COST-EFFECTIVENESS ANALYSES 
 
As previously mentioned, there are a number of methods available to evaluate 
alternatives in economic terms to assist decision makers in the allocation of resources.  
Cost-effectiveness analysis (CEA) is one method. 601 In CEA, the costs or resources 
required for each alternative or intervention designed to improve health are expressed in 
                                                 
598 Ibid. 
599 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; 
Marthe R. Gold et al., eds., Cost-effectiveness in Health and Medicine (Oxford University Press US, 1996). 
600 Drummond et al., Methods for the Economic Evaluation of Health Care Programmes. 
601 Ibid. 
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monetary terms such as U.S. dollars. The consequences or outcomes of each alternative 
are expressed in natural units representing the improvement in health as a result of that 
intervention.602  Comparisons between competing alternatives can be made with the 
resulting cost for each unit gained in improved health. These are often expressed as cost-
effectiveness ratios (CERs) in which each alternative is compared to no intervention, or 
incremental cost-effectiveness ratios (ICERs), which directly compares the alternatives to 
each other. The ICER takes the differences in cost between two alternatives and divides 








     
 
 
The resulting ICER can be displayed in a grid or plane for interpretation purposes 
as illustrated in Table 4.2 and Figure 4.2, respectively.  When comparing two competing 
alternatives (for example Drugs A and B), there can be one of four potential results;   
drug A costs more and is more effective, costs more but is less effective, costs less and is 
less effective, costs less and is more effective. Results can then be expressed in a cost-
effectiveness grid or plane.  604 
For illustration purposes, Table 4.2 shows the comparison of two alternatives, 
drugs one and two. Drug one can be a medication recently approved for use, and Drug 
                                                 
602 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; Gold 
et al., Cost-effectiveness in Health and Medicine. 
603 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice. 
604 J.L. Bootman, R.J. Townsend, and W.F. McGhan, Principles of Pharmacoeconomics, 3rd ed. 
(Cincinnati  OH: Harvey Whitney Books Co., 2005); K. L. Rascati, Essentials of Pharmacoeconomics 
(Philadelphia: Wolters Kluwer Health, 2009). 
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two can be the older, standard alternative and can be considered the “gold-standard” and 
the baseline for comparison. The darker gray areas of the grid represent scenarios where 
the new alternative (1) is dominated by the standard alternative (2) in that it either has 
equal costs with lower effectiveness or equal/ lower effectiveness with higher costs.  605 
The lighter gray squares represent scenarios where the newer alternative (1) would 
dominate over the standard alternative in that it has lower costs with equal or higher 
effectiveness, or equal costs with higher effectiveness.  606 
 
 
Table 4.2 Cost-Effectiveness Grid607 
 
  Costs 







s Lower A B C 
Equal D E F 
Higher G H I 
   
 
In Figure 4.2, the vertical and horizontal axes represent a continuum of costs or 
effectiveness respectively, and the origin is the point where costs and/or effectiveness 
would be equal among the alternatives. Each quadrant of the plane represents how the 
differences in costs and effectiveness between the comparator and traditional, baseline or 
                                                 
605 Bootman, Townsend, and McGhan, Principles of Pharmacoeconomics; Rascati, Essentials of 
Pharmacoeconomics. 
606 Rascati, Essentials of Pharmacoeconomics. 
607 Ibid. 
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“gold standard” alternative. There are two quadrants where one alternative will clearly 
dominate the other (II and IV) and two quadrants (I and III) where the decision maker 
must determine which they value more, greater effectiveness or lower costs. Quadrant II 
represents a scenario where the newer alternative costs less and has greater effectiveness 
thus dominating the baseline alternative. Results in quadrant IV represent the opposite 
scenario in which the newer alternative would both cost more and have lower 
effectiveness; thus, it is dominated by the older or standard therapy. 608 
In quadrants I or III, it would be up to the discretion of the decision-maker or 
stakeholder whether they value the lower cost or higher effectiveness. Quadrant I is a 
scenario where the newer alternative costs more but is also more effective; Quadrant III is 
the opposite scenario in which the newer alternative costs less but is also less effective. 
609 
  
                                                 
608 Bootman, Townsend, and McGhan, Principles of Pharmacoeconomics; Rascati, Essentials of 
Pharmacoeconomics. 
609 Bootman, Townsend, and McGhan, Principles of Pharmacoeconomics; Rascati, Essentials of 
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Advantages of CEA include the use of clinical natural units as the outcomes of 
interest which are often metrics that healthcare practitioners and decision makers already 
use and are already familiar with. Additionally, assigning monetary values to outcomes is 
not required.  Critics of CEA frequently cite a limitation that CEA does not address social 
welfare issues that can be addressed with other methods. 611 
 
4.4.2 DECISION ANALYSIS 
 
There are different types of decision analysis including decision trees and Markov 
models. 612 Decision trees are less complex forms of decision analysis but the concepts 
are similar. First, a question must be formulated that could be answered by the analysis, 
and there should be multiple alternatives in which to compare.   A decision tree is then 
constructed such that each alternative being compared has a branch from the initial node 
which is a decision node signifying a choice between the alternatives. This node is 
illustrated with a square and there should only be a single decision node for each tree. 613 
The subsequent nodes on each branch represent the probabilities of experiencing a 
particular outcome; these are chance nodes which are notated with circles.  The end result 
of each branch, or terminal node, is represented by a triangle and signifies the outcome of 
each branch.   
The outcomes can be measured in a number of units such as mortality, QALYs, 
symptom-free days or dollars.  614 The values at the end of each pathway comprise both 
                                                 
611 Gold et al., Cost-effectiveness in Health and Medicine. 
612 J. M Inadomi, “Decision Analysis and Economic Modelling: a Primer,” European Journal of 
Gastroenterology & Hepatology 16, no. 6 (2004): 535. 
613 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; 
Inadomi, “Decision Analysis and Economic Modelling.” 
614 Inadomi, “Decision Analysis and Economic Modelling.” 
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the cost and health effects of that respective intervention or alternative. 615 Once the 
model is structured, each chance node is assigned a probability. Then the analysis is 
performed by a procedure called folding back. The outcomes are multiplied by the 
probability of experiencing that outcome; these calculations continue from the right side 
of the tree to the left and these values are added together. After these values are obtained, 
sensitivity analysis is then performed in which one or more values in the model are varied 
to see if the end result stays consistent (i.e., is one alternative is found to be more cost-
effective with the initial analysis, if after values in the model are varied, the same result is 
achieved, the analysis is insensitive, which is desirable). 616 Figure 4.3 summarizes the 
steps for constructing decision trees. 617 
  
                                                 
615 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice. 
616 Inadomi, “Decision Analysis and Economic Modelling.” 
617 Xin Sun and Thomas Faunce, “Decision-analytical Modelling in Health-care Economic Evaluations,” 
The European Journal of Health Economics 9, no. 4 (2007): 313–323. 
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Develop Model Structure 
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Perform Incremental Analyses 
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Limitations of decision analysis include: the dependence on initial assumptions; 
complex health states are simplified (i.e., chronic disease states often lead to complicated 
models); and the choice of which costs to include is somewhat arbitrary. Additionally, 
decision trees represent events that occur at a single time point; thus, time-dependent 
variables are difficult to incorporate into the model. 619 
 
4.4.3 MARKOV MODELING 
 
In healthcare economics, a model is “any mathematical structure that represents 
the health and economic outcomes of patients or populations under a variety of 
scenarios.” (Drummond and McGuire, 2001) A Markov model is essentially a repetitive 
decision tree. Markov models are useful when the risk of an event is ongoing, the timing 
of events is important, and in diseases where events can occur more than once. Markov 
modeling compensates for the limitations of decision trees since the method incorporates 
the stages of chronic diseases that patients can be in at any given time as well as the 
passage of time. 620  
To conduct an analysis with a Markov model, first, the health states under 
examination must be determined; these must include all relevant states associated with 
the disease and/or treatment over time. These are depicted in a transition state diagram 
representing the possible states along with arrows showing allowable transitions between 
                                                 
619 Alan Brennan and Ron Akehurst, “Modelling in Health Economic Evaluation: What Is Its Place? What 
Is Its Value?,” Pharmacoeconomics 17, no. 5 (2000): 445; Drummond et al., Methods for the Economic 
Evaluation of Health Care Programmes; Inadomi, “Decision Analysis and Economic Modelling.” 
620 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice; 
Inadomi, “Decision Analysis and Economic Modelling”; F. A. Sonnenberg and J. R. Beck, “Markov 
Models in Medical Decision Making: A Practical Guide,” Medical Decision Making 13, no. 4 (1993): 322–
338. 
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them. The transition between states can be in either direction which would indicate that 
someone can move from one health state to another and back again; however, patients 
can only reside in one health state at any given time. The exception is an absorbing state 
(i.e., death); once someone transitions to an absorbing state, transition to other states is no 
longer possible. Additionally, a state may have an arrow leading to back to that same 
state, which indicates that once someone reaches that health state, they may remain there.  
621 
Temporary states and tunnel states may also exist in Markov models. A temporary 
state is used to represent states that have short-term effects such as a hospitalization. 
These states have arrows leading out since someone cannot remain in a temporary state 
for more than one cycle. These can be used to account for costs or utilities, and for the 
difference in transition probabilities which may differ if someone enters that state. Tunnel 
states can be considered a sequence of temporary states that occur in only a specified 
sequence. 622 
Like decision trees, once the model is constructed, inputs must have values 
assigned to them. Since Markov models account for time, the cycle length must be 
specified. Cycle length should realistically represent the time it would take to transition 
between the health states. Once that is determined, probabilities need to be assigned to 
each possible transition and the outcomes must be specified. In Markov Models, unlike 
decision trees where outcomes are only considered at the end, the outcomes are 
cumulative throughout the duration at the model.  623 
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Markov models can use either of two methods of evaluations, Monte Carlo 
simulations or cohort simulations. A Monte Carlo simulation has individual patients from 
the hypothetical cohort transition through model one at a time and the resulting outcome 
(such as QALY) is recorded for each individual. The overall outcome is determined by 
taking the average of those for all individuals. The advantages of Monte Carlo 
simulations are that states need only describe current clinical information because it 
allows past information to be tracked specifically for each patient transitioning through 
the model. The disadvantages are that the analysis takes longer to run and it is not 
considered as transparent as cohort simulations. 624  
Cohort simulations track the hypothetical cohort through model simultaneously; 
this produces a Markov trace which shows the movement of the cohort through the health 
states and the cumulative utilities and costs assigned. The model is run until entire cohort 
reaches the death (absorbing) state – after this cycle, the cumulative utility is the expected 
QALY of the cohort. While all members of the cohort begin the simulation 
simultaneously, they do not necessarily need to begin in the same health state. The 
advantages of cohort simulations are that they are faster to run, easier to debug, and are 
considered more transparent than Monte Carlo simulations. The disadvantage is that the 
state definitions need to include all of the relevant current and past clinical information, 
which can lead to extremely complex models.  625  
The advantages of using Markov models over decision analysis include the ability 
to transition between health states with representative probabilities of such transitions 
                                                 
624 Brennan and Akehurst, “Modelling in Health Economic Evaluation”; Andrew Briggs and Mark 
Sculpher, “An Introduction to Markov Modelling for Economic Evaluation.,” PharmacoEconomics 13, no. 
4 (April 1998): 397–409; Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory 
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625 Briggs and Sculpher, “An Introduction to Markov Modelling for Economic Evaluation.”; Drummond 
and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice. 
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may make models more realistic, and the outcomes are cumulative throughout the 
duration of the model, whereas in decision analysis, the outcomes are only considered at 
the end. Disadvantages or limitations of using Markov models include: outcomes may be 
measured by surrogate markers in lieu of the actual outcome of interest; the data are from 
diverse sources that can be subject to an indeterminate amount of bias from confounding 
factors (i.e., the patient selection and methods of data analysis); and transition 
probabilities depend only on the state the patient is in at that point (i.e., states do not 
incorporate prior health information). Critics also often mention that Markov models 
have the potential for a lack of transparency (i.e., black-box). 626 
All of these limitations can be minimized by careful and detailed documentation 
of data sources and any assumptions that are made regarding the construction of the 
model. Sensitivity analyses also reduce bias from the selection of certain values over 
others for each parameter. 627 
 
 




“Uncertainty refers to the fact we can never know for certain what the mean 
(expected) costs and effects would be if the treatment is provided for a particular 
population of patients, even if they had the same observed characteristics.” 628 When 
                                                 
626 Drummond and McGuire, Economic Evaluation in Health Care : Merging Theory with Practice. 
627 Ibid. 
628 Karl Claxton, “Exploring Uncertainty in Cost-Effectiveness Analysis.,” PharmacoEconomics 26, no. 9 
(June 2008): 781. 
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conducting decision analysis, it is preferred that the estimates for each parameter are 
obtained from published literature in which results are obtained from a study population 
with natural variation. However if obtaining estimates from published literature is not 
possible, the researcher may consult experts in the field for estimates. The estimates that 
are obtained from expert opinion have a degree of inherent uncertainty.  Sensitivity 
analyses are used to examine such uncertainty. In sensitivity analyses, values for model 
inputs are varied to determine if calculations yield similar conclusions. 629 
There are four types of uncertainty in Markov models; those include parameter, 
analytical or methodological, structure or model, and generalizability. 630 Parameter 
uncertainty relates to estimates used as model inputs such as costs, transition probabilities 
and utility estimates. Analytical uncertainty refers to specific methods chosen such as 
costing, outcome measures, and cycle length and termination conditions. Structure 
uncertainty refers to model structure, specifically, how accurately the model represents 
disease progression. Generalizability refers to how well the included population 
represents the population the study is intended to effect. 631 These four types ultimately 
represent uncertainty in either the data used as input for the model or uncertainty relating 









                                                 
629 Gold et al., Cost-effectiveness in Health and Medicine. 
630 Sun and Faunce, “Decision-analytical Modelling in Health-care Economic Evaluations.” 
631 Ibid. 
632 Gold et al., Cost-effectiveness in Health and Medicine. 
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4.5.2 TYPES OF SENSITIVITY ANALYSIS 
 
Sensitivity analyses can be either deterministic or probabilistic. In deterministic 
analyses (or simple sensitivity analyses), point estimates or range estimates are used to 
assess the variability of results; usually the extreme values for each parameter are used 
and threshold values are determined at which the decision changes. These are one-way 
sensitivity analyses where one parameter is varied and all others remain constant. These 
often underestimate uncertainty. 633 The problem with deterministic analyses is that the 
extreme but plausible ranges are somewhat arbitrary, the probability of the extreme 
values is small, and therefore if the results are sensitive with these values, it makes 
interpretation difficult, any interaction between parameters is ignored and it is unclear 
how to estimate the probability of the threshold value occurring for any given parameter. 
634  
Probabilistic sensitivity analyses will incorporate the probability distributions of 
variables; therefore, a distribution is specified for each parameter, and these distributions 
are sampled randomly which produces a distribution of the outcome. This is repeated to 
represent the possible range of values for the parameters. 635 The output gives the 
expected values for costs, effects and benefits as well as the probability that each 
alternative is cost-effective. 636 Distributions are chosen based on nature of the data, how 
the parameter is estimated and the research question. 637  
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Sensitivity analyses are important in the current study as the cost-effectiveness of 
a screening modality that is not currently used in the proposed setting is being compared 
to methods considered to be the “gold-standard.” Estimates for heart failure incidence are 
low since older trials did not screen for this adverse effect; therefore, patients were only 
reported if they became symptomatic. Probabilistic sensitivity analyses will be performed 
for all variables.  Beta distributions represent population values that are restricted to a 
range from zero to one, thus beta distributions were used for probabilities and utilities. 




4.6 Introduction to Utilities and HRQOL 
 
Quality of life can be defined as “a state of complete physical, mental and social 
well -being, and not merely the absence of disease.”  638 Since heart failure is a chronic 
condition for which there is no cure, the measurement or assessment of quality of life 
becomes important.  Health-related quality-of-life is comprised of several components 
(which can also be referred to as domains or dimensions). Those include physical, 
psychological and social functioning, Figure 4.4 illustrates how these domains or 
dimensions contribute to the overall HRQOL. 639  Physical functioning may include how 
symptoms affect someone’s daily life. Psychological functioning can be affected by 
depression from the realization of one’s mortality or from impaired physical functioning. 
Social functioning includes decreased interaction with others which may be due to 
                                                 
638 Colin Berry and John McMurray, “A Review of Quality-of-Life Evaluations in Patients with 
Congestive Heart Failure.,” PharmacoEconomics 16, no. 3 (1999): 247–271. 
639 Ibid. 
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symptoms, depression, inability to work due to recurrent hospitalizations, or physical 
limitations. 640 The decreased functioning with disease progression results in a decreased 
quality of life.  Instruments are designed to measure both how treatment is improving the 
patients’ well-being as well as the adverse effects of said treatment. 641 Quality of life can 
be measured either directly by obtaining responses from the patient, or indirectly by 
having the caregiver respond on the patients behalf or by obtaining the medical 




Figure 4.4 Domains of Health-Related Quality-of-Life643 
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4.6.1 QUALITY OF LIFE IN HEART FAILURE 
 
There are numerous consequences of heart failure that can decrease a patient’s 
quality of life such as physical, functional or social limitations as a result of the disease or 
due to the adverse effects of treatment. Figure 4.5 below illustrates a model of the quality 
of life in heart failure patients. There are many interacting factors in quality of life that 
can be affected for patients with heart failure. For example, symptoms can cause a 
limitation in the ability to perform activities of daily living (ADL), and increased 
symptoms can also affect mood, which can subsequently decrease willingness to perform 
certain activities. These interactions can therefore affect how quality of life is assessed in 
heart failure patients. For example, treatment that improves symptoms does not always 
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Quality-of-life in heart failure patients can be measured with both general 
instruments and disease-specific instruments. General instruments used include the 
Sickness Impact Profile (SIP), the 36- and 12-Item Short Form health surveys (SF-36 and 
SF-12), and the Quality of Well-Being Scale (QWB). Disease-specific instruments in 
heart failure include the Chronic Heart Failure Questionnaire, the Minnesota Living with 
Heart Failure Questionnaire (MLwHF), and the Quality-of-Life in Severe Heart Failure 
(QLQ-SFH).646 Quality of life estimates, for the purposes of this study, were obtained 
from previously published literature, and for purposes of simplicity, patients are 
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4.7 Model Inputs 
 
Estimates obtained for the model included the estimated number of patients 
expected to be included in the study population, incidence and prevalence estimates of 
heart failure, probability of correct diagnosis, probability of hospitalization and/or 
emergency department utilization, probability of symptomatic disease, probability of 
disease progression and expected mortality. Costs were obtained for the tests being 
compared, costs of treating discovered cardiac dysfunction (including medication cost, 
cardiology follow-up and medication management) and cost of potential 
hospitalization/emergency department utilization. 
 
4.7.1 STUDY POPULATION 
 
A hypothetical cohort of female patients diagnosed with invasive breast cancer 
and successfully treated (i.e., achieved complete remission) in the US during 2010 will be 
the population under study.  SEER estimates that there will be 209,060 new cases 
diagnosed in 2010, including 54,010 in situ cases and 1,970 male cases. Since in situ 
cases are not treated with chemotherapy, these patients will not be exposed to the 
cardiotoxic treatment and therefore, will not be subject to further monitoring.  Although 
male cases would be treated with the same chemotherapy regimens, cardiovascular 
outcomes would have to be modeled separately, thus they were also subtracted to reduce 
the model complexity. The resultant study population includes 153,080 patients. 648 All 
invasive cases are assumed to have received first-line therapy which includes the use of 
                                                 
648 Howlader et al., “SEER Cancer Statistics Review 1975-2008.” 
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anthracyclines. 649  The c-erb-B2 gene (or HER-2/neu) is overexpressed in 20-30% of 
invasive breast cancer cases; therefore, it is assumed that 25% (n = 30,616) will also 
receive trastuzumab, creating additional risk. Table 4.3 below summarizes the 
calculations used to determine the number of subjects in the hypothetical study 
population. 650  
 
Table 4.3 Summary of Study Population Calculation651 
 
Study Population 
New cases - 2010 209,060  
New in situ cases 54,010 (55,980) New male cases 1,970 
Total Study Population 209,060 - 55,980 153,080 
Trastuzumab Cases 153,080 * 0.25 38,270 





4.7.2 INCIDENCE OF HEART FAILURE 
 
It has been shown that incidence of heart failure in breast cancer patients varies 
with the chemotherapy regimen received, and for anthracycline-based regimens, the 
cumulative dose. Other considerations included whether the patient received trastuzumab 
                                                 
649 NCCN Breast Cancer Panel Members, “Breast Cancer Practice Guidelines V2.2011.” 
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with their chemotherapy regimen.652 Limitations in using published heart failure incident 
data are that trials historically only report late-stage or symptomatic disease (NYHA 
Classes III and IV), so patients who had declining cardiac function, yet were without 
symptoms, would not have the disease detected during the trial.653 Additionally, adverse 
effects are typically only recorded while the subjects are actively receiving the agent(s) 
under investigation and heart failure can develop up to 15 years after the completion of 
therapy. 654 
 In a pooled analysis of seven phase II/III trials where 202 patient records were 
reviewed, 112 (55%) experienced some type of cardiac dysfunction and 62 (30.7%) met 
criteria for heart failure.  However, of the seven trials, only one compared cardiac 
dysfunction in patients receiving the combination of doxorubicin and cyclophosphamide 
(rate of cardiac dysfunction = 8%) and those receiving that combination with trastuzumab 
(rate of cardiac dysfunction = 27%). 655 In a prospective evaluation of pediatric survivors 
of childhood cancer; patients that were treated with anthracyclines were subsequently 
monitored for up to 15 years. Lipschultz et al. found that 57% of children developed 
detectable cardiac dysfunction (Lipschultz et al. 1991). Frequently cited, dose-dependent 
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incidence rates of cardiac dysfunction are 3%, 7% and 18% for doses of 400, 550 and 700 
mg/m2, respectively.  Other common and more recent incidence values are 5%, 26% and 
48% for the same respective doses.  Table 4.4 below summarizes incidence rates reported 
in trials of anthracycline regimens with and without trastuzumab and the corresponding 
citation.  The studies in Table 4.4 give a range of incidence values of cardiac dysfunction 
of 0.6 to 57% (median = 15.4%) and 7 to 34% (median = 27%) for patients receiving 
anthracyclines and trastuzumab. The median values were the estimates used to calculate 
probabilities for each potential test outcome (Table 4.7). 
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Table 4.4 Incidence of Heart Failure Among Breast Cancer Patients Receiving 
Anthracyclines With and Without Trastuzumab 
 
Citation 









Seidman, et al, 20021 8 4 27 16 
Piccart-Gebhart, et al. 2005 2.21 0.06 7.08 2.27 
Suter, et al.2 NR 9.6 NR 28 
Suter, et al. 20071  NR NR 7 0.6 
Slamon, et al. 2005 1 0.6 1.2 2.4 2.3 
Rastogi, et al. 20071 NR 1.3 NR 4 
Slamon, et al. 2001 8 3 27 16 
Tan-Chiu, 2005 17 0.8 34 4.1 
Gennari, et al. 19991 20 9 NR NR 
Palmeri, et al. 20021 15.4 NR NR NR 
Erman, et al. 20051 8 NR NR NR 
LLuch, et al. 20001 27.2 NR NR NR 
Pagani, et al. 20001 51 2 NR NR 
Venturini, et al. 19963 11.25 3.75 NR NR 
Von Hoff, et al. 1979 NR 2.1 NR NR 
Swain, et al. 20003 23.6 5.1 NR NR 
Lefrak, et al. 1973 NR 2.76 NR NR 
Lipshultz, et al. 1991 57 10 NR NR 
Shapiro, et al. 1998 8 6.8 NR NR 
C.D.: Cardiac Dysfunction; H.F.: Heart Failure; NR = Not Reported 1 Prospective Trial 2Reporting 




4.7.3 SENSITIVITY/SPECIFICITY OF EACH MONITORING TECHNIQUE 
 
Test characteristics will be important to determine each test’s ability to detect 
cardiac dysfunction prior to the development of symptoms. Characteristics under 
consideration include: sensitivity, specificity, positive likelihood ratio, negative 
likelihood ratio, and the diagnostic odds-ratio.  Table 4.5 below describes the test 
characteristics for the various methods of screening for heart failure. The diagnostic 
odds-ratio (DOR) is a ratio of positivity in diseased divided by non-diseased patients and 
can be calculated using test characteristics such as the number of positive and negative 
test results, the test sensitivity and specificity, and positive and negative predictive 
values. 656 
 




 DOR =  
� PPV(1 − PPV)�
�(1 − NPV)NPV �
 
DOR =  
� Sensitivity(1 − Sensitivity)�
�1 − SpecificitySpecificity �










                                                 
656 Afina S. Glas et al., “The Diagnostic Odds Ratio: a Single Indicator of Test Performance,” Journal of 
Clinical Epidemiology 56, no. 11 (November 2003): 1129–1135. 
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The positive likelihood ratio (PLR) is the ratio of detecting positive results in 
patients who have the disease in question over detection of positive results in healthy 
patients (i.e., patients who do not have the disease). A negative likelihood ratio (NLR) is 
the ratio of getting a negative result in patients who have the disease in question over 
healthy patients. 657 Positive and negative likelihood ratios are expressed as follows:  
                    
 
PLR =  
Sensitivity
(1 − Specificity)







Table 4.5 Comparison of Test Characteristics for Methods Under Comparison658 
 




BNP1 0.93 0.74 39.50 3.57 0.09 
ECHO2 0.64 0.81 7.59 3.37 0.44 
MUGA 0.90 0.72 23.10 3.21 0.14 
1 Pooled results from 20 trials 2 Measured abnormal Fractional Shortening to predict either 
abnormal contractility or afterload in leukemia patients; DOR = Diagnostic Odds Ratio, PLR = 
Positive Likelihood Ratio, NLR = Negative Likelihood Ratio 
 
 
                                                 
657 Ibid. 
658 J Mant et al., “Systematic Review and Individual Patient Data Meta-analysis of Diagnosis of Heart 
Failure, with Modelling of Implications of Different Diagnostic Strategies in Primary Care,” Health 
Technology Assessment (Winchester, England) 13, no. 32 (July 2009): 1–207, iii; Lipshultz and Colan, 
“Cardiovascular Trials in Long-Term Survivors of Childhood Cancer”; Nousiainen et al., “Concomitant 
Impairment of Left Ventricular Systolic and Diastolic Function During Doxorubicin Therapy.” 
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Positive and negative predictive values are also related to test characteristics and 
are a function of the test’s ability to obtain a positive (or negative) result in those patients 
who indeed have (or do not have) the disease in question.  Table 4.6 below describes the 
relationship between test characteristics and positive/negative predictive values where 
TP=True Positives, FP= False Positives, FN=False Negatives, TN= True Negatives, 





Table 4.6 Calculation of the Number of Positive and Negative Results from Test 
Characteristics 
 
  Disease or Target Disorder  
  (+) (-)  
T
es
t (+) TP FP PPV =
TP
(TP + FP) 
(-) FN TN NPV =  
TN
(TN + FN) 
 
 Sens. =  
TP
(TP + FN)
 Spec. =  
TN
(TN + FP)
 P =  
TP + FN
TP + FP + FN + TN 
(+) Denotes Positive Test/Disease Present; (-) Denotes Negative 





                                                 
659 Glas et al., “The Diagnostic Odds Ratio: a Single Indicator of Test Performance.” 
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The model input probabilities for test results for patients receiving anthracyclines 
only and regimens with the addition of trastuzumab are listed in Table 4.7 below. 
Probabilities were determined using the test characteristics listed in Table 4.6. The 
probability of diagnosis is 0.795; therefore, true positive results in the model are divided 
among patients that are diagnoses with and without symptoms. Those probabilities for 
both exposure types are listed in Table 4.8 below.  
 
 
Table 4.7 Input Probabilities for Each Potential Test Result 
 
Exposure Type Test TP TN FP FN 
Anthracyclines 
BNP 0.143 0.626 0.220 0.011 
ECHO 0.099 0.685 0.161 0.055 
MUGA 0.139 0.609 0.237 0.015 
Anthracyclines 
with Trastuzumab 
BNP 0.251 0.540 0.190 0.019 
ECHO 0.173 0.591 0.139 0.097 














Table 4.8 True Positive Inputs for Diagnosing HER-2 (+) and HER-2 (-) 
 Patients as Asymptomatic  
 
 
TEST HER-2 (-) HER-2 (+) 
BNP 0.114 0.199 
ECHO 0.079 0.138 




There are several aspects that need to be considered with respect to mortality in 
this model. Patients may experience mortality from breast cancer, from heart failure, or 
from unrelated causes. Mortality estimates can vary by ACC/AHA stage and by age. 
Mortality from heart failure is reported a number of ways in the literature. One study 
found an annual mortality of 10 percent from heart failure (with 2.5 years of follow-up) 
regardless of clinical stage. 660 Multiple studies give mortality estimates in months or 
years from the index diagnosis of heart failure, while some report mortality by 
ACC/AHA stage or NYHA class. Additionally, some studies differentiate mortality in 
treated patients versus untreated patients, and those typically address specific treatment 
modalities.  In Table 4.9 below, published estimates of five-year survival stratified by 
                                                 
660 John G.F. Cleland et al., “The Effect of Cardiac Resynchronization on Morbidity and Mortality in 
Heart Failure,” N Engl J Med 352, no. 15 (April 14, 2005): 1539–1549. 
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ACC/AHA stage 661 were taken and converted into the annual probability of death for 







Table 4.9 Annual Heart Failure Mortality Stratified By ACC/AHA Stage662 
 A B C D  
Stage 5-Year Survival 
5-Year 
Mortality1 Hazard Rate
2 Annual Probability3 
Value 
Used 
A 0.97 0.03 0.006091841 0.006073323 0.006 
B 0.96 0.04 0.008164399 0.008131161 0.008 
C 0.75 0.25 0.057536414 0.055912488 0.056 
D 0.20 0.80 0.321887582 0.275220336 0.275 
1 Equals 1- Column A 
2 Hazard Rate= [-ln (1-column B)]/5 










                                                 
661 Khawaja Afzal Ammar et al., “Prevalence and Prognostic Significance of Heart Failure Stages: 
Application of the American College of Cardiology/American Heart Association Heart Failure Staging 





Only direct medical costs are considered relevant to the study as the perspective is 
that of the payer. Thus, lost wages, childcare, and transportation were not included. 
Indirect costs, such as decreased productivity, were also not included. The discount rate 
used was 3%.663  Input costs considered for purposes of this study included the following: 
cost of the screening/monitoring test used plus cost of confirmatory testing; cost of heart 
failure treatment if discovered (i.e., medications and outpatient follow-up with 





4.7.5.1 Costs of Screening/Monitoring 
 
The cost of screening/monitoring includes the cost of the test (the cost of 
specialized personnel for administering or interpreting test results are assumed to be 
included in Medicare reimbursement) and cost of confirmatory testing which for the 
purposes of this study will be assumed to be costs associated with an ECHO. Table 4.10 
lists the 2010 Medicare reimbursement amounts for each test based on CPT code. Table 




                                                 
663 Drummond et al., Methods for the Economic Evaluation of Health Care Programmes; Gold et al., 
Cost-effectiveness in Health and Medicine. 
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Table 4.10 Medicare Reimbursement Associated With Monitoring 





BNP1 83880 47.77 N/A 48 
ECHO 93306 265.07  522.12 393 
MUGA 
78472 269.90 357.30 
361 78481 231.63 358.77 
78494 291.65 368.73 
784962 102.73 N/A 103 
MUGA 
Total  373-395 
461-472 *464 
OPPS: Out-Patient Payment System – Maximum amount paid for a CPT code 1 CPT Code for Natriuretic 
Peptides, Reimbursement Amount from the Clinical Diagnostic Lab Fee Schedule; Descriptions 2 Code 
for add-on to procedure, * Used average of MUGA OPPS amounts plus add-on amount total MUGA 












Table 4.11 Other Published Costs for Screening/Monitoring Tests 
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Citation Test Cost ($)1 Year 2010 Cost ($)2,3 
Tang, et al. 664  BNP or NT-pro-BNP 50 2007 58 
Nakamura, et  al. 665  BNP 32 2005 40 ECHO 420 2005 526 
Heidenreich et al. 666  BNP 32 2001 48 ECHO4 420 2001 625 
Shureiqi et al. 667  MUGA 781 1996 1,375 
Dokainish et al. 668 BNP 38 2004 50 ECHO 338 2004 442 
1 Costs are reported in U.S. Dollars 
2 Costs realized at end of the 2010 calendar year  
3 Published Costs were standardized to 2010 using Medical CPI and rounded to the nearest dollar 
4 Cost for ECHO represented total reimbursement for CPT codes 93307, 93320 and 93325  
 
 
4.7.5.2 Costs of Heart Failure Treatment  
 
The cost of heart failure treatment includes the costs of optimal drug therapy for 
the corresponding heart failure stage, cardiology clinic follow-up, potential emergency 
department visits, and hospitalizations.  Table 4.12 below outlines interventions 
recommended for all or selected patients in the progressing stages of heart failure.  All 
patients in this hypothetical cohort begin in Stage A.  Treatment guidelines state that 
select patients in stage A could possibly be prescribed either an ACE-I or ARB. The 
population in this study is assumed to have no co-morbid conditions or contributing 
                                                 
664 Tang et al., “National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: 
Clinical Utilization of Cardiac Biomarker Testing in Heart Failure.” 
665 Motoyuki Nakamura et al., “B-Type Natriuretic Peptide Testing for Structural Heart Disease 
Screening: A General Population-Based Study,” Journal of Cardiac Failure 11, no. 9 (December 2005): 
705–712. 
666 Heidenreich et al., “Cost-effectiveness of Screening with B-type Natriuretic Peptide to Identify Patients 
with Reduced Left Ventricular Ejection Fraction.” 
667 Shureiqi et al., “Clinical and Economic Impact of Multiple Gated Acquisition Scan Monitoring During 
Anthracycline Therapy.” 
668 Hisham Dokainish et al., “Comparative Cost-Effectiveness of B-Type Natriuretic Peptide and 
Echocardiography for Predicting Outcome in Patients With Congestive Heart Failure,” The American 
Journal of Cardiology 97, no. 3 (February 1, 2006): 400–403. 
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factors adding to heart failure risk, thus it is assumed that patients in this hypothetical 
cohort have not been prescribed either agent; therefore cost of medications will only 




Table 4.12 Medical Interventions Stratified by ACC/AHA Heart Failure Stage669 
 
Stage Routine Medication(s)  Medication(s) in Select Patients Other Interventions 
A  ACE-I (or ARB)   




Diuretics, ACE-I or ARB, 
Beta- Blocker 
Aldosterone 





















                                                 
669 Hunt et al., “2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis 
and Management of Heart Failure in Adults: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration 
With the International Society for Heart and Lung Transplantation.” 
 271 
The costs of medications, for purposes of this study, are the costs for the optimal 
treatment for each corresponding heart failure stage. For simplicity, one representative 
agent was selected from each guideline-recommended class of medications prescribed at 
each heart failure stage. Representative medications from each class of medications used 
for treatment will be as follows: angiotensin-converting enzyme inhibitor = lisinopril; 
angiotensin-receptor blocker = losartan; beta-blocker = carvedilol; aldosterone inhibitor = 
spironolactone. Additionally, costs were obtained for medications frequently used for 
symptom control, including the following drug classes and medications: loop diuretic = 
furosemide; nitrate = isosorbide dinitrate (ISDN); and vasodilators = hydralazine. 
Lisinopril was chosen since it is the most commonly prescribed ACE-I and losartan was 
chosen since it is the only ARB currently available as a generic. Beta-blockers that have 
been shown to reverse remodeling in heart failure include metoprolol, carvedilol and 
bisoprolol. Both metoprolol and bisoprolol have high selectivity for the beta-1 receptor, 
where carvedilol blocks the beta-1, beta-2 and alpha-1 receptors. 670 Studies have 
suggested that the slight difference in mechanism improves mortality as well as more 
profound improvements in ejection fraction and NYHA class, therefore, carvedilol was 
chosen as the representative beta-blocker used in this study. 671 
All medications are available in a generic formulation and costs were obtained 
from the Texas Medicaid website; the median maximum allowable charge (MAC) value 
                                                 
670 Michael R. Bristow et al., “Selective Versus Nonselective Β-blockade for Heart Failure Therapy: Are 
There Lessons to Be Learned from the COMET Trial?,” Journal of Cardiac Failure 9, no. 6 (December 
2003): 444–453. 
671 Philip A Poole-Wilson et al., “Comparison of Carvedilol and Metoprolol on Clinical Outcomes in 
Patients with Chronic Heart Failure in the Carvedilol Or Metoprolol European Trial (COMET): 
Randomised Controlled Trial,” The Lancet 362, no. 9377 (July 5, 2003): 7–13; Farzan S. Rajput et al., 
“Choosing Metoprolol or Carvedilol in Heart Failure (a pre-COMET Commentary),” The American 
Journal of Cardiology 92, no. 2 (July 15, 2003): 218–221; John E Sanderson et al., “Beta-blockade in Heart 
Failure: A Comparison of Carvedilol with Metoprolol,” Journal of the American College of Cardiology 34, 
no. 5 (November 1, 1999): 1522–1528. 
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was used. For medications that have been shown to improve heart failure survival and 
reverse remodeling (i.e., ACE-I, ARB, β-Blocker, aldosterone inhibitors), estimates used 
were those representing the target daily dose. For medications prescribed to improve 
symptoms, such as nitrates and diuretics, the estimates were obtained for the most 
commonly prescribed regimens.   
For purposes of this study, the input costs for heart failure medication treatment 
was the total annual calculated cost of medication for either asymptomatic (B) or 
symptomatic (C/D) cardiac dysfunction. Asymptomatic patients in stage B were assumed 
to receive optimal drug therapy as recommended by the ACC/AHA guideline, which 
includes the use of either an ACE-I or ARB in addition to a beta-blocker.672  Drug 
therapy for symptomatic patients includes medications used for stage B, plus the addition 
of an aldosterone inhibitor (spironolactone) and medications prescribed for the 
management of symptoms, which includes the use of nitrates, vasodilators and diuretics. 
Patients who were initially prescribed an ACE-I instead of an ARB, may have an ARB 
added at this point. It will be assumed that symptomatic patients will be prescribed 
furosemide, plus ISDN and hydralazine.  Tables 4.13 and 4.14 illustrate the annual costs 
of the selected representative agents and the total costs for treating asymptomatic and 




                                                 
672 Hunt et al., “2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis 
and Management of Heart Failure in Adults: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration 
With the International Society for Heart and Lung Transplantation.” 
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Table 4.13 Drug Therapies Included in Heart Failure Regimens and Their 
Respective Costs 
 









ACE-I Lisinopril 40 0.124 0.124 44.64 
ARB Losartan 100 0.683 0.683 245.88 
B-Blocker Carvedilol 255  0.112 0.448 161.28 
Aldosterone Inhibitor Spironolactone 50 0.477 0.477 171.72 
Diuretic Furosemide 406 0.43 0.86 309.60 
Nitrate Isosorbide Dinitrate 207 0.042 0.252 90.72 
Vasodilator Hydralazine 1507 0.242 0.726 261.36 
1Representative Agents are drugs selected from each drug class to determine medication costs used in   
current study 
     2 Dose is the upper limit of target or usual dose in mg per day 
     3 Costs per-unit for generic medications are MAC for TX Medicaid 
     4 Annual cost based on cost of 30-day supply for 12 months 
    5 Largest tablet strength is 25mg; therefore dose estimation is two tablets twice daily 
    6 Furosemide dose range is 20-160mg daily, 40 mg twice daily used for estimation 
   7 Isosorbide dinitrate is available is 20mg tabs, dose is 40mg TID; Hydralazine dose range is 25-100mg  
   TID, used 50mg three times daily for estimation   
 
Table 4.14 Annual Estimated Cost of Heart Failure Medications by Stage 
Stage Cost per Year Value Used  Low1 High1 
B2 206 407 2263 
C/D4 1039 12855 1162 
1 Amount rounded to nearest dollar 
2 Includes ACE-I or ARB, and Beta-Blocker 
3 Reflects that 10% of patients will likely need to switch to an ARB from ACE-I as a result of 
adverse effects 
4Includes medications for stage B plus spironolactone, furosemide and ISDN + hydralazine 





4.7.5.3 Additional Costs of Heart Failure Management 
 
Since heart failure is a chronic condition, long-term management often involves 
frequent hospitalizations and/or emergency department visits, continual monitoring of 
cardiac function and office visits with a medical specialist. Patients may also receive 
outpatient medication management by a pharmacist, nurse practitioner or physician’s 
assistant.  Previously published costs with ranges that are relevant to the present study are 
outlined in Table 4.14; reported costs are adjusted to 2010 for comparison. 
 
 
Table 4.15 Previously Published Costs of Heart Failure Treatment 
 
Intervention Cost ($) Range ($) Year 2010 ($)1 
Lisinopril2 226 200-600 2001 336 
Carvedilol2 1,152 89-1,300 2001 1,715 
Outpatient  
Management2 1,700 500-3,000 2001 2,531 
Additional 
Testing2 2,200 0-3000 2001 3,275 
Hospitalization2 5,574 4000-10,000 2001 8,298 
Hospitalization3 5,501 NR 1997 9,360 
Hospitalization4 5,376 NR 2005 6,730 
NR = Not Reported; 1Costs standardized to 2010 using Medical CPI and 
Rounded to Nearest Dollar; 2 Heidenreich et al. 
673  ; 3Jessup et al.674 ; 
4 Hauptman et al. 675 
                                                 
673 Heidenreich et al., “Cost-effectiveness of Screening with B-type Natriuretic Peptide to Identify Patients 
with Reduced Left Ventricular Ejection Fraction.” 
674 Mariell Jessup and Susan Brozena, “Heart Failure,” The New England Journal of Medicine 348, no. 20 
(May 15, 2003): 2007–2018. 
675 Paul J. Hauptman et al., “Resource Utilization in Patients Hospitalized with Heart Failure: Insights 
from a Contemporary National Hospital Database,” American Heart Journal 155, no. 6 (June 2008): 978–
985.e1. 
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The cost for heart failure hospitalization was obtained from the Medicare 
reimbursement amount for heart failure Medicare-Severity Diagnosis-Related Group 
(MS-DRG) discharge codes (291, 292 and 293). Available estimates for 2009 are listed in 
Table 4.16 and adjusted to 2010.  The costs of emergency department (ED) visits were 
estimated by obtaining the Medicare facility limiting charge for the corresponding 
Medicare HCPCS codes (99283, 99284, and 99285). The costs of each respective 
HCPCS code are listed in Table 4.17.  
 
Table 4.16 Average Reimbursement for Heart Failure Medicare Severity – 
Diagnosis-Related Groups (MS-DRG) 
 
MS-DRG Description Average Payment (2009)1 2010 ($)
1,2 
291 HF & Shock w/ MCC 9,005 9,609 
292 HF & Shock w/ CC 5,794 6,183 
293 HF & Shock 3,969 4,235 
Averages:  6,256 6,676 
LOS: Length of Stay, MCC: Major Complication/Comorbidity, CC: Complication/Comorbidity 








Table 4.17 CMS Reimbursement for Emergency Department Visits in 2010 
 
HCPCS Code Description National Payment Amount 1,2 
99283 ED Visit 68 
99284 ED Visit 130 
99285 ED Visit 191 
Average:  130 
         12010 Facility-Limiting Charges from CMS Website; 2Rounded to Nearest Dollar 
 
The costs of office visits were determined using Medicare CPT Codes including 
the cost of care for new patients as well as established patients. It was assumed that 
patients would incur the cost for new patients once; the value used was the average 
charge for CPT codes 99203 and 99204. For established patients, the value used was the 
average of charges for CPT codes 99212, 99213, 99214 and 99215. The frequency of 
follow-up depends on stage of disease progression. Since guidelines for management do 
not specify a specific frequency of surveillance, it was assumed that patients in stage B 
disease would follow-up twice annually, those in stages C/D would follow-up quarterly. 
Additionally, the frequency of medication management would also vary depending on 
disease stage. It was assumed that patients in Stage B would incur these charges 






Table 4.18 Cost Estimates for Heart Failure Outpatient Management 
 
Code Description Reimbursement ($) Value Used1 
99203 Office/Outpatient Visit, New 81.37 110 99204 Office/Outpatient Visit, New 137.77 
    
99212 Office/Outpatient Visit, Est. 27.39 
70 99213 Office/Outpatient Visit, Est. 53.98 99214 Office/Outpatient Visit, Est. 82.98 
99215 Office/Outpatient Visit, Est. 117.23 
    
90862 Medication Management 62.84 63 









Table 4.19 Total Outpatient Management Costs by Stage 
 
 









Frequency Annual Amount ($) 
O.V. 70 2 140 4 280 
M.M. 63 4 252 12 756 
Meds   226  1,162 
Total   618  2,198 







4.7.6 ADDITIONAL RELEVANT PROBABILITIES 
 
 
Other relevant considerations include the discount rate, probability patients will 
be diagnosed without symptoms, probabilities for disease progression, probability of 
patients seeking acute care, and utility estimates. The discount rate used was 3%.676 The 
reported range of breast cancer patients testing positive for HER-2 overexpression is 20 – 
30%; therefore, 25% was chosen for use in this study. 677 
To determine the probability of heart failure severity on diagnosis several 
calculations had to be made. First, an estimation of the incidence of diastolic vs. systolic 
heart failure on diagnosis is required.  A recent review by McMurray estimates that 50% 
of patients will be diagnosed with either diastolic or systolic dysfunction. 678 Then, an 
estimation of the probability of symptomatic disease in each systolic and diastolic 
dysfunction was necessary. In systolic dysfunction, McDonagh estimates that 77% of 
patients will present with asymptomatic dysfunction. 679 While it is estimated that 82% of 
patients with diastolic dysfunction will present with asymptomatic disease. 680 These 
estimates yield a probability of diagnosis with asymptomatic of 0.795. The probability of 
progression of heart failure is dependent upon whether the patient is being treated 
appropriately.  For patients receiving treatment, the annual probability of progressing 
from asymptomatic to symptomatic dysfunction is 0.065. For those patients with 
                                                 
676 Drummond et al., Methods for the Economic Evaluation of Health Care Programmes. 
677 Abeloff et al., “Cancer of the Breast.” 
678 John J. V McMurray, “Systolic Heart Failure,” N Engl J Med 362, no. 3 (2010): 228–238. 
679 T A McDonagh et al., “Biochemical Detection of Left-ventricular Systolic Dysfunction,” Lancet 351, 
no. 9095 (January 3, 1998): 9–13. 
680 Richard J. Rodeheffer, “Measuring Plasma B-type Natriuretic Peptide in Heart Failure: Good to Go in 
2004?,” Journal of the American College of Cardiology 44, no. 4 (2004): 740–749. 
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asymptomatic dysfunction that are not receiving medical treatment, the annual 
probability of disease progression is 0.098. 681 
Additional health states for the model include two levels of acute care; 
hospitalizations and emergency department visits.  The probability of hospitalization 
depends on if patients have a history of heart failure symptoms. The probability of 
hospitalization for symptomatic patients has been previously published; the estimate for 
asymptomatic patients was obtained from subtracting that estimate from a published 
estimate for annual probability of hospitalization for all heart failure patients, which was 
0.209.682 Therefore, the annual probabilities of hospitalization are 0.11 and 0.099 for 
symptomatic and asymptomatic patients, respectively. The annual probability of an 
emergency department visit is 0.042.683 
Once patients have been hospitalized for heart failure, there is a high probability 
of readmission, especially within the first thirty days after discharge. Estimates of re-
hospitalization rates vary widely in the published literature ranging between 20 to 40%. 
Published rates typically depend on the length and type of follow-up after discharge. In 
the present study, an annual probability estimate of 0.33 was used for re-hospitalization 
and it is assumed this rate corresponds to the cycle length of one year.684 In addition to 
high readmission rates after an index admission, but the risk of mortality immediately 
following discharge increases substantially. Like the rates of re-hospitalization, post-
discharge mortality has a wide range of published estimates, often depending on the 
                                                 
681 Heidenreich et al., “Cost-effectiveness of Screening with B-type Natriuretic Peptide to Identify Patients 
with Reduced Left Ventricular Ejection Fraction.” 
682 Ibid.; J Mackowiak, “Cost of Heart Failure to the Healthcare System,” The American Journal of 
Managed Care 4, no. 6 Suppl (June 1998): S338–342. 
683 Mackowiak, “Cost of Heart Failure to the Healthcare System.” 
684 John J McMurray and Simon Stewart, “Epidemiology, Aetiology, and Prognosis of Heart Failure,” 
Heart 83, no. 5 (2000): 596–602. 
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length and type of follow-up. In the present study, the post-discharge mortality estimate 
was 0.22. 685 Additionally, for all patients that are hospitalized, there is a risk of mortality 
associated with while being treated as an in-patient. The estimate used for mortality 
associated with hospitalization is 0.061.686  
The utility estimates considered were that of various heart failure stages, disutility 
for additional testing required, and the utility associated with hospitalization. There are 
baseline assumptions made such that patients do not have a past medical history or 
additional risk factors for the development of heart failure and their cancer has been 
treated to complete remission, essentially eliminating consideration of co-morbid 
conditions. Thus, as all patients enter the model in Stage A, the utility estimate for all 
patients at baseline is 1.0. Heart failure progression to Stage B or Stages C/D has utility 
estimates of 0.865 and 0.710 respectively, and hospital admission has a utility estimate of 
0.57. 687 Table 4.18 is a comprehensive list of additional relevant probability estimates 




                                                 
685 Laura R. Loehr et al., “Heart Failure Incidence and Survival (from the Atherosclerosis Risk in 
Communities Study),” The American Journal of Cardiology 101, no. 7 (April 1, 2008): 1016–1022. 
686 Carisi A. Polanczyk et al., “Ten-Year Trends in Hospital Care for Congestive Heart Failure: Improved 
Outcomes and Increased Use of Resources,” Arch Intern Med 160, no. 3 (February 14, 2000): 325–332. 
687 Fryback et al., “The Beaver Dam Health Outcomes Study Initial Catalog of Health-State Quality 
Factors”; Graham Nichol et al., “Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with 
Symptomatic Heart Failure,” Annals of Internal Medicine 141, no. 5 (September 7, 2004): 343–351. 
 281 
Table 4.20 Additional Relevant Probabilities 
 
Citation Parameter Model Input 
Drummond, et al. 2005; 
Gold, et al. 1996 Discount Rate 0.030 
Abeloff, et al. 2008 HER-2 Positive 0.250 
 HF Type on Diagnosis  
 Stage B (ASX) on Diagnosis  0.795 
 Quality of Life Weights  
Assumption Stage A 1.000 
Fryback, et al. 1993 Stage B 0.865 Stages C/D 0.710 
Nichol, et al. 2004 Hospitalization 0.570 
SF-6D  Disutility Associated with Each ECHO or MUGA Scan 0.025 
 Mortality  
Loehr, et al. 2008 1-Year Mortality after Hospitalization 0.220 
Polanczyk, 2000 In- Hospital Mortality 0.061 
 HF Stage Progression  
Heidenreich, et al. 2004 
ASX (B) to SX (C or D)  
(With TX) 0.065 
ASX (B) to SX (C or D)  
(Without TX) 0.098 
 Acute Care States  
 Hospitalizations  
Heidenreich, et al. 2004 Hospitalization – SX Patients 0.110 
Mackowiak, 1998 HF-Hospitalizations- All Patients 0.209 
Hospitalizations for All 
Pts. – SX Pts. 
HF- Hospitalizations –ASX Patients 0.099 
McMurray and Stewart, 
2000 
Probability of Readmission 4 0.330 
 Emergency Department Visit  
Mackowiak, 1998 HF-ED Visits – All Patients 0.042 
1 Median medication compliance value from 19 studies reviewed 
4 Readmission within one year  
 ASX = Asymptomatic, SX = Symptomatic, TX = Treated appropriately 
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4.7.7 ADDITIONAL MODEL CONSIDERATIONS 
 
4.7.7.1 Cycle Length/Termination Condition 
 
The Markov model will simulate the duration and frequency of the expected 
follow-up/surveillance of breast cancer patients that is recommended by NCCN and 
ASCO. Each cycle will be a calendar year, monitoring will occur quarterly for the first 
three years, every six months for the following two years, then annually thereafter. 688 
 
 
4.7.7.2 Proposed Model Structure 
 
This section will provide a detailed structure of the proposed model to assess the 
cost-effectiveness of using BNP to monitor breast cancer patients compared to current 
standards.  The decision node gives the choice between using BNP, ECHO or MUGA as 
the method of monitoring or the option of doing nothing. Figure 4.6 illustrates the tree 
structure for the decision node with the available alternatives. The Markov node from 
each testing modality and HER-2 status can result in either true negative, false positive, 
false negative, diagnosed asymptomatic, or diagnosed symptomatic as shown in Figure 
4.7. The potential transitions included in the model are represented in the state-transition 
diagram for heart failure in Figure 4.8 and are depicted in tree structure in Figures 4.9 – 
4.13. Patients can remain in Stage A (asymptomatic, normal heart structure/ejection 
fraction), transition to Stage B (asymptomatic, change in heart structure or decreased 
ejection fraction), transition to Stages C/D (symptomatic) or reach the absorbing stage 
(i.e., death).  Additional transition states will be included to represent hospitalizations and 
                                                 
688 NCCN Breast Cancer Panel Members, “Breast Cancer Practice Guidelines V2.2011.” 
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emergency department visits. Probabilities of each outcome were obtained from 
published literature.  
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Figure 4.7 State Transition Diagram for Heart Failure 










































































































Figure 4.14 Tree Structure for the “No Monitoring” Branch 
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4.7.8 MODEL ASSUMPTIONS 
 
• All patients were diagnosed with invasive-type breast cancer, were treated 
successfully (i.e., to complete remission with treatment concluded)  
• Since the premise of the study is that all patients have been exposed to potentially cardiotoxic 
therapy, all patients begin in ACC/AHA Class A – however, since patients in the cohort are 
assumed to have no other risk factors for cardiac dysfunction above the exposure to the 
cardiotoxic agents under study, the patients enter the model without prior treatment with 
ACE-I or β- blockers 
• All invasive breast cancer patients have been treated with an anthracycline-based 
chemotherapy regimen, and patients testing HER-2 positive will have been treated 
with trastuzumab 
• Patients cannot transition backwards once they transition to a particular state  
• All patients will undergo the appropriate recommended surveillance upon completion of 
therapy  
• Each test is to be performed at follow-up intervals recommended by ASCO and NCCN  
• Patients with an abnormal BNP finding will have a confirmatory test utilizing ECHO 
• False positive results from BNP will yield the correct result with confirmatory testing  
• All patients with a diagnosis of heart failure will be prescribed the appropriate therapy as 
recommended by ACC/AHA guidelines for the corresponding stage of disease 





• Disutility for each additional appointment associated with ECHO/MUGA = 0.025  
• Patients cycling through the “No Monitoring” strategy that develop symptoms 
consistent with heart failure, will be treated appropriately 
 
4.8 Summary of Chapter Four: 
 
The perspective of the payer was chosen for the analysis; therefore, only direct 
costs are considered. Markov modeling was chosen over decision analysis since it was 
deemed important to represent the several stages of heart failure patients could potentially 
experience as well as varying mortality based on the stage the patient resides. Benefits of 
this study are represented by QALYs since heart failure is a chronic condition and there 
are numerous consequences of heart failure that can affect quality of life as well as length 
of life. It was decided to run the model over 15 years since there are reports of heart 
failure being diagnosed in exposed patients up to 15 years after treatment has concluded. 
The model will be analyzed using TreeAge Pro 2012® (TreeAge Software Inc., 
Williamstown, MA). Probabilistic sensitivity analyses will be conducted for all variables 
using beta distributions for both probabilities and utilities, and gamma distributions for 








CHAPTER FIVE: RESULTS 
 
5.1 Introduction 
This chapter includes the results for each of the study objectives, information on 
strategies under comparison, incidence of treatment-induced cardiac dysfunction, cost of 
monitoring, costs of outpatient heart failure treatment, and costs of acute care. The 
detailed results of cost-effectiveness analysis and sensitivity analyses are also included in 
this chapter. Results are divided into two sections by testable and non-testable 
hypotheses.  
 
5.2 Objectives  
5.2.1 OBJECTIVES WITHOUT TESTABLE HYPOTHESES 
5.2.1.1 Objective One 
Objective one was to describe each strategy under comparison in the current 
study. Many options exist for the monitoring of cardiac dysfunction after chemotherapy. 
These include invasive methods such as biopsies, radiological methods such as 
echocardiography and multi-gated acquisition scanning. In this study there are three 
monitoring alternatives being compared which include natriuretic peptides, ECHO and 
MUGA, as well as the option of doing nothing. Natriuretic peptides (BNP or NT-pro-
BNP) levels are estimated quantitatively from a blood sample that could be added to 
routine labs obtained during scheduled breast cancer surveillance. Both BNP and NT-pro- 
BNP are measured in pg/mL in U.S. assays. The suggested normal range is 0.5 – 30 
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pg/mL (0.15 – 8.7 pmol/L) for BNP and 68-112 pg/ml (8.2 – 13.3 pmol/L) for NT-pro-
BNP. The suggested cut-off point for the detection of heart failure is 100 pg / mL. 689  
Radiological procedures used for comparison include ECHO and MUGA; both 
procedures are non-invasive techniques. MUGA utilizes radionuclides that bind to red 
blood cells; the resulting blood pool can be visualized. The images can be used to assess 
a variety of cardiac functions; however, it is most commonly used to measure left 
ventricular ejection fraction. 690 ECHO utilizes ultrasound technology, and like MUGA, it 
is used to assess several different markers of cardiac function and structure. 691 Since 
both ECHO and MUGA would be obtained separate from an office visit during routine 
breast cancer surveillance, their use results in a slight disutility to compensate for patient 
time and convenience. The disutility estimate was obtained from the SF-6D. The 
instrument contains an item representing “social functioning” which includes a response 
choice that states “your health limits your social activities a little of the time”. This 
response was selected as it was determined to most closely represent the commitment to 
the additional testing required. The score associated with this item response is -0.055.692 
The listed estimate appeared somewhat high since the disutility is primarily due to the 
time commitment of the actual test plus transit time, therefore, the base estimate used was 
0.025 for each additional appointment required (range 0.020 to 0.030). Both tests are 
typically used to obtain an estimation of left-ventricular ejection fraction (LVEF), where 
a normal value is considered to be ≥ 55%. 693 The use of MUGA also involves the use of 
                                                 
689 M. R. Cowie et al., “Clinical Applications of B-type Natriuretic Peptide (BNP) Testing,” European 
Heart Journal 24, no. 19 (2003): 1710. 
690 Danias and Heller, “Non-Invasive Methods for Measurement of Left Ventricular Systolic 
Dysfunction.” 
691 Altena et al., “Cardiovascular Toxicity Caused by Cancer Treatment.” 
692 Drummond et al., Methods for the Economic Evaluation of Health Care Programmes. 
693 Vitarelli et al., “The Role of Echocardiography in the Diagnosis and Management of Heart Failure.” 
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99Technetium, which often limits repetition due to exposure to additional radiation. 694 
Refer to Chapter Three for additional information regarding monitoring strategies.  
 
5.2.1.2 Objective Two 
 
Objective two was to estimate the incidence of cardiac dysfunction in breast 
cancer patients. The reported incidence of cardiac dysfunction varies significantly. The 
most frequently cited incidence estimates are dose-dependent, which in older reviews 
were 3, 7, and 18 percent at doses of 400, 550, and 700 mg/m2 respectively.695 Newer evidence 
suggests that these estimates may be low. More recent dose-dependent values of 5, 26, and 48 
percent at doses of 400, 550, and 700 mg/m2, respectively, have been noted696. The entire 
spectrum of values range from a low of about 1 percent up to 57 percent; the estimate of 
57 percent was from a prospective study that followed a cohort of patients for fifteen 
years, which incidentally is the length of time patients are considered at risk for heart 
failure development. 697 After it was discovered that anthracyclines have the potential to 
cause cardiac dysfunction, clinical trials began reporting this adverse effect. However, the 
follow-up associated with a clinical trial usually ends when the trial ends, the adverse 
effects from chemotherapy experienced by these patients is often underestimated. There 
are many contributing factors to the development of cardiac dysfunction including total 
cumulative dose, prior radiation, and treatment with trastuzumab, all of which can be 
                                                 
694 Danias and Heller, “Non-Invasive Methods for Measurement of Left Ventricular 
Systolic Dysfunction.” 
695 Von Hoff et al., “Risk Factors for Doxorubicin-lnduced Congestive Heart Failure.” 
696 Swain, Whaley, and Ewer, “Congestive Heart Failure in Patients Treated with Doxorubicin.” 
697 Lipshultz and Colan, “Cardiovascular Trials in Long-Term Survivors of Childhood 
Cancer.” 
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controlled for in a clinical trial but may be experienced by typical patients receiving 
treatment.698 
 The point estimate for the incidence of cardiac dysfunction was 15.4 percent for 
patients receiving anthracycline therapy and 27 percent for patients receiving additional 
trastuzumab699.  Both are medians for the range of published incidence estimates for each 
treatment group.  The incidence ranges used in this study for the patients receiving 
anthracyclines and those receiving additional trastuzumab were 10 – 20 percent and 20 – 
34 percent, respectively. These ranges were selected to encompass the realistic reported 
incidence values reported in publications. For patients receiving anthracyclines, a range 
of 10 – 20 percent should be a realistic representation of incidence estimation when the 
reported range is 1 to 57 percent.  For patients receiving trastuzumab, the majority of 
reports cite incidence estimates of 27 percent or 34 percent; the lower value of 20 percent 
was selected to keep the interval equal (i.e., 27% ± 7%). Refer to Chapter Two for a more 





                                                 
698 Swain, Whaley, and Ewer, “Congestive Heart Failure in Patients Treated with Doxorubicin”; Yeh et 
al., “Cardiovascular Complications of Cancer Therapy.” 
699 S. Palmeri et al., “Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in 
Advanced Breast Cancer,” Oncology 63, no. 3 (2002): 205–212; Dennis J. Slamon et al., “Use of 
Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That 
Overexpresses HER2,” N Engl J Med 344, no. 11 (September 29, 2001): 783–792. 
700 Slamon et al., “Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic 
Breast Cancer That Overexpresses HER2.” 
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5.2.1.3 Objective Three 
 
 Objective three was to estimate the costs of using each monitoring strategy. The 
costs of using each monitoring strategy was estimated using Medicare reimbursement 
values for the calendar year 2010; these values were obtained via the CMS website 
(http://www.cms.gov/). The Medicare reimbursement for each natriuretic peptide test is 
$47.77; therefore, a value of $48 was used. The reimbursement for a complete ECHO 
(CPT 93306) is $265.07 and the OPPS amount is $533; the mean value of $393 was used. 
MUGA scanning has several possible CPT codes and Medicare reimbursement amounts 
range from $261 to $293 with $102.73 add-on. The OPPS amounts range from $357 to 
$368; $461 was used for estimation (average from reimbursement estimates and OPPS 
amounts plus $103 add-on amount, cost of irradiated cells (codes for 99Technetium range 
from A9500 to A9504) were not considered as this value is typically facility specific).  
Annual costs of each strategy were calculated based on the test cost estimate and 
the frequency of testing. Since frequencies change three times during the fifteen-year 
surveillance period, they are divided into three intervals. During interval one, patients are 
tested four times per year, this interval represents years one through three. Interval two 
represents years four and five and patients are tested twice annually. Interval three 
represents the remaining years (six through fifteen) where patients are tested once 
annually. Table 5.1 below lists each monitoring alternative, the cost of a single test and 
the annual cost of each strategy during each interval of surveillance. Refer to Chapter 






Table 5.1 Annual Cost of Each Monitoring Strategy for the Development of Cardiac 
Dysfunction During Each Interval of Surveillance 
 





 BNP 48 192 96 48 
ECHO 393 1,572 786 393 
MUGA 461 1,844 922 461 
1 Single Test Cost Was Obtained from Estimates of Medicare Reimbursement; 
http://www.cms.gov/; Refer to Chapter Four for Additional Information. Interval 1 is surveillance 
years 1-3 where patients are seen quarterly. Interval 2 corresponds to years 4 and 5 where patients 
are seen twice annually. Interval 3 corresponds to years 6 -15 where patients are seen annually  
 
 
5.2.2 OBJECTIVES WITH TESTABLE HYPOTHESES 
 
5.2.2.1 Objective Four  
Objective four was to estimate the direct costs of treating cardiac dysfunction 
discovered as a result of monitoring with each alternative. The hypothesis tested for this 
objective is that the average direct costs of treating cardiac dysfunction as a result of BNP 
will be greater than the strategy of doing nothing,  but less than using either ECHO or 
MUGA.  
 
• No Monitoring direct cost < BNP direct cost 
• BNP direct cost < ECHO direct cost 
• BNP direct cost < MUGA direct cost 
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The direct costs of treating cardiac dysfunction included the cost of medications, 
medication management, outpatient office visits, potential hospitalizations and 
emergency department visits. Costs of treatment are highly dependent on whether the 
patient is experiencing symptoms.  The average direct costs resulting from monitoring 
with BNP is $10,062 which when compared with doing nothing, has an incremental cost 
of -$3,565. This indicates that monitoring with BNP costs less than No Monitoring, 
leading to the rejection of the first hypothesis for this objective.    The average direct 
costs of treatment resulting from the use of ECHO and MUGA are $14,639 and $15,656, 
respectively. The ladder two hypotheses are accepted as the averages costs for both 
ECHO and MUGA are greater than the average cost of BNP.  Table 5.2 lists the average 
direct cost resulting from each strategy.  
 
Table 5.2 Average Direct Costs and Incremental Costs from Base-Case Analysis 
 
Strategy Average Direct Cost ($) Incremental Cost ($) 
BNP 10,062  
No Monitoring 13,627 3,565 
ECHO 14,639 4,677 
MUGA 15,656 5,593 




5.2.2.2 Objective Five  
Objective five was to estimate the difference in QALY’s gained between 
monitoring strategies. The hypothesis for this objective is that the QALY associated with 
the use of natriuretic peptides is greater than the options being compared (i.e., doing 
nothing, ECHO and MUGA).  
• No Monitoring QALY  < BNP QALY 
• ECHO QALY  < BNP QALY 
• MUGA QALY  < BNP QALY 
 
In the base-case analysis, BNP had an average effectiveness of 6.92 which is a gain of 
2.70 QALY’s when compared to the alternative of doing nothing. The average 
effectiveness of ECHO and MUGA were 6.61 and 6.49 QALY’s respectively. The 
comparison of BNP to ECHO and MUGA results in gains of 0.31 and 0.43 QALY’s 
respectively. All three hypotheses are accepted, the average QALY gained from BNP was 
greater than all three alternative strategies. The average effectiveness of each strategy is 










Table 5.3: Average and Incremental Effectiveness from Base-Case Analysis 
 
Strategy Effectiveness (QALY) I.E. (QALY) 
BNP 6.92  
No Monitoring 4.22 -2.70 
ECHO 6.61 -0.31 
MUGA 6.49 -0.43 
I.E: Incremental Effectiveness; QALY: Quality-Adjusted Life-Year 
 
 
5.2.2.3 Objective Six  
 
Objective six was to determine the incremental cost-effectiveness (ICER) of using 
BNP versus other comparators as measured by the percent of patients diagnosed. The 
hypothesis for this objective is that when effectiveness is measured by the percentage of 
patients diagnosed, the ICER of using BNP versus the alternative strategies would show 
that BNP is the dominant strategy. 
 
• ECHO % Diag  < BNP % Diag  , BNP cost   < ECHO  cost 
• MUGA % Diag   < BNP % Diag  ,  BNP cost   < MUGA  cost 




To determine the percentage of patients diagnosed for each testing modality, one must 
consider that the model structure allows patients to be diagnosed in asymptomatic or 
symptomatic stages, however, patients can also transition from the asymptomatic stage to 
the symptomatic stage as a function of disease progression. Therefore because patients 
residing in the symptomatic stage have multiple sources, only patients “Diagnosed ASX” 
was considered to determine the percentage of patients diagnosed for purposes on 
analysis. The percent of patients diagnosed is expressed by using the maximum 
percentage of patients residing in the “Diagnosed ASX” state as determined by Markov 
Cohort Analysis. Since each test has separate branches for HER-2 (+) and (-) patients, 
each had to be analyzed as separate cohorts. The cumulative cost from each cohort 
analysis was used as the cost to determine ICER for each alternative. Tables 5.4 and 5.5 
below list the results from the Markov Cohort Analyses. The diagnosed percentages for 
BNP were 21.8 and 31.6 for HER-2 (-) and HER-2 (+), respectively. The percentages for 
ECHO and MUGA were lower in both HER-2 (+) and (-) patients and corresponding 
costs were higher. The resulting ICER values indicate that BNP is the absolute dominant 
alternative when compared to either ECHO or MUGA; therefore, both hypotheses for this 




Table 5.4 Maximum Probability HER-2 (-) Patients Residing in Diagnosed 
Asymptomatic Stage with Associated Cumulative Costs 
 
Strategy ASX (%) I.E Cost ($) I.C. ICER 
BNP 21.8  9,785   
ECHO 20.8 -1.0 14,696 4,911 -4,911 
MUGA 21.7 -0.1 15,702 5917 -59,170 
      ASX (%) is the maximum percentage of patients residing in the “Diagnosed ASX” state;  
      Cost is the cumulative cost for each Markov Cohort Analysis at Stage 15;  
      I.E.: Incremental Effectiveness; I.C.: Incremental Cost; ICER: Incremental Cost-Effectiveness     
      Ratio  
 
Table 5.5 Maximum Probability HER-2 (+) Patients Residing in Diagnosed 
Asymptomatic Stage with Associated Cumulative Costs 
 
Strategy ASX (%) I.E Cost ($) I.C. ICER 
BNP 31.6 - 10,893 - - 
ECHO 29.7 -1.9 14,870 3,977 -2,093 
MUGA 31.5 -0.1 15,517 4,624 -46,240 
ASX (%) is the maximum percentage of patients residing in the “Diagnosed ASX” state; 
Cost is the cumulative cost for each Markov Cohort Analysis at Stage 15, I.E.: Incremental 
Effectiveness, I.C.: Incremental Cost, ICER: Incremental Cost-Effectiveness Ratio  
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5.2.2.4 Objective Seven 
 
Objective seven was to determine the incremental cost-utility of using BNP 
versus other comparators as measured by QALYs. The hypothesis for this objective is 
when comparing BNP to the alternatives, the incremental cost-utility results in an ICER 
that is below the WTP threshold of $50,000.  
 
•  BNP vs. No Monitoring; ICER < $50,000 WTP per QALY 
• BNP vs.  ECHO; ICER < $50,000 WTP per QALY 
• BNP vs.  MUGA; ICER < $50,000 WTP per QALY 
 
The results of the base-case cost-effectiveness analysis are listed in Table 5.6 and are 
illustrated in Figure 5.1. The base-case was calculated using a discount rate of 3 percent 
for costs and outcomes. The effectiveness of each strategy is measured in QALY’s and 
costs are in 2010 U.S. dollars. BNP yielded an average effectiveness of 6.92 QALY’s, 
which is greater than the average effectiveness of all competing strategies with 4.22, 6.61 
and 6.49 QALY’s for No monitoring, ECHO, and MUGA, respectively. The average cost 
of monitoring with BNP is $10,062 compared to $13,627, $14,739 and $15,656 for No 
Monitoring, ECHO, and MUGA, respectively. The resulting ICER values are therefore 
negative for all alternatives compared to BNP, leading to the acceptance of all three 





Table 5.6 Base-Case Cost-Effectiveness of Strategies Compared to BNP  
 
Strategy Cost ($) I.C. ($) Eff. I.E. ICER C/E 
BNP 10,062  6.92   1,454 
Nothing 13,627 3,565 4.22 -2.70 -1,322 3,226 
ECHO 14,739 4,677 6.61 -0.31 -14,888 2,231 
MUGA 15,656 5,593 6.49 -0.43 -12,964 2,413 
Cost in U.S. dollars, Effectiveness in QALY’s; Eff.: Effectiveness; I.C. = Incremental Cost, 
I.E. = Incremental Effectiveness, ICER = Incremental Cost-Effectiveness Ratio,  
























5.3 Sensitivity Analyses: 
Several sensitivity analyses were performed to determine the robustness of 
results. One-way sensitivity analyses included analyzing varying discount rates (0-5%), 
varying the probability of testing HER-2 positive (20-30%), varying the incidence of 
cardiac dysfunction in both anthracycline-only regimens (10-20%) and trastuzumab 
regimens (20 – 34%), and disutilities for additional tests (0.020 – 0.030) The summary of 
the results from one-way sensitivity analyses are listed in Tables 5.7 - 5.11. Results from 
each of those analyses are listed in their entirety in Appendix F. Tornado Diagrams were 
constructed to examine the effect of varying all values for transition probabilities, 
mortality, utility, costs and test characteristics. Resulting tornado diagrams are listed in 
Figures 5.2 – 5.8. The ranges used are listed in Appendix E, Tables E.1 - E.4. A 
probabilistic sensitivity analysis was conducted utilizing a Monte Carlo Simulation with 
10,000 iterations. Distributions were created for all study variables; gamma distributions 
were used for costs and beta distributions were used for probabilities and utilities.  
 
5.3.1 ONE-WAY SENSITIVITY ANALYSES:  
 
One-way sensitivity analyses were conducted with variables ranges for discount 
rate, the disutility estimate, the probability of testing HER-2 positive, incidence of 
cardiac dysfunction with anthracycline-based therapy, incidence of dysfunction with the 
addition of trastuzumab to anthracycline-based regimens, and the probability of a patient 
being diagnosed in an asymptomatic stage. Table 5.7 below lists the results from the 
analysis of variable discount rate. The base-case analysis was performed with a discount 
rate of 3 percent and was varied from 0 to 5 percent. Each alternative strategy when 
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compared to BNP had a negative ICER value, indicating that BNP is the absolute 




Table 5.7 Summary of CE and ICER for 0, 3, and 5% Discount Rates 
 
 
 C/E ($) ICER($/QALY) 





 BNP 1,369 1,454 1,512 - - - 
No 3,115 3,226 3,300 -1,024 -1,322 -1,539 
ECHO 2,087 2,231 2,327 -15,344 -14,888 -14,661 
MUGA 2,255 2,413 2,517 -12,598 -12,964 -13,195 
         DR: Discount Rate, C/E: Cost-Effectiveness Ratio, ICER: Incremental Cost-Effectiveness Ratio 
 
 
Table 5.8 below illustrates the summary of results of the one-way sensitivity 
analysis of varying the probability of testing positive for HER-2. The base-case analysis 
used a probability of 25 percent; sensitivity analysis examined a range of 20 – 30 percent.  
Similar to the results of the analysis with varying discount rate, the cost-effectiveness 
ratio for BNP remains the absolute dominant strategy the range of values for HER-2 




Table 5.8 Summary of CE and ICER for HER-2 (+) Rates of 20, 25 and 30% 
 
 
 CE ($) ICER ($/QALY) 





 BNP 1,432 1,454 1,476    
No 3,226 3,226 3,226 -1,310 -1,322 -1,335 
ECHO 2,203 2,231 2,254 -14,853 -14,888 -14,924 
MUGA 2,390 2,413 2,435 -13,042 -12,964 -12,884 
HER-2%: Percentage of Patients Testing Positive for HER-2 Overexpression, 
C/E: Cost-Effectiveness, ICER: Incremental Cost-Effectiveness 
 
 
Table 5.9 below lists the results of one-way sensitivity analysis examining the 
range of potential incidence values for cardiac dysfunction with anthracycline-only 
regimens, as well as varying incidence values with the addition of trastuzumab. The base-
case used an incidence value of 0.154 for anthracycline-only therapy with a range of 0.10 
to 0.20. The incidence of cardiac dysfunction with the addition of trastuzumab was 
estimated at 0.25 in the base-case analysis, with a range from 0.20 to 0.34.  Results are 
consistent with the previous one-way sensitivity analyses, since ICER results for all 














 CE ($) ICER ($/QALY) 
Incidence_AC 0.10 0.154 0.20 0.10 0.154 0.20 
BNP 1,180 1,454 1,636    
No 3,226 3,226 3,226 -1,320 -1,322 -1,397 
ECHO 1,943 2,231 2,420 -14,421 -14,888 -15,199 
MUGA 2,120 2,413 2,604 -13,686 -12,964 -12,413 
Incidence_T 0.20 0.27 0.34 0.20 0.27 0.34 
BNP 1,401 1,454 1,488    
No 3,226 3,226 3,226 -1,282 -1,322 -1,366 
ECHO 2,177 2,231 2,264 -14,810 -14,888 -14,928 
MUGA 2,359 2,413 2,444 -13,181 -12,964 -12,783 
C/E: Cost-Effectiveness, ICER: Incremental Cost-Effectiveness Ratio, Incidence_AC: incidence of cardiac 
dysfunction with anthracycline-based treatment; Incidence_T: incidence of cardiac dysfunction when 
trastuzumab is added to anthracyclines 
 
Table 5.10 below summarizes the results from the one-way sensitivity analysis 
with varying estimates that patients will be diagnosed in an asymptomatic stage.  The 
base-case analysis used an estimate of 0.7505, and the sensitivity analysis used a range of 
0.716 to 0.785. Similar to the previous one-way sensitivity analyses, the resulting ICER 
values for all other alternatives are negative; therefore, BNP is the absolute dominant 




Table 5.10 Resulting CE and ICER Values for Varying Estimates That Patients will 
be Diagnosed Asymptomatic 
 
  CE ($) ICER ($/QALY) 





 BNP 1,471 1,454 1,437    
No 3,226 3,226 3,226 -1,360 -1,322 -1,284 
ECHO 2,257 2,231 2,206 -15,174 -14,888 -14,294 
MUGA 2,442 2,413 2,384 -13,035 -12,964 -12,973 
C/E: Cost-Effectiveness; ICER: Incremental Cost-Effectiveness; p_diag_asx: probability 
that a patient will be diagnosed in an asymptomatic stage 
 
 
Table 5.11 below shows the results of a one-way sensitivity analysis of varying 
the disutility estimate accounting for additional time required by the patients. The base-
case estimate for utility was 0.025 and the range used for sensitivity analysis was 0.02 to 
0.03. The results are similar to all previous sensitivity analyses, leaving BNP as the only 








Table 5.11 Resulting CE and ICER Values for Each Alternative for Varying 
Disutility Estimates 
 
  CE ($) ICER ($/QALY) 





 BNP 1,454 1,454 1,454 - - - 
No 3,226 3,226 3,226 -1,322 -1,322 -1,322 
ECHO 2,201 2,231 2,262 -20,901 -14,888 -11,562 
MUGA 2,380 2,413 2,446 -16,334 -12,964 -10,746 
C/E: Cost-Effectiveness, ICER: Incremental Cost-Effectiveness 
 
 
Tornado Diagrams were constructed to analyze any differences in results by 
varying estimates for categories of variables. Categories that were examined include 
transition probabilities, mortality, utilities, costs, and test characteristics. The resulting 
tornado diagrams are illustrated in Figures 5.2 to 5.6. Ranges used for each variable are 
listed in Appendix F, Tables F.1 - F.4.  Figure 5.2 below shows the results of varying the 
probabilities of state transitions. The diagram shows that varying the probabilities of 
hospitalization and readmission had the greatest effect on the net benefit. With both of 
these variables, the outcomes remained insensitive to the variation in probabilities.  BNP 
was the absolute dominant strategy over all other alternatives regardless of the probability 














Figure 5.3 below illustrates the results when varying the estimates for all 
mortality variables. The results indicate that varying the estimates for mortality in Stages 
D and A have the greatest effect on cost-effectiveness. Similar to the results for transition 
probabilities, though mortality estimates in Stages D and A showed the greatest variation 
in net benefits, BNP remained the absolute dominant strategy over all other alternatives 


































Figure 5.4 below illustrates the results when varying estimates for all utility 
variables. The tornado diagram shows that the estimates for the utility during 
hospitalization have the greatest effect on cost-effectiveness. The cost-effectiveness 
through the range of estimates for utility during hospitalization is highly variable; 
however, when comparing the different alternatives, BNP remains an absolute dominant 






































Figure 5.5 illustrates the results when varying the estimates for all cost variables. 
The estimates for the cost of hospitalization had the greatest effect on cost-effectiveness, 
likely because it has the largest range of estimates. Consistent with other prior tornado 




































Figure 5.6 illustrates the results when estimates for test characteristics are varied 
for the three tests being compared. Characteristics of ECHO and MUGA did not have any 
effect on the results of the cost-effectiveness analysis, while the sensitivity of BNP had 
the greatest effect, although BNP remained the absolute dominant strategy over all other 





































5.3.2 SUMMARY OF ONE-WAY SENSITIVITY ANALYSES:  
 
One-way sensitivity analyses were performed for varying discount rate, 
probability of testing HER-2 positive, and incidence of cardiac dysfunction with 
anthracycline-based regimens ± trastuzumab, the probability a patient will be diagnosed 
in an asymptomatic stage and the disutility estimate for additional testing.  Additionally, 
tornado diagrams were constructed for the variation in estimates by category (i.e. costs, 
utilities, etc.).  Results from each of these analyses were consistent, regardless of the 




5.3.3 PROBABILISTIC SENSITIVITY ANALYSIS:  
 
A probabilistic sensitivity analysis was conducted utilizing a Monte Carlo 
Simulation where utilities and probabilities were varied using beta distributions; costs 
were varied using gamma distributions for 10,000 iterations.  The ranges of estimates for 
each variable were the same as those used for one-way sensitivity analyses. Table 5.9 
summarizes the results from the probabilistic sensitivity analysis. Figure 5.7 graphs the 
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overall mean cost-effectiveness and Figure 5.8 shows the cost-effectiveness scatterplots 
resulting from the probabilistic sensitivity analysis when comparing all strategies. The 
mean costs for each alternative are $6,441 (SD $9,898, Range 0.15 – 163,690), $12,209 
(SD 17,589, Range 0 – 190,105), $13,159 (SD 20,270, Range 0 – 367,070) and  $14,208 
(SD 20,563, Range 10.33 – 289,478) for BNP, ECHO, MUGA and No Monitoring 
respectively.  The mean effectiveness values are 8.72 (SD 2.50, Range 3.28 – 11.73), 
8.31 (SD 2.52, Range - 3.08 – 11.73), 8.24 (SD 2.58, Range -2.99 – 11.73) and 4.26 (SD 
0.35, Range 2.90 – 5.69) for BNP, ECHO, MUGA and No Monitoring respectively. BNP 
had the lowest average cost and the highest average effectiveness. When comparing BNP 
to the other strategies, the ICER’s were -$14,179/QALY, -$14,053/QALY and                 
-$1,744/QALY for ECHO, MUGA and No Monitoring respectively.  
 
 
Table 5.9 Summary of Results from Monte Carlo Simulation 
 
Alternative COST EFF IC IE ICER 
BNP $6,441 8.719 - - - 
ECHO $12,209 8.312 $5,768 -0.407 -$14,179 
MUGA $13,159 8.241 $6,718 -0.478 -$14,053 
No Monitoring $14,208 4.265 $7,768 -4.454 -$1,744 
Eff: Effectiveness; IC: Incremental Cost; IE: Incremental Effect;  
ICER: Incremental Cost-Effectiveness Ratio 
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Figures 5.9, 5.10 and 5.11 illustrate the incremental cost-effectiveness scatterplots 
for the comparisons of BNP with each other monitoring strategy. Each scatterplot lists the 
percentage of iterations that fall in quadrant IV which represents the proportion that BNP 
is an absolute dominant strategy.    Those proportions are 32%, 45% and 74% for ECHO, 
MUGA and No Monitoring respectively. With the addition of areas where BNP leads to 
an ICER that is below the WTP threshold of $50,000, the proportions where BNP is cost-














































Table 5.10 Summary of Tested Hypotheses 
 
 
Objective # Hypothesis Result 
4  
No Monitoring direct cost < BNP direct cost Rejected 
BNP direct cost < ECHO direct cost Accepted 




No Monitoring QALY  < BNP QALY Accepted 
ECHO QALY  < BNP QALY Accepted 




ECHO % Diag  < BNP % Diag   Accepted 




BNP vs. No Monitoring; ICER < $50,000 WTP per QALY Accepted 
BNP vs. ECHO; ICER < $50,000 WTP per QALY Accepted 





CHAPTER SIX: DISCUSSION 
 
6.1 Introduction 
This chapter includes a discussion of the base-case results, results of the 
sensitivity analyses, study limitations, study conclusions and possible directions for 
future research. This chapter also includes a description of the study population, 
strategies under comparison and incidence of cardiac dysfunction.  
 
6.2 Population Studied 
Breast cancer is the most commonly diagnosed cancer in women in the United 
States. It is estimated that one in eight women will be diagnosed with breast cancer at 
some time in their life. Current SEER data is only available through 2008; therefore the 
number of projected cases for 2010 was used in this study. SEER estimates that there will 
be a total of 209,060 new cases diagnosed in 2010, including 54,010 in situ cases, leaving 
155,050 invasive cases. Of those, 1,970 are expected to be men. 701 The population under 
study is women diagnosed with invasive breast cancer, therefore the hypothetical cohort 
consists of 153,080 total patients. It is estimated that 25 percent will test positive for 
HER-2 overexpression; therefore, receiving treatment with trastuzumab in addition to an 
anthracycline-based chemotherapy regimen. 702 Each treatment arm consists of 114,810 
and 38,270 patients in the anthracycline and trastuzumab groups, respectively. The cohort 
of patients is assumed to have been treated successfully with a result of complete 
remission. According to the ACC/AHA classification system, patients who have received 
                                                 
701 “SEER Web Site”, n.d., http://seer.cancer.gov/. 
702 Abeloff et al., “Cancer of the Breast.” 
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cardiotoxic therapy are classified as Stage A.703 Stage A identifies patients who are at 
risk of developing heart failure but are currently without symptoms or other evidence of 
cardiac dysfunction; therefore, all patients in this cohort enter the model in Stage A.   
 
 
6.3 Strategies Under Comparison 
  
There are three monitoring methods under comparison along with the option of 
doing nothing.  The three monitoring strategies include BNP, ECHO and MUGA. BNP is 
a hormone produced by the ventricles that primarily assists in fluid regulation. BNP is 
secreted from the ventricles in response to stretch of myocytes. Increases in BNP levels 
are proportional to increases in both fluid volume and ventricular dysfunction. BNP 
levels have also been shown to be elevated in asymptomatic cardiac dysfunction. 704 BNP 
levels can be obtained from a blood sample, and can be measured via a lab test or a 
bedside assay. In the study population, this test would be particularly useful as blood 
samples are already drawn during their routine scheduled follow-up, thus this test can be 
added to existing labs orders. This level of convenience adds to the appeal of using this 
strategy to monitor cardiac function. In addition to convenience, results are easily 
interpreted which demonstrates value to non-cardiologists. 705 
                                                 
703 Hunt et al., “2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis 
and Management of Heart Failure in Adults: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration 
With the International Society for Heart and Lung Transplantation.” 
704 Aviles and Aviles, “Advances in Cardiac Biomarkers”; de Lemos, McGuire, and Drazner, “B-type 
Natriuretic Peptide in Cardiovascular Disease.” 
705 Cowie et al., “Clinical Applications of B-type Natriuretic Peptide (BNP) Testing.” 
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ECHO and MUGA are tests obtained in radiology and nuclear medicine 
respectively. Both tests are commonly used in cardiology practice. MUGA, also known 
as radionuclide angiography, is considered the “gold standard” for monitoring cardiac 
function. 706 MUGA uses a radiolabeled tracer, 99Technetium (or Tc-99m), that binds to 
the patients red blood cells. The cells enable an image to be visualized to track blood 
flow through the patient’s chest, enabling the measurement of a number of functional 
parameters. MUGA has the advantage of high reproducibility and low inter- and intra-
operator variability. However, since the use of MUGA involves infusing patients with 
radiolabeled substance, the routine use of this test would be impractical as repeating tests 
at the recommended frequency would expose patients to a considerable amount of 
radiation. Like ECHO, MUGA is insensitive to small changes in cardiac function.707 For 
the purposes of this study, the cost and disutility associated with administration of Tc-
99m was not considered. Those estimates could not be obtained as cost of the Tc-99m is 
facility specific and the disutility corresponding to the administration of radiation could 
not be found in published literature.  
ECHO is a safe, non-invasive method to measure cardiac function. ECHO can 
provide measures of both systolic and diastolic function, and can provide more functional 
parameters than MUGA without exposing patients to additional radiation.708 There are 
many different types of ECHO that are in routine use; however, the technology is 
essentially the same. Ultrasonic reflection is used to visualize the structure of the heart, 
the addition of Doppler technology enables the visualization of blood flow, and the 
                                                 
706 Altena et al., “Cardiovascular Toxicity Caused by Cancer Treatment.” 
707 Ibid.; Danias and Heller, “Non-Invasive Methods for Measurement of Left Ventricular Systolic 
Dysfunction.” 
708 Vitarelli et al., “The Role of Echocardiography in the Diagnosis and Management of Heart Failure.” 
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addition of tissue Doppler technology enables the visualization of myocardial motion709. 
ECHO is frequently used to monitor patients for cardiotoxicity; the parameters that are 
typically measured are left-ventricular ejection-fraction and fractional shortening. ECHO 
has limitations because both LVEF and FS are insensitive to small changes in cardiac 
function and has the disadvantage of high inter- and intra-operator variability.710 The type 
of ECHO chosen for this study was a complete ECHO (CPT code 99306); see Appendix 
C for a full description of the procedure. The estimated costs used in this study were 
obtained from Medicare reimbursement amounts that are available on the CMS website 
(www.cms.gov). Costs for both ECHO and MUGA are likely underestimated as a 
significant number of patients in the cohort would have third party payers other than 
Medicare with a different reimbursement schedule.  
 
 
6.4 Incidence of Cardiac Dysfunction 
Incidence of chemotherapy-induced cardiac dysfunction has a large range of 
reported values. The incidence rates used in the current study were obtained from 
published literature; this is a major limitation of this study as these estimates are often 
considered low. There are several reasons why estimates from published studies would be 
considered low. Studies with prospective data collection that do report the number of 
patients with cardiac dysfunction, often only report patients that develop symptoms 
consistent with heart failure (often reported as NYHA Class III or IV, which would 
                                                 
709 Altena et al., “Cardiovascular Toxicity Caused by Cancer Treatment”; Vitarelli et al., “The Role of 
Echocardiography in the Diagnosis and Management of Heart Failure.” 
710 Shan, Lincoff, and Young, “Anthracycline-Induced Cardiotoxicity”; Wu, “Cardiotoxic Drugs: Clinical 
Monitoring and Decision Making.” 
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correspond to ACC/AHA late Stage C or Stage D). Studies that conduct routine screening 
for cardiac dysfunction as part of the study protocol, typically conduct the tests only 
while the patient is receiving the drug or regimen under study. Occasionally investigators 
will report events during a follow-up period; however, the follow-up duration may be for 
a year or less. Studies of chemotherapy-induced cardiac dysfunction have also included 
retrospective chart reviews, which is problematic because the definition of cardiac 
dysfunction may not be consistent.  Since reporting such effects to the Adverse Event 
Reporting System (AERS) is voluntary at the point-of-care level, cases are missed and 
not included in a comprehensive database that otherwise would be considered the best 
source of this information 
 Cardiac dysfunction from breast cancer therapy can develop at any time during 
the recommended surveillance period, which is 15 years. In this study, point estimates for 
incidence were 15.4% 711 and 27% for anthracycline-based therapy and for additional 
trastuzumab, respectively712. The ranges used for sensitivity analyses varied between 
10% and 20% for anthracycline therapy and 20% to 34% for patients treated with 
additional trastuzumab. Although the overall result of the analysis remained insensitive to 
changes in incidence, the trend showed increasing costs for all monitoring modalities as 
incidence increased, which would be expected as greater incidence would require more 
patients to be treated.  The highest incidence rate found in published literature was 57%, 
which is reported in a study that did prospectively monitor patients throughout the entire 
                                                 
711 Palmeri et al., “Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in 
Advanced Breast Cancer.” 
712 Seidman et al., “Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience”; D. Slamon et al., 
“Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC-
T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC-TH) with 
Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2 Positive Early Breast Cancer Patients: BCIRG 
006 Study.,” Breast Cancer Research and Treatment 94 (December 2005): S1–S301. 
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surveillance period of 15 years, however because the study population was pediatric 
leukemia survivors, this incidence value was not used as it would not accurately represent 
the population in this study.  713 
 
6.5 Average Costs 
The average costs for each strategy being compared are $10,062, $14,639, 
$15,656 and $13,627 for BNP, ECHO and MUGA, and No Monitoring, respectively. 
These total average costs include not only the costs of the tests performed but the 
treatment of cardiac dysfunction discovered as a result of the screening and costs of 
potential acute care.  Even with the option of No Monitoring, the costs of developing 
heart failure must be accounted for. Although the average cost does not include the cost 
of a test, because all patients are at risk, once patients develop symptoms, it is assumed 
they will be treated appropriately thus accumulating treatment costs for the remainder of 
the surveillance period once patients report symptoms consistent with heart failure. In the 
current study, only direct medical costs are being considered; therefore, the lost 
productivity due to additional radiological exams was not accounted for. Accounting for 
indirect medical costs could increase average costs for both ECHO and MUGA, which 
would unlikely change the overall conclusion since it would merely increase the 
incremental cost between each alternative and BNP.  
 
 
                                                 
713 Lipshultz and Colan, “Cardiovascular Trials in Long-Term Survivors of Childhood Cancer.” 
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6.6 Average Effectiveness 
The average effectiveness of each alternative was 6.92, 6.61, 6.49 and 4.22 
QALY’s for BNP, ECHO, MUGA and No Monitoring, respectively. When patients are 
screened with any of the test options under comparison, the average effectiveness is 
greater than that of doing nothing. This difference is likely because when patients are 
diagnosed after symptoms have manifested, the mortality is high. However, when 
patients are diagnosed in earlier stages of cardiac dysfunction, they are able to begin 
treatment that can slow disease progression, even reverse the remodeling process, and 
ultimately improve their prognosis.   
 
6.7 Cost-Effectiveness 
In the base-case analysis, cost-effectiveness results were $1,454, $3,226, $2,231 
and $2,413 per QALY for BNP, No Monitoring, ECHO and MUGA, respectively. The 
cost-effectiveness results indicate that BNP would be the most attractive monitoring 
strategy; however the incremental cost-effectiveness is a more accurate index of 
comparison between alternatives to determine cost-utility. When comparing BNP to all 
other alternatives, each resulting ICER was -$1,322, -$14,888, -$12,964 for comparisons 
to No Monitoring, ECHO and MUGA, respectively. Since all resulting ICER values are 
less than zero, this indicates that BNP is an absolute dominant strategy over all other 
alternatives under comparison.   
Typically, each ICER value is compared to the commonly accepted WTP 
threshold of $50,000 per QALY. Some argue that $50,000 is somewhat arbitrary and 
doesn’t adequately reflect factors such as inflation. An alternative to the commonly 
accepted WTP of $50,000 is to use the per capita GNP multiplied by two. In the calendar 
 340 
year 2010, which is the year under study, the per capita GNP is $47,800, resulting in a 
WTP threshold that would be approaching $100,000. If this higher WTP value was 
adopted in this study, the conclusions of the original analysis when comparing all 
strategies to BNP would not change. Alternatives can also be compared and decisions 
made simply on predetermined acceptable ICER values. Similar to increasing the WTP 
threshold, this would not change the original conclusions as ICER values for ECHO and 
MUGA were both negative numbers.  
 
6.8 Sensitivity Analysis  
Both one-way and probabilistic sensitivity analyses were performed. One-way 
sensitivity analyses tested the robustness of results over varying discount rates, disutility 
estimates, probability of testing positive for HER-2, incidence of cardiac dysfunction 
with anthracycline regimens, incidence of cardiac dysfunction with the addition of 
trastuzumab, and varying the probability of being diagnosed in an asymptomatic stage. 
The point estimates and ranges used for each variable are listed in Appendix E and full 
results are listed in Appendix F. Regardless of the variable under analysis, comparing 
BNP to all other strategies resulted in an ICER value less than zero, indicating that BNP 
is an absolute dominant strategy over No Monitoring, ECHO and MUGA. 
Tornado diagrams were constructed for each category of variables (i.e. transition 
probabilities, mortality, costs, test characteristics and utilities). The variables that had the 
greatest effect on the results included the following: probability that patients will be 
diagnosed in an asymptomatic stage, the probability patients will transition from an 
asymptomatic stage to symptomatic stage while being treated appropriately, the 
probability of death in Stages A and D, BNP sensitivity and specificity,  the cost of 
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hospitalization and cost of office visits for established patients, and the utility estimates 
for hospitalization and for patients in Stages C/D. Although the ranges of these variables 
had the greatest effect on results, the conclusions were consistent to those in the one-way 
analyses; over the range that each variable was analyzed, when comparing BNP to all 
other alternatives, the resulting ICER values were less than zero, indicating that BNP was 
an absolute dominant strategy over No Monitoring, ECHO and MUGA. 
  A probabilistic sensitivity analysis was performed via a Monte Carlo simulation 
with 10,000 iterations. Distributions were created for all variables. The resulting average 
costs were $6,441, $12,209, $13,159 and $14,208 and the average effectiveness estimates 
were 8.719, 8.312, 8.241, and 4.265 for BNP, ECHO, MUGA and No Monitoring, 
respectively. When comparing all options to BNP, each alternative has a higher cost and 
lower effectiveness, giving negative ICER values for each strategy. Thus, the 
probabilistic sensitivity analysis further supports the use of BNP to monitor for cardiac 
dysfunction is breast cancer patients.  
  
6.9 Study Limitations  
The biggest limitation of this study is that the transition probabilities were 
obtained from published literature. Sources of estimates were studies of all types and 
each has its own inherent limitations. The majority of literature using BNP is cardiology 
literature, not oncology, and in these studies BNP may be used in a variety of settings 
such as screening, diagnosis, monitor treatment effectiveness, and prediction of long-term 
outcomes. Oncology literature that does discuss the use of BNP typically involves 
proposing its use, not in scenarios where it has already been used. While there is 
oncology literature describing the use of ECHO and MUGA; studies typically describe 
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their use in pre-treatment assessment of cardiac function, as well as assessing cardiac 
function through the duration of treatment.  
 All disease state transitions were obtained from cardiology literature including 
annual risk of mortality, transitions from asymptomatic dysfunction to symptomatic 
dysfunction, probability of being diagnosed in an asymptomatic stage, probabilities of 
hospitalization and ED visits, and the probability of readmission.  It has been suggested 
that the prognosis of heart failure from chemotherapy is worse than heart failure of other 
etiologies; however, stage-specific estimates have not been made. Since cardiac 
dysfunction is rarely discovered prior to cancer patients experiencing symptoms, cancer-
specific transitions from asymptomatic dysfunction to symptomatic dysfunction would be 
difficult to obtain. As outlined in Chapter Two, there are many other cancer therapies that 
can cause cardiotoxicity. This study only considered the use of anthracyclines and 
trastuzumab, which could be considered another limitation. 
  The subjects in the hypothetical cohort are assumed to have no evidence of heart 
disease, are in complete remission from breast cancer and do not possess any risk factors 
other than exposure to cardiotoxic cancer therapy. It is also assumed that there are no 
patients that are lost to follow-up; the only exit from the model is death. The lack of 
consideration for patients lost to follow-up is not a realistic representation of current 
ambulatory practice. Additionally, the only source of mortality included in this study is 
that from the progression of heart failure, thus mortality from breast cancer recurrence 
and age-specific mortality is considered the same across all monitoring strategies.  
The utility estimates were from studies of heart failure patients; these estimates 
are for heart failure patients without mention of past medical history. This cohort has a 
past medical history of invasive breast cancer. An assumption had to be made that all 
patients are starting with a utility estimate in Stage A, which was given a value of 1.0. 
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Since there is an underlying assumption that patients do not possess any comorbid 
conditions that could potentially confound disease progression or mortality, and there 
would likely be a disutility estimate associated with a past medical history of cancer, this 
initial utility estimate is likely high.   
Most cost estimates used in this study are Medicare reimbursement amounts for 
the calendar year 2010 and were obtained from the CMS website. The one exception was 
the cost of medications, which were obtained from the Texas Medicaid website. The ages 
of breast cancer survivors can range anywhere from 20 years and up.  This study makes 
the assumption that all patients are monitored with the same frequency regardless of their 
age. Test costs were obtained from Medicate reimbursement amounts. For other payers 
this would be an underestimation of test costs, although since the median age of diagnosis 
for breast cancer is 61 years; this would be an accurate representation for the majority of 
patients in the study population.  
However, in reality, monitoring is more likely to be conducted in younger patients 
who were diagnosed with aggressive disease requiring received higher doses of 
anthracyclines and/or additional cycles. Therefore test costs in this study could 
potentially be underestimated. Medication costs were determined with the assumption 
that all patients would receive optimal treatment as recommended by heart failure 
treatment and management practice guidelines. In reality, these guidelines would not 
likely be followed by all prescribers. This would ultimately lead to lower overall 
medication costs but a potential increase in the probability of acute care, subsequently 
leading to an increase in emergency department and hospitalization costs.  
Medication costs were obtained from Texas Medicaid and were the median values 
for the Maximum Allowable Charge (MAC). These costs may be higher for some 
medications that are potentially on discount lists for some pharmacies (i.e. Wal-Mart® 
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$4/30-day supply / $10 / 90-day supply) which would lead to zero cost to the third party 
payer for those respective medications. The Wal-Mart list includes the following 
medications that would affect the total treatment costs relevant to this study: carvedilol 
25mg tablets, lisinopril 20mg tablets, spironolactone 25mg tablets, hydralazine 25mg 
tablets, furosemide 40mg tablets, and isosorbide mononitrate 30mg ER and 60mg ER 
tablets. Although using some of the medications from this list decreases the cost to the 
payer, it increases the tablet burden for patients; likely affecting medication compliance 
and ultimately increase costs for acute care and mortality.  
Additionally, it was assumed that patients with a positive result from BNP would 
receive confirmation with ECHO. This assumption has a number of implications. The 
false positive rate for anthracyclines and trastuzumab is 0.22 and 0.19 respectively which 
would lead to a high overall cost for additional testing with ECHO. In actual practice the 
need for confirmatory testing would likely only be required in patients that showed a 
significant increase from their baseline BNP level ( > 30% from baseline)  that was below 
what would be considered a positive result (i.e. < 100 ng/mL). An additional implication 
of this assumption is the assumption that the ECHO would recognize that initial result as 
false positive, thus that patient would not receive heart failure treatment. In this study, 
when a confirmatory test is used, it doesn’t take into account the test characteristics of 
ECHO, it is automatically assumed that it will produce the correct result. Although 
utilization of a confirmatory test can potentially introduce “work-up” bias, use of the 
confirmatory test was chosen because published studies in screening cardiology patients 
included ECHO as a confirmatory test. It has been shown that both either left-ventricular 
ejection fraction and fractional shortening have low sensitivity in detecting small changes 
in cardiac function, thus using a test of LVEF for confirmation may not be appropriate in 
this setting.   
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6.10 Conclusions and Directions for Further research 
Research should be conducted to obtain estimates from cancer patients who have 
developed cardiac dysfunction subsequent to their therapy.  Those studies would include 
attaining more accurate incidence estimates of cardiac dysfunction resulting from the use 
of anthracycline-based chemotherapy or trastuzumab. One way to obtain such data could 
include the development of policy that would create a practice-level or point-of-care 
protocol making reporting these effects to the FDA via the AERS reporting system 
required in this practice setting. Additional estimates of interest would include cancer-
specific estimates of treatment costs, disease progression, utilities and mortality.  
This study provides compelling evidence that BNP has potential utility in 
monitoring breast cancer for the development of cardiac dysfunction. The results of cost-
effectiveness analysis show that the incremental cost-effectiveness of BNP when 
compared to ECHO, MUGA, or No Monitoring, makes it an attractive choice. The 
probabilistic sensitivity analysis provides additional evidence as the results were 
confirmed to be insensitive to varying estimates for all included variables. As previously 
mentioned, the cost estimates used in this study are likely lower than one would expect in 
an actual breast cancer patient population, so it is unknown if more accurate cost 
estimates in the population of interest would change the results of the current study.  
Monitoring for cardiotoxicity in breast cancer patients needs to be conducted after 
completion of chemotherapy as well as during the course of treatment. The recommended 
frequency at which is required in this patient population, would ideally employ a strategy 
that has a low cost and the absence of any additional time commitment, both of these 
qualities make BNP a compelling option when compared to alternative strategies. Results 
of this study not only show that BNP is a cost-effective alternative, these results show 
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that the utilization of BNP has a lower cost and greater effectiveness of not monitoring at 
all, which is the most compelling reason to consider its implementation into current 
routine surveillance practice.  
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APPENDIX A:  CHEMOTHERAPY REGIMEN ABBREVIATIONS714 
 
Abb. Regimen 
TAC Docetaxel, Doxorubicin, Cyclophosphamide 
AC Doxorubicin, Cyclophosphamide 
TC Docetaxel, Cyclophosphamide 
FAC/CAF Fluorouracil, Doxorubicin, Cyclophosphamide 
FEC/CEF Fluorouracil, Epirubicin, Cyclophosphamide 
CMF Cyclophosphamide, Methotrexate, Fluorouracil 
EC Epirubicin, Cyclophosphamide 
AC→TH Doxorubicin, Cyclophosphamide  → Docetaxel/Paclitaxel and Trastuzumab 
TCH Docetaxel/Paclitaxel, Carboplatin and Trastuzumab 
TH→FEC Docetaxel/Paclitaxel and Trastuzumab → Fluorouracil, Epirubicin, Cyclophosphamide  











                                                 
714 NCCN Breast Cancer Panel Members, “Breast Cancer Practice Guidelines V2.2011.” 
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APPENDIX B: CHEMOTHERAPY REGIMENS AND SCHEDULES715 
 
Regimen  Drugs Dose (mg/m2) When Given Cycle Length # of Cycles 
TAC Docetaxel 75  Day 1 21 Days 6 
 Doxorubicin 50     
 Cyclophosphamide 500     
 With Filgrastim Support     
      
Dose-Dense AC →Paclitaxel Doxorubicin 60  Day 1 14 Days 4 
 Cyclophosphamide 600     
 Followed By:     
 Paclitaxel - 3 Hr Infusion 175  Day 1 14 Days 4 
 With Filgrastim Support     
± Trastuzumab 4  With 1st dose of Paclitaxel   
followed by: Trastuzumab 2  Weekly for 1 year   
or Trastuzumab 6  Every 3 weeks for 1 year   
      
AC →Paclitaxel Doxorubicin 60  Day 1 21 Days 4 
 Cyclophosphamide 600     
 Followed By:     
 Paclitaxel - 1 Hr Infusion 80   Weekly 12 
± Trastuzumab 4  With 1st dose of Paclitaxel One Dose  
followed by: Trastuzumab 2  Weekly  For 1 Yr. 
or Trastuzumab 6  Every 3 weeks   For 1 Yr. 
                                                 
715 Ibid. 
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Regimen Drugs Dose (mg/m2) When Given Cycle Length # of Cycles 
AC Doxorubicin 60 mg/ m2 Day 1 21 Days 4 
 Cyclophosphamide 600 mg/ m2    
     
 EC Epirubicin 100 mg/m2 Day 1 21 Days 8 
 Cyclophosphamide 830 mg/m2    
     
 Dose-Dense A-T-C Doxorubicin 60 mg/ m2 Day 1 14 days 4 
 Followed by:     
 Paclitaxel - 3 Hr Infusion 175 mg/m2 Day 1 14 days 4 
 Followed by:     
 Cyclophosphamide 600 mg/ m2 Day 1 14 days 4 
 With Filgrastim Support    
 
      
FEC →Docetaxel 5-Fluorouracil 500 mg/m2 Day 1 21 Days 3 
 Epirubicin 100 mg/m2    
 Cyclophosphamide 500 mg/m2    
 Followed by:    
 
 Docetaxel 100 mg/m2 Day 1 21 Days 3 
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Regimen  Drugs Dose (mg/m2) When Given Cycle Length # of Cycles 
FEC →Weekly Paclitaxel 5-Fluorouracil 600  Day 1 21 Days 4 
 Epirubicin 90     
 Cyclophosphamide 600     
 Followed by 3 weeks with No Treatment     
 Followed by:     
 Paclitaxel 100   Weekly 8 
      
FAC 5-Fluorouracil 500  1&8 or 1&4 21 Days 6 
 Doxorubicin - 72 hr infusion 50  Day 1   
 Cyclophosphamide 500    
      
CAF Cyclophosphamide (P.O.) 100  1 to 14 28 Days 6 
 Doxorubicin 30  1&8   
 5-Fluorouracil 500  1&8   
      
CEF Cyclophosphamide (P.O.) 75  1 to 14 28 Days 6 
 Epirubicin 60  1&8   
 5-Fluorouracil 500  1&8   
 With Cotrimoxazole Support     
      
CMF Cyclophosphamide (P.O.) 100  1 to 14 28 Days 6 
 Methotrexate 40  1&8   
 5-Fluorouracil 600  1&8   
 
 351 
Regimen Drugs Dose (mg/m2) When Given Cycle Length # of Cycles 
CMF Cyclophosphamide (P.O.) 100 1 to 14 28 Days 6 
 Methotrexate 40  1&8   
 5-Fluorouracil 600  1&8   
      
AC →Docetaxel Doxorubicin 60  Day 1 21 Days 4 
 Cyclophosphamide 600     
 Followed By:     
 Docetaxel 100  Day 1 21 days 4 
      
TCH Docetaxel 75  Day 1 21 Days 6 
 Carboplatin AUC 6    
 Trastuzumab 4 mg/kg Week 1   
Followed By: Trastuzumab 2 mg/kg Week 2 Weekly 17 
Followed By: Trastuzumab 6 mg/kg Week 18 Every 3 Weeks QS to 1 Yr. 
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APPENDIX C: FULL MEDICARE DESCRIPTIONS OF 
RADIOLOGY PROCEDURES 
 




Cardiac blood pool imaging, gated equilibrium; planar, single 
study at rest or stress (exercise and/or pharmacologic), wall 
motion study plus ejection fraction, with or without additional 
quantitative processing 
78473 
Cardiac blood pool imaging, gated equilibrium; multiple 
studies, wall motion study plus ejection fraction, at rest and 
stress (exercise and/or pharmacologic), with or without 
additional quantification 
78481 
Cardiac blood pool imaging (planar), first pass technique; 
single study, at rest or with stress (exercise and/or 
pharmacologic), wall motion study plus ejection fraction, with 
or without quantification 
78483 
Cardiac blood pool imaging (planar), first pass technique; 
multiple studies, at rest and with stress (exercise and/or 
pharmacologic), wall motion study plus ejection fraction, with 
or without quantification 
78494 
Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, 
wall motion study plus ejection fraction, with or without 
quantitative processing 
78496 
Cardiac blood pool imaging, gated equilibrium, single study, at 
rest, with right ventricular ejection fraction by first pass 
technique (List separately in addition to code for primary 
procedure) 
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Echocardiography, transthoracic, real-time with image documentation 
(2D) includes M-mode recording, when performed, complete, with 
spectral Doppler echocardiography, and with color flow Doppler 
echocardiography 
93307 
Echocardiography, transthoracic, real-time with image documentation 
(2D), includes M-mode recording, when performed, complete, without 
spectral or color Doppler echocardiography 
93308 
Echocardiography, transthoracic, real-time with image documentation 
(2D), includes M-mode recording, when performed, follow-up or limited 
study 
93312 
Echocardiography, transesophageal, real-time with image documentation 
(2D) (with or without M-mode recording); including probe placement, 
image acquisition, interpretation and report 
93313 
Echocardiography, transesophageal, real-time with image documentation 
(2D) (with or without M-mode recording); placement of transesophageal 
probe only 
93314 
Echocardiography, transesophageal, real-time with image documentation 
(2D) (with or without M-mode recording); image acquisition, 




APPENDIX D: VARIABLE DEFINITIONS 
 
Variable Definition 
BNP_Sensitivity Sensitivity of BNP Test 
BNP_Specificity Specificity of BNP Test 
ECHO_Sensitivity Sensitivity of Echocardiogram 
ECHO_Specificity Specificity of Echocardiogram 
MUGA_Sensitivity Sensitivity of Multi-gated Acquisition Scan 
MUGA_Specificity Specificity of Multi-gated Acquisition Scan 
DR Discount Rate 
Incidence_AC Incidence of cardiac dysfunction in patients who have received an anthracycline-based regimen 
Incidence_T Incidence of cardiac dysfunction in patients who have received  treatment with Trastuzumab 
C_acutecare Cost of Acute Care 
C_BNP Cost of BNP 
C_Confirm Cost of Confirmation Testing 
C_ECHO Cost of Echocardiogram 
C_ED Cost of Emergency Department Visit 
C_Hosp Cost of Hospitalization 
C_meds_asx Cost of Medications to Treat Heart Failure in Asymptomatic Stage 
C_meds_sx Cost of Medications to Treat Heart Failure in Symptomatic Stages 
C_MM Cost of Medication Management 




Variable Definitions Continued 
 
C_office_est Cost of Office Visit for Established Patient 
C_office_new Cost of Office Visit for New Patient 
C_outpt_B Total Cost of Outpatient Management in Stage B 
C_outpt_CD Total Cost of Outpatient Management in Stages C and D 
P_asxtosx_Tx Probability of Transitioning from an asymptomatic to symptomatic stage while being treated appropriately 
P_asxtosx_NoTx Probability of Transitioning from an asymptomatic to symptomatic stage without being treated appropriately 
P_ED Probability of an Emergency Department Visit 
P_death_A Probability of Death in Stage A 
P_death_B Probability of Death in Stage B 
P_death_C Probability of Death in Stage C 
P_death_D Probability of Death in Stage D 
P_death_Hosp Probability of Death While Hospitalized 
P_death_postDC Probability of Death in the Year After Being Hospitalized 
P_Hosp Probability of Hospitalization 
P_Readmit Probability of Readmission 
U_StageA Utility Estimate for Patients in Stage A 
U_StageB Utility Estimate for Patients in Stage B 
U_StageCD Utility Estimate for Patients in Stages C and D 
U_Hosp Utility Estimate for Hospitalized Patients 




APPENDIX E: SUMMARY OF MODEL INPUTS AND RANGES FOR 
SENSITIVITY ANALYSES 
 
Table E.1 Incidence Variables, Mortality and Transition Probabilities 
 
Parameter Base Case Low High 
DR 0.030 0.000 0.050 
P_HER-21 0.250 0.200 0.300 
Incidence_AC3 0.154 0.100 0.200 
Incidence_T3 0.270 0.200 0.340 
P_ASXtoSX_TX1 0.065 0.050 0.100 
P_ASXtoSX_NoTX1 0.098 0.050 0.150 
P_Death_A2 0.006 0.002 0.012 
P_Death_B2 0.008 0.005 0.012 
P_Death_C2 0.056 0.043 0.072 
P_Death_D2 0.275 0.113 0.316 
P_Death_Hosp3 0.062 0.056 0.068 
P_Death_postDC2 0.22 0.162 0.312 
P_Diag_ASX3 0.795 0.716 0.875 
P_ED3 0.042 0.038 0.046 
P_Hosp3 0.209 0.188 0.230 
P_Readmit1 0.269 0.196 0.370 
       1 Range represents that of the original cited source as high and low values 
       2 Range represents that of the original cited source as 95% CI 
       3 Estimated ranges   (± 10% of point estimate) 
 357 
Table E.2 Test Characteristics 
 
 
  Sensitivity Specificity 




BNP1 0.93 0.91 0.95 0.74 0.63 0.83 
ECHO2 0.64 0.62 0.66 0.81 0.75 0.87 
MUGA2 0.90 0.88 0.92 0.72 0.65 0.79 
1 Ranges from original cited source reported as 95% CI 2 Estimated Range 
 
 
Table E.3 Utility Estimates 
 
Parameter Base Case Low High 
U_BNP_A 1.000 - - 
U_BNP_B1,3 0.865 0.852 0.877 
U_BNP_CD1,3 0.710 0.624 0.795 
U_Hosp1 0.520 0.480 0.800 
U_disutil2 0.025 0.020 0.030 
1 Range used is reported range from point estimate cited source  






























  Costs are in 2010 U.S. Dollars; codes 
   1 Base-case estimates is the 2010 Medicare reimbursement for natriuretic peptides,  
   range is from previously published estimates of test costs adjusted to 2010 U.S. dollars; 
   2 Base-case estimates is cost of ECHO, range accounts for the possibility that not all positives 
    will require confirmatory testing – only results with BNP level in “grey area;” 
    3 High and low values represent the possible range for chosen medications obtained  
   TX Medicaid Drug Costs; 4 Estimated range; 5 Range represents high and low values from   
   Medicare Reimbursement for corresponding CPT or DRG  
 
Parameter Base Case ($) Low ($) High ($) 
C_BNP1 48 40 58 
C_ECHO 393 265 522 
c_MUGA 464 372 500 
C_confirm2 393 0 393 
C_meds_ASX3 226 206 407 
C_meds_SX3 1,162 1,039 1,285 
C_MM4 63 57 69 
C_office_est5 70 27 117 
C_office_new5 110 81 137 
C_ED5 130 68 191 
C_hosp5 6,676 4,235 9,609 
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APPENDIX F: FULL RESULTS FROM ONE-WAY SENSITIVITY ANALYSES 
 
Table F.1 One-Way Sensitivity Analysis of Cost-Effectiveness with Varying Discount Rate 
 





0.00 BNP 10,822.69 7.908 1,368.60 - - - 
0.00 No Monitoring 14,238.46 4.571 3,114.66 3,415.77 -3.336 -1,023.78 
0.00 ECHO 15,823.64 7.582 2,087.02 5,000.95 -0.326 -15,343.81 
0.00 MUGA 16,770.41 7.436 2,255.38 5,947.72 -0.472 -12,597.83 
        
0.03 BNP 10,062.37 6.920 1,454.04 - - - 
0.03 No Monitoring 13,627.34 4.224 3,226.48 3564.96 -2.697 -1,321.98 
0.03 ECHO 14,739.36 6.606 2,231.16 4676.98 -0.314 -14,888.06 
0.03 MUGA 15,655.56 6.489 2,412.70 5593.19 -0.431 -12,963.52 
        
0.05 BNP 9,656.12 6.385 1,512.35 - - - 
0.05 No Monitoring 13,287.12 4.026 3,300.26 3,631.00 -2.359 -1,539.37 
0.05 ECHO 14,146.89 6.079 2,327.35 4,490.78 -0.306 -14,661.27 
0.05 MUGA 15,043.99 5.977 2,517.19 5,387.88 -0.408 -13,194.53 
DR: Discount Rate; Costs in 2010 U.S. Dollars; Eff: Effectiveness in QALY, CE: Cost-Effectiveness;  
I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: Incremental Cost-Effectiveness Ratio 
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Table F.2 One-Way Sensitivity Analysis of HER-2 Probability 
 
 
HER-2 % STRATEGY COST ($) EFF (QALY) 
CE 





0.20 BNP 10,006.97 6.988 1,432.05 - - - 
0.20 No Monitoring 13,627.34 4.224 3,226.48 3,620.36 -2.764 -1,309.71 
0.20 ECHO 14,730.63 6.670 2,208.55 4,723.66 -0.318 -14,853.40 
0.20 MUGA 15,664.79 6.554 2,390.09 5,657.81 -0.434 -13,042.49 
        
0.25 BNP 10,062.37 6.920 1,454.04 - - - 
0.25 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.25 ECHO 14,739.36 6.606 2,231.16 4,676.98 -0.314 -14,888.06 
0.25 MUGA 15,655.56 6.489 2,412.69 5,593.19 -0.431 -12,963.53 
        
0.30 BNP 10,117.77 6.853 1,476.46 - - - 
0.30 No Monitoring 13,627.34 4.224 3,226.48 3,509.57 -2.629 -1,334.88 
0.30 ECHO 14,748.08 6.542 2,254.21 4,630.31 -0.310 -14,923.59 
0.30 MUGA 15,646.34 6.424 2,435.75 5,528.56 -0.429 -12,883.70 
HER-2%: Probability of Testing Positive for HER-2 Overexpression; Costs in 2010 U.S. Dollars; Eff: Effectiveness in  
QALY, CE: Cost-Effectiveness; I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: Incremental Cost-
Effectiveness Ratio 
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Table F.3 One-Way Sensitivity Analysis of Varying Incidence Estimates from Anthracycline-Only Regimens 
 
Incidence_AC STRATEGY COST ($) EFF (QALY) 
CE 





0.100 BNP 9,064.52 7.679 1,180.43 - - - 
0.100 No Monitoring 13,627.34 4.224 3,226.48 4,562.82 -3.455 -1,320.48 
0.100 ECHO 14,222.99 7.321 1,942.68 5,158.47 -0.358 -14,421.46 
0.100 MUGA 15,309.33 7.223 2,119.61 6,244.82 -0.456 -13,685.62 
        
0.154 BNP 10,062.37 6.920 1454.04 - - - 
0.154 No Monitoring 13,627.34 4.224 3226.48 3564.96 -2.697 -1,321.98 
0.154 ECHO 14,739.36 6.606 2231.16 4676.98 -0.314 -14,888.06 
0.154 MUGA 1,5655.56 6.489 2412.70 5593.19 -0.431 -12,963.52 
        
0.200 BNP 10,531.91 6.439 1,635.54 - - - 
0.200 No Monitoring 13,627.34 4.224 3,226.48 3,095.43 -2.216 -1,396.98 
0.200 ECHO 14,889.99 6.153 2,420.09 4,358.08 -0.287 -15,199.34 
0.200 MUGA 15,685.53 6.024 2,603.75 5,153.62 -0.415 -12,412.90 
Incidence_AC: Incidence of Cardiac Dysfunction in Patients who Received Anthracycline-Based Chemotherapy; Costs in 2010 
U.S. Dollars; Eff: Effectiveness in QALY, CE: Cost-Effectiveness; I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: 
Incremental Cost-Effectiveness Ratio 
 362 
Table F.4 One-Way Sensitivity Analysis of Varying Incidence Estimates for Trastuzumab Regimens 
Incidence_T STRATEGY COST ($) EFF (QALY) 
CE 





0.20 BNP 9,941.89 7.098 1,400.70 - - - 
0.20 No Monitoring 13,627.34 4.224 3,226.48 3,685.45 -2.874 -1,282.25 
0.20 ECHO 14,745.94 6.773 2,177.03 4,804.05 -0.324 -14,809.88 
0.20 MUGA 15,711.68 6.660 2,359.10 5,769.79 -0.438 -13,180.69 
        
0.27 BNP 10,062.37 6.920 1,454.04 - - - 
0.27 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.27 ECHO 14,739.36 6.606 2,231.16 4,676.98 -0.314 -14,888.06 
0.27 MUGA 15,655.56 6.489 2,412.69 5,593.19 -0.431 -12,963.53 
        
0.34 BNP 10,113.39 6.796 1,488.08 - - - 
0.34 No Monitoring 13,627.34 4.224 3,226.48 3,513.95 -2.573 -1,365.88 
0.34 ECHO 14,691.17 6.490 2,263.80 4,577.78 -0.307 -14,928.03 
0.34 MUGA 15,568.60 6.370 2,444.24 5,455.21 -0.427 -12,782.95 
Incidence_T: Incidence of Cardiac Dysfunction in Patients who Received Additional Treatment with Trastuzumab; Costs in 2010 
U.S. Dollars; Eff: Effectiveness in QALY, CE: Cost-Effectiveness; I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: 
Incremental Cost-Effectiveness Ratio 
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Table F.5 One-Way Sensitivity Analysis of Varying Probability Estimates of Diagnosis Without Symptoms 
P_Diag_ASX STRATEGY COST ($) EFF (QALY) CE ($/QALY) I.C. ($) I.E. (QALY) ICER (I.C. /I.E.) 
0.716 BNP 10,066.56 6.842 1,471.35 - - - 
0.716 No Monitoring 13,627.34 4.224 3,226.48 3,560.78 -2.618 -1,360.06 
0.716 ECHO 14,743.91 6.533 2,256.68 4,677.35 -0.308 -15,174.30 
0.716 MUGA 15,659.78 6.413 2,442.02 5,593.23 -0.429 -13,035.47 
        
0.795 BNP 10,062.37 6.920 1,454.04 - - - 
0.795 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.795 ECHO 14,739.36 6.606 2,231.16 4,676.98 -0.314 -14,888.10 
0.795 MUGA 15,655.56 6.489 2,412.69 5,593.19 -0.431 -12,963.50 
        
0.875 BNP 10,058.13 7.000 1,436.90 - - - 
0.875 No Monitoring 13,627.34 4.224 3,226.48 3,569.21 -2.776 -1,326.68 
0.875 ECHO 14,734.74 6.680 2,205.88 4,676.61 -0.320 -14,608.95 
0.875 MUGA 15,651.29 6.566 2,383.69 5,593.15 -0.434 -12,891.48 
P_Diag_ASX: Probability of Patients Being Diagnosed with Cardiac Dysfunction in an Asymptomatic Stage; Costs in 2010 U.S. Dollars; Eff:      
Effectiveness in QALY, CE: Cost-Effectiveness; I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: Incremental Cost-Effectiveness 
Ratio 
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Table F.6 One-Way Sensitivity Analysis of Varying the Disutility Estimate  
 





0.020 BNP 10,062.37 6.920 1,454.04 - - - 
0.020 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.020 ECHO 14,739.36 6.697 2,201.05 4,676.98 -0.224 -20,900.70 
0.020 MUGA 15,655.56 6.578 2,380.04 5,593.19 -0.342 -16,333.60 
        
0.025 BNP 10,062.37 6.920 1,454.04 - - - 
0.025 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.025 ECHO 14,739.36 6.606 2,231.16 4,676.98 -0.314 -14,888.10 
0.025 MUGA 15,655.56 6.489 2,412.69 5,593.19 -0.431 -12,963.50 
        
0.030 BNP 10,062.37 6.920 1,454.04 - - - 
0.030 No Monitoring 13,627.34 4.224 3,226.48 3,564.96 -2.697 -1,321.98 
0.030 ECHO 14,739.36 6.516 2,262.10 4,676.98 -0.405 -11,562.00 
0.030 MUGA 15,655.56 6.400 2,446.26 5,593.19 -0.520 -10,746.30 
U_Disutil: Disutility Estimate Associated with Additional Required Testing; Costs in 2010 U.S. Dollars; Eff: Effectiveness in QALY, CE: 
Cost-Effectiveness [Cost/Eff]; I.C.: Incremental Cost; I.E.: Incremental Effectiveness; ICER: Incremental Cost-Effectiveness Ratio [I.C/I.E.] 
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APPENDIX G STAGE AND CUMULATIVE COSTS FOR EACH STRATEGY 
Table G.1 BNP Stage and Cumulative Costs and Effectiveness 
 HER-2 Positive HER-2 Negative 
 









0 $192.00 $192.00 0.500 0.500 $192.00 $192.00 0.500 0.500 
1 $902.36 $1,094.36 0.958 1.458 $636.65 $828.65 0.961 1.461 
2 $1,238.16 $2,332.52 0.866 2.324 $864.49 $1,693.14 0.894 2.355 
3 $1,341.69 $3,674.21 0.750 3.074 $975.63 $2,668.77 0.810 3.164 
4 $1,279.88 $4,954.09 0.630 3.704 $961.37 $3,630.14 0.719 3.883 
5 $1,172.56 $6,126.65 0.516 4.220 $943.72 $4,573.87 0.629 4.512 
6 $1,022.42 $7,149.07 0.416 4.636 $876.57 $5,450.43 0.544 5.056 
7 $870.25 $8,019.32 0.330 4.966 $806.69 $6,257.12 0.465 5.521 
8 $723.49 $8,742.81 0.259 5.225 $727.26 $6,984.38 0.395 5.916 
9 $590.53 $9,333.34 0.201 5.426 $645.53 $7,629.91 0.334 6.250 
10 $474.95 $9,808.29 0.155 5.580 $566.14 $8,196.05 0.280 6.530 
11 $377.40 $10,185.70 0.118 5.698 $491.84 $8,687.89 0.235 6.765 
12 $296.87 $10,482.57 0.090 5.788 $424.08 $9,111.96 0.196 6.961 
13 $231.53 $10,714.10 0.068 5.856 $363.45 $9,475.41 0.163 7.123 
14 $179.25 $10,893.35 0.051 5.907 $309.97 $9,785.38 0.135 7.258 
15 - $10,893.35 - 5.907 - $9,785.38 - 7.258 
       S.C.: Stage Costs; C.C.: Cumulative Cost; S.E.: Stage Effectiveness; C.E.: Cumulative Effectiveness 
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Table G.2 ECHO Stage and Cumulative Costs and Effectiveness  
 
 
 HER-2 (+) HER-2 (-) 
Stage S.C. ($) C.C ($) S.E. (QALY) 
C.E. 





0 $1,572.00 $1,572.00 0.450 0.450 $1,572.00 $1,572.00 0.450 0.450 
1 $1,730.86 $3,302.86 0.852 1.302 $1,639.00 $3,211.00 0.859 1.309 
2 $1,858.64 $5,161.50 0.786 2.088 $1,705.95 $4,916.95 0.807 2.117 
3 $1,818.95 $6,980.45 0.690 2.778 $1,684.31 $6,601.26 0.737 2.854 
4 $1,449.37 $8,429.82 0.619 3.398 $1,226.38 $7,827.64 0.696 3.550 
5 $1,316.17 $9,745.99 0.512 3.909 $1,172.72 $9,000.36 0.611 4.161 
6 $1,092.44 $10,838.42 0.426 4.335 $962.87 $9,963.24 0.544 4.705 
7 $933.04 $11,771.46 0.339 4.675 $884.16 $10,847.40 0.467 5.172 
8 $777.64 $12,549.10 0.267 4.942 $795.69 $11,643.09 0.398 5.569 
9 $635.95 $13,185.05 0.208 5.150 $705.23 $12,348.32 0.336 5.906 
10 $512.25 $13,697.30 0.161 5.310 $617.69 $12,966.01 0.283 6.189 
11 $407.53 $14,104.83 0.123 5.433 $536.00 $13,502.02 0.237 6.426 
12 $320.89 $14,425.72 0.094 5.527 $461.67 $13,963.68 0.198 6.623 
13 $250.46 $14,676.19 0.071 5.598 $395.27 $14,358.95 0.165 6.788 
14 $194.04 $14,870.22 0.053 5.651 $336.78 $14,695.73 0.137 6.925 
15 - $14,870.22 - 5.651 - $14,695.73 - 6.925 
             S.C.: Stage Costs; C.C.: Cumulative Cost; S.E.: Stage Effectiveness; C.E.: Cumulative Effectiveness 
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Table G.3 MUGA Stage and Cumulative Costs and Effectiveness 
 
 HER-2 (+) HER-2 (-) 
Stage S.C. ($) C.C. ($) S.E. (QALY) 
C.E. 





0 $1,856.00 $1,856.00 0.450 0.450 $1,856.00 $1,856.00 0.450 0.450 
1 $2,025.19 $3,881.19 0.860 1.310 $1,924.63 $3,780.63 0.864 1.314 
2 $2,034.16 $5,915.35 0.779 2.090 $1,918.81 $5,699.44 0.804 2.118 
3 $1,906.40 $7,821.75 0.676 2.765 $1,838.57 $7,538.01 0.729 2.847 
4 $1,467.70 $9,289.45 0.600 3.365 $1,290.82 $8,828.83 0.684 3.531 
5 $1,307.18 $10,596.62 0.492 3.857 $1,213.94 $10,042.77 0.598 4.129 
6 $1,066.10 $11,662.72 0.407 4.264 $972.55 $11,015.32 0.531 4.661 
7 $902.30 $12,565.02 0.323 4.588 $885.74 $11,901.06 0.455 5.115 
8 $747.00 $13,312.02 0.254 4.841 $792.31 $12,693.37 0.387 5.502 
9 $607.78 $13,919.80 0.197 5.038 $699.02 $13,392.39 0.326 5.828 
10 $487.61 $14,407.41 0.152 5.190 $610.08 $14,002.48 0.274 6.103 
11 $386.68 $14,794.09 0.116 5.306 $527.92 $14,530.40 0.230 6.332 
12 $303.67 $15,097.76 0.088 5.394 $453.69 $14,984.08 0.191 6.524 
13 $236.51 $15,334.27 0.066 5.461 $387.73 $15,371.82 0.159 6.683 
14 $182.89 $15,517.16 0.050 5.511 $329.88 $15,701.70 0.132 6.815 
15 - $15,517.16 - 5.511 - $15,701.70 - 6.815 
                  S.C.: Stage Costs; C.C.: Cumulative Cost; S.E.: Stage Effectiveness; C.E.: Cumulative Effectiveness 
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